guid	_subjects_count	_unique_id	accession_number	analytical_fraction	authz	commons	commons_name	commons_url	data_availability	data_type	dbgap_accession_number	description	disease_type	doi	experiment_type	files_count	full_name	funding	image_types	primary_site	program_name	project_id	project_name	short_name	source	species	study_description	study_id	study_title	study_url	subjects_count	_tag_0	_tag_1	_tag_2	_tag_3	_tag_4	_tag_5	_tag_6	_tag_7	_tag_8
TOPMed_Common_Exchange_Area-Freeze_1	1	TOPMed_Common_Exchange_Area-Freeze_1_PROXY_Study			/programs/TOPMed_Common_Exchange_Area/projects/Freeze_1	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																				TOPMed_Common_Exchange_Area-Freeze_1_PROXY_Study		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..										
TOPMed_Common_Exchange_Area-Freeze_10a	1	TOPMed_Common_Exchange_Area-Freeze_10a_PROXY_Study			/programs/TOPMed_Common_Exchange_Area/projects/Freeze_10a	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																				TOPMed_Common_Exchange_Area-Freeze_10a_PROXY_Study		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..										
TOPMed_Common_Exchange_Area-Freeze_8	1	TOPMed_Common_Exchange_Area-Freeze_8			/programs/TOPMed_Common_Exchange_Area/projects/Freeze_8	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																				TOPMed_Common_Exchange_Area-Freeze_8		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..										
TOPMed_Common_Exchange_Area-Freeze_9b	1	TOPMed_Common_Exchange_Area-Freeze_9b_PROXY_Study			/programs/TOPMed_Common_Exchange_Area/projects/Freeze_9b	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																				TOPMed_Common_Exchange_Area-Freeze_9b_PROXY_Study		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..										
open_access-1000Genomes	3202	open_access-1000Genomes			/programs/open_access/projects/1000Genomes	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																			high_coverage_2019_Public	open_access-1000Genomes		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..		Data Type: Genotype	Data Type: Clinical Phenotype							
phs000007.v31.p12.c1	13070	phs000007.v31.p12.c1			/programs/parent/projects/FHS_HMB-IRB-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Framingham Cohort							FHS			"See Grouping of Framingham Phenotype Datasets Startup of Framingham Heart Study. Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study (FHS) -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute, NHLBI) -- embarked on a novel and ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. The objective of the FHS was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. Design of Framingham Heart Study. In 1948, the researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have returned to the study every two years for an examination consisting of a detailed medical history, physical examination, and laboratory tests, and in 1971, the study enrolled a second-generation cohort -- 5,124 of the original participants' adult children and their spouses -- to participate in similar examinations. The second examination of the Offspring cohort occurred eight years after the first examination, and subsequent examinations have occurred approximately every four years thereafter. In April 2002 the Study entered a new phase: the enrollment of a third generation of participants, the grandchildren of the original cohort. The first examination of the Third Generation Study was completed in July 2005 and involved 4,095 participants. Thus, the FHS has evolved into a prospective, community-based, three generation family study. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University. Research Areas in the Framingham Heart Study. Over the years, careful monitoring of the FHS population has led to the identification of the major CVD risk factors -- high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and physical inactivity -- as well as a great deal of valuable information on the effects of related factors such as blood triglyceride and HDL cholesterol levels, age, gender, and psychosocial issues. Risk factors have been identified for the major components of CVD, including coronary heart disease, stroke, intermittent claudication, and heart failure. It is also clear from research in the FHS and other studies that substantial subclinical vascular disease occurs in the blood vessels, heart and brain that precedes clinical CVD. With recent advances in technology, the FHS has enhanced its research capabilities and capitalized on its inherent resources by the conduct of high resolution imaging to detect and quantify subclinical vascular disease in the major blood vessels, heart and brain. These studies have included ultrasound studies of the heart (echocardiography) and carotid arteries, computed tomography studies of the heart and aorta, and magnetic resonance imaging studies of the brain, heart, and aorta. Although the Framingham cohort is primarily white, the importance of the major CVD risk factors identified in this group have been shown in other studies to apply almost universally among racial and ethnic groups, even though the patterns of distribution may vary from group to group. In the past half century, the Study has produced approximately 1,200 articles in leading medical journals. The concept of CVD risk factors has become an integral part of the modern medical curriculum and has led to the development of effective treatment and preventive strategies in clinical practice. In addition to research studies focused on risk factors, subclinical CVD and clinically apparent CVD, Framingham investigators have also collaborated with leading researchers from around the country and throughout the world on projects involving some of the major chronic illnesses in men and women, including dementia, osteoporosis and arthritis, nutritional deficiencies, eye diseases, hearing disorders, and chronic obstructive lung diseases. Genetic Research in the Framingham Heart Study. While pursuing the Study's established research goals, the NHLBI and the Framingham investigators has expanded its research mission into the study of genetic factors underlying CVD and other disorders. Over the past two decades, DNA has been collected from blood samples and from immortalized cell lines obtained from Original Cohort participants, members of the Offspring Cohort and the Third Generation Cohort. Several large-scale genotyping projects have been conducted in the past decade. Genome-wide linkage analysis has been conducted using genotypes of approximately 400 microsatellite markers that have been completed in over 9,300 subjects in all three generations. Analyses using microsatellite markers completed in the original cohort and offspring cohorts have resulted in over 100 publications, including many publications from the Genetics Analysis Workshop 13. Several other recent collaborative projects have completed thousands of SNP genotypes for candidate gene regions in subsets of FHS subjects with available DNA. These projects include the Cardiogenomics Program of the NHLBI's Programs for Genomics Applications, the genotyping of ~3000 SNPs in inflammation genes, and the completion of a genome-wide scan of 100,000 SNPs using the Affymetrix 100K Genechip. Framingham Cohort Phenotype Data. The phenotype database contains a vast array of phenotype information available in all three generations. These will include the quantitative measures of the major risk factors such as systolic blood pressure, total and HDL cholesterol, fasting glucose, and cigarette use, as well as anthropomorphic measures such as body mass index, biomarkers such as fibrinogen and CRP, and electrocardiography measures such as the QT interval. Many of these measures have been collected repeatedly in the original and offspring cohorts. Also included in the SHARe database will be an array of recently collected biomarkers, subclinical disease imaging measures, clinical CVD outcomes as well as an array of ancillary studies. The phenotype data is located here in the top-level study phs000007 Framingham Cohort. To view the phenotype variables collected from the Framingham Cohort, please click on the ""Variables"" tab above.  The Framingham Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000007 Framingham Cohort.  phs000342 Framingham SHARe phs000282 Framingham CARe phs000363 Framingham SABRe phs000307 Framingham Medical Resequencing phs000401 Framingham ESP Heart-GO phs000651 Framingham CHARGE-S phs000724 Framingham DNA Methylation phs001610 Framingham T2D-GENES   The unflagging commitment of the research participants in the NHLBI FHS has made more than a half century of research success possible. For decades, the FHS has made its data and DNA widely available to qualified investigators throughout the world through the Limited Access Datasets and the FHS DNA Committee, and the SHARe database will continue that tradition by allowing access to qualified investigators who agree to the requirements of data access. With the SHARe database, we continue with an ambitious research agenda and look forward to new discoveries in the decades to come.   Study Weblinks:   The Framingham Heart Study    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v31.p12 on 2021-03-25 and may not include exact formatting or images."	phs000007.v31.p12.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v31.p12		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000007.v31.p12.c2	2079	phs000007.v31.p12.c2			/programs/parent/projects/FHS_HMB-IRB-NPU-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Framingham Cohort							FHS			"See Grouping of Framingham Phenotype Datasets Startup of Framingham Heart Study. Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study (FHS) -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute, NHLBI) -- embarked on a novel and ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. The objective of the FHS was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. Design of Framingham Heart Study. In 1948, the researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have returned to the study every two years for an examination consisting of a detailed medical history, physical examination, and laboratory tests, and in 1971, the study enrolled a second-generation cohort -- 5,124 of the original participants' adult children and their spouses -- to participate in similar examinations. The second examination of the Offspring cohort occurred eight years after the first examination, and subsequent examinations have occurred approximately every four years thereafter. In April 2002 the Study entered a new phase: the enrollment of a third generation of participants, the grandchildren of the original cohort. The first examination of the Third Generation Study was completed in July 2005 and involved 4,095 participants. Thus, the FHS has evolved into a prospective, community-based, three generation family study. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University. Research Areas in the Framingham Heart Study. Over the years, careful monitoring of the FHS population has led to the identification of the major CVD risk factors -- high blood pressure, high blood cholesterol, smoking, obesity, diabetes, and physical inactivity -- as well as a great deal of valuable information on the effects of related factors such as blood triglyceride and HDL cholesterol levels, age, gender, and psychosocial issues. Risk factors have been identified for the major components of CVD, including coronary heart disease, stroke, intermittent claudication, and heart failure. It is also clear from research in the FHS and other studies that substantial subclinical vascular disease occurs in the blood vessels, heart and brain that precedes clinical CVD. With recent advances in technology, the FHS has enhanced its research capabilities and capitalized on its inherent resources by the conduct of high resolution imaging to detect and quantify subclinical vascular disease in the major blood vessels, heart and brain. These studies have included ultrasound studies of the heart (echocardiography) and carotid arteries, computed tomography studies of the heart and aorta, and magnetic resonance imaging studies of the brain, heart, and aorta. Although the Framingham cohort is primarily white, the importance of the major CVD risk factors identified in this group have been shown in other studies to apply almost universally among racial and ethnic groups, even though the patterns of distribution may vary from group to group. In the past half century, the Study has produced approximately 1,200 articles in leading medical journals. The concept of CVD risk factors has become an integral part of the modern medical curriculum and has led to the development of effective treatment and preventive strategies in clinical practice. In addition to research studies focused on risk factors, subclinical CVD and clinically apparent CVD, Framingham investigators have also collaborated with leading researchers from around the country and throughout the world on projects involving some of the major chronic illnesses in men and women, including dementia, osteoporosis and arthritis, nutritional deficiencies, eye diseases, hearing disorders, and chronic obstructive lung diseases. Genetic Research in the Framingham Heart Study. While pursuing the Study's established research goals, the NHLBI and the Framingham investigators has expanded its research mission into the study of genetic factors underlying CVD and other disorders. Over the past two decades, DNA has been collected from blood samples and from immortalized cell lines obtained from Original Cohort participants, members of the Offspring Cohort and the Third Generation Cohort. Several large-scale genotyping projects have been conducted in the past decade. Genome-wide linkage analysis has been conducted using genotypes of approximately 400 microsatellite markers that have been completed in over 9,300 subjects in all three generations. Analyses using microsatellite markers completed in the original cohort and offspring cohorts have resulted in over 100 publications, including many publications from the Genetics Analysis Workshop 13. Several other recent collaborative projects have completed thousands of SNP genotypes for candidate gene regions in subsets of FHS subjects with available DNA. These projects include the Cardiogenomics Program of the NHLBI's Programs for Genomics Applications, the genotyping of ~3000 SNPs in inflammation genes, and the completion of a genome-wide scan of 100,000 SNPs using the Affymetrix 100K Genechip. Framingham Cohort Phenotype Data. The phenotype database contains a vast array of phenotype information available in all three generations. These will include the quantitative measures of the major risk factors such as systolic blood pressure, total and HDL cholesterol, fasting glucose, and cigarette use, as well as anthropomorphic measures such as body mass index, biomarkers such as fibrinogen and CRP, and electrocardiography measures such as the QT interval. Many of these measures have been collected repeatedly in the original and offspring cohorts. Also included in the SHARe database will be an array of recently collected biomarkers, subclinical disease imaging measures, clinical CVD outcomes as well as an array of ancillary studies. The phenotype data is located here in the top-level study phs000007 Framingham Cohort. To view the phenotype variables collected from the Framingham Cohort, please click on the ""Variables"" tab above.  The Framingham Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000007 Framingham Cohort.  phs000342 Framingham SHARe phs000282 Framingham CARe phs000363 Framingham SABRe phs000307 Framingham Medical Resequencing phs000401 Framingham ESP Heart-GO phs000651 Framingham CHARGE-S phs000724 Framingham DNA Methylation phs001610 Framingham T2D-GENES   The unflagging commitment of the research participants in the NHLBI FHS has made more than a half century of research success possible. For decades, the FHS has made its data and DNA widely available to qualified investigators throughout the world through the Limited Access Datasets and the FHS DNA Committee, and the SHARe database will continue that tradition by allowing access to qualified investigators who agree to the requirements of data access. With the SHARe database, we continue with an ambitious research agenda and look forward to new discoveries in the decades to come.   Study Weblinks:   The Framingham Heart Study    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v31.p12 on 2021-03-25 and may not include exact formatting or images."	phs000007.v31.p12.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v31.p12		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000166.v2.p1.c1	4046	phs000166.v2.p1.c1			/programs/parent/projects/SHARP_ARR_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									National Heart, Lung, and Blood Institute SNP Health Association Asthma Resource Project (SHARP)							SHARP			SNP Health Association Resource (SHARe) Asthma Resource project (SHARP) is conducting a genome-wide analysis in adults and children who have participated in National Heart, Lung, and Blood Institute's clinical research trials on asthma. This includes 1041 children with asthma who participated in the Childhood Asthma Management Program (CAMP), 994 children who participated in one or five clinical trials conducted by the Childhood Asthma Research and Education (CARE) network, and 701 adults who participated in one of six clinical trials conducted by the Asthma Clinical Research Network (ACRN). There are three study types. The longitudinal clinical trials can be subsetted for population-based and/or case-control analyses. Each of the childhood asthma studies has a majority of children participating as part of a parent-child trio. The ACRN (adult) studies are probands alone. Control genotypes will be provided for case-control analyses.   Study Weblinks:   CAMP CARE ACRN    Study Design:       Cross-Sectional    Study Type:  Longitudinal Parent-Offspring Trios Case-Control   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000166.v2.p1 on 2021-03-25 and may not include exact formatting or images.	phs000166.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000166.v2.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000179.v6.p2.c1	10099	phs000179.v6.p2.c1			/programs/parent/projects/COPDGene_HMB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Genetic Epidemiology of COPD (COPDGene) Funded by the National Heart, Lung, and Blood Institute							COPDGene			"Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States and the only leading cause of death that is steadily increasing in frequency. This project will establish a racially diverse cohort that is sufficiently large and appropriately designed for genome-wide association analysis of COPD. A total of 10,000 subjects will be recruited, including control smokers, definite COPD cases (GOLD Stage 2 to 4), and subjects not included in either group (GOLD 1 or GOLD-Unclassified). This cohort will be used for cross-sectional analysis, although long-term longitudinal follow-up will be a future goal. The primary focus of the study will be genome-wide association analysis to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes. Detailed phenotyping of both cases and controls, including chest CT scan assessment of emphysema and airway disease, will allow identification of genetic determinants for the heterogeneous components of the COPD syndrome. The hypotheses to be studied are: 1) Precise phenotypic characterization of COPD subjects using computed tomography, as well as clinical and physiological measures, will provide data that will enable the broad COPD syndrome to be decomposed into clinically significant subtypes. 2) Genome-wide association studies will identify genetic determinants for COPD susceptibility that will provide insight into clinically relevant COPD subtypes. 3) Distinct genetic determinants influence the development of emphysema and airway disease. The initial phase of genome-wide association analysis included 500 COPD cases and 500 control subjects (all non-Hispanic White) genotyped with the Illumina Omni-1 chip. The second phase genotyped the entire study cohort using the Illumina Omni-Express chip. Unique aspects of the study include: 1) Inclusion of large numbers of African American subjects (approximately 1/3 of the cohort); 2) Obtaining chest CT scans (including inspiratory and expiratory images); and 3) Inclusion of the full range of disease severity. The COPDGene_v6 Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" section of this top-level study page phs000179 COPDGene_v6 Cohort.  phs000296 ESP LungGO COPDGene phs000765 COPDGene_Geno     Study Weblinks:   COPDGene    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2 on 2021-03-25 and may not include exact formatting or images."	phs000179.v6.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000179.v6.p2.c2	272	phs000179.v6.p2.c2			/programs/parent/projects/COPDGene_DS-CS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Genetic Epidemiology of COPD (COPDGene) Funded by the National Heart, Lung, and Blood Institute							COPDGene			"Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States and the only leading cause of death that is steadily increasing in frequency. This project will establish a racially diverse cohort that is sufficiently large and appropriately designed for genome-wide association analysis of COPD. A total of 10,000 subjects will be recruited, including control smokers, definite COPD cases (GOLD Stage 2 to 4), and subjects not included in either group (GOLD 1 or GOLD-Unclassified). This cohort will be used for cross-sectional analysis, although long-term longitudinal follow-up will be a future goal. The primary focus of the study will be genome-wide association analysis to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes. Detailed phenotyping of both cases and controls, including chest CT scan assessment of emphysema and airway disease, will allow identification of genetic determinants for the heterogeneous components of the COPD syndrome. The hypotheses to be studied are: 1) Precise phenotypic characterization of COPD subjects using computed tomography, as well as clinical and physiological measures, will provide data that will enable the broad COPD syndrome to be decomposed into clinically significant subtypes. 2) Genome-wide association studies will identify genetic determinants for COPD susceptibility that will provide insight into clinically relevant COPD subtypes. 3) Distinct genetic determinants influence the development of emphysema and airway disease. The initial phase of genome-wide association analysis included 500 COPD cases and 500 control subjects (all non-Hispanic White) genotyped with the Illumina Omni-1 chip. The second phase genotyped the entire study cohort using the Illumina Omni-Express chip. Unique aspects of the study include: 1) Inclusion of large numbers of African American subjects (approximately 1/3 of the cohort); 2) Obtaining chest CT scans (including inspiratory and expiratory images); and 3) Inclusion of the full range of disease severity. The COPDGene_v6 Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" section of this top-level study page phs000179 COPDGene_v6 Cohort.  phs000296 ESP LungGO COPDGene phs000765 COPDGene_Geno     Study Weblinks:   COPDGene    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2 on 2021-03-25 and may not include exact formatting or images."	phs000179.v6.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000200.v12.p3.c1	117675	phs000200.v12.p3.c1			/programs/parent/projects/WHI_HMB-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Women's Health Initiative Clinical Trial and Observational Study							WHI			"The Women's Health Initiative (WHI) is a long-term national health study that has focused on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. The original WHI study included 161,808 postmenopausal women enrolled between 1993 and 1998. The Fred Hutchinson Cancer Research Center in Seattle, WA serves as the WHI Clinical Coordinating Center for data collection, management, and analysis of the WHI. The WHI has two major parts: a partial factorial randomized Clinical Trial (CT) and an Observational Study (OS); both were conducted at 40 Clinical Centers nationwide. The CT enrolled 68,132 postmenopausal women between the ages of 50-79 into trials testing three prevention strategies. If eligible, women could choose to enroll in one, two, or all three of the trial components. The components are:  Hormone Therapy Trials (HT): This double-blind component examined the effects of combined hormones or estrogen alone on the prevention of coronary heart disease and osteoporotic fractures, and associated risk for breast cancer. Women participating in this component with an intact uterus were randomized to estrogen plus progestin (conjugated equine estrogens [CEE], 0.625 mg/d plus medroxyprogesterone acetate [MPA] 2.5 mg/d] or a matching placebo. Women with prior hysterectomy were randomized to CEE or placebo. Both trials were stopped early, in July 2002 and March 2004, respectively, based on adverse effects. All HT participants continued to be followed without intervention until close-out. Dietary Modification Trial (DM): The Dietary Modification component evaluated the effect of a low-fat and high fruit, vegetable and grain diet on the prevention of breast and colorectal cancers and coronary heart disease. Study participants were randomized to either their usual eating pattern or a low-fat dietary pattern. Calcium/Vitamin D Trial (CaD): This double-blind component began 1 to 2 years after a woman joined one or both of the other clinical trial components. It evaluated the effect of calcium and vitamin D supplementation on the prevention of osteoporotic fractures and colorectal cancer. Women in this component were randomized to calcium (1000 mg/d) and vitamin D (400 IU/d) supplements or a matching placebo.   The Observational Study (OS) examines the relationship between lifestyle, environmental, medical and molecular risk factors and specific measures of health or disease outcomes. This component involves tracking the medical history and health habits of 93,676 women not participating in the CT. Recruitment for the observational study was completed in 1998 and participants were followed annually for 8 to 12 years. Extension Studies: The original protocol allowed for follow-up until March 2005, after which participants were invited to enroll in the first WHI Extension Study for follow-up through 2010. Participants were invited again to participate in the second WHI Extension Study with continued follow up from 2010 to at least 2015. As of March 31, 2011 there were 93,122 women enrolled in the second extension. In Extension Study 2, the overall WHI study population was divided into two new subsamples, the Medical Records Cohort (MRC) and the Self-Report Cohort (SRC). The MRC consists of all former hormone trial participants and all African American and Hispanic participants from all study components. The SRC consists of the remaining participants. The extent of outcome information collected differs between the two cohorts, with more extensive outcomes information collection on the MRC. As part of Extension Study 2, selected older WHI participants were invited to participate in an In Person Visit (a.k.a., Long Life Study) at their homes during which additional blood samples were collected and various measurements were taken (such as blood pressure, height, weight, waist circumference, grip strength, etc.). In October 2015, Extension Study 2 was renewed with continued follow-up planned through October 2020, pending annual contract review and renewal. Additional Information: The WHI website, https://www.whi.org/about/SitePages/About%20WHI.aspx has much more information about the study. For WHI data collection forms used over the years, please see https://www.whi.org/researchers/studydoc/SitePages/Forms.aspx. For additional dataset documentation, see https://www.whi.org/researchers/data/Pages/Available%20Data.aspx. For data preparation and use, please refer to 'WHI dbGaP Cohort Data Release Data Preparation Guide May 2018' for additional details about the WHI data. The WHI Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000200 WHI Cohort.  phs000386 WHI SHARe phs000281 GO-ESP WHISP phs000315 WHI GARNET phs000503 WHISE phs000227 PAGE WHI phs000675 WHIMS+ phs000746 WHI Harmonized and Imputed GWAS phs001334 WHI Metabolomics of CHD phs001335 WHI BA23 phs001614 WHI LLS Phase III GWAS     Study Weblinks:   Scientific Resources Website: Women's Health Initiative NHLBI Women's Health Initiative    Study Design:       Prospective Longitudinal Cohort    Study Type:  Partial Factorial Randomized Double-Blind Placebo-Controlled Cohort Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3 on 2021-03-25 and may not include exact formatting or images."	phs000200.v12.p3.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000200.v12.p3.c2	25538	phs000200.v12.p3.c2			/programs/parent/projects/WHI_HMB-IRB-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Women's Health Initiative Clinical Trial and Observational Study							WHI			"The Women's Health Initiative (WHI) is a long-term national health study that has focused on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. The original WHI study included 161,808 postmenopausal women enrolled between 1993 and 1998. The Fred Hutchinson Cancer Research Center in Seattle, WA serves as the WHI Clinical Coordinating Center for data collection, management, and analysis of the WHI. The WHI has two major parts: a partial factorial randomized Clinical Trial (CT) and an Observational Study (OS); both were conducted at 40 Clinical Centers nationwide. The CT enrolled 68,132 postmenopausal women between the ages of 50-79 into trials testing three prevention strategies. If eligible, women could choose to enroll in one, two, or all three of the trial components. The components are:  Hormone Therapy Trials (HT): This double-blind component examined the effects of combined hormones or estrogen alone on the prevention of coronary heart disease and osteoporotic fractures, and associated risk for breast cancer. Women participating in this component with an intact uterus were randomized to estrogen plus progestin (conjugated equine estrogens [CEE], 0.625 mg/d plus medroxyprogesterone acetate [MPA] 2.5 mg/d] or a matching placebo. Women with prior hysterectomy were randomized to CEE or placebo. Both trials were stopped early, in July 2002 and March 2004, respectively, based on adverse effects. All HT participants continued to be followed without intervention until close-out. Dietary Modification Trial (DM): The Dietary Modification component evaluated the effect of a low-fat and high fruit, vegetable and grain diet on the prevention of breast and colorectal cancers and coronary heart disease. Study participants were randomized to either their usual eating pattern or a low-fat dietary pattern. Calcium/Vitamin D Trial (CaD): This double-blind component began 1 to 2 years after a woman joined one or both of the other clinical trial components. It evaluated the effect of calcium and vitamin D supplementation on the prevention of osteoporotic fractures and colorectal cancer. Women in this component were randomized to calcium (1000 mg/d) and vitamin D (400 IU/d) supplements or a matching placebo.   The Observational Study (OS) examines the relationship between lifestyle, environmental, medical and molecular risk factors and specific measures of health or disease outcomes. This component involves tracking the medical history and health habits of 93,676 women not participating in the CT. Recruitment for the observational study was completed in 1998 and participants were followed annually for 8 to 12 years. Extension Studies: The original protocol allowed for follow-up until March 2005, after which participants were invited to enroll in the first WHI Extension Study for follow-up through 2010. Participants were invited again to participate in the second WHI Extension Study with continued follow up from 2010 to at least 2015. As of March 31, 2011 there were 93,122 women enrolled in the second extension. In Extension Study 2, the overall WHI study population was divided into two new subsamples, the Medical Records Cohort (MRC) and the Self-Report Cohort (SRC). The MRC consists of all former hormone trial participants and all African American and Hispanic participants from all study components. The SRC consists of the remaining participants. The extent of outcome information collected differs between the two cohorts, with more extensive outcomes information collection on the MRC. As part of Extension Study 2, selected older WHI participants were invited to participate in an In Person Visit (a.k.a., Long Life Study) at their homes during which additional blood samples were collected and various measurements were taken (such as blood pressure, height, weight, waist circumference, grip strength, etc.). In October 2015, Extension Study 2 was renewed with continued follow-up planned through October 2020, pending annual contract review and renewal. Additional Information: The WHI website, https://www.whi.org/about/SitePages/About%20WHI.aspx has much more information about the study. For WHI data collection forms used over the years, please see https://www.whi.org/researchers/studydoc/SitePages/Forms.aspx. For additional dataset documentation, see https://www.whi.org/researchers/data/Pages/Available%20Data.aspx. For data preparation and use, please refer to 'WHI dbGaP Cohort Data Release Data Preparation Guide May 2018' for additional details about the WHI data. The WHI Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000200 WHI Cohort.  phs000386 WHI SHARe phs000281 GO-ESP WHISP phs000315 WHI GARNET phs000503 WHISE phs000227 PAGE WHI phs000675 WHIMS+ phs000746 WHI Harmonized and Imputed GWAS phs001334 WHI Metabolomics of CHD phs001335 WHI BA23 phs001614 WHI LLS Phase III GWAS     Study Weblinks:   Scientific Resources Website: Women's Health Initiative NHLBI Women's Health Initiative    Study Design:       Prospective Longitudinal Cohort    Study Type:  Partial Factorial Randomized Double-Blind Placebo-Controlled Cohort Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3 on 2021-03-25 and may not include exact formatting or images."	phs000200.v12.p3.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000209.v13.p3.c1	7440	phs000209.v13.p3.c1			/programs/parent/projects/MESA_HMB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Multi-Ethnic Study of Atherosclerosis (MESA) Cohort							MESA			"MESA The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by four examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. MESA Air The general goal of the Multi-Ethnic Study of Atherosclerosis and Air Pollution ('MESA Air') is to prospectively examine the relation between an individual level assessment of long-term ambient air pollution exposures (including PM2.5 and the progression of subclinical cardiovascular disease in a multi-city, multi-ethnic cohort. MESA Air will also prospectively examine the relationship between an individual level assessment of long-term ambient air pollution exposures and the incidence of cardiovascular disease, including myocardial infarction and cardiovascular death. MESA AIR is funded by a grant from the United States Environmental Protection Agency to the University of Washington and subcontracts from the UW to other participating institutions. MESA Air will assess if ambient air pollution is associated with changes over time in subclinical measures of atherosclerosis and plasma markers of inflammation, oxidative damage, and endothelial activation in a longitudinal data model, adjusting for age, race/ethnicity, socioeconomic status, and specific cardiovascular risk factors (such as diabetes, hypertension, smoking, and diet). The study will similarly assess if the incidence of cardiovascular events is associated with long-term exposure to ambient air pollution, using a proportional hazards model. The study includes refinement of statistical tools, and explores joint/independent effects of acute and long-term pollutant exposure in the occurrence of cardiovascular disease. The MESA Air study is built on the foundation of the ongoing MESA study. The parent MESA Study cohort is located in six geographic areas ('Field Centers') that capture tremendous exposure heterogeneity, comparable to or greater than the variability in locations of prior U.S. cohort studies. In addition to the six Field Centers, the study involves a Coordinating Center, a Central Laboratory, and Reading Centers for Computed Tomography (CT), ultrasound and air pollution data. The cohort for the MESA Air study currently includes 6226 subjects: 5479 enrolled in the parent MESA study; 257 recruited specifically for this study, and 490 recruited from the MESA Family study. The entire MESA Air cohort will be followed over a 10-year project period for the occurrence of cardiovascular disease events. On two occasions over the ten-year study period, 3600 subjects from the MESA Air cohort, residing in nine locales, will undergo computed tomography scanning to assess presence and extent of coronary artery calcification (CAC), and ultrasound of the carotid artery to determine intima-media thickness (IMT). We will also repeatedly assess plasma markers of inflammation, oxidative damage, and endothelial function in 720 subjects. MESA Air adds state-of-the-art air pollution exposure assessment information to the MESA cohort study, and introduces new subjects and outcome measures to achieve our aims. The study will assess long-term individual-level exposure to ambient air pollutants for each subject using community-scale monitoring, outdoor spatial variation, subject proximity to pollution sources, pollutants' infiltration efficiency, and personal time-activity information. The exposure models will be validated using detailed monitoring in a subset of subjects. The MESA Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000209 MESA Cohort.  phs000420 MESA SHARe phs000283 MESA CARe phs000403 MESA ESP Heart-GO     Study Weblinks:   MESA MESA Air    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal Family   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v13.p3 on 2021-03-25 and may not include exact formatting or images."	phs000209.v13.p3.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v13.p3		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000209.v13.p3.c2	856	phs000209.v13.p3.c2			/programs/parent/projects/MESA_HMB-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Multi-Ethnic Study of Atherosclerosis (MESA) Cohort							MESA			"MESA The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by four examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. MESA Air The general goal of the Multi-Ethnic Study of Atherosclerosis and Air Pollution ('MESA Air') is to prospectively examine the relation between an individual level assessment of long-term ambient air pollution exposures (including PM2.5 and the progression of subclinical cardiovascular disease in a multi-city, multi-ethnic cohort. MESA Air will also prospectively examine the relationship between an individual level assessment of long-term ambient air pollution exposures and the incidence of cardiovascular disease, including myocardial infarction and cardiovascular death. MESA AIR is funded by a grant from the United States Environmental Protection Agency to the University of Washington and subcontracts from the UW to other participating institutions. MESA Air will assess if ambient air pollution is associated with changes over time in subclinical measures of atherosclerosis and plasma markers of inflammation, oxidative damage, and endothelial activation in a longitudinal data model, adjusting for age, race/ethnicity, socioeconomic status, and specific cardiovascular risk factors (such as diabetes, hypertension, smoking, and diet). The study will similarly assess if the incidence of cardiovascular events is associated with long-term exposure to ambient air pollution, using a proportional hazards model. The study includes refinement of statistical tools, and explores joint/independent effects of acute and long-term pollutant exposure in the occurrence of cardiovascular disease. The MESA Air study is built on the foundation of the ongoing MESA study. The parent MESA Study cohort is located in six geographic areas ('Field Centers') that capture tremendous exposure heterogeneity, comparable to or greater than the variability in locations of prior U.S. cohort studies. In addition to the six Field Centers, the study involves a Coordinating Center, a Central Laboratory, and Reading Centers for Computed Tomography (CT), ultrasound and air pollution data. The cohort for the MESA Air study currently includes 6226 subjects: 5479 enrolled in the parent MESA study; 257 recruited specifically for this study, and 490 recruited from the MESA Family study. The entire MESA Air cohort will be followed over a 10-year project period for the occurrence of cardiovascular disease events. On two occasions over the ten-year study period, 3600 subjects from the MESA Air cohort, residing in nine locales, will undergo computed tomography scanning to assess presence and extent of coronary artery calcification (CAC), and ultrasound of the carotid artery to determine intima-media thickness (IMT). We will also repeatedly assess plasma markers of inflammation, oxidative damage, and endothelial function in 720 subjects. MESA Air adds state-of-the-art air pollution exposure assessment information to the MESA cohort study, and introduces new subjects and outcome measures to achieve our aims. The study will assess long-term individual-level exposure to ambient air pollutants for each subject using community-scale monitoring, outdoor spatial variation, subject proximity to pollution sources, pollutants' infiltration efficiency, and personal time-activity information. The exposure models will be validated using detailed monitoring in a subset of subjects. The MESA Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000209 MESA Cohort.  phs000420 MESA SHARe phs000283 MESA CARe phs000403 MESA ESP Heart-GO     Study Weblinks:   MESA MESA Air    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal Family   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v13.p3 on 2021-03-25 and may not include exact formatting or images."	phs000209.v13.p3.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000209.v13.p3		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000284.v2.p1.c1	1473	phs000284.v2.p1.c1			/programs/parent/projects/CFS_DS-HLBS-IRB-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe)							CFS			The Cleveland Family Study is the largest family-based study of sleep apnea world-wide, consisting of 2284 individuals (46% African American) from 361 families studied on up to 4 occasions over a period of 16 years. The study was begun in 1990 with the initial aims of quantifying the familial aggregation of sleep apnea. NIH renewals provided expansion of the original cohort (including increased minority recruitment) and longitudinal follow-up, with the last exam occurring in February 2006. Index probands (n=275) were recruited from 3 area hospital sleep labs if they had a confirmed diagnosis of sleep apnea and at least 2 first-degree relatives available to be studied. In the first 5 years of the study, neighborhood control probands (n=87) with at least 2 living relatives available for study were selected at random from a list provided by the index family and also studied. All available first degree relatives and spouses of the case and control probands also were recruited. Second-degree relatives, including half-sibs, aunts, uncles and grandparents, were also included if they lived near the first degree relatives (cases or controls), or if the family had been found to have two or more relatives with sleep apnea. Blood was sampled and DNA isolated for participants seen in the last two exam cycles (n=1447). The sample, which is enriched with individuals with sleep apnea, also contains a high prevalence of individuals with sleep apnea-related traits, including: obesity, impaired glucose tolerance, and HTN. Phenotyping data have been collected over 4 exam cycles, each occurring ~every 4 years. The last three exams targeted all subjects who had been studied at earlier exams, as well as new minority families and family members of previously studied probands who had been unavailable at prior exams. Data from one, two, three and four visits are available for 412, 630, 329 and 67, participants, respectively. In the first 3 exams, participants underwent overnight in-home sleep studies, allowing determination of the number and duration of hypopneas and apneas, sleep period, heart rate, and oxygen saturation levels; anthropometry (weight, height, and waist, hip, and neck circumferences); resting blood pressure; spirometry; standardized questionnaire evaluation of symptoms, medications, sleep patterns, quality of life, daytime sleepiness measures and health history; venipuncture and measurement of total and HDL cholesterol. The 4th exam (2001-2006) was designed to collect more detailed measurements of sleep, metabolic and CVD phenotypes and included measurement of state-of-the-art polysomnography, with both collection of blood and measurement of blood pressure before and after sleep, and anthropometry, upper airway assessments, spirometry, exhaled nitric oxide, and ECG performed the morning after the sleep study. Data have been collected by trained research assistants or GCRC nurses following written Manuals of Procedures who were certified following standard approaches for each study procedure. Ongoing data quality, with assessment of within or between individual drift, has been monitored on an ongoing basis, using statistical techniques as well as regular re-certification procedures. Between and within scorer reliabilities for key sleep apnea indices have been excellent, with intra-class correlation coefficients (ICCs) exceeding 0.92 for the apnea-hypopnea index (AHI). Sleep staging, assessed with epoch specific comparisons, also demonstrate excellent reliability for stage identification (kappas>0.82). There has been no evidence of significant time trends-between or within scorers- for the AHI variables. We also have evaluated the night-to-night variability of the AHI and other sleep variables in 91 subjects, with each measurement made 1-3 months apart. There is high night to night consistency for the AHI (ICC: 0.80), the arousal index (0.76), and the % sleep time in slow-wave sleep (0.73). We have demonstrated the comparability of the apnea estimates (AHI) determined from limited channel studies obtained at in-home settings with in full in-laboratory polysomnography. In addition to our published validation study, we more recently compared the AHI in 169 Cleveland Family Study participants undergoing both assessments (in-home and in-laboratory) within one week apart. These showed excellent levels of agreement (ICC=0.83), demonstrating the feasibility of examining data from either in-home or in-laboratory studies for apnea phenotyping. Data collected in the GCRC were obtained, when possible, with comparable, if not identical techniques, as were the same measures collected at prior exams performed in the participants' homes. To address the comparability of data collected over different exams, we calculated the crude age-adjusted correlations ~3 year within individual correlations between measures made in the most recent GCRC exam with measures made in a prior exam and demonstrated excellent levels of agreement for BMI (r=.91); waist circumference (0.91); FVC (0.88); and FEV1 (0.86). As expected due to higher biological and measurement variability, 149 somewhat lower 3-year correlations were demonstrated for SBP (0.56); Diastolic BP (0.48); AHI (0.62); and nocturnal oxygen desaturation (0.60). NHLBI Candidate-gene Association Resource. The NHLBI initiated the Candidate gene Association Resource (CARe) to create a shared genotype/phenotype resource for analyses of the association of genotypes with phenotypes relevant to the mission of the NHLBI. The resource comprises nine cohort studies funded by the NHLBI: Atherosclerosis Risk in Communities (ARIC), Cardiovascular Health Study (CHS), Cleveland Family Study (CFS), Coronary Artery Risk Development in Young Adults (CARDIA), Cooperative Study of Sickle Cell Disease (CSSCD), Framingham Heart Study (FHS), Jackson Heart Study (JHS), Multi-Ethnic Study of Atherosclerosis (MESA), and the Sleep Heart Health Study (SHHS). A database of genotype and phenotype data will be created that includes records for approximately 50,000 study participants with approximately 50,000 SNPs from more than 1,200 selected candidate genes. In addition, a genome wide association study using a 1,000K SNP Chip will be conducted on approximately 9,500 African American participants drawn from the 50,000 participants in the nine cohorts. Some relevant CARe publications CARe Study: PMID 20400780 CVD Chip Design: PMID 18974833    Study Weblinks:   Cleveland Family Study    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000284.v2.p1 on 2021-03-25 and may not include exact formatting or images.	phs000284.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000284.v2.p1		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000286.v6.p2.c1	797	phs000286.v6.p2.c1			/programs/parent/projects/JHS_HMB-IRB-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Jackson Heart Study (JHS) Cohort							JHS			"The Jackson Heart Study (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, MS metropolitan statistical area (MSA). Participants were enrolled from each of 4 recruitment pools: random, 17%; volunteer, 30%; currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study, 31% and secondary family members, 22%. The final cohort of 5,306 participants included 6.59% of all African American Jackson MSA residents aged 35-84 during the baseline exam (N-76,426, US Census 2000). Among these, approximately 3,600 gave consent that allows genetic research and deposition of data into dbGaP. Major components of three clinic examinations (Exam 1 - 2000-2004; Exam 2 - 2005-2008; Exam 3 - 2009-2013) include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. Extensive clinical phenotyping includes anthropometrics, electrocardiography, carotid ultrasound, ankle-brachial blood pressure index, echocardiography, CT chest and abdomen for coronary and aortic calcification, liver fat, and subcutaneous and visceral fat measurement, and cardiac MRI. At 12-month intervals after the baseline clinic visit (Exam 1), participants have been contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths. CMS data are currently being incorporated into the dataset. A note regarding date variables warehoused in the Jackson Heart Study (JHS) Cohort on dbGaP: The coordinating center has developed an algorithm that will systematically review and de-identify any of the (nearly 100) date-related variable types stored in the data package. To simultaneously minimize (i) de-identifiability of the data and (ii) impact on analyses utilizing sensitive data elements, a participant-level random number was generated to avoid the necessity of sharing any potentially sensitive data. The coordinating center maintains an archived linkage of these data in their raw form and regularly reviews ad hoc requests to utilize the raw data on a project-by-project basis. The JHS Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" section of this of this top-level study page phs000286 JHS Cohort.  phs000402 HeartGO JHS phs000498 JHS Allelic Spectrum Seq phs000499 JHS CARe phs001098 T2D GENES Exome Seq phs001069 MIGen JHS phs001356 Exome Chip     Study Weblinks:   Jackson Heart Study JHS Publications    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2 on 2021-03-25 and may not include exact formatting or images."	phs000286.v6.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000286.v6.p2.c2	180	phs000286.v6.p2.c2			/programs/parent/projects/JHS_DS-FDO-IRB-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Jackson Heart Study (JHS) Cohort							JHS			"The Jackson Heart Study (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, MS metropolitan statistical area (MSA). Participants were enrolled from each of 4 recruitment pools: random, 17%; volunteer, 30%; currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study, 31% and secondary family members, 22%. The final cohort of 5,306 participants included 6.59% of all African American Jackson MSA residents aged 35-84 during the baseline exam (N-76,426, US Census 2000). Among these, approximately 3,600 gave consent that allows genetic research and deposition of data into dbGaP. Major components of three clinic examinations (Exam 1 - 2000-2004; Exam 2 - 2005-2008; Exam 3 - 2009-2013) include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. Extensive clinical phenotyping includes anthropometrics, electrocardiography, carotid ultrasound, ankle-brachial blood pressure index, echocardiography, CT chest and abdomen for coronary and aortic calcification, liver fat, and subcutaneous and visceral fat measurement, and cardiac MRI. At 12-month intervals after the baseline clinic visit (Exam 1), participants have been contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths. CMS data are currently being incorporated into the dataset. A note regarding date variables warehoused in the Jackson Heart Study (JHS) Cohort on dbGaP: The coordinating center has developed an algorithm that will systematically review and de-identify any of the (nearly 100) date-related variable types stored in the data package. To simultaneously minimize (i) de-identifiability of the data and (ii) impact on analyses utilizing sensitive data elements, a participant-level random number was generated to avoid the necessity of sharing any potentially sensitive data. The coordinating center maintains an archived linkage of these data in their raw form and regularly reviews ad hoc requests to utilize the raw data on a project-by-project basis. The JHS Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" section of this of this top-level study page phs000286 JHS Cohort.  phs000402 HeartGO JHS phs000498 JHS Allelic Spectrum Seq phs000499 JHS CARe phs001098 T2D GENES Exome Seq phs001069 MIGen JHS phs001356 Exome Chip     Study Weblinks:   Jackson Heart Study JHS Publications    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2 on 2021-03-25 and may not include exact formatting or images."	phs000286.v6.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000286.v6.p2.c3	2131	phs000286.v6.p2.c3			/programs/parent/projects/JHS_HMB-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Jackson Heart Study (JHS) Cohort							JHS			"The Jackson Heart Study (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, MS metropolitan statistical area (MSA). Participants were enrolled from each of 4 recruitment pools: random, 17%; volunteer, 30%; currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study, 31% and secondary family members, 22%. The final cohort of 5,306 participants included 6.59% of all African American Jackson MSA residents aged 35-84 during the baseline exam (N-76,426, US Census 2000). Among these, approximately 3,600 gave consent that allows genetic research and deposition of data into dbGaP. Major components of three clinic examinations (Exam 1 - 2000-2004; Exam 2 - 2005-2008; Exam 3 - 2009-2013) include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. Extensive clinical phenotyping includes anthropometrics, electrocardiography, carotid ultrasound, ankle-brachial blood pressure index, echocardiography, CT chest and abdomen for coronary and aortic calcification, liver fat, and subcutaneous and visceral fat measurement, and cardiac MRI. At 12-month intervals after the baseline clinic visit (Exam 1), participants have been contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths. CMS data are currently being incorporated into the dataset. A note regarding date variables warehoused in the Jackson Heart Study (JHS) Cohort on dbGaP: The coordinating center has developed an algorithm that will systematically review and de-identify any of the (nearly 100) date-related variable types stored in the data package. To simultaneously minimize (i) de-identifiability of the data and (ii) impact on analyses utilizing sensitive data elements, a participant-level random number was generated to avoid the necessity of sharing any potentially sensitive data. The coordinating center maintains an archived linkage of these data in their raw form and regularly reviews ad hoc requests to utilize the raw data on a project-by-project basis. The JHS Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" section of this of this top-level study page phs000286 JHS Cohort.  phs000402 HeartGO JHS phs000498 JHS Allelic Spectrum Seq phs000499 JHS CARe phs001098 T2D GENES Exome Seq phs001069 MIGen JHS phs001356 Exome Chip     Study Weblinks:   Jackson Heart Study JHS Publications    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2 on 2021-03-25 and may not include exact formatting or images."	phs000286.v6.p2.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000286.v6.p2.c4	488	phs000286.v6.p2.c4			/programs/parent/projects/JHS_DS-FDO-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Jackson Heart Study (JHS) Cohort							JHS			"The Jackson Heart Study (JHS) is a large, community-based, observational study whose participants were recruited from urban and rural areas of the three counties (Hinds, Madison and Rankin) that make up the Jackson, MS metropolitan statistical area (MSA). Participants were enrolled from each of 4 recruitment pools: random, 17%; volunteer, 30%; currently enrolled in the Atherosclerosis Risk in Communities (ARIC) Study, 31% and secondary family members, 22%. The final cohort of 5,306 participants included 6.59% of all African American Jackson MSA residents aged 35-84 during the baseline exam (N-76,426, US Census 2000). Among these, approximately 3,600 gave consent that allows genetic research and deposition of data into dbGaP. Major components of three clinic examinations (Exam 1 - 2000-2004; Exam 2 - 2005-2008; Exam 3 - 2009-2013) include medical history, physical examination, blood/urine analytes and interview questions on areas such as: physical activity; stress, coping and spirituality; racism and discrimination; socioeconomic position; and access to health care. Extensive clinical phenotyping includes anthropometrics, electrocardiography, carotid ultrasound, ankle-brachial blood pressure index, echocardiography, CT chest and abdomen for coronary and aortic calcification, liver fat, and subcutaneous and visceral fat measurement, and cardiac MRI. At 12-month intervals after the baseline clinic visit (Exam 1), participants have been contacted by telephone to: update information; confirm vital statistics; document interim medical events, hospitalizations, and functional status; and obtain additional sociocultural information. Questions about medical events, symptoms of cardiovascular disease and functional status are repeated annually. Ongoing cohort surveillance includes abstraction of medical records and death certificates for relevant International Classification of Diseases (ICD) codes and adjudication of nonfatal events and deaths. CMS data are currently being incorporated into the dataset. A note regarding date variables warehoused in the Jackson Heart Study (JHS) Cohort on dbGaP: The coordinating center has developed an algorithm that will systematically review and de-identify any of the (nearly 100) date-related variable types stored in the data package. To simultaneously minimize (i) de-identifiability of the data and (ii) impact on analyses utilizing sensitive data elements, a participant-level random number was generated to avoid the necessity of sharing any potentially sensitive data. The coordinating center maintains an archived linkage of these data in their raw form and regularly reviews ad hoc requests to utilize the raw data on a project-by-project basis. The JHS Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" section of this of this top-level study page phs000286 JHS Cohort.  phs000402 HeartGO JHS phs000498 JHS Allelic Spectrum Seq phs000499 JHS CARe phs001098 T2D GENES Exome Seq phs001069 MIGen JHS phs001356 Exome Chip     Study Weblinks:   Jackson Heart Study JHS Publications    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2 on 2021-03-25 and may not include exact formatting or images."	phs000286.v6.p2.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000286.v6.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000287.v7.p1.c1	5382	phs000287.v7.p1.c1			/programs/parent/projects/CHS_HMB-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older							CHS			"The Cardiovascular Health Study (CHS) is a prospective study of risk factors for development and progression of CHD and stroke in people aged 65 years and older. The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort, enrolled in 1989-90, totaled 5,201 participants. A supplemental cohort of 687 predominantly African-American participants was enrolled in 1992-93.  Clinic examinations were performed at study baseline and at annual visits through 1998-1999, and again in 2005-2006. Examination components included medical and personal history, medication inventory, ECG, blood pressure, anthropometry, assessment of physical and cognitive function, and depression screening. Other components done less frequently included phlebotomy, spirometry, echocardiography, carotid ultrasound, cerebral magnetic resonance imaging, measurement of ankle-brachial index and retinal exam. Participants were contacted by telephone annually between exams to collect information about hospitalizations and potential cardiovascular events. Since 1999, participants have been contacted every six months by phone, primarily to identify cardiovascular events and to assess physical and cognitive health.  Standard protocols for the identification and adjudication of events were implemented during follow-up. The adjudicated events are myocardial infarction, angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication and mortality.The Cardiovascular Health Study Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000287 Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older.  phs000226 STAMPEED: Cardiovascular Health Study (CHS) phs000301 PAGE: CaLiCo: Cardiovascular Health Study (CHS) phs000377 CARe: Candidate Gene Association Resource (CARe) phs000400 GO-ESP: Heart Cohorts Exome Sequencing Project (CHS) phs000667 CHARGE: Cardiovascular Health Study (CHS)   Study Weblinks:   CHS    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1 on 2021-03-25 and may not include exact formatting or images."	phs000287.v7.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000287.v7.p1.c2	217	phs000287.v7.p1.c2			/programs/parent/projects/CHS_HMB-NPU-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older							CHS			"The Cardiovascular Health Study (CHS) is a prospective study of risk factors for development and progression of CHD and stroke in people aged 65 years and older. The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort, enrolled in 1989-90, totaled 5,201 participants. A supplemental cohort of 687 predominantly African-American participants was enrolled in 1992-93.  Clinic examinations were performed at study baseline and at annual visits through 1998-1999, and again in 2005-2006. Examination components included medical and personal history, medication inventory, ECG, blood pressure, anthropometry, assessment of physical and cognitive function, and depression screening. Other components done less frequently included phlebotomy, spirometry, echocardiography, carotid ultrasound, cerebral magnetic resonance imaging, measurement of ankle-brachial index and retinal exam. Participants were contacted by telephone annually between exams to collect information about hospitalizations and potential cardiovascular events. Since 1999, participants have been contacted every six months by phone, primarily to identify cardiovascular events and to assess physical and cognitive health.  Standard protocols for the identification and adjudication of events were implemented during follow-up. The adjudicated events are myocardial infarction, angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication and mortality.The Cardiovascular Health Study Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000287 Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older.  phs000226 STAMPEED: Cardiovascular Health Study (CHS) phs000301 PAGE: CaLiCo: Cardiovascular Health Study (CHS) phs000377 CARe: Candidate Gene Association Resource (CARe) phs000400 GO-ESP: Heart Cohorts Exome Sequencing Project (CHS) phs000667 CHARGE: Cardiovascular Health Study (CHS)   Study Weblinks:   CHS    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1 on 2021-03-25 and may not include exact formatting or images."	phs000287.v7.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000287.v7.p1.c3	2	phs000287.v7.p1.c3			/programs/parent/projects/CHS_DS-CVD-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older							CHS			"The Cardiovascular Health Study (CHS) is a prospective study of risk factors for development and progression of CHD and stroke in people aged 65 years and older. The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort, enrolled in 1989-90, totaled 5,201 participants. A supplemental cohort of 687 predominantly African-American participants was enrolled in 1992-93.  Clinic examinations were performed at study baseline and at annual visits through 1998-1999, and again in 2005-2006. Examination components included medical and personal history, medication inventory, ECG, blood pressure, anthropometry, assessment of physical and cognitive function, and depression screening. Other components done less frequently included phlebotomy, spirometry, echocardiography, carotid ultrasound, cerebral magnetic resonance imaging, measurement of ankle-brachial index and retinal exam. Participants were contacted by telephone annually between exams to collect information about hospitalizations and potential cardiovascular events. Since 1999, participants have been contacted every six months by phone, primarily to identify cardiovascular events and to assess physical and cognitive health.  Standard protocols for the identification and adjudication of events were implemented during follow-up. The adjudicated events are myocardial infarction, angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication and mortality.The Cardiovascular Health Study Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000287 Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older.  phs000226 STAMPEED: Cardiovascular Health Study (CHS) phs000301 PAGE: CaLiCo: Cardiovascular Health Study (CHS) phs000377 CARe: Candidate Gene Association Resource (CARe) phs000400 GO-ESP: Heart Cohorts Exome Sequencing Project (CHS) phs000667 CHARGE: Cardiovascular Health Study (CHS)   Study Weblinks:   CHS    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1 on 2021-03-25 and may not include exact formatting or images."	phs000287.v7.p1.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000287.v7.p1.c4	8	phs000287.v7.p1.c4			/programs/parent/projects/CHS_DS-CVD-NPU-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older							CHS			"The Cardiovascular Health Study (CHS) is a prospective study of risk factors for development and progression of CHD and stroke in people aged 65 years and older. The 5,888 study participants were recruited from four U.S. communities and have undergone extensive clinic examinations for evaluation of markers of subclinical cardiovascular disease. The original cohort, enrolled in 1989-90, totaled 5,201 participants. A supplemental cohort of 687 predominantly African-American participants was enrolled in 1992-93.  Clinic examinations were performed at study baseline and at annual visits through 1998-1999, and again in 2005-2006. Examination components included medical and personal history, medication inventory, ECG, blood pressure, anthropometry, assessment of physical and cognitive function, and depression screening. Other components done less frequently included phlebotomy, spirometry, echocardiography, carotid ultrasound, cerebral magnetic resonance imaging, measurement of ankle-brachial index and retinal exam. Participants were contacted by telephone annually between exams to collect information about hospitalizations and potential cardiovascular events. Since 1999, participants have been contacted every six months by phone, primarily to identify cardiovascular events and to assess physical and cognitive health.  Standard protocols for the identification and adjudication of events were implemented during follow-up. The adjudicated events are myocardial infarction, angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication and mortality.The Cardiovascular Health Study Cohort is utilized in the following dbGaP substudies. To view genotypes, analysis, expression data, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs000287 Cardiovascular Health Study (CHS) Cohort: an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older.  phs000226 STAMPEED: Cardiovascular Health Study (CHS) phs000301 PAGE: CaLiCo: Cardiovascular Health Study (CHS) phs000377 CARe: Candidate Gene Association Resource (CARe) phs000400 GO-ESP: Heart Cohorts Exome Sequencing Project (CHS) phs000667 CHARGE: Cardiovascular Health Study (CHS)   Study Weblinks:   CHS    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1 on 2021-03-25 and may not include exact formatting or images."	phs000287.v7.p1.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000287.v7.p1		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000289.v2.p1.c1	2597	phs000289.v2.p1.c1			/programs/parent/projects/Mayo_VTE_GRU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									National Human Genome Research Institute (NHGRI) GENEVA Genome-Wide Association Study of Venous Thrombosis (GWAS of VTE)							Mayo_VTE			"Overview: Our overall long-term goal is to determine risk factors for the complex (multifactorial) disease, venous thromboembolism (VTE), that will allow physicians to stratify individual patient risk and target VTE prophylaxis to those who would benefit most. In this genome-wide association case-control study (1300 cases and 1300 controls) we hope to identify susceptibility variants for VTE. Mutations within genes encoding for important components of the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways are risk factors for VTE. We hypothesize that other genes within these four pathways or within other pathways also are VTE disease-susceptibility genes. Therefore, we performed a genome wide association (GWA) screen and analysis using the Illumina 660W platform to identify SNPs within 1,300 clinic-based, non-cancer VTE cases primarily from Minnesota and the upper Midwest USA, and 1300 clinic-based, unrelated controls frequency-matched on patient age, gender, myocardial infarction/stroke status and state of residence. This is a subset of a slightly larger candidate gene study using 1500 case-control pairs to identify haplotype-tagging SNPs (ht-SNPs) in a large set of candidate genes (n~750) within the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways. Study Populations. Cases. VTE cases were consecutive Mayo Clinic outpatients with objectively-diagnosed deep vein thrombosis (DVT) and/or pulmonary embolism (PE) residing in the upper Midwest and referred by Mayo Clinic physician to the Mayo Clinic Special Coagulation Laboratory for clinical diagnostic testing to evaluate for an acquired or inherited thrombophilia, or to the Mayo Clinic Thrombophilia Center. Any person contacted to be a control but discovered to have had a VTE was evaluated for inclusion as a case. Cases were primarily residents from Minnesota, Wisconsin, Iowa, Michigan, Illinois, North or South Dakota, Nebraska, Kansas, Missouri and Indiana. A DVT or PE was categorized as objectively diagnosed when (a) confirmed by venography or pulmonary angiography, or pathology examination of thrombus removed at surgery, or (b) if at least one non-invasive test (compression duplex ultrasonography, lung scan, computed tomography scan, magnetic resonance imaging) was positive. A VTE was defined as:  Proximal leg deep vein thrombosis (DVT), which includes the common iliac, internal iliac, external iliac, common femoral, superficial [now termed ""femoral""] femoral, deep femoral [sometimes referred to as ""profunda"" femoral] and/or popliteal veins. (Note: greater and lesser saphenous veins, or other superficial or perforator veins, were not included as proximal or distal leg DVT). Distal leg DVT (or ""isolated calf DVT""), which includes the anterior tibial, posterior tibial and/or peroneal veins. (Note: gastrocnemius, soleal and/or sural [e.g., ""deep muscular veins"" of the calf] vein thrombosis was not included as distal leg DVT). Arm DVT, which includes the axillary, subclavian and/or innominate (brachiocephalic) veins. (Note: jugular [internal or external], cephalic and brachial vein thrombosis was not included in ""arm DVT""). Hepatic, portal, splenic, superior or inferior mesenteric, and/or renal vein thrombosis. (Note: ovarian, testicular, peri-prostatic and/or pelvic vein thrombosis was not included). Cerebral vein thrombosis (includes cerebral or dural sinus or vein, saggital sinus or vein, and/or transverse sinus or vein thrombosis). Inferior vena cava (IVC) thrombosis Superior vena cava (SVC) thrombosis Pulmonary embolism   Patients with VTE related to active cancer, antiphospholipid syndrome, inflammatory bowel disease, vasculitis, a rheumatoid or other autoimmune disorder, a vascular anomaly (e.g., Klippel-Trnaunay syndrome, etc.), heparin-induced thrombocytopenia, or a mechanical cause for DVT (e.g., arm DVT or SVC thrombosis related to a central venous catheter or transvenous pacemaker, portal and/or splenic vein thrombosis related to liver cirrhosis, IVC thrombosis related to retroperitoneal fibrosis, etc.), with hemodialysis arteriovenous fistula thrombosis, or with prior liver or bone marrow transplantation were excluded.  Controls. A Mayo Clinic outpatient control group was prospectively recruited for this study. Controls were frequency-matched on the age group (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years), sex, myocardial infarction/stroke status, and state of residence distribution of the cases. We selected clinic-based controls using a controls' database of persons undergoing general medical examinations in the Mayo Clinic Departments of General Internal Medicine or Primary Care Internal Medicine. Additionally persons undergoing evaluation at the Mayo Clinic Sports Medicine Center, and the Department of Family Medicine were screened for inclusion as controls. This study is part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org) funded by the trans-NIH Genes, Environment, and Health Initiative (GEI). The overarching goal is to identify novel genetic factors that contribute to venous thrombosis through large-scale genome-wide association studies of 1,300 clinic-based, VTE cases and 1300 clinic-based, unrelated controls. Genotyping was performed at the Johns Hopkins University Center for Inherited Disease Research (CIDR). Data cleaning and harmonization were done at the GEI-funded GENEVA Coordinating Center at the University of Washington.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000289.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs000289.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000289.v2.p1		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000422.v1.p1.c1	191	phs000422.v1.p1.c1			/programs/parent/projects/Asthma_GRU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI GO-ESP: Lung Cohorts Exome Sequencing Project (Asthma): Genetic variants affecting susceptibility and severity							Asthma			"The NHLBI ""Grand Opportunity"" Exome Sequencing Project (GO-ESP), a signature project of the NHLBI Recovery Act investment, was designed to identify genetic variants in coding regions (exons) of the human genome (the ""exome"") that are associated with heart, lung and blood diseases. These and related diseases that are of high impact to public health and individuals from diverse racial and ethnic groups will be studied. These data may help researchers understand the causes of disease, contributing to better ways to prevent, diagnose, and treat diseases, as well as determine whether to tailor prevention and treatments to specific populations. This could lead to more effective treatments and reduce the likelihood of side effects. GO-ESP is comprised of five collaborative components: 3 cohort consortia - HeartGO, LungGO, and WHISP - and 2 sequencing centers - BroadGO and SeattleGO. The exome sequencing asthma project includes 200 African-Americans with asthma from the NHLBI multicenter Severe Asthma Research Program (SARP). SARP participants were recruited at the NHLBI SARP sites with an emphasis on recruiting severe asthmatics (Moore et al., Am J Respir Crit Care Med, 2010. PMID: 19892860). Asthma status was based on both a physician's diagnosis and either bronchodilator reversibility or hyper-responsiveness to methacholine as well as less than 5 pack years of smoking. All subjects were carefully characterized using the standardized SARP protocol which included spirometry (medication withheld), maximum bronchodilator reversibility, hyper-responsiveness to methacholine (not performed in subjects with low baseline FEV1), skin-tests to common allergens, questionnaires on health care utilization and medication use and sputum, lung imaging and bronchoscopy in a subset. In addition GWAS data are available (phs000355, Illumina platform).   Study Design:       Case Set    Study Type:  Case Set   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000422.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs000422.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000422.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000571.v6.p2.c1	11558	phs000571.v6.p2.c1			/programs/PCGC/projects/CHD-GENES_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Congenital Heart Disease Genetic Network Study							CHD-GENES_HMB			This substudy phs000571 PCGC contains whole exome sequences, targeted sequences, and SNP array data. Summary level phenotypes for the PCGC Cohort study participants can be viewed at the top-level study page phs001194 PCGC Cohort. Individual level phenotype data and molecular data for all PCGC top-level study and substudies are available by requesting Authorized Access to the PCGC Cohort study phs001194.  Multi-center, prospective observational cohort study of individuals with congenital heart defects (CHD). Phenotypic data and source DNA derived from 10,000 probands, parents, and families of interest are being collected to investigate relationships between genetic factors and phenotypic and clinical outcomes in patients with CHD. Study Weblinks:Bench to Bassinet Program Study Design:     Prospective Longitudinal Cohort Study Type:Parent-Offspring TriosCohortdbGaP estimated ancestry usingGRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-10-11 and may not include exact formatting or images.	phs000571.v6.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000571.v6.p2		Study Registration: dbGaP								
phs000703.v1.p1.c1	3304	phs000703.v1.p1.c1			/programs/parent/projects/CATHGEN_DS-CVD-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									CATHeterization GENetics (CATHGEN)							CATHGEN			The CATHGEN biorepository consists of biological samples collected on 9334 sequential consenting individuals undergoing cardiac catheterization at Duke University Medical Center between 2001 and 2010 inclusive. The Institutional Review Board informed consent allowed for 50 mL of blood to be collected from fasting patients through the femoral arterial sheath during the catheterization procedure. Three 7.5 mL EDTA tubes for DNA extraction are stored at -80C. The Duke Database for Cardiovascular Disease (DDCD) provides the bulk of the clinical data used for analysis. Follow-up includes mortality information gleaned from the National Death Index and Social Security Death Index plus follow-up phone calls and written questionnaires regarding MI, stroke, re-hospitalization, coronary re-vascularization procedures, smoking, exercise, and medication use.   Study Weblinks:   CATHGEN    Study Design:       Cross-Sectional    Study Type:  Longitudinal   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000703.v1.p1 on 2021-03-25 and may not include exact formatting or images.	phs000703.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000703.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000784.v3.p1.c1	1675	phs000784.v3.p1.c1			/programs/parent/projects/GenSalt_DS-HCR-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Genetic Epidemiology Network of Salt Sensitivity (GenSalt)							GenSal			The GenSalt study is aimed at identifying novel genes which interact with the effect of dietary sodium and potassium intake or cold pressor on blood pressure.   Study Design:       Interventional    Study Type:  Family Interventional     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000784.v3.p1 on 2021-03-25 and may not include exact formatting or images.	phs000784.v3.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000784.v3.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000810.v1.p1.c1	3681	phs000810.v1.p1.c1			/programs/parent/projects/HCHS-SOL_HMB-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Hispanic Community Health Study /Study of Latinos (HCHS/SOL)							HCHS-SOL			"The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH). The goals of the HCHS/SOL include studying the prevalence and development of disease in Hispanics/Latinos, including the role of acculturation, and identifying disease risk factors that play protective or harmful roles in Hispanics/Latinos. A total of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American backgrounds were recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami. Seven additional academic centers serve as scientific and logistical support centers. Study participants aged 18-74 years took part in an extensive clinic exam and assessments to ascertain socio-demographic, cultural, environmental and biomedical characteristics. Annual follow-up interviews are conducted to determine a range of health outcomes. The HCHS SOL Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" box located on the right hand side of this top-level study page phs000810 HCHS SOL Cohort.  phs000555 PAGE CALiCo SOL phs000880 HCHS/SOL Omics in Latinos (Ola)     Study Weblinks:   Hispanic Community Health Study / Study of Latinos    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs000810.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000810.v1.p1.c2	9214	phs000810.v1.p1.c2			/programs/parent/projects/HCHS-SOL_HMB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Hispanic Community Health Study /Study of Latinos (HCHS/SOL)							HCHS-SOL			"The Hispanic Community Health Study / Study of Latinos (HCHS/SOL) is a multi-center epidemiologic study in Hispanic/Latino populations to determine the role of acculturation in the prevalence and development of disease, and to identify risk factors playing a protective or harmful role in Hispanics/Latinos. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and six other institutes, centers, and offices of the National Institutes of Health (NIH). The goals of the HCHS/SOL include studying the prevalence and development of disease in Hispanics/Latinos, including the role of acculturation, and identifying disease risk factors that play protective or harmful roles in Hispanics/Latinos. A total of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American backgrounds were recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami. Seven additional academic centers serve as scientific and logistical support centers. Study participants aged 18-74 years took part in an extensive clinic exam and assessments to ascertain socio-demographic, cultural, environmental and biomedical characteristics. Annual follow-up interviews are conducted to determine a range of health outcomes. The HCHS SOL Cohort is utilized in the following dbGaP sub-studies. To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the ""Sub-studies"" box located on the right hand side of this top-level study page phs000810 HCHS SOL Cohort.  phs000555 PAGE CALiCo SOL phs000880 HCHS/SOL Omics in Latinos (Ola)     Study Weblinks:   Hispanic Community Health Study / Study of Latinos    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs000810.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000810.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000820.v1.p1.c1	543	phs000820.v1.p1.c1			/programs/parent/projects/CCAF_GRU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Cleveland Clinic Foundation's Lone Atrial Fibrillation GWAS Study							CCAF			Blood samples were taken from patients who have lone atrial fibrillation. DNA samples were processed with Illumina Hap550 and Hap 610 chips.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000820.v1.p1 on 2021-03-25 and may not include exact formatting or images.	phs000820.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000820.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000914.v1.p1.c1	3501	phs000914.v1.p1.c1			/programs/parent/projects/SAS_GRU-IRB-PUB-COL-NPU-GSO_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Genome-Wide Association Study of Adiposity in Samoans							SAS			The research goal of this study is to identify genetic variation that increases susceptibility to obesity and cardiometabolic phenotypes among adult Samoans using genome-wide association (GWAS) methods. DNA from peripheral blood and phenotypic information were collected from 3,119 adult Samoans, 23 to 70 years of age. The participants reside throughout the independent nation of Samoa, which is experiencing economic development and the nutrition transition. Genotyping was performed with the Affymetrix Genome-Wide Human SNP 6.0 Array using a panel of approximately 900,000 SNPs. Anthropometric, fasting blood biomarkers and detailed dietary, physical activity, health and socio-demographic variables were collected. We are replicating the GWAS findings in an independent sample of 2,500 Samoans from earlier studies. After replication of genomic regions and informative SNPs in those regions, we will determine sequences of the important genes, and determine the specific genetic variants in the sequenced genes that are associated with adiposity and related cardiometabolic conditions. We will also identify gene by environment interactions, focusing on dietary intake patterns and nutrients.   Study Design:       Cross-Sectional    Study Type:  Cross-Sectional Population     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000914.v1.p1 on 2021-03-25 and may not include exact formatting or images.	phs000914.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000914.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs000920.v4.p2.c2	4707	phs000920.v4.p2.c2			/programs/topmed/projects/GALAII_DS-LD-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Genes-Environments and Admixture in Latino Asthmatics (GALA II)							GALAII			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a case-only pharmacogenetic study of bronchodilator drug response among racially admixed Latino children with asthma. Each participant had two spirometry measurements using the KoKo PFT System. With the first spirometry test, participant was administered with 4 puffs of HFA Albuterol. The second albuterol measurement was based on age, for participants under 16 years of age, additional 2 puffs were administered and for those over 16 years of age, additional 4 puffs were administered. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants are 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications. Comprehensive phenotypic data for GALAII study participants are available through dbGaP phs001180.   Study Weblinks:   Study Populations and Research Staff    Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000920.v4.p2 on 2021-03-25 and may not include exact formatting or images."	phs000920.v4.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000920.v4.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000921.v4.p1.c2	2105	phs000921.v4.p1.c2			/programs/topmed/projects/SAGE_DS-LD-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Study of African Americans, Asthma, Genes and Environment (SAGE)							SAGE			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a parallel case-control pharmacogenetic study of bronchodilator drug response among African American children with and without asthma. Each participant had spirometry measured using the KoKo PFT System. Asthmatic participants were administered with 4 puffs of HFA Albuterol. Healthy participants were given a baseline spirometry test. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants were 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications.   Study Weblinks:   Study Populations and Research Staff    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000921.v4.p1 on 2021-03-25 and may not include exact formatting or images."	phs000921.v4.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000921.v4.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs000946.v5.p1.c1	74	phs000946.v5.p1.c1			/programs/topmed/projects/EOCOPD_DS-CS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Boston Early-Onset COPD Study (EOCOPD)							EOCOPD_DS-CS-RD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States and the only leading cause of death that is steadily increasing in frequency. This project collected a set of extended pedigrees ascertained through subjects with severe, early-onset COPD. This study has enrolled subjects with severe COPD (forced expiratory volume in one second (FEV1) < 40% predicted) at an early age (< 53 years) without alpha-1 antitrypsin deficiency (a known Mendelian risk factor for COPD). Extended pedigrees are enrolled, primarily in New England, although some more geographically distant subjects have been included. This study has been used for epidemiological studies, familial aggregation analysis, linkage analysis, and candidate gene association analysis. Approximately 80 of the severe, early-onset COPD probands will undergo whole genome sequencing in this project with sequencing data available through dbGaP. Study Weblinks: Boston COPD Study Design:     Family/Twin/Trios Study Type:Pedigree Whole Genome Sequencing dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000946.v5.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000946.v5.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000951.v4.p4.c1	10333	phs000951.v4.p4.c1			/programs/topmed/projects/COPDGene_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene)							COPDGene			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, and the only leading cause of death that is steadily increasing in frequency. This project established a racially diverse cohort that is sufficiently large and appropriately designed for genome-wide association analysis of COPD. A total of 10,720 subjects were recruited, including control smokers and nonsmokers, definite COPD cases (GOLD Stage 2 to 4), and subjects not included in either group (GOLD 1 and PRISm). This cohort is being used for cross-sectional analysis, and long-term longitudinal follow-up visits after five years and after ten years are also being performed. The primary focus of the study is to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes. Detailed phenotyping of both cases and controls, including chest CT scan assessment of emphysema and airway disease, will allow identification of genetic determinants for the heterogeneous components of the COPD syndrome. The aims for this study are:  Precise phenotypic characterization of COPD subjects using computed tomography, as well as clinical and physiological measures, that will provide data to enable the broad COPD syndrome to be decomposed into clinically significant subtype; Genome-wide association studies will identify genetic determinants for COPD susceptibility that will provide insight into clinically relevant COPD subtypes; Distinct genetic determinants influence the development of emphysema and airway disease. The TOPMed analysis will include approximately 10,500 subjects with whole genome sequencing after quality control is completed.  Comprehensive phenotypic data for COPDGene subjects is available through dbGaP study phs000179.   Study Weblinks:   COPDGene phs000179    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000951.v4.p4 on 2021-03-25 and may not include exact formatting or images."	phs000951.v4.p4.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000951.v4.p4		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000951.v4.p4.c2	290	phs000951.v4.p4.c2			/programs/topmed/projects/COPDGene_DS-CS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetic Epidemiology of COPD (COPDGene)							COPDGene			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, and the only leading cause of death that is steadily increasing in frequency. This project established a racially diverse cohort that is sufficiently large and appropriately designed for genome-wide association analysis of COPD. A total of 10,720 subjects were recruited, including control smokers and nonsmokers, definite COPD cases (GOLD Stage 2 to 4), and subjects not included in either group (GOLD 1 and PRISm). This cohort is being used for cross-sectional analysis, and long-term longitudinal follow-up visits after five years and after ten years are also being performed. The primary focus of the study is to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes. Detailed phenotyping of both cases and controls, including chest CT scan assessment of emphysema and airway disease, will allow identification of genetic determinants for the heterogeneous components of the COPD syndrome. The aims for this study are:  Precise phenotypic characterization of COPD subjects using computed tomography, as well as clinical and physiological measures, that will provide data to enable the broad COPD syndrome to be decomposed into clinically significant subtype; Genome-wide association studies will identify genetic determinants for COPD susceptibility that will provide insight into clinically relevant COPD subtypes; Distinct genetic determinants influence the development of emphysema and airway disease. The TOPMed analysis will include approximately 10,500 subjects with whole genome sequencing after quality control is completed.  Comprehensive phenotypic data for COPDGene subjects is available through dbGaP study phs000179.   Study Weblinks:   COPDGene phs000179    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000951.v4.p4 on 2021-03-25 and may not include exact formatting or images."	phs000951.v4.p4.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000951.v4.p4		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000954.v4.p2.c1	1293	phs000954.v4.p2.c1			/programs/topmed/projects/CFS_DS-HLBS-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Cleveland Family Study (CFS)							CFS_DS-HLBS-IRB-NPU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Cleveland Family Study (CFS) is one cohort involved in the WGS project. The CFS was designed to provide fundamental epidemiological data on genetic and non-genetic risk factors for sleep disordered breathing (SDB). In brief, the CFS is a family-based study that enrolled a total of 2284 individuals from 361 families between 1990 and 2006. The sample was selected by identifying affected probands who had laboratory diagnosed obstructive sleep apnea. All first degree relatives, spouses and available second degree relatives of affected probands were studied. In addition, during the first 5 study years, neighborhood control families were identified through a neighborhood proband, and his/her spouses and first degree relatives. Each exam, occurring at approximately 4 year intervals, included new enrollment as well as follow up exams for previously enrolled subjects. For the first three visits, data, including an overnight sleep study, were collected in the participants' homes while the last visit occurred in a general clinical research center (GCRC). Phenotypic characterization of the entire cohort included overnight sleep apnea studies, blood pressure, spirometry, anthropometry and questionnaires. The GCRC exam (n=735 selected individuals) included more comprehensive phenotype data on a focused subsample of the larger cohort, to permit linking SDB phenotypes with cardio-metabolic phenotypes, with an interest in identifying genetic loci that are associated with these related phenotypes. In this last round of data collection, a subset of 735 individuals was selected based on expected genetic informativity by choosing pedigrees where siblings had extremes of the apnea hypopnea index (AHI). Participants underwent detailed phenotyping including laboratory polysomnography (PSG), ECG, spirometry, nasal and oral acoustic reflectometry, vigilance testing, and blood and urine collection before and after sleep and after an oral glucose tolerance test. A wide range of biochemical measures of inflammation and metabolism were assayed by a Core Laboratory at the University of Vermont. 994 individuals were sequenced as part of TOPMed Phase 1, including 507 African-Americans and 487 European-Americans. Among the sequenced individuals, 156 were probands with diagnosed sleep apnea, an additional 706 were members of families with probands, and 132 were from neighborhood control families.  298 individuals were sequenced as part of TOPMed Phase 3.5, including 169 African-Americans and 129 European-Americans. Among the newly sequenced individuals, 33 were probands with diagnosed sleep apnea, an additional 214 were members of families with probands, and 51 were from neighborhood control families. Please note: Phenotype and pedigree data are available through ""NHLBI Cleveland Family Study (CFS) Candidate Gene Association Resource (CARe)"", phs000284.  Study Weblinks: Cleveland Family Study (CFS) Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000954.v4.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000954.v4.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000956.v4.p1.c2	1111	phs000956.v4.p1.c2			/programs/topmed/projects/Amish_HMB-IRB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish							Amish			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Amish Complex Disease Research Program includes a set of large community-based studies focused largely on cardiometabolic health carried out in the Old Order Amish (OOA) community of Lancaster, Pennsylvania (http://medschool.umaryland.edu/endocrinology/amish/research-program.asp). The OOA population of Lancaster County, PA immigrated to the Colonies from Western Europe in the early 1700's. There are now over 30,000 OOA individuals in the Lancaster area, nearly all of whom can trace their ancestry back 12-14 generations to approximately 700 founders. Investigators at the University of Maryland School of Medicine have been studying the genetic determinants of cardiometabolic health in this population since 1993. To date, over 7,000 Amish adults have participated in one or more of our studies. Due to their ancestral history, the OOA may be enriched for rare variants that arose in the population from a single founder (or small number of founders) and propagated through genetic drift. Many of these variants have large effect sizes and identifying them can lead to new biological insights about health and disease. The parent study for this WGS project provides one (of multiple) examples. In our parent study, we identified through a genome-wide association analysis a haplotype that was highly enriched in the OOA that is associated with very high LDL-cholesterol levels. At the present time, the identity of the causative SNP - and even the implicated gene - is not known because the associated haplotype contains numerous genes, none of which are obvious lipid candidate genes. A major goal of the WGS that will be obtained through the NHLBI TOPMed Consortium will be to identify functional variants that underlie some of the large effect associations observed in this unique population.   Study Weblinks:   University of Maryland School of Medicine - Amish Studies    Study Design:       Family/Twin/Trios    Study Type:  Family     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000956.v4.p1 on 2021-03-25 and may not include exact formatting or images."	phs000956.v4.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000956.v4.p1		Program: TOPMed	Data Type: DCC Harmonized	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP				
phs000964.v5.p1.c1	1518	phs000964.v5.p1.c1			/programs/topmed/projects/JHS_HMB-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Jackson Heart Study (JHS)							JHS_HMB-IRB-NPU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Since there is a greater prevalence of cardiovascular disease among African Americans, the purpose of the Jackson Heart Study (JHS) is to explore the reasons for this disparity and to uncover new approaches to reduce it. The JHS is a large, community-based, observational study whose 5306 participants were recruited from among the non-institutionalized African-American adults from urban and rural areas of the three counties (Hinds, Madison, and Rankin) that make up the Jackson, MS, metropolitan statistical area (MSA). Jackson is the capital of Mississippi, the state with the largest percentage (36.3%) of African Americans in the United States. The JHS design included participants from the Jackson ARIC study who had originally been recruited through random selection from a drivers' license registry. Approximately six months before the JHS was to begin, an amendment to the federal Driver's Privacy Protection Act was passed that changed the level of consent for public release of personal information from driver's license lists from an ""opt out"" to an ""opt in"" basis. The Mississippi Highway Patrol was no longer able to release a complete listing of all persons with driver's licenses or state identification cards, which prevented its use in the JHS. New JHS participants were chosen randomly from the Accudata America commercial listing, which provides householder name, address, zip code, phone number (if available), age group in decades, and family components. The Accudata list was deemed to provide the most complete count of households for individuals aged 55 years and older in the Jackson MSA. A structured volunteer sample was also included in which demographic cells for recruitment were designed to mirror the eligible population. Enrollment was opened to volunteers who met census-derived age, sex, and socioeconomic status (SES) eligibility criteria for the Jackson MSA. In addition, a family component was included in the JHS. The sampling frame for the family study was a participant in any one of the ARlC, random, or volunteer samples whose family size met eligibility requirements. Eligibility included having at least two full siblings and four first degree relatives (parents, siblings, children over the age of 21) who lived in the Jackson MSA and who were willing to participate in the study. No upper age limit was placed on the family sample. Known contact information was obtained during the baseline clinic examination from the index family member with a verbal pedigree format to identify name(s), age(s), address (es), and telephone number(s). Recruitment was limited to persons 35-84 years old except in the family cohort, where those 21 years old and above were eligible. Only persons who otherwise met study criteria but were deemed to be physically or mentally incompetent by trained recruiters were excluded from study eligibility.1  1 Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH et al. A community-driven model of research participation: the Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13(4):438-455 (PMID: 14632263). Study Weblinks: Jackson Heart Study Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000964.v5.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000964.v5.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000964.v5.p1.c2	342	phs000964.v5.p1.c2			/programs/topmed/projects/JHS_DS-FDO-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Jackson Heart Study (JHS)							JHS_DS-FDO-IRB-NPU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Since there is a greater prevalence of cardiovascular disease among African Americans, the purpose of the Jackson Heart Study (JHS) is to explore the reasons for this disparity and to uncover new approaches to reduce it. The JHS is a large, community-based, observational study whose 5306 participants were recruited from among the non-institutionalized African-American adults from urban and rural areas of the three counties (Hinds, Madison, and Rankin) that make up the Jackson, MS, metropolitan statistical area (MSA). Jackson is the capital of Mississippi, the state with the largest percentage (36.3%) of African Americans in the United States. The JHS design included participants from the Jackson ARIC study who had originally been recruited through random selection from a drivers' license registry. Approximately six months before the JHS was to begin, an amendment to the federal Driver's Privacy Protection Act was passed that changed the level of consent for public release of personal information from driver's license lists from an ""opt out"" to an ""opt in"" basis. The Mississippi Highway Patrol was no longer able to release a complete listing of all persons with driver's licenses or state identification cards, which prevented its use in the JHS. New JHS participants were chosen randomly from the Accudata America commercial listing, which provides householder name, address, zip code, phone number (if available), age group in decades, and family components. The Accudata list was deemed to provide the most complete count of households for individuals aged 55 years and older in the Jackson MSA. A structured volunteer sample was also included in which demographic cells for recruitment were designed to mirror the eligible population. Enrollment was opened to volunteers who met census-derived age, sex, and socioeconomic status (SES) eligibility criteria for the Jackson MSA. In addition, a family component was included in the JHS. The sampling frame for the family study was a participant in any one of the ARlC, random, or volunteer samples whose family size met eligibility requirements. Eligibility included having at least two full siblings and four first degree relatives (parents, siblings, children over the age of 21) who lived in the Jackson MSA and who were willing to participate in the study. No upper age limit was placed on the family sample. Known contact information was obtained during the baseline clinic examination from the index family member with a verbal pedigree format to identify name(s), age(s), address (es), and telephone number(s). Recruitment was limited to persons 35-84 years old except in the family cohort, where those 21 years old and above were eligible. Only persons who otherwise met study criteria but were deemed to be physically or mentally incompetent by trained recruiters were excluded from study eligibility.1  1 Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH et al. A community-driven model of research participation: the Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13(4):438-455 (PMID: 14632263). Study Weblinks: Jackson Heart Study Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000964.v5.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000964.v5.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000964.v5.p1.c3	4036	phs000964.v5.p1.c3			/programs/topmed/projects/JHS_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Jackson Heart Study (JHS)							JHS_HMB-IRB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Since there is a greater prevalence of cardiovascular disease among African Americans, the purpose of the Jackson Heart Study (JHS) is to explore the reasons for this disparity and to uncover new approaches to reduce it. The JHS is a large, community-based, observational study whose 5306 participants were recruited from among the non-institutionalized African-American adults from urban and rural areas of the three counties (Hinds, Madison, and Rankin) that make up the Jackson, MS, metropolitan statistical area (MSA). Jackson is the capital of Mississippi, the state with the largest percentage (36.3%) of African Americans in the United States. The JHS design included participants from the Jackson ARIC study who had originally been recruited through random selection from a drivers' license registry. Approximately six months before the JHS was to begin, an amendment to the federal Driver's Privacy Protection Act was passed that changed the level of consent for public release of personal information from driver's license lists from an ""opt out"" to an ""opt in"" basis. The Mississippi Highway Patrol was no longer able to release a complete listing of all persons with driver's licenses or state identification cards, which prevented its use in the JHS. New JHS participants were chosen randomly from the Accudata America commercial listing, which provides householder name, address, zip code, phone number (if available), age group in decades, and family components. The Accudata list was deemed to provide the most complete count of households for individuals aged 55 years and older in the Jackson MSA. A structured volunteer sample was also included in which demographic cells for recruitment were designed to mirror the eligible population. Enrollment was opened to volunteers who met census-derived age, sex, and socioeconomic status (SES) eligibility criteria for the Jackson MSA. In addition, a family component was included in the JHS. The sampling frame for the family study was a participant in any one of the ARlC, random, or volunteer samples whose family size met eligibility requirements. Eligibility included having at least two full siblings and four first degree relatives (parents, siblings, children over the age of 21) who lived in the Jackson MSA and who were willing to participate in the study. No upper age limit was placed on the family sample. Known contact information was obtained during the baseline clinic examination from the index family member with a verbal pedigree format to identify name(s), age(s), address (es), and telephone number(s). Recruitment was limited to persons 35-84 years old except in the family cohort, where those 21 years old and above were eligible. Only persons who otherwise met study criteria but were deemed to be physically or mentally incompetent by trained recruiters were excluded from study eligibility.1  1 Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH et al. A community-driven model of research participation: the Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13(4):438-455 (PMID: 14632263). Study Weblinks: Jackson Heart Study Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000964.v5.p1.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000964.v5.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000964.v5.p1.c4	916	phs000964.v5.p1.c4			/programs/topmed/projects/JHS_DS-FDO-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Jackson Heart Study (JHS)							JHS_DS-FDO-IRB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Since there is a greater prevalence of cardiovascular disease among African Americans, the purpose of the Jackson Heart Study (JHS) is to explore the reasons for this disparity and to uncover new approaches to reduce it. The JHS is a large, community-based, observational study whose 5306 participants were recruited from among the non-institutionalized African-American adults from urban and rural areas of the three counties (Hinds, Madison, and Rankin) that make up the Jackson, MS, metropolitan statistical area (MSA). Jackson is the capital of Mississippi, the state with the largest percentage (36.3%) of African Americans in the United States. The JHS design included participants from the Jackson ARIC study who had originally been recruited through random selection from a drivers' license registry. Approximately six months before the JHS was to begin, an amendment to the federal Driver's Privacy Protection Act was passed that changed the level of consent for public release of personal information from driver's license lists from an ""opt out"" to an ""opt in"" basis. The Mississippi Highway Patrol was no longer able to release a complete listing of all persons with driver's licenses or state identification cards, which prevented its use in the JHS. New JHS participants were chosen randomly from the Accudata America commercial listing, which provides householder name, address, zip code, phone number (if available), age group in decades, and family components. The Accudata list was deemed to provide the most complete count of households for individuals aged 55 years and older in the Jackson MSA. A structured volunteer sample was also included in which demographic cells for recruitment were designed to mirror the eligible population. Enrollment was opened to volunteers who met census-derived age, sex, and socioeconomic status (SES) eligibility criteria for the Jackson MSA. In addition, a family component was included in the JHS. The sampling frame for the family study was a participant in any one of the ARlC, random, or volunteer samples whose family size met eligibility requirements. Eligibility included having at least two full siblings and four first degree relatives (parents, siblings, children over the age of 21) who lived in the Jackson MSA and who were willing to participate in the study. No upper age limit was placed on the family sample. Known contact information was obtained during the baseline clinic examination from the index family member with a verbal pedigree format to identify name(s), age(s), address (es), and telephone number(s). Recruitment was limited to persons 35-84 years old except in the family cohort, where those 21 years old and above were eligible. Only persons who otherwise met study criteria but were deemed to be physically or mentally incompetent by trained recruiters were excluded from study eligibility.1  1 Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH et al. A community-driven model of research participation: the Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13(4):438-455 (PMID: 14632263). Study Weblinks: Jackson Heart Study Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000964.v5.p1.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000964.v5.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000972.v4.p1.c1	1285	phs000972.v4.p1.c1			/programs/topmed/projects/SAS_GRU-IRB-PUB-COL-NPU-GSO	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genome-Wide Association Study of Adiposity in Samoans							SAS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The individuals sequenced here represent a small subset of the parent study (described below) and were carefully selected for the purpose of creating a Samoan-specific reference panel for imputation back into the parent study. The INFOSTIP algorithm of Gusev et. al. (2012) (PMID: 22135348) was used to optimally choose the individuals for sequencing. The research goal of the parent study (dbGaP ID phs000914) is to identify genetic variation that increases susceptibility to obesity and cardiometabolic phenotypes among adult Samoans using genome-wide association (GWAS) methods. DNA from peripheral blood and phenotypic information were collected from 3,119 adult Samoans, 23 to 70 years of age. The participants reside throughout the independent nation of Samoa, which is experiencing economic development and the nutrition transition. Genotyping was performed with the Affymetrix Genome-Wide Human SNP 6.0 Array using a panel of approximately 900,000 SNPs. Anthropometric, fasting blood biomarkers and detailed dietary, physical activity, health and socio-demographic variables were collected. We are replicating the GWAS findings in an independent sample of 2,500 Samoans from earlier studies. After replication of genomic regions and informative SNPs in those regions, we will determine sequences of the important genes, and determine the specific genetic variants in the sequenced genes that are associated with adiposity and related cardiometabolic conditions. We will also identify gene by environment interactions, focusing on dietary intake patterns and nutrients.   Study Design:       Cross-Sectional    Study Type:  Cross-Sectional Population     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000972.v4.p1 on 2021-03-25 and may not include exact formatting or images."	phs000972.v4.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000972.v4.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000974.v5.p3.c1	3555	phs000974.v5.p3.c1			/programs/topmed/projects/FHS_HMB-IRB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genomic Activities such as Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study (FHS)							FHS_HMB-IRB-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents,  ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2"" and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Framingham Heart Study (FHS) is a prospective cohort study of 3 generations of subjects who have been followed up to 65 years to evaluate risk factors for cardiovascular disease. Its large sample of ~15,000 men and women who have been extensively phenotyped with repeated examinations make it ideal for the study of genetic associations with cardiovascular disease risk factors and outcomes. DNA samples have been collected and immortalized since the mid-1990s and are available on ~8000 study participants in 1037 families. These samples have been used for collection of GWAS array data and exome chip data in nearly all with DNA samples, and for targeted sequencing, deep exome sequencing and light coverage whole genome sequencing in limited numbers. Additionally, mRNA and miRNA expression data, DNA methylation data, metabolomics and other 'omics data are available on a sizable portion of study participants. This project will focus on deep whole genome sequencing (mean 30X coverage) in ~4100 subjects and imputed to all with GWAS array data to more fully understand the genetic contributions to cardiovascular, lung, blood and sleep disorders. Comprehensive phenotypic and pedigree data for study participants are available through dbGaP phs000007. Study Weblinks:Framingham Heart Study Study Design:     Prospective Longitudinal Cohort Study Type:CohortdbGaP estimated ancestry usingGRAF-popNumber of study subjects that have individual-level data available through Authorized Access:NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/phs000974 on 2021-03-17 and may not include exact formatting or images."	phs000974.v5.p3.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974.v5.p3		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000974.v5.p3.c2	600	phs000974.v5.p3.c2			/programs/topmed/projects/FHS_HMB-IRB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genomic Activities such as Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study (FHS)							FHS_HMB-IRB-NPU-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents,  ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2"" and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Framingham Heart Study (FHS) is a prospective cohort study of 3 generations of subjects who have been followed up to 65 years to evaluate risk factors for cardiovascular disease. Its large sample of ~15,000 men and women who have been extensively phenotyped with repeated examinations make it ideal for the study of genetic associations with cardiovascular disease risk factors and outcomes. DNA samples have been collected and immortalized since the mid-1990s and are available on ~8000 study participants in 1037 families. These samples have been used for collection of GWAS array data and exome chip data in nearly all with DNA samples, and for targeted sequencing, deep exome sequencing and light coverage whole genome sequencing in limited numbers. Additionally, mRNA and miRNA expression data, DNA methylation data, metabolomics and other 'omics data are available on a sizable portion of study participants. This project will focus on deep whole genome sequencing (mean 30X coverage) in ~4100 subjects and imputed to all with GWAS array data to more fully understand the genetic contributions to cardiovascular, lung, blood and sleep disorders. Comprehensive phenotypic and pedigree data for study participants are available through dbGaP phs000007. Study Weblinks:Framingham Heart Study Study Design:     Prospective Longitudinal Cohort Study Type:CohortdbGaP estimated ancestry usingGRAF-popNumber of study subjects that have individual-level data available through Authorized Access:NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/phs000974 on 2021-03-17 and may not include exact formatting or images."	phs000974.v5.p3.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974.v5.p3		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000988.v4.p1.c1	3855	phs000988.v4.p1.c1			/programs/topmed/projects/CRA_DS-ASTHMA-IRB-MDS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Genetic Epidemiology of Asthma in Costa Rica							CRA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This administrative supplement to the project, ""The Genetic Epidemiology of Asthma in Costa Rica"" (R37 HL066289) is in response to NOT-HL-14-029 to perform whole genome sequencing (WGS) on existing NHLBI populations. We focus on asthma because of its public health significance. Asthma affects 26 million U.S. children and adults, remains a major cause of morbidity (one-half million hospitalizations a year) and is the most common cause of school and work days lost. Asthma-related costs are estimated to be over $12.7 billion annually. The Asthma Probands for both the extended pedigrees and the trios utilized in this study were selected on the basis of a physician diagnosis of asthma; a history of recurrent asthma attacks or at least 2 respiratory symptoms; and either airway hyperresponsiveness to methacholine or significant response to bronchodilator (Albuterol) administration. These criteria are identical to the criteria used in the Childhood Asthma Management Program (CAMP). The three primary goals of this project are to: (1) identify common and rare genetic variants that determine asthma and its associated phenotypes (height, weight, IgE level, lung function, bronchodilator response, steroid treatment response) through whole genome sequencing (WGS); (2) perform novel family based association analysis of our WGS data to identify novel genes for asthma; and (3) integrate epigenomic and transcriptomic data with our WGS data and determine the epistatic interactions present using systems genomics approaches. Identification of the molecular determinants of asthma remains an important priority in translational science. Genome-wide association studies (GWAS) have been successful in this regard, identifying at least 10 novel susceptibility genes for asthma. However, as with most complex traits, the variants identified by GWAS explain only a fraction of the estimated heritability of this disorder. Herein, we propose a novel family-based study design and state-of-the-art genome sequencing techniques to map a set of sequence variants for asthma and its associated phenotypes and assess the interrelationships of the identified genes and variants using systems genomics methods. We have assembled a team of investigators highly-skilled and expert in whole genome sequencing (Drs. Michael Cho and Benjamin Raby), genetic association analysis (Drs. Scott T. Weiss, Jessica Lasky-Su and Christoph Lange), integrative genomics (Drs. Raby, Kelan Tantisira, Augusto Litonjua and Dawn DeMeo), and systems genomics (Drs. Weiss, Amitabh Sharma, Lange and Raby) to address this important problem with both a novel study design and data set.   Study Design:       Family/Twin/Trios    Study Type:  Parent-Offspring Trios     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000988.v4.p1 on 2021-03-25 and may not include exact formatting or images."	phs000988.v4.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000988.v4.p1		Program: TOPMed	Data Type: DCC Harmonized	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP				
phs000993.v5.p2.c1	686	phs000993.v5.p2.c1			/programs/topmed/projects/HVH_HMB-IRB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Heart and Vascular Health Study (HVH)							HVH_HMB-IRB-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Objectives The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State. Only VT cases and early-onset AF cases are included as part of TOPMed. Background The HVH study originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants which have added case subjects with stroke, VT, and AF. Study aims focused on the associations of medication use with cardiovascular events, and starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotypic data in dbGaP. Design As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen. Subjects Only VT and early-onset AF cases from HVH are included in TOPMed. Within the HVH study, VT and AF cases were diagnosed in both inpatient and outpatient settings, and only incident cases are eligible for inclusion in TOPMed. Genetic Research Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples. Phenotype data for HVH study participants are available through dbGaP phs001013. Study Design:     Case Set Study Type:Case Set dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000993.v5.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000993.v5.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000993.v5.p2.c2	12	phs000993.v5.p2.c2			/programs/topmed/projects/HVH_DS-CVD-IRB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Heart and Vascular Health Study (HVH))							HVH_DS-CVD-IRB-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Objectives The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State. Only VT cases and early-onset AF cases are included as part of TOPMed. Background The HVH study originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants which have added case subjects with stroke, VT, and AF. Study aims focused on the associations of medication use with cardiovascular events, and starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotypic data in dbGaP. Design As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen. Subjects Only VT and early-onset AF cases from HVH are included in TOPMed. Within the HVH study, VT and AF cases were diagnosed in both inpatient and outpatient settings, and only incident cases are eligible for inclusion in TOPMed. Genetic Research Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples. Phenotype data for HVH study participants are available through dbGaP phs001013. Study Design:     Case Set Study Type:Case Set dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000993.v5.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000993.v5.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs000997.v5.p2.c1	173	phs000997.v5.p2.c1			/programs/topmed/projects/VAFAR_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: The Vanderbilt AF Ablation Registry							VAFAR_HMB-IRB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Vanderbilt Atrial Fibrillation Ablation Registry (VAFAR) was founded in 2011. Patients with AF referred for AF ablation are prospectively enrolled. A detailed clinical history is recorded, along with imaging data (cardiac MRI or CT). Blood samples are obtained for DNA extraction at the time of ablation. Details of the ablation procedure are recorded. Patients are longitudinally followed to monitor for AF recurrence. VAFAR contributed 171 samples submitted to dbGaP for WGS: 115 were from male subjects, of which 113 were white/non-Hispanic and 2 were Hispanic; 56 were from females, of which all 56 were white/non-Hispanic. Study Design:     Case Set Study Type:Case Set dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs000997.v5.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000997.v5.p2		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001001.v1.p1.c1	933	phs001001.v1.p1.c1			/programs/parent/projects/MGH_AF_HMB-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Massachusetts General Hospital (MGH) Atrial Fibrillation Study							MGH_AF			"The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained. The Massachusetts General Hospital (MGH) Atrial Fibrillation Study is utilized in the following dbGaP substudies. To view genotypes, analysis, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs001001 Massachusetts General Hospital (MGH) Atrial Fibrillation Study.  phs001116 MGH AF CHARGE-S phs001117 MGH AF Exome Sequencing phs001118 MGH AF Medical Resequencing     Study Design:       Case Set    Study Type:  Case Set   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001001.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001001.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001001.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001001.v1.p1.c2	92	phs001001.v1.p1.c2			/programs/parent/projects/MGH_AF_DS-AF-IRB-RD_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Massachusetts General Hospital (MGH) Atrial Fibrillation Study							MGH_AF			"The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained. The Massachusetts General Hospital (MGH) Atrial Fibrillation Study is utilized in the following dbGaP substudies. To view genotypes, analysis, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs001001 Massachusetts General Hospital (MGH) Atrial Fibrillation Study.  phs001116 MGH AF CHARGE-S phs001117 MGH AF Exome Sequencing phs001118 MGH AF Medical Resequencing     Study Design:       Case Set    Study Type:  Case Set   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001001.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001001.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001001.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001012.v1.p1.c1	1177	phs001012.v1.p1.c1			/programs/parent/projects/DHS_DS-DRC-IRB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Diabetes Heart Study (DHS)							DHS			The Diabetes Heart Study is a family based study enriched for type 2 diabetes (T2D). The cohort included 1220 self-reported European Americans from 475 families (Bowden et al 2010 Review of Diabetic Studies 7:188-201: PMID: 21409311; Bowden et al 2008 Annals of Human Genetics 72:598-601 PMID: 18460048) and included siblings concordant for T2D; where possible unaffected siblings were also recruited. The cohort was recruited between 1998 and 2006. Participants were extensively phenotyped for measures of subclinical CVD and other known CVD risk factors. Primary outcomes were quantified burden of vascular calcified plaque in the coronary artery, carotid artery and abdominal aorta all determined from non-contrast computed tomography scans.    Study Design:       Cross-Sectional    Study Type:  Cross-Sectional Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001012.v1.p1 on 2021-03-25 and may not include exact formatting or images.	phs001012.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001012.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001013.v3.p2.c1	1179	phs001013.v3.p2.c1			/programs/parent/projects/HVH_HMB-IRB-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Heart and Vascular Health Study (HVH)							HVH			Objectives The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State. Background The HVH originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants, which have added case subjects with stroke, VT, and AF, and used a common control group. Study aims have focused on the associations of medication use with cardiovascular events. Starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later and who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotype data in dbGaP. Design As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen. Genetic Research Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001013.v3.p2 on 2021-03-25 and may not include exact formatting or images.	phs001013.v3.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001013.v3.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001013.v3.p2.c2	25	phs001013.v3.p2.c2			/programs/parent/projects/HVH_DS-CVD-IRB-MDS_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Heart and Vascular Health Study (HVH)							HVH			Objectives The Heart and Vascular Health Study (HVH) is a case-control study of risk factors for the development of myocardial infarction (MI), stroke, venous thrombosis (VT), and atrial fibrillation (AF). The study setting is Group Health, an integrated health care delivery system in Washington State. Background The HVH originated in 1988 with the examination of risk factors for MI. Over the ensuing years, the study has been funded by a series of grants, which have added case subjects with stroke, VT, and AF, and used a common control group. Study aims have focused on the associations of medication use with cardiovascular events. Starting in 1997, the study aims expanded to include genetic associations with cardiovascular disease. Participants recruited in 2009 or later and who provided blood samples for genetic analysis were asked for consent to deposit genetic and phenotype data in dbGaP. Design As part of the HVH study, case subjects were identified by searching for ICD-9 codes consistent with MI, stroke, VT, or AF, and medical records were reviewed to confirm the diagnosis. Control subjects were identified at random from the Group Health enrollment and were matched to MI cases. All subjects have an index date. For cases, the index date was assigned as the date that the cardiovascular event (MI, stroke, VT, or AF) came to clinical attention. For controls, the index date was a random date within the range of the case index dates. For both cases and controls, information was collected from the inpatient and outpatient medical record, by telephone interview with consenting survivors, and from the Group Health pharmacy and laboratory databases. Consenting participants provided a blood specimen. Genetic Research Genetic factors underlying cardiovascular disease are studied using DNA isolated from the blood samples.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001013.v3.p2 on 2021-03-25 and may not include exact formatting or images.	phs001013.v3.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001013.v3.p2		Program: Parent	Data Type: DCC Harmonized	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001024.v4.p1.c1	128	phs001024.v4.p1.c1			/programs/topmed/projects/PARTNERS_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Partners HealthCare Biobank							PARTNERS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Atrial Fibrillation Genetics Consortium (AFGen) was organized to identify common and rare genetic variation associated with atrial fibrillation risk. In the current study, we have performed whole genome sequencing in cases with early-onset atrial fibrillation. Samples in this study were enrolled as a part of the Partners HealthCare Biobank. Cases with early-onset atrial fibrillation were identified from the Biobank (defined as atrial fibrillation onset prior to 61 years and in the absence of structural heart disease).    Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/phs001024 on 2021-03-17 and may not include exact formatting or images."	phs001024.v4.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001024.v4.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001032.v6.p2.c1	1134	phs001032.v6.p2.c1			/programs/topmed/projects/VU_AF_GRU-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Heart and Vascular Health Study (HVH)							VU_AF_GRU-IRB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Vanderbilt Atrial Fibrillation (AF) Registry was founded in 2001. Patients with AF and family members are prospectively enrolled. At enrollment a detailed past medical history is obtained along with an AF symptom severity assessment. Blood samples are obtained for DNA extraction. Patients are followed longitudinally along with serial collection of AF symptom severity assessments. Study Design:     Case Set Study Type:Case Set dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001032.v6.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001032.v6.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001040.v4.p1.c1	117	phs001040.v4.p1.c1			/programs/topmed/projects/WGHS_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women							WGHS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Women's Genome Health Study (WGHS) is a prospective cohort comprised of over 25,000 initially healthy female health professionals enrolled in the Women's Health Study, which began in 1992-1994. All participants in WGHS provided baseline blood samples and extensive survey data. Women who reported atrial fibrillation during the course of the study were asked to report diagnoses of AF at baseline, 48 months, and then annually thereafter. Participants enrolled in the continued observational follow-up who reported an incident AF event on at least one yearly questionnaire were sent an additional questionnaire to confirm the episode and to collect additional information. They were also asked for permission to review their medical records, particularly available ECGs, rhythm strips, 24-hour ECGs, and information on cardiac structure and function. For all deceased participants who reported AF during the trial and extended follow-up period, family members were contacted to obtain consent and additional relevant information. An end-point committee of physicians reviewed medical records for reported events according to predefined criteria. An incident AF event was confirmed if there was ECG evidence of AF or if a medical report clearly indicated a personal history of AF. The earliest date in the medical records when documentation was believed to have occurred was set as the date of onset of AF.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001040.v4.p1 on 2021-03-25 and may not include exact formatting or images."	phs001040.v4.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001040.v4.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001062.v4.p2.c1	908	phs001062.v4.p2.c1			/programs/topmed/projects/MGH_AF_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study							MGH_AF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained. For the TOPMed WGS project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial fibrillation was defined as an age of onset prior to 66 years of age. Comprehensive phenotypic and pedigree data for study participants are available through dbGaP phs001001.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001062.v4.p2 on 2021-03-25 and may not include exact formatting or images."	phs001062.v4.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001062.v4.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001062.v4.p2.c2	255	phs001062.v4.p2.c2			/programs/topmed/projects/MGH_AF_DS-AF-IRB-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Massachusetts General Hospital (MGH) Atrial Fibrillation Study							MGH_AF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained. For the TOPMed WGS project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial fibrillation was defined as an age of onset prior to 66 years of age. Comprehensive phenotypic and pedigree data for study participants are available through dbGaP phs001001.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/phs001062 on 2021-03-17 and may not include exact formatting or images."	phs001062.v4.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001062.v4.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001074.v1.p1.c2	250	phs001074.v1.p1.c2			/programs/parent/projects/GeneSTAR_DS-CVD-IRB-NPU-RD_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									GeneSTAR (Genetic Study of Atherosclerosis Risk) NextGen Consortium: Functional Genomics of Platelet Aggregation Using iPS and Derived Megakaryocytes							GeneSTAR			"The causal mechanisms of common diseases and their therapies have been only marginally illuminated by genetic variants identified in genome wide association studies (GWAS) utilizing single nucleotide polymorphism (SNPs). Platelet activation pathways reflecting hemostasis and thrombosis are the underlying substrate for many cardiovascular diseases and related acute events. To overcome GWAS limitations, genomic studies are needed that integrate molecular surrogates for platelet-related phenotypes assayed in cell-based models derived from individuals of known genotypes and phenotypes. In our GWAS study of native platelet aggregation phenotypes and aggregation in response to low dose aspirin in 2200 subjects (GeneSTAR, Genetic Study of Aspirin Responsiveness), important genome wide ""signals"" (p<5x10-8) associated with native platelet aggregation and important ""signals"" associated with platelet responsiveness to aspirin were identified and replicated. Although we are currently performing functional genomics studies to elucidate our most promising findings in known genes (PEAR1, MET, PIKC3G), most ""signals"" occurred in intergenic regions or in introns. Mechanistic interpretation is limited by uncertainty as to which gene(s) are up- or down-regulated in the presence of most SNP modifications. In this 3 phase proposal, we will (1) create pluripotent stem cells (iPS) from peripheral blood mononuclear cells, and then differentiate these stem cells into megakaryocytes (2) develop an efficient strategy to produce iPS and megakaryocytes using a novel pooling method, and (3) produce iPS and megakaryocytes from 250 subjects in GeneSTAR (European Americans and African Americans), selected based on specific hypotheses derived from GWAS signals in native and post aspirin platelet function; characterize genetic mRNA transcripts using a comprehensive Affymetrix array; measure protein expression for transcripts of interest using mass spectrometry; examine mRNA and protein expression patterns for each GWAS signal to determine the functional pathway(s) involved in native platelet phenotypes; and examine the functional genomics of variations in responsiveness to aspirin using our prior genotyped and phenotyped population. Precise information about the exact functional processes in megakaryocytes and platelets may lead to innovative and tailored approaches to risk assessment and novel therapeutic targets to prevent first and recurrent cardiovascular and related thrombotic events.   Study Weblinks:   GeneSTAR Research Center, Genetic Studies of Atherosclerosis Risk    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal Cohort Family     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001074.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001074.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001074.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001143.v4.p1.c1	1003	phs001143.v4.p1.c1			/programs/topmed/projects/BAGS_GRU-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: The Genetics and Epidemiology of Asthma in Barbados							BAGS_GRU-IRB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Asthma is a complex disease where the interplay between genetic factors and environmental exposures influences susceptibility and disease prognosis. Asthmatics of African descent tend to have more severe asthma and more severe clinical symptoms than individuals of European ancestry. The baseline prevalence of asthma in Barbados is high (~20%), and from admixture analyses, we have determined that the proportion of African ancestry among Barbadian founders is similar to U.S. African Americans, rendering this a unique population to disentangle the genetic basis for asthma disparities among African ancestry populations in general. We therefore performed whole genome sequencing on 1,100 individuals from the Barbados Genetics of Asthma Study (BAGS), in order to generate additional discovery of rare and structural variants that may control risk to asthma. Study Design:     Family/Twin/Trios Study Type:Family dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001143.v4.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001143.v4.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001180.v2.p1.c2	4458	phs001180.v2.p1.c2			/programs/parent/projects/GALAII_DS-LD-IRB-COL_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Genes-Environments and Admixture in Latino Asthmatics (GALA II) Study							GALAII			"A case-control pharmacogenetic study of bronchodilator drug response among racially admixed Latino children with asthma. Each participant had two spirometry measurements using the KoKo PFT System. With the first spirometry test, participant was administered with 4 puffs of HFA Albuterol. The second albuterol measurement was based on age, for participants under 16 years of age, additional 2 puffs were administered and for those over 16 years of age, additional 4 puffs were administered. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants are 8-21 years old at time of recruitment. Children with asthma have physician-diagnosed asthma, symptoms and medications. The GALAII Study is utilized in the following dbGaP substudies. To view genotypes, analysis, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" box located on the right hand side of this top-level study page phs001180 GALAII Study.  phs001274phs001274 GALAII GWAS     Study Weblinks:   Asthma Collaboratory    Study Design:       Case-Control    Study Type:  Case-Control   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001180.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001180.v2.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001180.v2.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001189.v4.p1.c1	363	phs001189.v4.p1.c1			/programs/topmed/projects/CCAF_AF_GRU-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Cleveland Clinic Atrial Fibrillation (CCAF) Study							CCAF_AF_GRU-IRB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Cleveland Clinic Atrial Fibrillation Study consists of clinical and genetic data of patients with atrial fibrillation and control cohorts from the Cleveland Clinic CV/Arrhythmia Biobank, including the Cleveland Clinic Lone Atrial Fibrillation GeneBank. The Cleveland Clinic Lone AF GeneBank Study has enrolled patients with lone AF, defined as AF in the absence of significant structural heart disease. The CV/Arrhythmia Biobank has also enrolled participants with non-lone atrial fibrillation. All patients provided written informed consent. Study Design:     Case Set Study Type:Case Set dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001189.v4.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001189.v4.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001194.v2.p2.c1	9431	phs001194.v2.p2.c1			/programs/parent/projects/PCGC_HMB_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									National Heart, Lung, and Blood Institute (NHLBI) Bench to Bassinet Program: The Pediatric Cardiac Genetics Consortium (PCGC) Study							PCGC			"Multi-center, prospective observational cohort study of individuals with congenital heart defects (CHD). Phenotypic data and source DNA derived from 10,000 probands, parents, and families of interest are being collected to investigate relationships between genetic factors and phenotypic and clinical outcomes in patients with CHD. The PCGC Cohort is utilized in the following dbGaP substudies. To view genotypes, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs001194 PCGC Cohort.  phs000571 The Pediatric Cardiac Genetics Consortium (PCGC)   The Gabriella Miller Kids First Pediatric Research Program (Kids First) subset of the PCGC project (phs001194) is now accessible through a separate dbGaP study accession: phs001138. To access this dataset, please submit a Data Access Request (DAR) for phs001138. Approval of this DAR will be expedited for approved users of phs001194. To learn about other Kids First datasets visit https://kidsfirstdrc.org/.   Study Weblinks:   From Bench to Bassinet: CHD Genes    Study Design:       Prospective Longitudinal Cohort    Study Type:  Parent-Offspring Trios Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001194.v2.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194.v2.p2		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001194.v2.p2.c2	32	phs001194.v2.p2.c2			/programs/parent/projects/PCGC_DS-CHD_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									National Heart, Lung, and Blood Institute (NHLBI) Bench to Bassinet Program: The Pediatric Cardiac Genetics Consortium (PCGC) Study							PCGC			"Multi-center, prospective observational cohort study of individuals with congenital heart defects (CHD). Phenotypic data and source DNA derived from 10,000 probands, parents, and families of interest are being collected to investigate relationships between genetic factors and phenotypic and clinical outcomes in patients with CHD. The PCGC Cohort is utilized in the following dbGaP substudies. To view genotypes, other molecular data, and derived variables collected in these substudies, please click on the following substudies below or in the ""Substudies"" section of this top-level study page phs001194 PCGC Cohort.  phs000571 The Pediatric Cardiac Genetics Consortium (PCGC)   The Gabriella Miller Kids First Pediatric Research Program (Kids First) subset of the PCGC project (phs001194) is now accessible through a separate dbGaP study accession: phs001138. To access this dataset, please submit a Data Access Request (DAR) for phs001138. Approval of this DAR will be expedited for approved users of phs001194. To learn about other Kids First datasets visit https://kidsfirstdrc.org/.   Study Weblinks:   From Bench to Bassinet: CHD Genes    Study Design:       Prospective Longitudinal Cohort    Study Type:  Parent-Offspring Trios Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001194.v2.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001194.v2.p2		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001207.v2.p1.c1	934	phs001207.v2.p1.c1			/programs/topmed/projects/Sarcoidosis_DS-SAR-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: African American Sarcoidosis Genetics Resource							Sarcoidosis			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This study aims to comprehensively interrogate the genomes of African American sarcoidosis families. Sarcoidosis is characterized by a hyperimmune response resulting in granuloma formation in multiple organs. It affects African Americans (AAs) more frequently and more severely than whites. While previous linkage, admixture, candidate gene and genome-wide association (GWA) studies show statistically compelling effects, causal variants are still unknown and much of sarcoidosis heritability is yet to be explained. This ""missing"" heritability likely includes effects of both common (minor allele frequency (MAF)>5%) and rare variants (MAF<5%), since, in AAs, the former are inadequately represented and the latter are completely unexplored by commercial genotyping arrays. These facts, coupled with the availability of next-generation sequencing compel us to perform an exhaustive search for genetic variants that form the basis of sarcoidosis. The data generated are certain to identify candidate causal variants, provide fundamental insight for functional studies and lead to important new hypotheses of inflammation resulting in new treatments in not only sarcoidosis but other inflammatory diseases as well.   Study Design:       Family/Twin/Trios    Study Type:  Family Affected Sib Pairs     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001207.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001207.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001207.v2.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001211.v3.p2.c1	4016	phs001211.v3.p2.c1			/programs/topmed/projects/ARIC_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC)							ARIC			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession.  Participants from the Atherosclerosis Risk in Communities (ARIC) Study, a large population-based longitudinal cohort study, have been included in this Project and whole genome sequencing will be performed to contribute to analyses of early-onset atrial fibrillation and venous thromboembolism. Additional phenotype and genotype data are available for these individuals on dbGaP and can be accessed through the parent ARIC Cohort accession (phs000280). The National Heart, Lung and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program seeks to uncover factors that increase or decrease the risk of disease, identify subtypes of disease, and develop more targeted and personalized treatments. The Whole Genome Sequencing (WGS) Project is part of NHLBI's TOPMed program and serves as an initial step for the larger initiative.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001211.v3.p2 on 2021-03-25 and may not include exact formatting or images."	phs001211.v3.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001211.v3.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001211.v3.p2.c2	1	phs001211.v3.p2.c2			/programs/topmed/projects/ARIC_DS-CVD-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Atherosclerosis Risk in Communities (ARIC)							ARIC			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession.  Participants from the Atherosclerosis Risk in Communities (ARIC) Study, a large population-based longitudinal cohort study, have been included in this Project and whole genome sequencing will be performed to contribute to analyses of early-onset atrial fibrillation and venous thromboembolism. Additional phenotype and genotype data are available for these individuals on dbGaP and can be accessed through the parent ARIC Cohort accession (phs000280). The National Heart, Lung and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program seeks to uncover factors that increase or decrease the risk of disease, identify subtypes of disease, and develop more targeted and personalized treatments. The Whole Genome Sequencing (WGS) Project is part of NHLBI's TOPMed program and serves as an initial step for the larger initiative.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001211.v3.p2 on 2021-03-25 and may not include exact formatting or images."	phs001211.v3.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001211.v3.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001215.v3.p2.c1	2587	phs001215.v3.p2.c1			/programs/topmed/projects/SAFHS_DS-DHD-IRB-PUB-MDS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: San Antonio Family Heart Study (SAFHS)							SAFHS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The San Antonio Family Heart Study (SAFHS) is a complex pedigree-based mixed longitudinal study designed to identify low frequency or rare variants influencing susceptibility to cardiovascular disease, using whole genome sequence (WGS) information from 2,590 individuals in large Mexican American pedigrees from San Antonio, Texas. The major objectives of this study are to identify low frequency or rare variants in and around known common variant signals for CVD, as well as to find novel low frequency or rare variants influencing susceptibility to CVD. WGS of the SAFHS cohort has been obtained through three efforts. Approximately 540 WGS were performed commercially at 50X by Complete Genomics, Inc (CGI) as part of the large T2D-GENES Project. The phenotype and genotype data for this group is available at dbGaP under accession number phs000462. An additional ~900 WGS at 30X were obtained through Illumina as part of the R01HL113322 ""Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD Risk"" project. Finally, ~1,150 WGS at 30X WGS were obtained through Illumina funded by a supplement as part of the NHLBI's TOPMed program. Extensive phenotype data are provided for sequenced individuals primarily obtained from the P01HL45522 ""Genetics of Atherosclerosis in Mexican Americans"" for adults and R01HD049051 for children in these same families. Phenotype information was collected between 1991 and 2016. For this dataset, the SAFHS appellation represents an amalgamation of the original SAFHS participants and an expansion that reexamined families previously recruited for the San Antonio Family Diabetes Study (R01DK042273) and the San Antonio Family Gall Bladder Study (R01DK053889). Due to this substantial examination history, participants may have information from up to five visits. The clinical variables reported are coordinated with TOPMed and include major adverse cardiac events (MACE), T2D status and age at diagnosis, glycemic traits (fasting glucose and insulin), blood pressure, blood lipids (total cholesterol, HDL cholesterol, calculated LDL cholesterol and triglycerides). Additional phenotype data include the medication status at each visit, classified in four categories as any current use of diabetes, hypertension or lipid-lowering medications, and, for females, current use of female hormones. Anthropometric measurements include age, sex, height, weight, hip circumference, waist circumference and derived ratios. PBMC derived gene expression assays for a subset of ~1,060 individuals obtained using the Illumina Sentrix-6 chip is also available from the baseline examination. The WGS data have been jointly called and are available in the current TOPMed accession (phs001215).   Study Design:       Family/Twin/Trios    Study Type:  Family     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001215.v3.p2 on 2021-03-25 and may not include exact formatting or images."	phs001215.v3.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001215.v3.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001217.v2.p1.c1	1863	phs001217.v2.p1.c1			/programs/topmed/projects/GenSalt_DS-HCR-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetic Epidemiology Network of Salt Sensitivity (GenSalt)							GenSalt			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The GenSalt study aims to identify genes which interact with dietary sodium and potassium intake to influence blood pressure in Han Chinese participants from rural north China. Whole genome sequencing will be conducted among 1,860 participants of the Genetic Epidemiology Network of Salt Sensitivity (GenSalt) Study. We will work in collaboration with participating TOPMed studies to identify novel common, low-frequency and rare variants associated with an array of cardiometabolic phenotypes. In addition, we will explore the relation of low-frequency and rare variants with salt-sensitivity among GenSalt study participants.   Study Design:       Family/Twin/Trios    Study Type:  Parent-Offspring Trios Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001217.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001217.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001217.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001218.v2.p1.c2	1783	phs001218.v2.p1.c2			/programs/topmed/projects/GeneSTAR_DS-CVD-IRB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetic Study of Atherosclerosis Risk (GeneSTAR)							GeneSTAR			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. GeneSTAR began in 1982 as the Johns Hopkins Sibling and Family Heart Study, a prospective longitudinal family-based study conducted originally in healthy adult siblings of people with documented early onset coronary disease under 60 years of age. Commencing in 2003, the siblings, their offspring, and the coparent of the offspring participated in a 2 week trial of aspirin 81 mg/day with pre and post ex vivo platelet function assessed using multiple agonists in whole blood and platelet rich plasma. Extensive additional cardiovascular testing and risk assessment was done at baseline and serially. Follow-up was carried out to determine incident cardiovascular disease, stroke, peripheral arterial disease, diabetes, cancer, and related comorbidities, from 5 to 30 years after study entry. The goal of several additional phenotyping and interventional substudies has been to discover and amplify understanding of the mechanisms of atherogenic vascular diseases and attendant comorbidities.   Study Weblinks:   GeneSTAR    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal Cohort Family     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001218.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001218.v2.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001218.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001237.v2.p1.c1	9001	phs001237.v2.p1.c1			/programs/topmed/projects/WHI_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Women's Health Initiative (WHI)							WHI			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is Whole Genome Sequencing data from the TOPMed participation of the Women's Health Initiative. Approximately 11,100 subjects were involved in this study: approximately 1,100 cases of VTE, 4,000 cases of ischemic stroke, 900 cases of hemorrhagic stroke, and 5,100 controls. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page phs000200 WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study phs000200.   Study Weblinks:   WHI NHLBI Women's Health Initiative    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001237.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001237.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001237.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001237.v2.p1.c2	2026	phs001237.v2.p1.c2			/programs/topmed/projects/WHI_HMB-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Women's Health Initiative (WHI)							WHI			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is Whole Genome Sequencing data from the TOPMed participation of the Women's Health Initiative. Approximately 11,100 subjects were involved in this study: approximately 1,100 cases of VTE, 4,000 cases of ischemic stroke, 900 cases of hemorrhagic stroke, and 5,100 controls. Summary level phenotypes for the WHI Cohort study participants can be viewed at the top-level study page phs000200 WHI Cohort. Individual level phenotype data and molecular data for all WHI top-level study and substudies are available by requesting Authorized Access to the WHI Cohort study phs000200.   Study Weblinks:   WHI NHLBI Women's Health Initiative    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001237.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001237.v2.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001237.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001238.v2.p1.c1	3462	phs001238.v2.p1.c1			/programs/parent/projects/GENOA_DS-ASC-RF-NPU_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Genetic Epidemiology Network of Arteriopathy (GENOA)							GENOA			The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four networks in the NHLBI Family-Blood Pressure Program (FBPP). GENOA's long-term objective is to elucidate the genetics of target organ complications of hypertension, including both atherosclerotic and arteriolosclerotic complications involving the heart, brain, kidneys, and peripheral arteries. The longitudinal GENOA Study recruited European-American and African-American sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. All other members of the sibship were invited to participate regardless of their hypertension status. Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis of hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic blood pressure  140 mm Hg or diastolic blood pressure  90 mm Hg based on the second and third readings at the time of their clinic visit. The Family Blood Pressure Program (FBPP), GENOA's parent program, is an unprecedented collaboration to identify genes influencing blood pressure (BP) levels, hypertension, and its target-organ damage. This program has conducted over 21,000 physical examinations, assembled a shared database of several hundred BP and hypertension-related phenotypic measurements, completed genome-wide linkage analyses for BP, hypertension, and hypertension associated risk factors and complications, and published over 130 manuscripts on program findings. The FBPP emerged from what was initially funded as four independent networks of investigators (HyperGEN, GenNet, SAPPHIRe and GENOA) competing to identify genetic determinants of hypertension in multiple ethnic groups. Realizing the greater likelihood of success through collaboration, the investigators created a single confederation with program-wide and network-specific goals.   Study Weblinks:   FBPP STAMPEED    Study Design:       Prospective Longitudinal Cohort    Study Type:  Sibling Cohort   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001238.v2.p1 on 2021-03-25 and may not include exact formatting or images.	phs001238.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001238.v2.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001252.v1.p1.c1	2746	phs001252.v1.p1.c1			/programs/parent/projects/ECLIPSE_DS-COPD-RD_	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)							ECLIPSE			ECLIPSE was a longitudinal observational study of 2164 COPD subjects and a smaller number of smoking controls (337) and nonsmoking controls (245) followed regularly for three years, with three chest CT scans (at baseline, one year, and three years) (Vestbo, European Respiratory Journal 2008; 31: 869). Inclusion criteria included age 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases) or normal spirometry with post-bronchodilator FEV1 >85% predicted and FEV1/FVC>0.7 (controls). Study visits were performed at enrollment, three months, and every six months thereafter with spirometry, questionnaires, and other clinical evaluations. The ECLIPSE CT scans have been analyzed with the VIDA software for emphysema and airway phenotypes. ECLIPSE has provided key insights into the clinical epidemiology of COPD, including COPD exacerbations (Hurst, NEJM 2010; 363: 1128) and lung function decline in COPD (Vestbo, NEJM 2011; 365: 1184). ECLIPSE has been used in a number of genetic studies of COPD susceptibility and protein biomarkers(Faner, Thorax 2014; 69: 666). Genome-wide gene expression microarray data are available in 147 induced sputum samples from COPD subjects and 248 peripheral blood samples from COPD and control subjects.   Study Weblinks:   ECLIPSE    Study Design:       Case-Control    Study Type:  Case-Control Longitudinal Cohort Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001252.v1.p1 on 2021-03-25 and may not include exact formatting or images.	phs001252.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001252.v1.p1		Program: Parent	Data Type: Clinical Phenotype	Study Registration: dbGaP						
phs001293.v2.p1.c1	1771	phs001293.v2.p1.c1			/programs/topmed/projects/HyperGEN_GRU-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy							HyperGEN			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Hypertension Genetic Epidemiology Network Study (HyperGEN) - Genetics of Left Ventricular (LV) Hypertrophy is a familial study aimed to understand genetic risk factors for LV hypertrophy by conducting genetic studies of continuous traits from echocardiography exams. The originating HyperGEN study aimed to understand genetic risk factors for hypertension. Data from detailed clinical exams as well as genotyping data for linkage studies, candidate gene studies and GWAS have been collected and is shared between HyperGEN and the ancillary HyperGEN - Genetics of LV Hypertrophy study.   Study Design:       Family/Twin/Trios    Study Type:  Family     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001293.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001293.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001293.v2.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001293.v2.p1.c2	329	phs001293.v2.p1.c2			/programs/topmed/projects/HyperGEN_DS-CVD-IRB-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy							HyperGEN			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Hypertension Genetic Epidemiology Network Study (HyperGEN) - Genetics of Left Ventricular (LV) Hypertrophy is a familial study aimed to understand genetic risk factors for LV hypertrophy by conducting genetic studies of continuous traits from echocardiography exams. The originating HyperGEN study aimed to understand genetic risk factors for hypertension. Data from detailed clinical exams as well as genotyping data for linkage studies, candidate gene studies and GWAS have been collected and is shared between HyperGEN and the ancillary HyperGEN - Genetics of LV Hypertrophy study.   Study Design:       Family/Twin/Trios    Study Type:  Family     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001293.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001293.v2.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001293.v2.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001345.v2.p1.c1	1266	phs001345.v2.p1.c1			/programs/topmed/projects/GENOA_DS-ASC-RF-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetic Epidemiology Network of Arteriopathy (GENOA)							GENOA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four networks in the NHLBI Family-Blood Pressure Program (FBPP). GENOA's long-term objective is to elucidate the genetics of target organ complications of hypertension, including both atherosclerotic and arteriolosclerotic complications involving the heart, brain, kidneys, and peripheral arteries. The longitudinal GENOA Study recruited European-American and African-American sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. All other members of the sibship were invited to participate regardless of their hypertension status. Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis of hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic blood pressure  140 mm Hg or diastolic blood pressure  90 mm Hg based on the second and third readings at the time of their clinic visit. Only participants of the African-American Cohort were sequenced through TOPMed. The Family Blood Pressure Program (FBPP), GENOA's parent program, is an unprecedented collaboration to identify genes influencing blood pressure (BP) levels, hypertension, and its target-organ damage. This program has conducted over 21,000 physical examinations, assembled a shared database of several hundred BP and hypertension-related phenotypic measurements, completed genome-wide linkage analyses for BP, hypertension, and hypertension associated risk factors and complications, and published over 130 manuscripts on program findings. The FBPP emerged from what was initially funded as four independent networks of investigators (HyperGEN, GenNet, SAPPHIRe and GENOA) competing to identify genetic determinants of hypertension in multiple ethnic groups. Realizing the greater likelihood of success through collaboration, the investigators created a single confederation with program-wide and network-specific goals. Comprehensive phenotypic data for GENOA study participants are available through dbGaP phs001238.   Study Weblinks:   FBPP STAMPEED    Study Design:       Family/Twin/Trios    Study Type:  Cohort Sibling Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001345.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001345.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001345.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001359.v2.p1.c1	1063	phs001359.v2.p1.c1			/programs/topmed/projects/GOLDN_DS-CVD-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: GOLDN Epigenetic Determinants of Lipid Response to Dietary Fat and Fenofibrate							GOLDN			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The GOLDN study was initiated to assess how genetic factors interact with environmental (diet and drug) interventions to influence blood levels of triglycerides and other atherogenic lipid species and inflammation markers (registered at clinicaltrials.gov, number NCT00083369). The study recruited Caucasian participants primarily from three-generational pedigrees from two NHLBI Family Heart Study (FHS) field centers (Minneapolis, MN and Salt Lake City, UT). Only families with at least two siblings were recruited and only participants who did not take lipid-lowering agents (pharmaceuticals or nutraceuticals) for at least 4 weeks prior to the initial visit were included. The diet intervention followed the protocol of Patsch et al. (1992). The whipping cream (83% fat) meal had 700 Calories/m2 body surface area (2.93 mJ/m2 body surface area): 3% of calories were derived from protein (instant nonfat dry milk) and 14% from carbohydrate (sugar). The ratio of polyunsaturated to saturated fat was 0.06 and the cholesterol content of the average meal was 240 mg. The mixture was blended with ice and flavorings. Blood samples were drawn immediately before (fasting) and at 3.5 and 6 hours after consuming the high-fat meal. The diet intervention was administered at baseline as well as after a 3-week treatment with 160 mg micronized fenofibrate. Participants were given the option to complete one or both (diet and drug) interventions. Of all participants, 1079 had phenotypic data and provided appropriate consent, and underwent whole genome sequencing through the Trans-Omics for Precision Medicine (TOPMed) program. Comprehensive phenotypic and pedigree data for GOLDN study participants are available through dbGaP phs000741.   Study Weblinks:   GOLDN    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001359.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001359.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001359.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001368.v3.p2.c1	4737	phs001368.v3.p2.c1			/programs/topmed/projects/CHS_HMB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Project: Cardiovascular Health Study							CHS_HMB-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001368.v3.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001368.v3.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001368.v3.p2.c2	130	phs001368.v3.p2.c2			/programs/topmed/projects/CHS_HMB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Project: Cardiovascular Health Study							CHS_HMB-NPU-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001368.v3.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001368.v3.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001368.v3.p2.c4	3	phs001368.v3.p2.c4			/programs/topmed/projects/CHS_DS-CVD-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Project: Cardiovascular Health Study							CHS_DS-CVD-NPU-MDS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Participants from the Cardiovascular Health Study (CHS), a large population-based longitudinal cohort study (phs000287), have been included in the TOPMed project. Whole genome sequencing will be performed to contribute to multiple analyses, including cardiovascular disease risk factors, subclinical disease measures, the occurrence of myocardial infarction (MI) and stroke, and analyses of venous thromboembolism (VTE). Study Weblinks: CHS-NHLBI Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001368.v3.p2.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001368.v3.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001387.v2.p1.c3	2329	phs001387.v2.p1.c3			/programs/topmed/projects/THRV_DS-CVD-IRB-COL-NPU-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Rare Variants for Hypertension in Taiwan Chinese (THRV)							THRV			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The THRV-TOPMed study consists of three cohorts: The SAPPHIRe Family cohort (N=1,271), TSGH (Tri-Service General Hospital, a hospital-based cohort, N=160), and TCVGH (Taichung Veterans General Hospital, another hospital-based cohort, N=922), all based in Taiwan. 1,271 subjects were previously recruited as part of the NHLBI-sponsored SAPPHIRe Network (which is part of the Family Blood Pressure Program, FBPP). The SAPPHIRe families were recruited to have two or more hypertensive sibs, some families also with one normotensive/hypotensive sib. The two Hospital-based cohorts (TSGH and TCVGH) both recruited unrelated subjects with different recruitment criteria (matched with SAPPHIRe subjects for age, sex, and BMI category).   Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001387.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001387.v2.p1.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001387.v2.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001395.v1.p1.c1	1290	phs001395.v1.p1.c1			/programs/topmed/projects/HCHS-SOL_HMB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Hispanic Community Health Study/Study of Latinos (HCHS/SOL)							HCHS-SOL			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This study contains whole genome sequence data. A case-control sample of individuals from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a multicenter prospective cohort study of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American background (phs000810), was selected for whole genome sequencing, including participants with a history of physician-diagnosed asthma and asthma-free participants.   Study Weblinks:   Hispanic Community Health Study / Study of Latinos NHLBI Trans-Omics for Precision Medicine Whole Genome Sequencing Program    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001395.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001395.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001395.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001395.v1.p1.c2	6853	phs001395.v1.p1.c2			/programs/topmed/projects/HCHS-SOL_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Hispanic Community Health Study/Study of Latinos (HCHS/SOL)							HCHS-SOL			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This study contains whole genome sequence data. A case-control sample of individuals from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a multicenter prospective cohort study of 16,415 persons of Cuban, Dominican, Mexican, Puerto Rican, Central American, and South American background (phs000810), was selected for whole genome sequencing, including participants with a history of physician-diagnosed asthma and asthma-free participants.   Study Weblinks:   Hispanic Community Health Study / Study of Latinos NHLBI Trans-Omics for Precision Medicine Whole Genome Sequencing Program    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001395.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001395.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001395.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001402.v2.p1.c1	1369	phs001402.v2.p1.c1			/programs/topmed/projects/Mayo_VTE_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Whole Genome Sequencing of Venous Thromboembolism (WGS of VTE)							Mayo_VTE			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This study consists of 338 VTE cases from an inception cohort of Olmsted County, MN residents (OC) with a first lifetime objectively-diagnosed idiopathic VTE during the 40-year study period, 1966-2005. All living study subjects were invited to provide a whole blood sample at the Mayo Clinical Research Unit for leukocyte genomic DNA and plasma collection. For living study subjects who did not provide a blood sample, we retrieved any leftover blood (""waste"" blood) from samples collected as part of routine clinical diagnostic testing and used this to extract DNA after obtaining patient consent. For deceased cases, with IRB approval, we extracted DNA from any available stored tissue within the Mayo Tissue Archive. This ""tissue"" DNA has been successfully genotyped in prior studies. Three trained and experienced study nurse abstractors reviewed the complete medical records in the community of all potential cases. Note: WGS sample IDs for the previous GENEVA study cases (phs000289) are included in this dataset. The phenotypes for the GENEVA study are located under the above phs number.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001402.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001402.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001402.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001412.v3.p1.c1	400	phs001412.v3.p1.c1			/programs/topmed/projects/AACAC_HMB-IRB-COL-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC)							AACAC_HMB-IRB-COL-NPU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Diabetes Heart Study (DHS) is a family-based study enriched for type 2 diabetes (T2D). The cohort included 1443 European American and African American participants from 564 families with multiple cases of type 2 diabetes (Bowden et al., 2010. Review of Diabetic Studies 7:188-201. PMID: 21409311). The cohort was recruited between 1998 and 2006. Participants were extensively phenotyped for measures of subclinical CVD and other known CVD risk factors. Primary outcomes were quantified burden of vascular calcified plaque in the coronary artery, carotid artery, and abdominal aorta all determined from non-contrast computed tomography scans. Study Design:     Cross-Sectional Study Type:CohortCross-Sectional dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001412.v3.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001412.v3.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001412.v3.p1.c2	3	phs001412.v3.p1.c2			/programs/topmed/projects/AACAC_DS-DHD-IRB-COL-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Diabetes Heart Study (DHS) African American Coronary Artery Calcification (AA CAC)							AACAC_DS-DHD-IRB-COL-NPU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Diabetes Heart Study (DHS) is a family-based study enriched for type 2 diabetes (T2D). The cohort included 1443 European American and African American participants from 564 families with multiple cases of type 2 diabetes (Bowden et al., 2010. Review of Diabetic Studies 7:188-201. PMID: 21409311). The cohort was recruited between 1998 and 2006. Participants were extensively phenotyped for measures of subclinical CVD and other known CVD risk factors. Primary outcomes were quantified burden of vascular calcified plaque in the coronary artery, carotid artery, and abdominal aorta all determined from non-contrast computed tomography scans. Study Design:     Cross-Sectional Study Type:CohortCross-Sectional dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001412.v3.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001412.v3.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001416.v3.p1.c1	7058	phs001416.v3.p1.c1			/programs/topmed/projects/MESA_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: MESA and MESA Family AA-CAC (AACAC)							MESA_HMB			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry phs000209. MESA Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. Study Weblinks: MESA Study Design:     Prospective Longitudinal Cohort Study Type:FamilyLongitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001416.v3.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001416.v3.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001416.v3.p1.c2	820	phs001416.v3.p1.c2			/programs/topmed/projects/MESA_HMB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: MESA and MESA Family AA-CAC (AACAC)							MESA_HMB-NPU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. Comprehensive phenotypic and pedigree data for MESA study participants are available through dbGaP entry phs000209. MESA Participants were recruited from six field centers across the United States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern University and University of California - Los Angeles. Each participant received an extensive physical exam and determination of coronary calcification, ventricular mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures and risk factors at follow-up visits allows study of the progression of disease. Blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted and lymphocytes cryopreserved (for possible immortalization) for study of candidate genes and possibly, genome-wide scanning, expression, and other genetic techniques. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. In addition to the six Field Centers, MESA involves a Coordinating Center, a Central Laboratory, and Central Reading Centers for Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, and Electrocardiography (ECG). Protocol development, staff training, and pilot testing were performed in the first 18 months of the study. The first examination took place over two years, from July 2000 - July 2002. It was followed by five examination periods that were 17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical morbidity and mortality. MESA Family The general goal of the MESA Family Study, an ancillary study to MESA funded by a grant from NHLBI, is to apply modern genetic analysis and genotyping methodologies to delineate the genetic determinants of early atherosclerosis. This is being accomplished by utilizing all the current organizational structures of the Multi-Ethnic Study of Atherosclerosis (MESA) and Genetic Centers at Cedars-Sinai Medical Center and University of Virginia. In the MESA Family Study, the goal is to locate and identify genes contributing to the genetic risk for cardiovascular disease (CVD), by looking at the early changes of atherosclerosis within families (mainly siblings). 2128 individuals from 594 families, yielding 3,026 sibpairs divided between African Americans and Hispanic-Americans, were recruited by utilizing the existing framework of MESA. MESA Family studied siblings of index subjects from the MESA study and from new sibpair families (with the same demographic characteristics) and is determining the extent of genetic contribution to the variation in coronary calcium (obtained via CT Scan) and carotid artery wall thickness (B-mode ultrasound) in the two largest non-majority U.S. populations. In a small proportion of subjects, parents of MESA index subjects participating in MESA Family were studied but only to have blood drawn for genotyping. The MESA Family cohort was recruited from the six MESA Field Centers. MESA Family participants underwent the same examination as MESA participants during May 2004 - May 2007. DNA was extracted and lymphocytes immortalized for study of candidate genes, genome-wide linkage scanning, and analyzed for linkage with these subclinical cardiovascular traits. While linkage analysis is the primary approach being used, an additional aspect of the MESA Family Study takes advantage of the existing MESA study population for testing a variety of candidate genes for association with the same subclinical traits. Genotyping and data analysis will occur throughout the study. Study Weblinks: MESA Study Design:     Prospective Longitudinal Cohort Study Type:FamilyLongitudinal dbGaP estimated ancestry using GRAF-popSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-07-24 and may not include exact formatting or images."	phs001416.v3.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001416.v3.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001434.v1.p1.c1	65	phs001434.v1.p1.c1			/programs/topmed/projects/miRhythm_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Defining the time-dependent genetic and transcriptomic responses to cardiac injury among patients with arrhythmias							miRhythm			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The UMMS miRhythm Study is an ongoing study of adult patients undergoing an elective electrophysiology study or arrhythmia ablation procedure for a supraventricular or ventricular arrhythmia, including atrial fibrillation (AF). Atrial fibrillation is a major clinical and public health problem that is related to atrial pathologic remodeling. Few tools are available to quantify the activity or extent of this remodeling, rendering it difficult to identify individuals at risk for AF. Previous studies have suggested an important role for miRNA in cardiovascular disease through gene expression regulation, making this a promising avenue for studying AF mechanisms. The aim of the study is to determine the time-dependent changes to key circulating miRNAs in a model of planned atrial injury and remodeling via ablation. Such knowledge might provide additional insight into the biology and activity of the acute atrial injury response, and furthermore, inform new targets for development of preventative interventions or allow for better AF risk stratification. To assess pathways regulating atrial pathological remodeling, patient blood samples are collected prior to their ablation procedures and also at a regularly scheduled 1-month follow-up appointment. Plasma expression of miRNA is measured using high-throughput quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), providing novel insights into the regulatory processes underlying AF, as well as acute atrial injury in vivo. Additionally, data collected from whole-genome sequencing (WGS) is used to supplement miRNA analyses and further explore new relations between genes and abnormal heart rhythm.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001434.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001434.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001434.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001435.v1.p1.c1	120	phs001435.v1.p1.c1			/programs/topmed/projects/AustralianFamilialAF_HMB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Australian Familial Atrial Fibrillation Study							AustralianFamilialAF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. In the Australian Familial AF Study, a cohort of probands with familial AF was recruited for genetics studies at the Victor Chang Cardiac Research Institute. Familial AF cases were identified from in-patient and out-patient populations at St. Vincent's Hospital and by referral from collaborating physicians throughout Australia. Study subjects underwent clinical evaluation with history, ECG and echocardiogram, and informed consent was obtained from all participants. 151 probands aged <66 years at the time of diagnosis were included in this analysis. The control cohort was comprised of age- and sex-matched individuals (n=151) who had no history of cardiovascular disease. In the current TOPMed study, we have performed whole genome sequencing in European Ancestry cases with early-onset atrial fibrillation (defined as atrial fibrillation onset prior to 61 years).   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001435.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001435.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001435.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001466.v1.p1.c1	740	phs001466.v1.p1.c1			/programs/topmed/projects/pharmHU_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU)							pharmHU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS) within circulating erythrocytes resulting in hemolytic anemia, vascular occlusion, and end organ damage due to alterations in the shape and deformability of the cell membrane. The disease is inherited in an autosomal recessive pattern, and is most commonly caused by a single nucleotide substitution in the hemoglobin subunit beta (HBB) gene located on chromosome 11. Participants in this study include children with SCD treated with hydroxyurea to pharmacologically increase fetal hemoglobin (HbF) levels and reduce disease severity. Therefore, the primary phenotype of interest in this study is the change in HbF levels in response to hydroxyurea treatment. Genetic factors have been shown to influence inter-individual variation in drug response, and identification of novel genes and variants associated with clinical outcomes in SCD will be achieved through collaboration between Baylor College of Medicine, Augusta University, Columbia University Medical Center, Emory University School of Medicine and Children's Healthcare of Atlanta, and St. Jude Children's Research Hospital. The NHLBI TOPMed Program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001466.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001466.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001466.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001466.v1.p1.c2	58	phs001466.v1.p1.c2			/programs/topmed/projects/pharmHU_DS-SCD-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU)							pharmHU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS) within circulating erythrocytes resulting in hemolytic anemia, vascular occlusion, and end organ damage due to alterations in the shape and deformability of the cell membrane. The disease is inherited in an autosomal recessive pattern, and is most commonly caused by a single nucleotide substitution in the hemoglobin subunit beta (HBB) gene located on chromosome 11. Participants in this study include children with SCD treated with hydroxyurea to pharmacologically increase fetal hemoglobin (HbF) levels and reduce disease severity. Therefore, the primary phenotype of interest in this study is the change in HbF levels in response to hydroxyurea treatment. Genetic factors have been shown to influence inter-individual variation in drug response, and identification of novel genes and variants associated with clinical outcomes in SCD will be achieved through collaboration between Baylor College of Medicine, Augusta University, Columbia University Medical Center, Emory University School of Medicine and Children's Healthcare of Atlanta, and St. Jude Children's Research Hospital. The NHLBI TOPMed Program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001466.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001466.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001466.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001466.v1.p1.c3	102	phs001466.v1.p1.c3			/programs/topmed/projects/pharmHU_DS-SCD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU)							pharmHU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin (HbS) within circulating erythrocytes resulting in hemolytic anemia, vascular occlusion, and end organ damage due to alterations in the shape and deformability of the cell membrane. The disease is inherited in an autosomal recessive pattern, and is most commonly caused by a single nucleotide substitution in the hemoglobin subunit beta (HBB) gene located on chromosome 11. Participants in this study include children with SCD treated with hydroxyurea to pharmacologically increase fetal hemoglobin (HbF) levels and reduce disease severity. Therefore, the primary phenotype of interest in this study is the change in HbF levels in response to hydroxyurea treatment. Genetic factors have been shown to influence inter-individual variation in drug response, and identification of novel genes and variants associated with clinical outcomes in SCD will be achieved through collaboration between Baylor College of Medicine, Augusta University, Columbia University Medical Center, Emory University School of Medicine and Children's Healthcare of Atlanta, and St. Jude Children's Research Hospital. The NHLBI TOPMed Program is designed to generate scientific resources to enhance understanding of fundamental biological processes that underlie heart, lung, blood and sleep disorders (HLBS). It is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001466.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001466.v1.p1.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001466.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001467.v1.p1.c1	4861	phs001467.v1.p1.c1			/programs/topmed/projects/SAPPHIRE_asthma_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)							SAPPHIRE_asthma			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Started in 2007, the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE) is one of the largest asthma cohort studies in the United States. Its overarching goal is to elucidate the genetic underpinnings of asthma and asthma medication treatment response. The cohort was recruited from a large health care system serving southeast Michigan and the Detroit metropolitan area, and the participants broadly represent the demographic and socioeconomic diversity of the region. Control participants (i.e., patients without a diagnosis with asthma) were recruited from the same health system and geographic region. By virtue of their health system enrollment, both asthma case and control patients have longitudinal clinical information which was routinely collected as part of their care. Both case and control patients underwent at detailed evaluation at the time of enrollment which included lung function testing and bronchodilator response. The SAPPHIRE cohort is a member of the Asthma Translational Genomics Collaborative (ATGC). The latter was selected for whole genome sequencing in Phase 3 of the National Heart Lung and Blood Institute's TOPMed Program. The SAPPHIRE sample selected for sequencing includes African American and/or Latino individuals with and without asthma.   Study Weblinks:   Williams Lab - SAPPHIRE    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001467.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001467.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001467.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001468.v2.p1.c1	2748	phs001468.v2.p1.c1			/programs/topmed/projects/REDS-III_Brazil_SCD_GRU-IRB-PUB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: REDS-III Brazil Sickle Cell Disease Cohort (REDS-BSCDC)							REDS-III_Brazil_SCD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Establishing a Brazilian Sickle Cell Disease Cohort and Identifying Molecular Determinants of Response to Transfusions, Genetic Determinants of Alloimmunization, and Risk Factors Associated with HIV Infection. The REDS-III Brazil SCD Cohort study focused on transfusion practices and predictors of health outcomes in patients with Sickle Cell Disease (SCD) and began in the Fall of 2013. The four primary aims of this study are: 1) Aim A - Establish a cohort of SCD patients with a comprehensive centralized electronic database of detailed clinical, laboratory and transfusion information, as well as establish a repository of blood samples to support biological studies relevant to SCD pathogenesis and transfusion complications; 2) Aim B - Characterize changes in markers of inflammation in response to transfusion by analyzing chemokine/cytokine panels in serial post transfusion specimens; 3) Aim C - Identify single nucleotide polymorphisms (SNPs) that contribute to the risk of red blood cell alloimmunization in SCD by performing a genome-wide association (GWA) study in transfused SCD patients; and, 4) Aim D - Characterize risk of HIV and HIV outcomes in the Brazilian SCD population and compare SCD outcomes among HIV sero-positive and sero-negative SCD patients. Patients are enrolled from six hospitals affiliated with the participating four REDS-III Brazil hemocenters.   Study Weblinks:   REDS-III    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001468.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001468.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001468.v2.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001472.v1.p1.c1	2465	phs001472.v1.p1.c1			/programs/topmed/projects/ECLIPSE_DS-COPD-MDS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE)							ECLIPSE			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. ECLIPSE was a longitudinal observational study of 2164 COPD subjects and a smaller number of smoking controls (337) and nonsmoking controls (245) followed regularly for three years, with three chest CT scans (at baseline, one year, and three years) (Vestbo et al., 2008, PMID:  18216052). Subjects were enrolled at clinical centers in the US, Canada, Europe, and New Zealand. Inclusion criteria included subjects ages 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases) or normal spirometry with post-bronchodilator FEV1 >85% (predicted) and FEV1/FVC>0.7 (controls). Study visits were performed at enrollment, three months, and every six months thereafter with spirometry, questionnaires, and other clinical evaluations. The ECLIPSE CT scans have been analyzed with the VIDA software for emphysema and airway phenotypes. ECLIPSE has provided key insights into the clinical epidemiology of COPD, including COPD exacerbations (Hurst, et. al., 2010, PMID:  20843247) and lung function decline in COPD (Vestbo, et. al., 2011, PMID:  21991892). ECLIPSE has been used in a number of genetic studies of COPD susceptibility and protein biomarkers (Faner, et. al., 2014, PMID:  24310110). Genome-wide gene expression microarray data are available in 147 induced sputum samples from COPD subjects and 248 peripheral blood samples from COPD and control subjects. Phenotype data for ECLIPSE subjects is available through dbGaP phs001252.   Study Weblinks:   What is ECLIPSE    Study Design:       Case-Control    Study Type:  Case-Control Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001472.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001472.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001472.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001514.v1.p1.c1	390	phs001514.v1.p1.c1			/programs/topmed/projects/Walk_PHaSST_SCD_HMB-IRB-PUB-COL-NPU-MDS-GSO	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Walk-PHaSST Sickle Cell Disease (SCD)							Walk_PHaSST_SCD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Walk-PHaSST study is a multi-center clinical trial to evaluate the effects of sildenafil on Sickle Cell Disease (SCD) population with low exercise capacity associated with an increased Doppler-estimated pulmonary artery systolic pressure (as assessed by the tricuspid regurgitant velocity (TRV)). It is a double-blind, placebo-controlled trial to assess the safety, tolerability, and efficacy of sildenafil in patients with SCD who had both an elevated TRV and decreased exercise capacity. The screening phase of the study enrolled 720 subjects and 74 of them were randomized for the clinical trial. For the screening cohort, we have collected general demographics and race/ethnicity, hemoglobin genotype, physical examination, laboratory screening, transthoracic Doppler echocardiography, and 6 minute walk test in 9 US and 1 UK site. The walk-PHaSST biorepository have banked samples from 610 of the screening subjects. A total of 592 subjects from the screening phase are included in the TOPMed program for WGS.   Study Design:       Cross-Sectional    Study Type:  Cross-Sectional Clinical Trial     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001514.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001514.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001514.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001514.v1.p1.c2	50	phs001514.v1.p1.c2			/programs/topmed/projects/Walk_PHaSST_SCD_DS-SCD-IRB-PUB-COL-NPU-MDS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Walk-PHaSST Sickle Cell Disease (SCD)							Walk_PHaSST_SCD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Walk-PHaSST study is a multi-center clinical trial to evaluate the effects of sildenafil on Sickle Cell Disease (SCD) population with low exercise capacity associated with an increased Doppler-estimated pulmonary artery systolic pressure (as assessed by the tricuspid regurgitant velocity (TRV)). It is a double-blind, placebo-controlled trial to assess the safety, tolerability, and efficacy of sildenafil in patients with SCD who had both an elevated TRV and decreased exercise capacity. The screening phase of the study enrolled 720 subjects and 74 of them were randomized for the clinical trial. For the screening cohort, we have collected general demographics and race/ethnicity, hemoglobin genotype, physical examination, laboratory screening, transthoracic Doppler echocardiography, and 6 minute walk test in 9 US and 1 UK site. The walk-PHaSST biorepository have banked samples from 610 of the screening subjects. A total of 592 subjects from the screening phase are included in the TOPMed program for WGS.   Study Design:       Cross-Sectional    Study Type:  Cross-Sectional Clinical Trial     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001514.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001514.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001514.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001515.v1.p1.c1	5132	phs001515.v1.p1.c1			/programs/topmed/projects/MLOF_HMB-PUB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: MyLifeOurFuture (MLOF) Research Repository of patients with hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency)							MLOF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Hemophilia A and B are X-linked bleeding disorders resulting from a deficiency in coagulation factor VIII (FVIII) or factor IX (FIX), respectively. Hemophilia affects approximately 1/5000 male births worldwide, and results in premature death and disability due to bleeding if coagulation factor replacement therapy is not used effectively. Hemophilia is clinically categorized by coagulation factor activity levels and ranges in severity from mild (6% to 30%) to moderate (1-5%) to severe (<1%). Many female ""carriers"" of hemophilia also have decreased factor activity and morbidity from bleeding. Hemophilia A and B are almost always caused by identifiable mutations in the F8 and F9 genes, respectively, and these mutations are found throughout the structural genes. Although the hemophilias are monogenic disorders, there are wide variations in disease severity and therapeutic outcomes which are not readily explained by the disease causing mutations alone. The My Life Our Future (MLOF) project (www.mylifeourfuture.org) is a national resource developed by a partnership of BloodworksNW (BWNW, formerly the Puget Sound Blood Center), the American Thrombosis and Hemostasis Network (ATHN), the National Hemophilia Foundation (NHF) and Bioverativ, to provide free F8 and F9 gene variant analysis to patients with hemophilia A or B, and to establish a research repository of DNA sequence, DNA, RNA, buffy coat, serum and plasma. The sequence analysis and serum samples are linked to a phenotypic database hosted by ATHN, with samples submitted and clinical data entered at ~100 hemophilia treatment centers (HTCs) nationwide. (See ATHN Research Report Brief in the resource center at www.athn.org). MLOF has become the largest hemophilia genetic project worldwide. The roles of the MLOF partners are: BWNW, to serve as the central laboratory for the project and house the research repository; ATHN, to support and provide the administrative link with HTCs, to facilitate the collection of accurate phenotypic data, to conduct research review and approval for use of the repository and with BWNW to provide samples and data for research projects; NHF, to provide consumer education and facilitate consumer input into the project; and Bioverativ, to provide financial support and scientific input. The project is governed by a Steering Committee consisting of one representative from each organization. Subject samples chosen from the MLOF parent study for TOPMed and WGS were drawn from those who gave (or parents gave) informed consent for the Research Repository and included patients of all severities and type, but with an emphasis on those with severe hemophilia and others at increased risk of neutralizing antibody (inhibitor) formation and who had samples in the Research Repository (plasma, serum, RNA) for potential additional -omic studies. Also included were samples from subjects where a likely causative variant for hemophilia was not found in the F8 or F9 coding region, intron-exon boundaries or immediate upstream and downstream regions. Since hemophilia is an X-linked disorder, the majority of subjects are male. Racial distribution is similar to the overall population distribution.   Study Weblinks:   mylifeourfuture    Study Design:       Cross-Sectional    Study Type:  Cross-Sectional     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001515.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001515.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001515.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001542.v1.p1.c2	1024	phs001542.v1.p1.c2			/programs/topmed/projects/GALA_DS-LD-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetics of Asthma in Latino Americans (GALA)							GALA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. A Case pharmacogenetic study of bronchodilator drug response (Albuterol) among racially admixed Latino children with asthma between the ages of 8-40. Lung function testing was performed using the KoKo PFT system and each participant was administered albuterol dependent on age. Participants under 16 years of age, were administered 2 puffs of albuterol from a standard metered dose inhaler and 4 puffs for participants over 16 years old. The overall goal is to identify genetic factors which are predictive of drug response in children with asthma. The principal tools include a questionnaire and biological specimen collection. Participants with asthma have physician-diagnosed asthma, symptoms and medications.   Study Weblinks:   Asthma Collaboratory    Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001542.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001542.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001542.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001543.v1.p1.c1	350	phs001543.v1.p1.c1			/programs/topmed/projects/AFLMU_HMB-IRB-PUB-COL-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: AF Biobank LMU in the context of the MED Biobank LMU							AFLMU			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Atrial Fibrillation Biobank Ludwig Maximilian University (AFLMU) Study contributes to the spectrum of disease by adding carefully characterized patients with atrial fibrillation. Atrial fibrillation, one of the most common human arrhythmias confers major morbidity, mortality and health care cost, and has been demonstrated to be caused and influenced by genetic and -omics factors. Particularly, AFLMU enrolled patients with an early onset of atrial fibrillation to increase the genetic burden on disease pathophysiology. All patients were recruited applying standardized protocols to maintain homogeneity in data and DNA quality.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001543.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001543.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001543.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001544.v1.p1.c1	121	phs001544.v1.p1.c1			/programs/topmed/projects/MPP_HMB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Malmo Preventive Project (MPP)							MPP			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Malm Preventive Project (MPP) was a community-based disease prevention program including 33,346 inhabitants from the city of Malm in Southern Sweden. Complete birth cohorts between 1921-1949 were invited, and the participation rate was 71%. Participants underwent screening between 1974 to 1992 for cardiovascular risk factors, alcohol abuse, and breast cancer. Between 2002-2006, surviving participants were invited to a reexamination which included blood sampling from which DNA has been extracted. Subjects with prevalent or incident AF were identified from national registers as previously described, and cases with DNA were then matched in a 1:1 fashion to controls with DNA from the same cohort by sex, age (1 year), and date of baseline exam (1 year). Also, controls required a follow-up exceeding that of the corresponding AF case.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001544.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001544.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001544.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001545.v1.p1.c1	475	phs001545.v1.p1.c1			/programs/topmed/projects/INSPIRE_AF_DS-MULTIPLE_DISEASES-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Intermountain INSPIRE Registry							INSPIRE_AF_DS-MULTIPLE			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The INtermountain Healthcare Biological Samples Collection Project and Investigational REgistry for the On-going Study of Disease Origin, Progression and Treatment (Intermountain INSPIRE Registry) purpose is to collect biological samples, clinical information and laboratory data from Intermountain Healthcare patients. The registry originally collected samples in patients undergoing a coronary angiography as part of the Intermountain Heart Collaborative Study. It has been expanded to collect samples in patients diagnosed with all types of medical conditions, and patients from the general population including those who have not been diagnosed with health related issues. Just over 25,000 individuals have provided samples as part of this registry. The registry enables researchers to develop a comprehensive collection of information that may help in disease management, including determining best medical practices for predicting, preventing and treating medical conditions.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001545.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001545.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001545.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001546.v1.p1.c1	6	phs001546.v1.p1.c1			/programs/topmed/projects/DECAF_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Determining the association of chromosomal variants with non-PV triggers and ablation-outcome in AF (DECAF)							DECAF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The DECAF trial was conducted at the Texas Cardiac Arrhythmia Institute (TCAI) in 2013 in collaboration with the University of Texas at Austin. Four hundred consecutive AF patients undergoing catheter ablation were enrolled. All participants provided voluntary informed consents. Blood samples were collected before the ablation procedure and labeled with anonymous patient identifier. The researchers at UT Austin responsible for DNA extraction and genetic analysis were blinded about the clinical characteristics and identification of the study participants. AF cases included adults >18 years of age from both sex and all AF types.   Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001546.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001546.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001546.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001547.v1.p1.c1	90	phs001547.v1.p1.c1			/programs/topmed/projects/GENAF_HMB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: The GENetics in Atrial Fibrillation (GENAF) Study							GENAF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Genetics in AF (GENAF) study enrolled individuals with early-onset lone AF before age 50 in Norway between 2009 and 2016. Early-onset was defined as diagnosis of AF before age 50. Lone AF was defined as AF in the absence of clinical or echocardiographic findings of cardiovascular disease, hypertension, metabolic or pulmonary disease. AF was documented in ECG. All participants underwent clinical examination, including ECG, echocardiography, and blood draw, from which DNA has been extracted. The study conforms to the principles of the Declaration of Helsinki and was approved by the Regional Ethics Committee (REK) in Norway (Protocol reference number: 2009/2224-5). All included patients gave written informed consent.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001547.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001547.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001547.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001598.v1.p1.c1	290	phs001598.v1.p1.c1			/programs/topmed/projects/JHU_AF_HMB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: The Johns Hopkins University School of Medicine Atrial Fibrillation Genetics Study							JHU_AF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is the primary cause of many hospital admissions, and is associated with significant secondary morbidity by increasing the risk of stroke, heart failure, and all-cause mortality. The incidence of AF is on the rise, and it is projected that by the year 2050 more than 10 million patients will be affected by AF in the United States alone. Anti-arrhythmic medications have limited success in maintaining sinus rhythm, are associated with side effects, and appear ineffective at reducing mortality compared to a strategy of rate control and anticoagulation. Given the significant morbidity associated with this common arrhythmia, surgical and catheter ablation techniques have been developed to treat AF. However, despite the incorporation of various strategies for ablation, long-term recurrence rates of AF remain higher than 25 percent after ablation. Current techniques for catheter ablation of AF include pulmonary vein isolation and complex fractionated atrial electrogram (CFAE) ablation. However, the contribution of each strategy to long-term procedural success and the relative importance of each strategy for different patients remain unknown. Recent advances in cardiac imaging have allowed detailed analysis of left atrial myocardial anatomy. Parallel advances in molecular genetics have identified several candidate genes involved in familial and non-familial AF. However, the pathophysiology of AF generation and maintenance, and the potential contribution of such genetic or anatomic substrates for patient selection, and for target identification during catheter ablation have not yet been examined. Advances in molecular genetics and imaging, coupled with techniques for endocardial and epicardial mapping in the electrophysiology laboratory present an opportunity to significantly improve our understanding of (1) The relation of paroxysmal versus persistent AF with (a) structural left atrial changes (left/right atrial scar, wall thinning, pulmonary vein anomalies, and coronary sinus dilation) and with (b) candidate genetic variants. (2) The relation of candidate genetic variants with (a) structural left atrial changes and with (b) electrophysiologic properties (atrial effective refractory period (AERP) inhomogeneity, voltage abnormalities, trigger burden and location, C FAE extent and location), (3) The relation of structural left atrial changes with (a) CFAE location as targets for catheter ablation and with (b) reversible conduction block/myocardial injury after pulmonary vein isolation, and (4) Individualized endocardial targets for AF ablation based on candidate genes and anatomic substrates. The proposed study will improve our understanding of the underlying pathophysiology of AF, and may improve current techniques for treatment of this important arrhythmia.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001598.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001598.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001598.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001599.v1.p1.c1	943	phs001599.v1.p1.c1			/programs/topmed/projects/BostonBrazil_SCD_HMB-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Boston-Brazil Sickle Cell Disease (SCD) Cohort							BostonBrazil_SCD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.This study involves sequencing of patients with a diagnosis of sickle cell disease from Brazil. No exclusionary criteria were employed and any eligible patients that consented to this study were recruited. Study Design:     Prospective Longitudinal Cohort Study Type:Cohort dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-07-13 and may not include exact formatting or images."	phs001599.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001599.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001600.v2.p2.c1	1271	phs001600.v2.p2.c1			/programs/topmed/projects/CATHGEN_DS-CVD-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Early-onset Atrial Fibrillation in the CATHeterization GENetics (CATHGEN) Cohort							CATHGEN			'This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ''TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4'' and ''TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4''. Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The CATHeterization GENetics (CATHGEN) biorepository collected biospecimens and clinical data on individuals age 18 undergoing cardiac catheterization for concern of ischemic heart disease at a single center (Duke University Medical Center) from 2000-2010; a total of N=9334 individuals were collected. Samples were matched at the individual level to clinical data collected at the time of catheterization and stored in the Duke Databank for Cardiovascular Diseases (DDCD). Clinical data included subject demographics, cardiometabolic risk factors, cardiac history including symptoms, age-of-onset of cardiovascular diseases, coronary anatomy and cardiac function at catheterization, laboratory data, and yearly follow-up for hospitalizations, vital status, medication use and lifestyle factors. AF cases were defined as individuals who had ever had AF based on any ECG available at Duke University or ICD-9 code for AF used for inpatient or outpatient billing. Study Design:     Case Set Study Type:Case Set dbGaP estimated ancestry using GRAF-pop NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-03-29 and may not include exact formatting or images.'	phs001600.v2.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001600.v2.p2		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001601.v1.p1.c1	2235	phs001601.v1.p1.c1			/programs/topmed/projects/CCDG_PMBB_AF_HMB-IRB-PUB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: Penn Medicine BioBank Early Onset Atrial Fibrillation Study							CCDG_PMBB_AF			This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   'TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2'  and 'TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4'.  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Cases with early-onset atrial fibrillation were selected from the Penn Biobank based on an age of atrial fibrillation onset prior to 61 years of age, and in the absence of a myocardial infarction, heart failure or severe valvular disease.   Study Design:       Case Set    Study Type:  Case Set        dbGaP estimated ancestry using     GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2021-07-07 and may not include exact formatting or images.	phs001601.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001601.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001602.v1.p1.c1	7	phs001602.v1.p1.c1			/programs/topmed/projects/ChildrensHS_GAP_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Children's Health Study (CHS) Integrative Genetic Approaches to Gene-Air Pollution Interactions in Asthma (GAP)							ChildrensHS_GAP			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Integrative Genetic Approaches to Gene-Air Pollution Interactions in Asthma (GAP) study was proposed to use an innovative genetics approach in mice and humans to identify novel variants that interact with traffic-related pollutant exposures to affect lung function phenotypes and the risk of childhood asthma. The study participants were enrolled from the original southern California Children's Health Study (CHS). In the TOPMed project, seven Hispanic White participants who did not have asthma history were included in the WGS analysis.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001602.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001602.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001602.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001603.v1.p1.c1	156	phs001603.v1.p1.c1			/programs/topmed/projects/ChildrensHS_IGERA_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Children's Health Study (CHS) Integrative Genomics and Environmental Research of Asthma (IGERA)							ChildrensHS_IGERA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Integrative Genomics and Environmental Research of Asthma (IGERA) Study was proposed to collect immortalized cell lines, RNA, cDNA and DNA from 400 well-characterized subjects who participated in the southern California Children's Health Study (CHS) and to develop an accompanying database for these samples consisting of extensive phenotype, exposure, genome-wide genotype, gene expression, and methylation data. A subset of Hispanic-White participants (n=160) were included in the TOPMed project, including 77 asthma cases and 83 controls.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001603.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001603.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001603.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001604.v1.p1.c1	56	phs001604.v1.p1.c1			/programs/topmed/projects/ChildrensHS_MetaAir_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Children's Health Study (CHS) Effects of Air Pollution on the Development of Obesity in Children (Meta-AIR)							ChildrensHS_MetaAir			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Effects of Air Pollution on the Development of Obesity in Children (Meta-AIR) study was proposed to study a subset of the Children's Health Study (CHS) participants representing the extremes of long-term traffic-related air pollution exposure occurring in Southern California CHS communities. The primary aim of the Meta-AIR study was to investigate whether lifetime exposure to air pollution increases risk for obesity and metabolic dysfunction at 17-18 years of age. A total of 56 Hispanic White participants (16 asthma cases and 40 controls) were included in the TOPMed project.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001604.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001604.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001604.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001605.v1.p1.c2	292	phs001605.v1.p1.c2			/programs/topmed/projects/CHIRAH_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Chicago Initiative to Raise Asthma Health Equity (CHIRAH)							CHIRAH			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The CHIRAH project was a community based study of the factors associated with asthma morbidity in the African American population. CHIRAH evaluated the role of various variables (biologic / environmental, psychologic / behavioral, and socioeconomic) on asthma morbidity and the function of changes in these variables on asthma morbidity in a longitudinal fashion. This involved collection of a cohort based on school screening which was sampled to include similar numbers of underprivileged and non-underprivileged subjects which roughly equally represented self-classified African Americans and self-classified non-African Americans. Subjects were followed-up every 3 months of this cohort over the course of 2 years.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001605.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001605.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001605.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001606.v1.p1.c1	324	phs001606.v1.p1.c1			/programs/topmed/projects/EGCUT_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Early-onset Atrial Fibrillation in the Estonian Biobank							EGCUT			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Estonian Biobank is the population-based biobank of the Estonian Genome Centre of University of Tartu. The biobank is conducted according to the Estonian Gene Research Act and all participants have signed broad informed consent. The cohort size is currently 51,535 people from 18 years of age and up.   Study Weblinks:   EGCUT Estonian BioBank    Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001606.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001606.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001606.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001607.v2.p2.c1	234	phs001607.v2.p2.c1			/programs/topmed/projects/IPF_DS-ILD-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pulmonary Fibrosis Whole Genome Sequencing							IPF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a set of cases diagnosed with idiopathic pulmonary fibrosis, a fatal interstitial lung disease. These cases were included in the TOPMed phase three studies. The planned study will compare these cases to within-TOPMed controls for genome-wide association studies.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001607.v2.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001607.v2.p2.c2	692	phs001607.v2.p2.c2			/programs/topmed/projects/IPF_DS-LD-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pulmonary Fibrosis Whole Genome Sequencing							IPF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a set of cases diagnosed with idiopathic pulmonary fibrosis, a fatal interstitial lung disease. These cases were included in the TOPMed phase three studies. The planned study will compare these cases to within-TOPMed controls for genome-wide association studies.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001607.v2.p2.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001607.v2.p2.c3	83	phs001607.v2.p2.c3			/programs/topmed/projects/IPF_DS-PFIB-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pulmonary Fibrosis Whole Genome Sequencing							IPF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a set of cases diagnosed with idiopathic pulmonary fibrosis, a fatal interstitial lung disease. These cases were included in the TOPMed phase three studies. The planned study will compare these cases to within-TOPMed controls for genome-wide association studies.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001607.v2.p2.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001607.v2.p2.c4	282	phs001607.v2.p2.c4			/programs/topmed/projects/IPF_DS-PUL-ILD-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pulmonary Fibrosis Whole Genome Sequencing							IPF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a set of cases diagnosed with idiopathic pulmonary fibrosis, a fatal interstitial lung disease. These cases were included in the TOPMed phase three studies. The planned study will compare these cases to within-TOPMed controls for genome-wide association studies.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001607.v2.p2.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001607.v2.p2.c5	176	phs001607.v2.p2.c5			/programs/topmed/projects/IPF_HMB-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pulmonary Fibrosis Whole Genome Sequencing							IPF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. This is a set of cases diagnosed with idiopathic pulmonary fibrosis, a fatal interstitial lung disease. These cases were included in the TOPMed phase three studies. The planned study will compare these cases to within-TOPMed controls for genome-wide association studies.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2 on 2021-03-25 and may not include exact formatting or images."	phs001607.v2.p2.c5		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001607.v2.p2		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001608.v1.p1.c1	640	phs001608.v1.p1.c1			/programs/topmed/projects/OMG_SCD_DS-SCD-IRB-PUB-COL-MDS-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Outcome Modifying Genes in Sickle Cell Disease (OMG)							OMG_SCD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Sickle cell disease (SCD) is caused by homozygosity for a single mutation of the beta hemoglobin gene. Despite the constancy of this genetic abnormality, the clinical course of patients with SCD is remarkably variable. SCD can affect the function and cause the failure of multiple organ systems through the pathophysiologic processes of vaso-occlusion and hemolysis. These pathophysiological processes are complex and expected to impact multiple organ systems in a variety of ways. This study, therefore, was designed to identify genetic factors that predispose SCD patients to develop specific end-organ complications and to experience more or less severe clinical courses. We enrolled > 700 patients with Hb SS, Hb S-beta0 thalassemia and HbSC being followed primarily at three southeastern U.S. regional institutions (Duke University Medical Center, University of North Carolina Medical Center, and Emory University Medical Center). Medical information obtained included the presence or absence of specific targeted outcomes (overall disease severity as well as specific types of end organ damage). Clinical data include medical status (history, physical, examination, and laboratory results) and information regarding potentially confounding environmental factors. Limited plasma samples are available for correlative studies (e.g. of cytokine levels, coagulation activation). Targeted SNP for candidate gene analysis as well as GWAS has been performed on most samples. Whole genome sequencing has been conducted through the TOPMed Consortium. The subjects in this analysis were collected as part of a larger study, ""Outcome Modifying Genes in Sickle Cell Disease"" (OMG-SCD) aimed at identifying genetic modifiers for sickle cell disease. More information about the study can be found in Elmariah et al. (2014), PMID: 24478166. Clinical and genetic data have been used to identify genetic characteristics predisposing patients with SCD to a more or less severe overall clinical course as well as to individual organ-specific complications. It is anticipated that identification of such genetic factors will reveal new therapeutic targets individualized to specific complications of SCD, leading to improved outcomes and increased life expectancy for patients with SCD.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001608.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001608.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001608.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001612.v1.p1.c1	2866	phs001612.v1.p1.c1			/programs/topmed/projects/CARDIA_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Coronary Artery Risk Development in Young Adults (CARDIA)							CARDIA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women, aged 18-30 years, were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less, and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25) and 2015-2016 (Year 30). In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted. While the specifics of each examination have differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease, such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements, such as weight and skinfold fat, as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20.   Study Weblinks:   CARDIA: Coronary Artery Risk Development in Young Adults    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001612.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001612.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001612.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001612.v1.p1.c2	559	phs001612.v1.p1.c2			/programs/topmed/projects/CARDIA_HMB-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Coronary Artery Risk Development in Young Adults (CARDIA)							CARDIA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. CARDIA is a study examining the etiology and natural history of cardiovascular disease beginning in young adulthood. In 1985-1986, a cohort of 5115 healthy black and white men and women, aged 18-30 years, were selected to have approximately the same number of people in subgroups of age (18-24 and 25-30), sex, race, and education (high school or less, and more than high school) within each of four US Field Centers. These same participants were asked to participate in follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), 2010-2011 (Year 25) and 2015-2016 (Year 30). In addition to the follow-up examinations, participants are contacted regularly for the ascertainment of information on out-patient procedures and hospitalizations experienced between contacts. Within the past five years, 95% of the original surviving cohort has been contacted. While the specifics of each examination have differed somewhat, data have been collected on a variety of factors believed to be related to heart disease. These include conditions with clear links to heart disease, such as blood pressure, cholesterol and other lipids. Data have also been collected on physical measurements, such as weight and skinfold fat, as well as lifestyle factors such as substance use (tobacco and alcohol), dietary and exercise patterns, behavioral and psychological variables, medical and family history, and other chemistries (e.g., insulin and glucose). In addition, subclinical atherosclerosis was measured via echocardiography during Years 5, 10, and 25, computed tomography during Years 15 and 20, and carotid ultrasound during Year 20.   Study Weblinks:   CARDIA: Coronary Artery Risk Development in Young Adults    Study Design:       Prospective Longitudinal Cohort    Study Type:  Longitudinal     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001612.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001612.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001612.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001624.v1.p1.c1	1753	phs001624.v1.p1.c1			/programs/topmed/projects/BioVU_AF_HMB-GSO	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: The Vanderbilt University BioVU Atrial Fibrillation Genetics Study							BioVU_AF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. At least 2.7 million Americans are living with AFib. Individuals with early onset atrial fibrillation (AF) are included in this study of cases from the BioVU sample repository. BioVU is Vanderbilt's biobank of DNA extracted from leftover and otherwise discarded clinical blood specimens. BioVU operates as a consented biorepository; all individuals must sign the BioVU consent form in order to donate future specimens. BioVU subjects are de-identified and linked to the Synthetic Derivative enabling researchers to access genetic data/DNA material as well as dense, longitudinal electronic medical record (EMR) information.   Study Design:       Case Set    Study Type:  Case Set     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001624.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001624.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001624.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001644.v1.p1.c1	15974	phs001644.v1.p1.c1			/programs/topmed/projects/BioMe_HMB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed - NHGRI CCDG: The BioMe Biobank at Mount Sinai							BioMe			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The IPM BioMe Biobank, founded in September 2007, is an ongoing, broadly-consented electronic health record (EHR)-linked clinical care biobank that enrolls participants non-selectively from the Mount Sinai Medical Center patient population. BioMe currently comprises >42,000 participants from diverse ancestries, characterized by a broad spectrum of longitudinal biomedical traits. Participants enroll through an opt-in process and consent to be followed throughout their clinical care (past, present, and future) in real-time, allowing us to integrate their genomic information with their EHRs for discovery research and clinical care implementation. BioMe participants consent for recall, based on their genotype and/or phenotype, permitting in-depth follow-up and functional studies for selected participants at any time. Phenotypic and genomic data are stored in a secure database and made available to investigators, contingent on approval by the BioMe Governing Board. BioMe uses a ""data-broker"" system to protect confidentiality. Ancestral diversity - BioMe participants represent a broad racial, ethnic and socioeconomic diversity with a distinct and population-specific disease burden. Specifically, BioMe participants are of African (AA), Hispanic/Latino (HL), European (EA) and other/mixed ancestry (Table 1, Figure 1). BioMe participants are predominantly of African (AA, 24%), Hispanic/Latino (HL, 35%), European (EA, 32%), and other ancestry (OA, 10%) (Table 1, Figure 1). Participants who self-identify as Hispanic/Latino further report to be of Puerto Rican (39%), Dominican (23%), Central/South American (17%), Mexican (5%) or other Hispanic (16%) ancestry. More than 40% of European ancestry participants are genetically determined to be of Ashkenazi Jewish ancestry. With this broad ancestral diversity, BioMe is uniquely positioned to examine the impact of demographic and evolutionary forces that have shaped common disease risk. Phenotypes available in BioMe - BioMe has available a high-quality and validated set of fully implemented clinical phenotype data that has been culled by a multi-disciplinary team of experienced investigators, clinicians, information technologists, data-managers, and programmers who apply advanced medical informatics and data mining tools to extract and harmonize EHRs. BioMe, as a cohort, offers great versatility for designing nested case-control sample-sets, particularly for studying longitudinal traits and co-morbidity in disease burden.  ** Biomedical and clinical outcomes: The BioMe Biobank is linked to Mount Sinai's system-wide Epic EHR, which captures a full spectrum of biomedical phenotypes, including clinical outcomes, covariate and exposure data from past, present and future health care encounters. As such, the BioMe Biobank has a longitudinal design as participants consent to make all of their EHR data from past (dating back as far as 2003), present and future inpatient or outpatient encounters available for research, without restriction. The median number of outpatient encounters is 21 per participant, reflecting predominant enrollment of participants with common chronic conditions from primary care facilities. ** Environmental data: The clinical and EHR information is complemented by detailed demographic and lifestyle information, including ancestry, residence history, country of origin, personal and familial medical history, education, socio-economic status, physical activity, smoking, dietary habits, alcohol intake, and body weight history, which is collected in a systematic manner by interview-based questionnaire at time of enrollment. The IPM BioMe Biobank contributed ~10,600 DNA samples for whole genome sequencing to the TOPMed program. Samples were selected for the Coronary Artery Disease (CAD) and the Chronic Obstructive Pulmonary Disease (COPD) working groups. Using a Case-Definition-Algorithm (CDA), we identified ~4,100 individuals with CAD (~50% women) and ~3,000 individuals as controls (65% women). In addition, we identified ~800 individual with COPD (62% women) and 1800 as controls (72% women). Another 600 BioMe participants with Atrial Fibrillation, all of African ancestry, were included.   Study Weblinks:   The Charles Bronfman Institute for Personalized Medicine    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001644.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001644.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001644.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001661.v2.p1.c1	5464	phs001661.v2.p1.c1			/programs/topmed/projects/GCPD-A_DS-ASTHMA-GSO	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Genetic Causes of Complex Pediatric Disorders - Asthma (GCPD-A)							GCPD-A			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia (CHOP) is focused on addressing the roles of both single nucleotide variants and structural copy number variants, and their functional impact, together with gene-environment interactions and their influence on asthma drug response.   Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001661.v2.p1 on 2021-03-25 and may not include exact formatting or images."	phs001661.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001661.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001662.v1.p1.c2	1602	phs001662.v1.p1.c2			/programs/topmed/projects/LTRC_HMB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Lung Tissue Research Consortium (LTRC)							LTRC			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Chronic obstructive pulmonary disease (COPD), a disease state characterized by airflow limitation that is not fully reversible, is the third leading cause of death in the U.S. COPD is a heterogeneous syndrome, with affected individuals demonstrating marked differences in lung structure (emphysema vs. airway disease); physiology (airflow obstruction); and other clinical features (e.g., exacerbations, co-morbid illnesses). Multiple genomic regions influencing COPD susceptibility have been identified by genome-wide association studies (GWAS), and rare coding variants can also influence risk for COPD. However, only a small percentage of the estimated heritability for COPD risk can be explained by known genetic loci. Like most complex diseases, COPD is influenced by multiple genetic determinants (each with modest individual effects). Emerging evidence supports the paradigm that complex disease genetic determinants are part of a network of interacting genes and proteins; perturbations of this network can increase disease risk. To identify this network, multiple Omics data will need to be analyzed with methods to account for nonlinear relationships and interactions between key genes and proteins. Our overall hypothesis is that integrated network analysis of genetic, transcriptomic, proteomic, and epigenetic data from biospecimens ranging from lung tissue to nasal epithelial cells to blood in highly phenotyped subjects will provide insights into COPD pathogenesis and heterogeneity. We will leverage the well-phenotyped, NHLBI-funded Lung Tissue Research Consortium (LTRC) to address these questions. We will perform multi-omics analysis in 1548 lung tissue and blood samples from the LTRC. With these multi-omics data, we will utilize a systems biology approach to understand relationships between multiple genetic determinants and multiple types of Omics data. We will begin by performing single Omics analyses in COPD vs. control lung, nasal, and blood samples. Next, we will integrate single Omics data with genetic variants identified by WGS to assist in fine mapping genetic determinants of COPD. We will then perform integrated network analysis of COPD with genetic and multiple Omics data using correlation-based, gene regulatory, and Bayesian networks. Subjects were recruited from Mayo Clinic, Universities of Colorado, Michigan, and Pittsburg, and Temple University.   Study Weblinks:   LTRC    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001662.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001662.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001662.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001682.v1.p1.c1	432	phs001682.v1.p1.c1			/programs/topmed/projects/PUSH_SCD_DS-SCD-IRB-PUB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH)							PUSH_SCD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. During Visit One, the PUSH Study will perform echocardiography on 600 children and adolescent with patients with SCD and 100 control children and adolescents at three Field Centers, namely Howard University, Children's National Medical Center and University of Michigan. Patients or their parents will be approached and asked to give informed consent. If they appear to have difficulty reading, reading of the consent will be offered. Patients or their parents not appearing to comprehend the consent will not be eligible. As a part of this visit, each participant or parent will sign informed consent, complete a Participant Contact Information Form, complete a Medical History Form, undergo physical examination with completion of a Physical Examination Form and have blood drawn. Each participant must have echocardiography performed with measurement of Tricuspid Regurgitant Jet Velocity (TRV). In addition attempts will be made 1) to perform a six-minute walk test, 2) to collect information from a recent (within six months) Transcranial Doppler Study (TCD) or to perform TCD, and 3) to perform pulmonary function tests. Study personnel will review all forms for completeness and conduct phlebotomy. Blood will be shipped to the Central Lab. Results of all procedures and tests will be transmitted to the Data Manager at Howard University. Sequencing was only done on sickle cell participants.    Study Design:       Case-Control    Study Type:  Case-Control     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001682.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001682.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001682.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001725.v1.p1.c1	640	phs001725.v1.p1.c1			/programs/topmed/projects/GGAF_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed CCDG: Groningen Genetics of Atrial Fibrillation (GGAF) Study							GGAF			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. The Groningen Genetics of Atrial Fibrillation (GGAF) cohort is a cohort composed from 5 different sources of individuals with atrial fibrillation (AF) and age and sex-matched controls. Written informed consent was provided from all participating individuals, and all 5 studies were approved by the ethical committee at the University Medical Center (www.atrialfibrillationresearch.nl) and Maastricht University. All samples selected for TOPMed WGS are from individuals with atrial fibrillation.   Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001725.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001725.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001725.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001726.v1.p1.c1	2290	phs001726.v1.p1.c1			/programs/topmed/projects/CAMP_DS-AST-COPD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Childhood Asthma Management Program (CAMP)							CAMP			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. The Childhood Asthma Management Program (CAMP) was designed to evaluate whether continuous, long-term treatment (over a period of four to six years) with either an inhaled corticosteroid (budesonide) or an inhaled noncorticosteroid drug (nedocromil) safely produces an improvement in lung growth as compared with treatment for symptoms only (with albuterol and, if necessary, prednisone, administered as needed). The primary outcome in the study was lung growth, as assessed by the change in forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. Secondary outcomes included the degree of airway responsiveness, morbidity, physical growth, and psychological development.   Study Design:       Family/Twin/Trios    Study Type:  Parent-Offspring Trios     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001726.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001726.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001726.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001727.v1.p1.c2	73	phs001727.v1.p1.c2			/programs/topmed/projects/PIMA_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pathways to Immunologically Mediated Asthma (PIMA)							PIMA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Study designed to further our understanding of the pathogenesis of asthma exacerbations in children. Children enrolled in the study (n=217) were all asthmatic and primarily Hispanic white. The children were followed for 18 months until they experienced an asthma exacerbation or completed the follow-up without an exacerbation. The time to the first asthma exacerbation was considered the outcome. The acute and convalescent immune phenotype of each asthma exacerbation was documented.   Study Weblinks:   PIMA    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001727.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001727.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001727.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001728.v1.p1.c2	50	phs001728.v1.p1.c2			/programs/topmed/projects/CARE_BADGER_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)							CARE_BADGER			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. BADGER is a 56-week randomized, double-blind, three-treatment, three-period cross-over trial that will evaluate the differential improvement in control that is achieved following three separate treatment interventions in children whose asthma is not acceptably controlled on a low dose of ICS (per NAEPP guidelines). All participants will enter an 8-week run-in period during which time they will receive a dose of 1x ICS (fluticasone 200 g/day). During this 8-week time period, running 2-week averages to establish the lack of acceptable asthma control will be calculated. Thus, a child could qualify for randomization at any time during this 8-week run-in period. This approach should maximize both patient safety and successful enrollment. Children will continue to receive 1x ICS during the entire treatment phase. During each period of the treatment phase, they also will receive one add-on therapy in the form of LABA, LTRA or additional 1x ICS. The order of the add-on therapy assignment will be determined by randomization into one of six treatment sequences (order determined randomly). Each treatment period will be 16 weeks in length; the initial 4 weeks of each period will be considered to be the washout period for the previous treatment. The primary outcome measures will be frequency of asthma exacerbations, asthma control days, and FEV1.   Study Weblinks:   BADGER    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001728.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001728.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001728.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001729.v1.p1.c2	19	phs001729.v1.p1.c2			/programs/topmed/projects/CARE_CLIC_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Characterizing the Response to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid (CLIC)							CARE_CLIC			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. Within-subject clinical responses to either inhaled corticosteroids or Montelukast were compared in 126 children with mild to moderate asthma.   Study Weblinks:   CLIC    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001729.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001729.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001729.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001730.v1.p1.c2	41	phs001730.v1.p1.c2			/programs/topmed/projects/CARE_PACT_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pediatric Asthma Controller Trial (PACT)							CARE_PACT			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. After a 2-4 week assessment/characterization run-in period, 6-14 year-old children who met NAEPP criteria for mild-moderate persistent asthma specifically based on symptom criteria and methacholine PC20  12.5 mg/ml and FEV1  80% were randomized to one of the three active treatment arms for 12 months. Randomization was stratified according to clinical center, bronchodilator response (< 12% or  12%), race (Caucasian or non-Caucasian), and methacholine PC20 (< 2 or  2 mg/ml). The primary outcome variable was the proportion of asthma-free days during the 12-month treatment period. Secondary outcomes included other measures of asthma control (percentage of rescue-free days, albuterol-free days, and episode-free days; the number of asthma exacerbations requiring prednisone therapy and the time to the first asthma exacerbation), forced oscillation and spirometry, reversibility (FEV1 pre- and post 2 puffs of albuterol MDI), methacholine PC20, exhaled nitric oxide, and asthma-related quality of life.   Study Weblinks:   PACT    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001730.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001730.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001730.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001732.v1.p1.c2	89	phs001732.v1.p1.c2			/programs/topmed/projects/CARE_TREXA_DS-ASTHMA-IRB-COL	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: TReating Children to Prevent EXacerbations of Asthma (TREXA)							CARE_TREXA			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed)  Whole Genome Sequencing Program. TOPMed is part of a broader  Precision Medicine Initiative,  which aims to provide disease treatments that are tailored to an individual's  unique genes and environment. TOPMed will contribute to this initiative through the  integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles,  protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental,  and clinical data. In doing so, this program aims to uncover factors that increase or decrease  the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized  treatments. Two genotype call sets derived from WGS are now available,  Freeze 5b (GRCh38) and Freeze 8 (GRCh38), with largely overlapping sample sets.  Information about how to identify other TOPMed WGS accessions for cross-study analysis,  as well as descriptions of TOPMed methods of data acquisition, data processing and quality control,  are provided in the accompanying documents,   ""TOPMed Whole Genome Sequencing Project - Freeze 5b, Phases 1 and 2""  and ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"".  Please check the study list at the top of each of these methods documents to determine whether  it applies to this study accession. TREXA is a 44-week randomized, double-blind, double-masked, four-treatment, parallel trial that will evaluate the weaning strategy that provides the best protection against the development of exacerbations in children whose asthma is acceptably controlled on a low dose of ICS (per NAEPP guidelines). Following the 4 weeks of the run-in period on a 1x dose of ICS (100 g fluticasone b.i.d. or its equivalent), children who do not meet the definition of acceptable asthma control will be randomized to the parallel BADGER protocol; those who meet the definition of acceptable asthma control will be enrolled into the 44-week treatment phase of the study. The primary outcome measure will be time to first exacerbation requiring a prednisone course.   Study Weblinks:   TREXA    Study Design:       Prospective Longitudinal Cohort    Study Type:  Cohort     dbGaP estimated ancestry using  GRAF-pop  Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001732.v1.p1 on 2021-03-25 and may not include exact formatting or images."	phs001732.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001732.v1.p1		Program: TOPMed	Data Type: Genotype	Data Type: Clinical Phenotype	Study Registration: dbGaP					
phs001735.v2.p1.c1	4542	phs001735.v2.p1.c1			/programs/topmed/projects/PCGC_CHD_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pediatric Cardiac Genomics Consortium (PCGC)'s Congenital Heart Disease Biobank							PCGC_CHD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Pediatric Cardiovascular Genetics Consortium (PCGC) proposes to define genetic causes for congenital heart defects (CHD) as part of the TOPMed Program are the most common form of heart disease in childhood and are also the most prevalent form of birth defects, occurring in 2-3% of live births. The PCGC has recruited and clinically characterized = 10,000 CHD probands and parents (CHD trios). From whole exome sequencing (WES) of >2800 CHD trios, we identified a substantial enrichment of damaging de novo mutations in genes important for cardiogenesis, particularly implicating histone modifier enzyme gene defects. Analysis of whole genome sequencing (WGS) of 350 probands with CHD unexplained by WES and their parents preliminarily implicated de novo mutations in enhancers of genes previously shown to cause CHD in mouse knock out models. Sequencing of RNA (RNAseq) from discarded cardiac tissues from CHD probands has revealed likely causal allele-specific expression (ASE) as well as biallelic loss of expression (LOE). We have also discovered de novo epimutations, differentially methylated regions (DMRs), some with underlying de novo DNA variation, that are detectable in peripheral blood leukocytes and appear to underlie 10% of CHD. Of note, these assorted 'omic' approaches have enabled one another, both for attributing causality and assessing functional impact. Based on these extensive preliminary data, we hypothesize that PCGC probands with uninformative exomic analyses (WES-negative) harbor de novo genetic and/or epigenetic mutations in critical regulatory elements that participate in developmental expression of cardiac genes. To identify these etiologies, we propose analyses of WGS in 1000 WES-negative CHD trios, prioritizing those with probands with banked CHD tissues (n=78), one damaging variant in a recessive CHD gene, and older fathers (age>45). We also request WGS for 230 probands, for whom we have cardiac tissues but not parental DNAs. We request RNAseq for 308 cardiac tissues. For DNA methylation, which TOPMed will offer through the Illumina 850k array platform, we are requesting analysis of DNAs from peripheral blood leukocytes for all probands for whom WGS will be performed (1000 from trios, 230 singletons) as well as DNAs from cardiac tissues (n=308) to pair with the WGS, RNAseq and blood DNA methylation data. We will use existing resources and capabilities of the PCGC to confirm relevant mutations and those of its companion consortium in the Bench to Bassinet Program, the Cardiovascular Development Consortium, to inform analyses of non-coding mutations as well as to perform confirmatory functional genomics studies using cell and animal models. We expect that the studies resulting from data generated through TOPMed will provide novel insights into the molecular basis for CHD and fundamental knowledge about genes and pathways involved in cardiac development. Aside from being relevant to CHD, we anticipate that our findings will inform the understanding of later-onset cardiovascular diseases, including some arising in adulthood. Study Weblinks: From Bench to Bassinet: CHD Genes Study Design:     Prospective Longitudinal Cohort Study Type:Case SetParent-Offspring Trios dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-07-13 and may not include exact formatting or images."	phs001735.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001735.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001735.v2.p1.c2	8	phs001735.v2.p1.c2			/programs/topmed/projects/PCGC_CHD_DS-CHD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Pediatric Cardiac Genomics Consortium (PCGC)'s Congenital Heart Disease Biobank							PCGC_CHD			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.The Pediatric Cardiovascular Genetics Consortium (PCGC) proposes to define genetic causes for congenital heart defects (CHD) as part of the TOPMed Program are the most common form of heart disease in childhood and are also the most prevalent form of birth defects, occurring in 2-3% of live births. The PCGC has recruited and clinically characterized = 10,000 CHD probands and parents (CHD trios). From whole exome sequencing (WES) of >2800 CHD trios, we identified a substantial enrichment of damaging de novo mutations in genes important for cardiogenesis, particularly implicating histone modifier enzyme gene defects. Analysis of whole genome sequencing (WGS) of 350 probands with CHD unexplained by WES and their parents preliminarily implicated de novo mutations in enhancers of genes previously shown to cause CHD in mouse knock out models. Sequencing of RNA (RNAseq) from discarded cardiac tissues from CHD probands has revealed likely causal allele-specific expression (ASE) as well as biallelic loss of expression (LOE). We have also discovered de novo epimutations, differentially methylated regions (DMRs), some with underlying de novo DNA variation, that are detectable in peripheral blood leukocytes and appear to underlie 10% of CHD. Of note, these assorted 'omic' approaches have enabled one another, both for attributing causality and assessing functional impact. Based on these extensive preliminary data, we hypothesize that PCGC probands with uninformative exomic analyses (WES-negative) harbor de novo genetic and/or epigenetic mutations in critical regulatory elements that participate in developmental expression of cardiac genes. To identify these etiologies, we propose analyses of WGS in 1000 WES-negative CHD trios, prioritizing those with probands with banked CHD tissues (n=78), one damaging variant in a recessive CHD gene, and older fathers (age>45). We also request WGS for 230 probands, for whom we have cardiac tissues but not parental DNAs. We request RNAseq for 308 cardiac tissues. For DNA methylation, which TOPMed will offer through the Illumina 850k array platform, we are requesting analysis of DNAs from peripheral blood leukocytes for all probands for whom WGS will be performed (1000 from trios, 230 singletons) as well as DNAs from cardiac tissues (n=308) to pair with the WGS, RNAseq and blood DNA methylation data. We will use existing resources and capabilities of the PCGC to confirm relevant mutations and those of its companion consortium in the Bench to Bassinet Program, the Cardiovascular Development Consortium, to inform analyses of non-coding mutations as well as to perform confirmatory functional genomics studies using cell and animal models. We expect that the studies resulting from data generated through TOPMed will provide novel insights into the molecular basis for CHD and fundamental knowledge about genes and pathways involved in cardiac development. Aside from being relevant to CHD, we anticipate that our findings will inform the understanding of later-onset cardiovascular diseases, including some arising in adulthood. Study Weblinks: From Bench to Bassinet: CHD Genes Study Design:     Prospective Longitudinal Cohort Study Type:Case SetParent-Offspring Trios dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-07-13 and may not include exact formatting or images."	phs001735.v2.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001735.v2.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001843.v1.p2.c1	127	phs001843.v1.p2.c1			/programs/PCGC/projects/CMG_WGS_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Pediatric Cardiac Genomics Consortium (PCGC) Study - Centers for Mendelian Genomics Collaboration							CMG_WGS_HMB			This substudy phs001843 PCGC Study - CMG Collaboration contains whole genome sequences. Summary level phenotypes for the PCGC Cohort study participants can be viewed at the top-level study page phs001194 PCGC Cohort. Individual level phenotype data and molecular data for all PCGC top-level study and substudies are available by requesting Authorized Access to the PCGC Cohort study phs001194. Mendelian cardiovascular disorders provide crucial insights into the genetic susceptibility to more common forms of cardiovascular disease. While Mendelian cardiovascular disorders are individually rare, collectively they impose a significant public health burden. This proposal focuses on 2 specific categories of cardiovascular disease for which we have extensive research expertise and existing cohorts, congenital heart disease (CHD) and inherited arrhythmia syndromes. The tremendous burden on the health care system and on families with these Mendelian cardiovascular disorders underscore the urgency to understand their genomic bases, in order to design improved strategies for risk stratification, surveillance and medical intervention. Emerging evidence supports the use of whole-genome sequencing (WGS) over whole-exome sequencing (WES) for detecting coding variants in discovery projects, in addition to the obvious advantages of detecting features invisible to WES: structural variants (SV) and non-coding variants. We believe the way forward lies in widening the scope for discovery to include the patient's entire genome - and all types of variants. While family-based studies are crucial for genomic discovery, obtaining a sufficient number of high-risk pedigrees to achieve meaningful conclusions remains a challenge for most research institutions. For this proposal, we will leverage 2 powerful resources for the identification, ascertainment and recruitment of high-risk cardiovascular disease pedigrees: (1) the NHLBI-sponsored Pediatric Cardiac Genomics Consortium (PCGC) and (2) the Utah Population Database (UPDB). We propose to perform WGS on PCGC and UPDB cohorts with autosomal dominant disease to achieve the following Specific Aims: Aim 1) Identify the genomic basis for CHD in high-risk pedigrees derived from the PCGC and UPDB; and Aim 2) Identify the genomic basis for inherited arrhythmia disorders, using extended pedigrees derived from the UPDB. Aim 2 focuses on familial forms of AF, undiagnosed Long QT Syndrome, Wolff-Parkinson White syndrome and progressive conduction disorders. A WGS approach in high-risk pedigrees coupled with our validated bioinformatics pipeline, will allow the identification and prioritization of disease-causing SVs and sequence variants in coding and non-coding regulatory elements. These variants will be functionally characterized and validated in downstream experiments (heterologous expression systems, zebrafish cardiac assays, induced pluripotent stem cell-derived cardiomyocytes) that are beyond the scope of this X01. For this proposal, we have assembled the right combination of clinical expertise, resources for patient recruitment and computational know-how to enable these game-changing methodologies and to apply them to the challenge of cardiovascular Mendelian disease-gene discovery. Study Weblinks: Bench to Bassinet Program Study Design:     Family/Twin/Trios Study Type:FamilyCohortNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-03-29 and may not include exact formatting or images.	phs001843.v1.p2.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001843.v1.p2		Data Type: Clinical Phenotype	Study Registration: dbGaP							
phs001927.v1.p1.c1	3	phs001927.v1.p1.c1			/programs/topmed/projects/SPIROMICS_DS-COPD-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)							SPIROMICS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Subpopulations and Intermediate Outcome Measures in COPD Study Description Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. It is funded by the National Heart, Lung, and Blood Institute and is coordinated by the University of North Carolina at Chapel Hill. Molecular fingerprinting and extensive subject phenotyping will be performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity, which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD. Participating Institutions: Research participants for SPIROMICS will be enrolled, phenotyped, and followed at twelve SPIROMICS Clinical Centers: Columbia University, Temple University, Johns Hopkins University, Wake Forest University, University of Michigan, University of Illinois at Chicago, University of Iowa, University of Utah, National Jewish Health, University of California at San Francisco, and University of California at Los Angeles. The University of North Carolina at Chapel Hill serves as the Genomics and Informatics Center. The Radiology Reading Center is based at the University of Iowa. The PFT Reading Center is based at the University of California at Los Angeles. Study Design: SPIROMICS is a prospective cohort study that enrolled approximately 2,981 participants at twelve clinical centers over five years. Participants are distributed across four enrollment strata (i.e., Never-smokers, Smokers without COPD, Mild/Moderate COPD, and Severe COPD). Study Visits: Participants have up to four in-person visits (Baseline and Annual Clinic Visits at years 1, 2, 3 after Baseline). Study questionnaires and spirometry are completed at all main study visits. Blood and urine samples are collected at visits 1, 2, and 4. Sputum samples are collected at Visit 1. The CT scans are completed and Baseline and Visit 2. Participants also receive quarterly follow-up calls to assess health status and determine if an exacerbation has occurred. Substudies  Bronchoscopy and Immunophenotyping Substudy The Bronchoscopy Substudy will enroll 50 subjects per site, for a total of 300 participants. These participants will be recruited across all four study strata. This substudy includes two study visits. During the first visit, sputum samples are collected for Immunophenotyping analysis at the Immunophenotyping Core Lab based at the University of Michigan. Participants then return for a second visit during which samples are collected via bronchoscopy, including bronchoalveolar lavage, epithelial brushings and bronchial biopsies. Immunophenotyping analysis is also conducted on BAL and blood collected during the bronchoscopy study visit. Repeatability Substudy The entire baseline clinic visit was repeated on 98 volunteers to determine reliability of measurement procedures. All baseline study-related procedures and questionnaires, including the CT scan, were re-administered and new samples of blood, urine, saliva, and sputum were collected. Field center staff processed these biospecimen samples according to the same protocol. Exacerbation Substudy The Exacerbation Substudy is a prospective, longitudinal observational study of up to 400 participants, which will allow the assessment of participant-driven health care utilization (HCU) events and symptom-defined exacerbation events over time. HCU-driven events are defined by change in medical treatment in response to a perceived COPD Exacerbation. Symptom-based events will be defined by using EXACT-PRO (EXacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcome), a daily symptom diary developed to measure the frequency, severity, and duration of exacerbations in clinical trials. All participants are provided with a PDA on which to complete the diary. Participants reporting a possible COPD exacerbation will be brought into the study clinic for a study visit to collect biological specimens and questionnaire data.  The overall objectives of the Exacerbation Substudy are to:  Obtain clinical data and specimens on SPIROMICS participants before and during an acute COPD exacerbation defined by  Health care utilization triggered by the subject, or Symptomatic change (triggered by an EXACT defined threshold)   Describe symptomatic changes occurring around HCU and symptom-defined (EXACT) events and their relationship to clinical and specimen data, Characterize the non-exacerbation ""stable"" state in COPD using the EXACT, including:  Symptom variability (EXACT), Clinical data and specimen parameters during a stable state (baseline), The relationship between clinical and specimen data and symptom severity and variability.   Explore the characteristics of stable patients, defined as those who do not experience HCU or symptom-defined (EXACT) events during the sub-study period, using baseline clinical data and specimens, and compare these characteristics with patients who experience HCU and/or symptom-defined events. Examine the relationship between HCU and symptom-defined exacerbation frequency during the first one-year period of follow-up for exacerbations and health outcomes, including 12-month change in lung function and COPD health status, and longer-term morbidity and mortality, with the latter derived from long-term data from the larger SPIROMICS study.  Study Weblinks: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study Design:     Prospective Longitudinal Cohort Study Type:Cohort dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-05-24 and may not include exact formatting or images."	phs001927.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001927.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001927.v1.p1.c2	133	phs001927.v1.p1.c2			/programs/topmed/projects/SPIROMICS_DS-COPD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)							SPIROMICS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Subpopulations and Intermediate Outcome Measures in COPD Study Description Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. It is funded by the National Heart, Lung, and Blood Institute and is coordinated by the University of North Carolina at Chapel Hill. Molecular fingerprinting and extensive subject phenotyping will be performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity, which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD. Participating Institutions: Research participants for SPIROMICS will be enrolled, phenotyped, and followed at twelve SPIROMICS Clinical Centers: Columbia University, Temple University, Johns Hopkins University, Wake Forest University, University of Michigan, University of Illinois at Chicago, University of Iowa, University of Utah, National Jewish Health, University of California at San Francisco, and University of California at Los Angeles. The University of North Carolina at Chapel Hill serves as the Genomics and Informatics Center. The Radiology Reading Center is based at the University of Iowa. The PFT Reading Center is based at the University of California at Los Angeles. Study Design: SPIROMICS is a prospective cohort study that enrolled approximately 2,981 participants at twelve clinical centers over five years. Participants are distributed across four enrollment strata (i.e., Never-smokers, Smokers without COPD, Mild/Moderate COPD, and Severe COPD). Study Visits: Participants have up to four in-person visits (Baseline and Annual Clinic Visits at years 1, 2, 3 after Baseline). Study questionnaires and spirometry are completed at all main study visits. Blood and urine samples are collected at visits 1, 2, and 4. Sputum samples are collected at Visit 1. The CT scans are completed and Baseline and Visit 2. Participants also receive quarterly follow-up calls to assess health status and determine if an exacerbation has occurred. Substudies  Bronchoscopy and Immunophenotyping Substudy The Bronchoscopy Substudy will enroll 50 subjects per site, for a total of 300 participants. These participants will be recruited across all four study strata. This substudy includes two study visits. During the first visit, sputum samples are collected for Immunophenotyping analysis at the Immunophenotyping Core Lab based at the University of Michigan. Participants then return for a second visit during which samples are collected via bronchoscopy, including bronchoalveolar lavage, epithelial brushings and bronchial biopsies. Immunophenotyping analysis is also conducted on BAL and blood collected during the bronchoscopy study visit. Repeatability Substudy The entire baseline clinic visit was repeated on 98 volunteers to determine reliability of measurement procedures. All baseline study-related procedures and questionnaires, including the CT scan, were re-administered and new samples of blood, urine, saliva, and sputum were collected. Field center staff processed these biospecimen samples according to the same protocol. Exacerbation Substudy The Exacerbation Substudy is a prospective, longitudinal observational study of up to 400 participants, which will allow the assessment of participant-driven health care utilization (HCU) events and symptom-defined exacerbation events over time. HCU-driven events are defined by change in medical treatment in response to a perceived COPD Exacerbation. Symptom-based events will be defined by using EXACT-PRO (EXacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcome), a daily symptom diary developed to measure the frequency, severity, and duration of exacerbations in clinical trials. All participants are provided with a PDA on which to complete the diary. Participants reporting a possible COPD exacerbation will be brought into the study clinic for a study visit to collect biological specimens and questionnaire data.  The overall objectives of the Exacerbation Substudy are to:  Obtain clinical data and specimens on SPIROMICS participants before and during an acute COPD exacerbation defined by  Health care utilization triggered by the subject, or Symptomatic change (triggered by an EXACT defined threshold)   Describe symptomatic changes occurring around HCU and symptom-defined (EXACT) events and their relationship to clinical and specimen data, Characterize the non-exacerbation ""stable"" state in COPD using the EXACT, including:  Symptom variability (EXACT), Clinical data and specimen parameters during a stable state (baseline), The relationship between clinical and specimen data and symptom severity and variability.   Explore the characteristics of stable patients, defined as those who do not experience HCU or symptom-defined (EXACT) events during the sub-study period, using baseline clinical data and specimens, and compare these characteristics with patients who experience HCU and/or symptom-defined events. Examine the relationship between HCU and symptom-defined exacerbation frequency during the first one-year period of follow-up for exacerbations and health outcomes, including 12-month change in lung function and COPD health status, and longer-term morbidity and mortality, with the latter derived from long-term data from the larger SPIROMICS study.  Study Weblinks: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study Design:     Prospective Longitudinal Cohort Study Type:Cohort dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-05-24 and may not include exact formatting or images."	phs001927.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001927.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001927.v1.p1.c3	71	phs001927.v1.p1.c3			/programs/topmed/projects/SPIROMICS_GRU-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)							SPIROMICS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Subpopulations and Intermediate Outcome Measures in COPD Study Description Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. It is funded by the National Heart, Lung, and Blood Institute and is coordinated by the University of North Carolina at Chapel Hill. Molecular fingerprinting and extensive subject phenotyping will be performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity, which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD. Participating Institutions: Research participants for SPIROMICS will be enrolled, phenotyped, and followed at twelve SPIROMICS Clinical Centers: Columbia University, Temple University, Johns Hopkins University, Wake Forest University, University of Michigan, University of Illinois at Chicago, University of Iowa, University of Utah, National Jewish Health, University of California at San Francisco, and University of California at Los Angeles. The University of North Carolina at Chapel Hill serves as the Genomics and Informatics Center. The Radiology Reading Center is based at the University of Iowa. The PFT Reading Center is based at the University of California at Los Angeles. Study Design: SPIROMICS is a prospective cohort study that enrolled approximately 2,981 participants at twelve clinical centers over five years. Participants are distributed across four enrollment strata (i.e., Never-smokers, Smokers without COPD, Mild/Moderate COPD, and Severe COPD). Study Visits: Participants have up to four in-person visits (Baseline and Annual Clinic Visits at years 1, 2, 3 after Baseline). Study questionnaires and spirometry are completed at all main study visits. Blood and urine samples are collected at visits 1, 2, and 4. Sputum samples are collected at Visit 1. The CT scans are completed and Baseline and Visit 2. Participants also receive quarterly follow-up calls to assess health status and determine if an exacerbation has occurred. Substudies  Bronchoscopy and Immunophenotyping Substudy The Bronchoscopy Substudy will enroll 50 subjects per site, for a total of 300 participants. These participants will be recruited across all four study strata. This substudy includes two study visits. During the first visit, sputum samples are collected for Immunophenotyping analysis at the Immunophenotyping Core Lab based at the University of Michigan. Participants then return for a second visit during which samples are collected via bronchoscopy, including bronchoalveolar lavage, epithelial brushings and bronchial biopsies. Immunophenotyping analysis is also conducted on BAL and blood collected during the bronchoscopy study visit. Repeatability Substudy The entire baseline clinic visit was repeated on 98 volunteers to determine reliability of measurement procedures. All baseline study-related procedures and questionnaires, including the CT scan, were re-administered and new samples of blood, urine, saliva, and sputum were collected. Field center staff processed these biospecimen samples according to the same protocol. Exacerbation Substudy The Exacerbation Substudy is a prospective, longitudinal observational study of up to 400 participants, which will allow the assessment of participant-driven health care utilization (HCU) events and symptom-defined exacerbation events over time. HCU-driven events are defined by change in medical treatment in response to a perceived COPD Exacerbation. Symptom-based events will be defined by using EXACT-PRO (EXacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcome), a daily symptom diary developed to measure the frequency, severity, and duration of exacerbations in clinical trials. All participants are provided with a PDA on which to complete the diary. Participants reporting a possible COPD exacerbation will be brought into the study clinic for a study visit to collect biological specimens and questionnaire data.  The overall objectives of the Exacerbation Substudy are to:  Obtain clinical data and specimens on SPIROMICS participants before and during an acute COPD exacerbation defined by  Health care utilization triggered by the subject, or Symptomatic change (triggered by an EXACT defined threshold)   Describe symptomatic changes occurring around HCU and symptom-defined (EXACT) events and their relationship to clinical and specimen data, Characterize the non-exacerbation ""stable"" state in COPD using the EXACT, including:  Symptom variability (EXACT), Clinical data and specimen parameters during a stable state (baseline), The relationship between clinical and specimen data and symptom severity and variability.   Explore the characteristics of stable patients, defined as those who do not experience HCU or symptom-defined (EXACT) events during the sub-study period, using baseline clinical data and specimens, and compare these characteristics with patients who experience HCU and/or symptom-defined events. Examine the relationship between HCU and symptom-defined exacerbation frequency during the first one-year period of follow-up for exacerbations and health outcomes, including 12-month change in lung function and COPD health status, and longer-term morbidity and mortality, with the latter derived from long-term data from the larger SPIROMICS study.  Study Weblinks: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study Design:     Prospective Longitudinal Cohort Study Type:Cohort dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-05-24 and may not include exact formatting or images."	phs001927.v1.p1.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001927.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001927.v1.p1.c4	2099	phs001927.v1.p1.c4			/programs/topmed/projects/SPIROMICS_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)							SPIROMICS			"This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, ""TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4"" and ""TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4"". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.Subpopulations and Intermediate Outcome Measures in COPD Study Description Subpopulations and intermediate outcome measures in COPD study (SPIROMICS) supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. It is funded by the National Heart, Lung, and Blood Institute and is coordinated by the University of North Carolina at Chapel Hill. Molecular fingerprinting and extensive subject phenotyping will be performed to identify disease subpopulations and to identify and validate surrogate markers of disease severity, which will be useful as intermediate outcome measures for future clinical trials. Secondary aims are to clarify the natural history of COPD, to develop bioinformatic resources that will enable the utilization and sharing of data in studies of COPD and related diseases, and to create a collection of clinical, biomarker, radiographic, and genetic data that can be used by external investigators for other studies of COPD. Participating Institutions: Research participants for SPIROMICS will be enrolled, phenotyped, and followed at twelve SPIROMICS Clinical Centers: Columbia University, Temple University, Johns Hopkins University, Wake Forest University, University of Michigan, University of Illinois at Chicago, University of Iowa, University of Utah, National Jewish Health, University of California at San Francisco, and University of California at Los Angeles. The University of North Carolina at Chapel Hill serves as the Genomics and Informatics Center. The Radiology Reading Center is based at the University of Iowa. The PFT Reading Center is based at the University of California at Los Angeles. Study Design: SPIROMICS is a prospective cohort study that enrolled approximately 2,981 participants at twelve clinical centers over five years. Participants are distributed across four enrollment strata (i.e., Never-smokers, Smokers without COPD, Mild/Moderate COPD, and Severe COPD). Study Visits: Participants have up to four in-person visits (Baseline and Annual Clinic Visits at years 1, 2, 3 after Baseline). Study questionnaires and spirometry are completed at all main study visits. Blood and urine samples are collected at visits 1, 2, and 4. Sputum samples are collected at Visit 1. The CT scans are completed and Baseline and Visit 2. Participants also receive quarterly follow-up calls to assess health status and determine if an exacerbation has occurred. Substudies  Bronchoscopy and Immunophenotyping Substudy The Bronchoscopy Substudy will enroll 50 subjects per site, for a total of 300 participants. These participants will be recruited across all four study strata. This substudy includes two study visits. During the first visit, sputum samples are collected for Immunophenotyping analysis at the Immunophenotyping Core Lab based at the University of Michigan. Participants then return for a second visit during which samples are collected via bronchoscopy, including bronchoalveolar lavage, epithelial brushings and bronchial biopsies. Immunophenotyping analysis is also conducted on BAL and blood collected during the bronchoscopy study visit. Repeatability Substudy The entire baseline clinic visit was repeated on 98 volunteers to determine reliability of measurement procedures. All baseline study-related procedures and questionnaires, including the CT scan, were re-administered and new samples of blood, urine, saliva, and sputum were collected. Field center staff processed these biospecimen samples according to the same protocol. Exacerbation Substudy The Exacerbation Substudy is a prospective, longitudinal observational study of up to 400 participants, which will allow the assessment of participant-driven health care utilization (HCU) events and symptom-defined exacerbation events over time. HCU-driven events are defined by change in medical treatment in response to a perceived COPD Exacerbation. Symptom-based events will be defined by using EXACT-PRO (EXacerbations of Chronic Pulmonary Disease Tool - Patient Reported Outcome), a daily symptom diary developed to measure the frequency, severity, and duration of exacerbations in clinical trials. All participants are provided with a PDA on which to complete the diary. Participants reporting a possible COPD exacerbation will be brought into the study clinic for a study visit to collect biological specimens and questionnaire data.  The overall objectives of the Exacerbation Substudy are to:  Obtain clinical data and specimens on SPIROMICS participants before and during an acute COPD exacerbation defined by  Health care utilization triggered by the subject, or Symptomatic change (triggered by an EXACT defined threshold)   Describe symptomatic changes occurring around HCU and symptom-defined (EXACT) events and their relationship to clinical and specimen data, Characterize the non-exacerbation ""stable"" state in COPD using the EXACT, including:  Symptom variability (EXACT), Clinical data and specimen parameters during a stable state (baseline), The relationship between clinical and specimen data and symptom severity and variability.   Explore the characteristics of stable patients, defined as those who do not experience HCU or symptom-defined (EXACT) events during the sub-study period, using baseline clinical data and specimens, and compare these characteristics with patients who experience HCU and/or symptom-defined events. Examine the relationship between HCU and symptom-defined exacerbation frequency during the first one-year period of follow-up for exacerbations and health outcomes, including 12-month change in lung function and COPD health status, and longer-term morbidity and mortality, with the latter derived from long-term data from the larger SPIROMICS study.  Study Weblinks: SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study Design:     Prospective Longitudinal Cohort Study Type:Cohort dbGaP estimated ancestry using GRAF-popNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-05-24 and may not include exact formatting or images."	phs001927.v1.p1.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001927.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs001961.v2.p1.c1	20	phs001961.v2.p1.c1			/programs/LungMAP/projects/MALD_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									LungMAP: Molecular Atlas of Lung Development  Human Lung Tissue							MALD_GRU			Mammalian fetal lung development is a complex biological process. Despite considerable progress, a comprehensive understanding of the dynamic regulatory networks that govern postnatal alveolar lung development is still lacking. The purpose of this study as part of the LungMAP consortium (www.lungmap.net) is to understand the transcriptional changes in the process of mammalian lung development. Study Weblinks: NCBI GEO GSE161383 Study Design:     Control Set Study Type:LongitudinalSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-06-01 and may not include exact formatting or images.	phs001961.v2.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001961.v2.p1		Study Registration: dbGaP								
phs002299.v1.p1.c1	479	phs002299.v1.p1.c1			/programs/COVID19/projects/ORCHID_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									PETAL Network: Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among Inpatients With Symptomatic Disease (ORCHID) Trial							ORCHID			ORCHID was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US between April 2 and June 19, 2020. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients with five interim analyses; however, the trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients.The distribution of the day 14 clinical status score (measured using a 7-category ordinal scale) was not significantly different for patients randomized to receive hydroxychloroquine compared with placebo.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact.    Study Weblinks:   PETAL Network ORCHID Study    Study Design:       Clinical Trial    Study Type:  Clinical Trial Controlled Trial Placebo-Controlled Randomized Randomized Controlled Clinical Trial   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002299.v1.p1 on 2021-03-25 and may not include exact formatting or images.	phs002299.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002299.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002348.v1.p1.c1	357	phs002348.v1.p1.c1			/programs/BioLINCC/projects/MSH_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Multicenter Study of Hydroxyurea (MSH)							MSH			This study aimed to determine whether or not treatment with hydroxyurea titrated to maximum tolerated doses would reduce the frequency of vaso-occlusive (painful) crises by at least 50% in 299 men and women between 18 and 50 years old with a diagnosis of sickle cell anemia by gel electrophoresis conducted by a Core Laboratory. A secondary objective investigated correlations of fetal hemoglobin (HbF) levels and other patient or treatment characteristics with the occurrence of vaso-occlusive (painful) crises, and the effect of treatment on the quality of life.This controlled trial made hydroxyurea the first drug of proven benefit in preventing vaso-occlusive pain crisis and acute chest syndrome caused by sickle cell disease, with additional findings including reduced mortality in adult patients taking hydroxyurea for frequent painful sickle cell episodes after 9 of years follow-up. No significant side-effects of hydroxyurea therapy were noted.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact.    Study Weblinks:      ClinicalTrials.gov (MSH) NHLBI BioLINCC (MSH)    Study Design:       Clinical Trial    Study Type:  Double-Blind Randomized Controlled Clinical Trial   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2021-07-07 and may not include exact formatting or images.	phs002348.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002348.v1.p1		Program: BioLINCC	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002362.v1.p1.c1	4085	phs002362.v1.p1.c1			/programs/BioLINCC/projects/CSSCD_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Cooperative Study of Sickle Cell Disease (CSSCD)							CSSCD			The Cooperative Study of Sickle Cell Disease was initiated in 1977 to determine the natural history of sickle cell disease (SCD) from birth to death in order to identify those factors contributing to the morbidity and mortality of the disease. Specific objectives included: 1) to study the effect of sickle cell disease on growth and development from birth through adolescence 2) to study the conditions or events that may be related to the onset of painful crises 3) to obtain data on the nature, duration, and outcome of major complications of SCD 4) determine the nature, prevalence, and age- related incidence of organ damage due to SCD, and 5) study the role of SCD and its interaction with selected health events.Phases 2 and 3 of the study involved followup of the infant cohort. A total of 709 infants (age less than 6 months) were enrolled during Phase 1 of the Cooperative Study of Sickle Cell Disease (CSSCD), and Phases 2 and 3 of the CSSCD was designed to follow these children for an additional 10 years. The study objectives included: 1) define prospectively the natural history of sickle cell disease; 2) determine the relationships between cognitive and academic functioning and brain status as determined by MRI; 3) determine the cognitive or behavioral markers of silent infarct; 4) determine the relationship of family functioning on the Family Environment Scale (FES) to brain status, cognitive functioning, and social and demographic factors; 5) continue studies that will enhance the state of knowledge on the influence of sickle cell disease on the psychosocial adjustment of children and adolescents. Phase 2A of the study sought to examine the progression of organ damage in the heart, lung, kidney, and liver in adult cohort patients (born before 1/1/56) enrolled in phase 1 of the study between 3/79 and 5/81. A total of 620 patients from 11 centers were eligible for phase 2A.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact.     Study Weblinks:      ClinicalTrials.gov (CSSCD) BioLINCC (CSSCD) - For biospecimen requests    Study Design:       Clinical Trial    Study Type:  Case-Control Clinical Trial   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2021-07-07 and may not include exact formatting or images.	phs002362.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002386.v1.p1		Program: BioLINCC	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002363.v1.p1.c1	1480	phs002363.v1.p1.c1			/programs/COVID19/projects/RED_CORAL_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									PETAL - Repository of Electronic Data COVID-19 Observational Study							RED_CORAL_HMB			To describe characteristics, treatment, and outcomes among patients hospitalized with COVID-19 early in the pandemic, 1480 consecutive adult inpatients with laboratory-confirmed, symptomatic SARS-CoV-2 infection admitted to 57 US hospitals from March 1 to April 1, 2020 were studied.It was found that in a geographically diverse early-pandemic COVID-19 cohort with complete hospital folllow-up, hospital mortality was associated with older age, comorbidity burden, and male sex. Intensive care unit admissions occurred early and were associated with protracted hospital stays. Survivors often required new health care services or respiratory support at discharge.The PETAL Network central institutional review board at Vanderbilt University and the institutional review boards at each participating hospital approved the study or determined that the study was exempt from review.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact. Study Weblinks: PETAL Network RED CORAL StudyNHLBI BioLINCC (RED CORAL) Study Design:     Control Set Study Type:Case-CohortClinical CohortCohortMulticenter NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-03-29 and may not include exact formatting or images.	phs002363.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002363.v1.p1		Program: COVID 19	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002383.v1.p1.c1	720	phs002383.v1.p1.c1			/programs/BioLINCC/projects/Walk_PHaSST_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy (walk-PHaSST)							Walk_PHaSST_GRU			Pulmonary arterial hypertension (PAH) is a progressive condition characterized by narrowing or stiffening pulmonary arterioles resulting in increased pulmonary blood pressure and reduced delivery of oxygenated blood to the body. It is a common complication of sickle cell disease and initially presents with the symptom of shortness of breath (dyspnea) on exertion. As the condition worsens, other symptoms such as dizziness, lower extremity edema, and chest pain can develop. The drug, sildenafil, works by relaxing blood vessels in the lungs which reduces pulmonary blood pressure and allows more oxygenated blood to circulate. Increased levels of oxygenated blood allows individuals with PAH to tolerate more activity, but guidelines for using sildenafil in patients with PAH and sickle cell disease were unavailable at the time of the Walk-PHaSST trial.Participants were screened for the existence of pulmonary hypertension with a six minute walk test and a Doppler echocardiogram that assessed TRV, diastolic function, and valvular and systolic function. Subjects with TRV  2.7 m/s received further clinical evaluation for possible causes of pulmonary hypertension. Other screening data included medical history, a physical exam, and standard laboratory testing. For individuals with moderate to severe pulmonary hypertension (TRV  3.0), a cardiac catheterization was done at the baseline and week 16 data collection periods.Subjects eligible for the main intervention trial based on screening results were randomized in a 1:1 double blind fashion to receive sildenafil or placebo for 16 weeks. Subjects received 20 mg of oral sildenafil or matching placebo 3 times daily for 6 weeks, followed by 40 mg 3 times daily for 4 weeks, followed by 80 mg 3 times daily for 6 weeks, as tolerated. Participants could also receive other therapies as needed to manage sickle cell and related complications. The primary outcome measure of the trial was change in the six minute walk test, a standard indicator of a person's heart and lung function and exercise capacity, from baseline to week 16. After completing the study treatment (or placebo), participants could choose to be part of the open-label follow-up phase of the study and continue to be assessed for up to one year.The study was intended to screen about 1000 subjects and randomize 132 subjects, however it was terminated early due to the unforeseen increase in adverse events in participants treated with sildenafil as compared to placebo. When the study was stopped, 33 participants had completed the trial. Subjects continued to be monitored, but were instructed to taper sildenafil treatment over three to seven days.There was no evidence that treatment with sildenafil impacted the six minute walk distance from baseline to week 16. In addition, treatment with sildenafil appeared to increase rates of hospitalization due to sickle cell disease pain.Due to in part to the early termination of the trial, the majority of subject data was collected from the screening phase of the study (n=720), as opposed to the main intervention trial (n=74).Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact.   Study Weblinks:      ClinicalTrials.gov (Walk-PHaSST) BioLINCC (Walk-PHaSST)    Study Design:       Clinical Trial    Study Type:  Clinical Trial Double-Blind   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2021-07-07 and may not include exact formatting or images.	phs002383.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002383.v1.p1		Program: BioLINCC	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002385.v1.p1.c1	1518	phs002385.v1.p1.c1			/programs/BioLINCC/projects/CIBMTR_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Hematopoietic Cell Transplant for Sickle Cell Disease (HCT for SCD)							CIBMTR			The Center for International Blood and Marrow Transplant Research (CIBMTR) is a hematopoietic cell transplant registry that was established in 1972 at the Medical College of Wisconsin. The overarching goal of the registry is to study trends in transplantations and to advance the understanding and application of allogeneic hematopoietic cell transplantation for malignant and non-malignant diseases. Included in this dataset are children, adolescents and young adults with severe sickle cell disease who received an allogeneic hematopoietic cell transplant in the United States and provided written informed consent for research.Hematopoietic cell transplant for sickle cell disease is curative. Offering this treatment for patients with severe disease is challenging as only about 20-25% of patients expected to benefit have an HLA-matched sibling. Consequently, several transplantations have utilized an HLA-matched or mismatched unrelated adult donor and HLA-mismatched relative. Transplantation strategies have also evolved over time that has included transplant conditioning regimens of varying intensity, grafts other than bone marrow and novel approaches to overcome the donor-recipient histocompatibility barrier and limit graft-versus-host disease. The data that is available for sickle cell disease transplants have been utilized to report on outcomes after transplantation and compare outcomes after transplantation of grafts HLA-matched related, HLA-mismatched related, HLA-matched and HLA-mismatched unrelated donors. Collectively, these data have advanced our knowledge and understanding of hematopoietic cell transplant for this disease. These data can also serve as 'contemporaneous controls' for comparison with other more recent curative treatments like gene therapy and gene editing.Data available for request include allogeneic hematopoietic cell transplants for sickle cell disease (Hb SS and Hb S thalassemia) in the United States from 1991 to 2019. Follow-up data through December 2020 are available.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact.   Study Weblinks:      ClinicalTrials.gov (HCT for SCD) BioLINCC (HCT for SCD)    Study Design:       Prospective Longitudinal Cohort    Study Type:  Clinical Cohort Cohort Control Set Longitudinal Longitudinal Cohort Multicenter Observational   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2021-07-07 and may not include exact formatting or images.	phs002385.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002385.v1.p1		Program: BioLINCC	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002386.v1.p1.c1	77	phs002386.v1.p1.c1			/programs/BioLINCC/projects/STOPII_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Optimizing Primary Stroke Prevention in Children with Sickle Cell Anemia (STOP II)							STOPII			The STOP II trial evaluated whether prophylactic transfusion in patients with sickle cell disease and high risk of stroke can be safely halted after 30 months of treatment during which patients became low risk for stroke.Stroke causes substantial morbidity in children with sickle cell disease. To prevent first strokes, the Stroke Prevention Trial in Sickle Cell Anemia (STOP) used prophylactic transfusions in children who were identified by transcranial Doppler (TCD) ultrasonography as being at high risk for stroke. This strategy reduced the incidence of stroke among such children from 10% per year to less than 1% per year, leading to recommendations for TCD screening and prophylactic transfusion for children with abnormal velocities on ultrasonography. Despite the reduced risk of stroke, long-term use of transfusions can cause adverse side effects, such as iron overload or alloimmunization. However, cessation of transfusions is associated with recurrence of stroke, and at the time of the STOP II trial, there were no clinical or laboratory indicators to guide the duration of prophylaxis. Therefore the STOP II trial was initiated to determine whether transfusions could be limited by monitoring patients with TCD examinations after transfusions were halted and resuming transfusions if the examination indicated a high risk of stroke.The trial was halted for safety concerns after 79 of a planned 100 children were randomized. Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease resulted in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke incidence.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact.    Study Weblinks:      BioLINCC (STOP II) ClinicalTrials.gov (STOP II)    Study Design:       Clinical Trial    Study Type:  Clinical Trial Randomized   Number of study subjects that have individual-level data available through Authorized Access:  NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2021-07-07 and may not include exact formatting or images.	phs002386.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002386.v1.p1		Program: BioLINCC	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002415.v1.p1.c1	204	phs002415.v1.p1.c1			/programs/BioLINCC/projects/BabyHug_DS-SCD-IRB-RD	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Hydroxyurea to Prevent Organ Damage in Children with Sickle Cell Anemia (BABY HUG)							BabyHug			Sickle cell anemia is associated with substantial morbidity from acute complications and organ dysfunction beginning in the first year of life. In 1995, the Multicenter Study of Hydroxyurea (MSH) (dbGaP phs002348) demonstrated that, in adults, hydroxyurea is effective in decreasing the frequency of painful crises, hospitalizations for crises, acute chest syndrome, and blood transfusions by 50%. The phase I/II study of hydroxyurea in children (HUG KIDS) demonstrated that children have a response to hydroxyurea similar to that seen in adults in terms of increasing fetal hemoglobin levels and total hemoglobin, and decreasing complications associated with sickle cell anemia. In addition, this study demonstrated that the drug does not adversely affect growth and development between the ages of 5 and 15. A pilot study of hydroxyurea (HUSOFT) given to children between the ages of 6 months and 24 months demonstrated that the drug was well tolerated and that the fetal hemoglobin levels rose and remained elevated compared to baseline with continued hydroxyurea administration.A Special Emphasis Panel (SEP) met on April 12, 1996 to review the results of the MSH trial and the progress to date of the HUG KIDS study. The SEP recommended that NHLBI undertake the BABY HUG trial.The BABY HUG Randomized Controlled Trial concluded that hydroxyurea treatment in very young children seemed to have an acceptable safety profile and to reduce complications of sickle cell anemia. However, more data were needed on the long-term safety of hydroxyurea use in very young children. As a result, follow-up studies were initiated. The Follow-Up Study II provided longer follow-up than Follow-Up Study I, and included more assessment types than Follow-Up Study I.The BABY HUG program consisted of three related studies, each of which has associated datasets and bio-specimens.A randomized controlled trial comparing hydroxyurea to placebo in very young children with sickle cell anemia (BABY HUG Randomized Controlled Trial)The first observational follow-up study of children from the randomized controlled trial (BABY HUG Follow-Up Study I). All children in Follow-Up Study I were offered the option of taking open-label hydroxyurea, with treatment decisions made by the family and the clinical team caring for the child.The second observational follow-up study of children from BABY HUG Follow-Up Study I. All children in Follow-Up Study II were offered the option of taking open-label hydroxyurea, with treatment decisions made by the family and the clinical team caring for the child.The purpose of the Randomized Controlled Trial was to determine if hydroxyurea can safely prevent early end organ damage in very young children with sickle cell anemia.The purpose of the BABY HUG Follow-up Study I was to provide structured follow-up of the children enrolled in the BABY HUG Randomized Controlled Trial, in order to characterize the long-term toxicities and unexpected risks (if any) associated with treatment with hydroxyurea at an early age.The objective of Follow-Up Study II was to obtain additional data about the long-term safety and efficacy of hydroxyurea use in children with Sickle Cell Anemia through at least the first decade of life.Instructions for requesting individual-level data are available on BioData Catalyst at https://biodatacatalyst.nhlbi.nih.gov/resources/data/. Apply for data access in dbGaP. Upon approval, users may begin accessing requested data in BioData Catalyst. For questions about availability, you may contact the BioData Catalyst team at https://biodatacatalyst.nhlbi.nih.gov/contact. Study Weblinks:     Randomized Control TrialFollow-Up Study IFollow-Up Study IIBioLINCC - BABY HUG Study Design:     Clinical Trial Study Type:Clinical CohortClinical TrialCollectionControlled TrialDouble-BlindNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-03-29 and may not include exact formatting or images.	phs002415.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002415.v1.p1		Study Registration: dbGaP	Data Type: Clinical Phenotype							
phs002694.v3.p1.c1	2545	phs002694.v3.p1.c1			/programs/COVID19/projects/ACTIV4A_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)							ACTIV4A_GRU			This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients. Study Design:     Interventional Study Type:Clinical TrialControlled TrialInterventionalRandomizedRandomized Controlled Clinical TrialSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-06-07 and may not include exact formatting or images.	phs002694.v3.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002694.v3.p1		Program: COVID 19	Study Registration: dbGaP							
phs002710.v1.p1.c1	657	phs002710.v1.p1.c1			/programs/COVID19/projects/ACTIV4B_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									COVID-19 Outpatient Thrombosis Prevention Trial (ACTIV-4B)							ACTIV-4B			An adaptive randomized double-blind placebo-controlled platform trial to compare the effectiveness of anticoagulation with antiplatelet agents and with placebo to prevent thrombotic events in patients diagnosed with COVID-19 who are not admitted to hospital as COVID-19 related symptoms are currently stable. Study Design:     Interventional Study Type:Clinical TrialDouble-BlindInterventionalPlacebo-ControlledRandomizedRandomized Controlled Clinical TrialNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-03-29 and may not include exact formatting or images.	phs002710.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002710.v1.p1		Program: COVID 19	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002715.v1.p1.c1	710	phs002715.v1.p1.c1			/programs/NSRR/projects/NSRR-CFS_DS-HLBS-IRB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Cleveland Family Study							NSRR-CFS			The Cleveland Family Study (CFS) is a family-based study of sleep apnea, consisting of 2,284 individuals (46% African American) from 361 families studied on up to 4 occasions over a period of 16 years. The study began in 1990 with the initial aims of quantifying the familial aggregation of sleep apnea. National Institutes of Health (NIH) renewals provided expansion of the original cohort, including increased minority recruitment, and longitudinal follow-up, with the last exam occurring in February 2006. The CFS was designed to provide fundamental epidemiological data on risk factors for sleep disordered breathing (SDB). The sample was selected by identifying affected probands who had laboratory diagnosed obstructive sleep apnea. All first-degree relatives, spouses and available second-degree relatives of affected probands were studied. In addition, during the first 5 study years, neighborhood control families were identified through a neighborhood proband, and his/her spouses and first-degree relatives. Each exam, occurring at approximately 4-year intervals, included new enrollment as well as follow up exams for previously enrolled subjects. For the first three visits, data, including an overnight sleep study, were collected in participants' homes while the last visit occurred in a general clinical research center (GCRC). Phenotypic characterization of the entire cohort included overnight sleep apnea studies, blood pressure, spirometry, anthropometry and questionnaires. Currently, data of 710 individuals are available for use through BioData Catalyst (with genotype data available through dbGaP).The National Sleep Research Resource (NSRR) is a NIH-supported sleep data repository that offers free access to large collections of de-identified physiological signals and related clinical data from a large range of cohort studies, clinical trials and other data sources from children and adults, including healthy individuals from the community and individuals with known sleep or other health disorders.  The goals of NSRR are to facilitate rigorous research that requires access to large or more diverse data sets, including raw physiological signals, to promote a better understanding of risk factors for sleep and circadian disorders and/or the impact of sleep disturbances on health-related outcomes.  Data from over 15 data sources and more than 40,000 individual sleep studies, many linked to dozens if not hundreds of clinical data elements, are available (as of Feb. 2022). Query tools are available to identify variables of interest, and their meta-data and provenance. Study Weblinks: Cleveland Family Study Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal CohortNOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2022-05-24 and may not include exact formatting or images.	phs002715.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002715.v1.p1		Study Registration: dbGaP								
phs002752.v1.p1.c1	511	phs002752.v1.p1.c1			/programs/COVID19/projects/C3PO_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Clinical-trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)							C3PO			The overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunization.The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration.This study will enroll adults presenting to the emergency department (ED) with mild, symptomatic, laboratory-confirmed COVID-19 illness, who are at high risk for progression to severe/critical illness, but who are clinically stable for outpatient management at randomization.	phs002752.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002752.v1.p1		Program: COVID 19	Study Registration: dbGaP	Data Type: Clinical Phenotype						
phs002808.v1.p1.c1	8872	phs002808.v1.p1.c1			/programs/topmed/projects/nuMoM2b_GRU-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									NHLBI TOPMed: Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b)							nuMoM2b_GRU-IRB			Participants from study sites that recruited during the original study funded by NICHD of pregnant people, called nuMoM2b, participated in this study. The nuMoM2b-HHS1 was a prospective observational follow-up study of the nuMoM2b cohort consisting of interval contacts via phone or web every 6 months to about a year, and an in-person visit 2 to 7 years after the end of the nuMoM2b pregnancy including: Demographics Self-administered questionnaires Clinical measurements Lab results An in-home sleep breathing assessment for the subset of participants with at least one valid sleep breathing assessment during nuMoM2b Abstraction of medical records for pregnancies subsequent to nuMoM2b involving self-reported adverse pregnancy outcomes or multiple births Abstraction of medical records of selected cardiovascular risk-related events or procedures reported by participants. The study capitalized on the rich and unique data prospectively collected during nuMoM2b (biomarkers, uterine artery Doppler studies, fetal growth, psychosocial determinants, sleep, and blood pressure) and rigorous definitions of adverse pregnancy outcomes. These data are stored in the NICHD repository DASH (https://dash.nichd.nih.gov/study/226675). A total of 8,838 nuMoM2b participants were targeted for contact during nuMoM2b-HHS and 7,872 participants were reached, of whom 7,003 completed one or more interval contacts. Of these, 5,206 agreed to the visit, and 4,508 attended an in-person visit. Study Weblinks: nuMoM2b website Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-04-25 and may not include exact formatting or images.	phs002808.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002808.v1.p1		Program: TOPMed	Data Type: Genotype	Study Registration: dbGaP						
phs002911.v1.p1.c1	3097	phs002911.v1.p1.c1			/programs/COVID19/projects/C4R_FHS_HMB-IRB-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Framingham Heart Study (FHS)							C4R_FHS_HMB-IRB-MDS			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort DescriptionIn 1948, the researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have returned to the study every two years for an examination consisting of a detailed medical history, physical examination, and laboratory tests, and in 1971, the study enrolled a second-generation cohort -- 5,124 of the original participants' adult children and their spouses -- to participate in similar examinations. The second examination of the Offspring cohort occurred eight years after the first examination, and subsequent examinations have occurred approximately every four years thereafter. In 1994, the need to establish a new study reflecting a more diverse community of Framingham was recognized, and the first Omni cohort of the Framingham Heart Study, consisting of 506 participants, was enrolled. In April 2002 4095 third generation of participants, the grandchildren of the original cohort, were added. In 2003, 103 spouses of the offspring Cohort (NOS), and a second group of 410 Omni participants were enrolled. Through 2019, the original cohort has completed a total of 32 exams, the Offspring cohort 9 exams, the OMNI1 cohort 4 exams, and GEN3, NOS and OMNI2 cohorts each have completed 3 exams. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University.Data Being Submitted Wave 1 questionnaire data includes 3967 variables for up to 3112 FHS participants in C4R.Wave 2 questionnaire data includes 448 variables for up to 2337 FHS participants in C4R.Dried Blood Spot/Serosurvey data includes 7 variables for up to 2189 FHS participants in C4R.Derived data includes 43 variables for up to 3151 FHS participants in C4R.Phenotype data includes 113 variables for up to 3151 FHS participants in C4R. Study Weblinks: Collaborative Cohort of Cohorts for COVID-19 Research, (C4R)Framingham Heart Study (FHS) Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 7270    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002911.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002911.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002911.v1.p1.c2	238	phs002911.v1.p1.c2			/programs/COVID19/projects/C4R_FHS_HMB-IRB-NPU-MDS	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Framingham Heart Study (FHS)							C4R_FHS_HMB-IRB-NPU-MDS			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort DescriptionIn 1948, the researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts, and began the first round of extensive physical examinations and lifestyle interviews that they would later analyze for common patterns related to CVD development. Since 1948, the subjects have returned to the study every two years for an examination consisting of a detailed medical history, physical examination, and laboratory tests, and in 1971, the study enrolled a second-generation cohort -- 5,124 of the original participants' adult children and their spouses -- to participate in similar examinations. The second examination of the Offspring cohort occurred eight years after the first examination, and subsequent examinations have occurred approximately every four years thereafter. In 1994, the need to establish a new study reflecting a more diverse community of Framingham was recognized, and the first Omni cohort of the Framingham Heart Study, consisting of 506 participants, was enrolled. In April 2002 4095 third generation of participants, the grandchildren of the original cohort, were added. In 2003, 103 spouses of the offspring Cohort (NOS), and a second group of 410 Omni participants were enrolled. Through 2019, the original cohort has completed a total of 32 exams, the Offspring cohort 9 exams, the OMNI1 cohort 4 exams, and GEN3, NOS and OMNI2 cohorts each have completed 3 exams. The FHS is a joint project of the National Heart, Lung and Blood Institute and Boston University.Data Being Submitted Wave 1 questionnaire data includes 3967 variables for up to 3112 FHS participants in C4R.Wave 2 questionnaire data includes 448 variables for up to 2337 FHS participants in C4R.Dried Blood Spot/Serosurvey data includes 7 variables for up to 2189 FHS participants in C4R.Derived data includes 43 variables for up to 3151 FHS participants in C4R.Phenotype data includes 113 variables for up to 3151 FHS participants in C4R. Study Weblinks: Collaborative Cohort of Cohorts for COVID-19 Research, (C4R)Framingham Heart Study (FHS) Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 7270    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002911.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002911.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002913.v1.p1.c1	23	phs002913.v1.p1.c1			/programs/COVID19/projects/C4R_SARP_GRU-PUB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)							C4R_SARP_GRU-PUB-NPU			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. Data Being Submitted  Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.Derived data includes 43 variables for up to 463 SARP participants in C4R.Phenotype data includes 113 variables for up to 463 SARP participants in C4R. Study Weblinks: C4RSARP Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 479    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002913.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002913.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002913.v1.p1.c2	105	phs002913.v1.p1.c2			/programs/COVID19/projects/C4R_SARP_GRU-PUB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)							C4R_SARP_GRU-PUB			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. Data Being Submitted  Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.Derived data includes 43 variables for up to 463 SARP participants in C4R.Phenotype data includes 113 variables for up to 463 SARP participants in C4R. Study Weblinks: C4RSARP Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 479    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002913.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002913.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002913.v1.p1.c3	26	phs002913.v1.p1.c3			/programs/COVID19/projects/C4R_SARP_DS-AAI-PUB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)							C4R_SARP_DS-AAI-PUB-NPU			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. Data Being Submitted  Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.Derived data includes 43 variables for up to 463 SARP participants in C4R.Phenotype data includes 113 variables for up to 463 SARP participants in C4R. Study Weblinks: C4RSARP Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 479    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002913.v1.p1.c3		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002913.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002913.v1.p1.c4	307	phs002913.v1.p1.c4			/programs/COVID19/projects/C4R_SARP_DS-AAI-PUB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Severe Asthma Research Program (SARP)							C4R_SARP_DS-AAI-PUB			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Severe Asthma Research Program (SARP) has been investigating the clinical, physiologic and molecular phenotypes of asthma since 2000. It is currently following ~400 deeply phenotyped asthma patients. Data Being Submitted  Wave 1 questionnaire data includes 397 variables for up to 375 SARP participants in C4R.Wave 2 questionnaire data includes 448 variables for up to 289 SARP participants in C4R.Dried Blood Spot/Serosurvey data includes 7 variables for up to 290 SARP participants in C4R.Derived data includes 43 variables for up to 463 SARP participants in C4R.Phenotype data includes 113 variables for up to 463 SARP participants in C4R. Study Weblinks: C4RSARP Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 479    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002913.v1.p1.c4		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002913.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002919.v1.p1.c1	8707	phs002919.v1.p1.c1			/programs/COVID19/projects/C4R_REGARDS_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): REasons for Geographic and Racial Differences in Stroke (REGARDS)							C4R_REGARDS_HMB-IRB			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects. Cohort DescriptionThe REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort is one of the nation's largest, most comprehensive population-based cohorts, and it uses innovative home- and telephone-based data collection. REGARDS centrally recruited and initially examined 30,239 Black and White men and women aged 45 years in 2003-7 to understand why Southerners and Black Americans have a higher incidence of stroke and related diseases that affect brain health.Data Being Submitted  Wave 1 questionnaire data includes 397 variables for 8109 REGARDS participants in C4R. Wave 2 questionnaire data includes 448 variables for 6421 REGARDS participants in C4R. Dried Blood Spot/Serosurvey data includes 7 variables for 4058 REGARDS participants in C4R. Derived data includes 43 variables for 8606 REGARDS participants in C4R. Phenotype data includes 113 variables for 7880 REGARDS participants in C4R.  Study Weblinks: 1) C4R: www.c4r-nih.org2) REGARDS: https://www.uab.edu/soph/regardsstudy/ Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 8707    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002919.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002919.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002988.v1.p1.c1	5254	phs002988.v1.p1.c1			/programs/COVID19/projects/C4R_ARIC_HMB-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R)- Atherosclerosis Risk in Communities (ARIC)							C4R_ARIC_HMB-IRB			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Atherosclerosis Risk in Communities (ARIC) study began in the mid-1980s with the initial aims being to describe the presence of subclinical atherosclerosis, the progression of atherosclerosis to clinical cardiovascular disease (CVD), and the association of novel risk factors with CVD. ARIC recruited its cohort of men and women aged 45-64 in 1987-89 from four communities (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD). As of 2020, ARIC counts over 6,000 participants.Data Submitted Wave 1 questionnaire data includes 397 variables for up to 5326 ARIC participants in C4R. Wave 2 questionnaire data includes 448 variables for up to 4619 ARIC participants in C4R. Dried Blood Spot/Serosurvey data includes 7 variables for up to 2083 ARIC participants in C4R. Derived data includes 43 variables for up to 5449 ARIC participants in C4R. Phenotype data includes 113 variables for up to 5449 ARIC participants in C4R.  Study Weblinks: C4R:https://c4r-nih.org/ARIC:https://sites.cscc.unc.edu/aric/desc_pub Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 6523    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002988.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002988.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs002988.v1.p1.c2	200	phs002988.v1.p1.c2			/programs/COVID19/projects/C4R_ARIC_DS-CVD-IRB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R)- Atherosclerosis Risk in Communities (ARIC)							C4R_ARIC_DS-CVD-IRB			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Atherosclerosis Risk in Communities (ARIC) study began in the mid-1980s with the initial aims being to describe the presence of subclinical atherosclerosis, the progression of atherosclerosis to clinical cardiovascular disease (CVD), and the association of novel risk factors with CVD. ARIC recruited its cohort of men and women aged 45-64 in 1987-89 from four communities (Forsyth County, NC; Jackson, MS; suburban Minneapolis, MN; and Washington County, MD). As of 2020, ARIC counts over 6,000 participants.Data Submitted Wave 1 questionnaire data includes 397 variables for up to 5326 ARIC participants in C4R. Wave 2 questionnaire data includes 448 variables for up to 4619 ARIC participants in C4R. Dried Blood Spot/Serosurvey data includes 7 variables for up to 2083 ARIC participants in C4R. Derived data includes 43 variables for up to 5449 ARIC participants in C4R. Phenotype data includes 113 variables for up to 5449 ARIC participants in C4R.  Study Weblinks: C4R:https://c4r-nih.org/ARIC:https://sites.cscc.unc.edu/aric/desc_pub Study Design:     Prospective Longitudinal Cohort Study Type:Longitudinal Cohort    Total number of consented subjects: 6523    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs002988.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002988.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs003028.v1.p1.c1	999	phs003028.v1.p1.c1			/programs/COVID19/projects/C4R_NOMAS_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									The Collaborative Cohort of Cohorts for COVID-19 Research (C4R): Northern Manhattan Study (NOMAS)							C4R_NOMAS_GRU			Adverse effects of the coronavirus disease 2019 (COVID19) pandemic on US society, health, and economy are widespread. The Collaborative Cohort of Cohorts for COVID-19 Research (C4R) aims to advance our knowledge on the impact of the COVID-19 pandemic in the United States. C4R is a diverse national prospective study comprising 14 long-standing prospective cohort studies and over 49,000 participants with extensive pre-COVID-19 phenotype data. C4R links pre-pandemic data on clinical and subclinical diseases and their risk factors, including behavior, cognition, biomarkers, and social determinants of health, to information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute and post-acute COVID-related illness. Ascertainment of COVID-19 infection occurs via standardized questionnaires, adjudication of COVID-related hospitalizations and deaths, and SARS-CoV-2 serosurvey via dried blood spot cards. C4R is investigating the following research questions: 1) how pre-existing health conditions affect risk of severe or prolonged COVID-19 related illness; 2) how SARS-CoV-2 infection and COVID-19 illness affect long-term health; and 3) how the pandemic has affected health-related behaviors and non-COVID health outcomes. This resource will allow evaluation of risk and resilience factors for COVID-19 severity and long-term health effects.Cohort Description The Northern Manhattan Study (NOMAS) is a study of the population of Washington Heights in Northern Manhattan. The ongoing study, which began in 1990, has enrolled over 4,400 people, some of whom have suffered a stroke or related neurological syndromes. As the cohort aged, the specific aims grew to include not only vascular determinants of stroke but also cognitive decline, mild cognitive impairment (MCI) and dementia. The overall goal of NOMAS is to investigate stroke risk factors in different race-ethnic groups. NOMAS is also committed to developing better stroke prevention programs to improve the health of the community. The Hispanic population in Northern Manhattan is largely Dominican, along with Puerto Rican, Cuban, and Central and South American components.Data Being Submitted  Wave 1 questionnaire data includes 397 variables for up to 887 NOMAS participants in C4R Wave 2 questionnaire data includes 448 variables for up to 815 NOMAS participants in C4R Derived data includes 43 variables for up to 995 NOMAS participants in C4R Phenotype data includes 113 variables for up to 995 NOMAS participants in C4R   Study Weblinks: C4RNOMAS Study Design:     Prospective Longitudinal Cohort Study Type:    Total number of consented subjects: 995    Subject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-11-14 and may not include exact formatting or images.	phs003028.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003028.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs003063.v1.p1.c1	1217	phs003063.v1.p1.c1			/programs/COVID19/projects/ACTIV4C_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									COVID-19 Post-hospital Thrombosis Prevention Study (ACTIV-4C)							ACTIV4C_GRU			This study is an adaptive, prospective, randomized trial designed to compare the effectiveness and safety of antithrombotic therapy with no antithrombotic therapy after hospitalization for 48 hours or longer for COVID-19. For Stage 1 of this study, participants will be randomized to either prophylactic anticoagulation or no anticoagulant therapy for 30 days, and then followed for an additional 60 days after the completion of treatment (total duration of follow-up, approximately 90 days). Biobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. Samples will be collected at the time of enrollment and after the completion of 30 days of therapy. Study Weblinks: Clinical Trials Study Design:     Interventional Study Type:Clinical TrialDouble-BlindInterventionalPlacebo-ControlledRandomizedRandomized Controlled Clinical TrialSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-06-01 and may not include exact formatting or images.	phs003063.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003063.v1.p1		Program: COVID 19	Study Registration: dbGaP							
phs003212.v1.p1.c1	10	phs003212.v1.p1.c1			/programs/DIR/projects/Eculizumab_GRU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients with Severe Thrombocytopenia (DIR-Eculizumab_GRU)							Eculizumab_GRU			Platelet transfusion can be a life-saving procedure in preventing or treating serious bleeding in patients who have low and/or dysfunctional platelets. Heavily transfused patients frequently develop human leukocyte antigen (HLA) allo-immunization resulting in platelet transfusion refractoriness and a high risk for life-threatening thrombocytopenia. Data suggest complement activation leading to the destruction of platelets bound by HLA allo-antibodies may play a pathophysiologic role in platelet refractoriness. We conducted a pilot trial to investigate the use of eculizumab to treat platelet transfusion refractoriness in allo-immunized patients with severe thrombocytopenia. We hypothesized that when we treated patients having platelet refractoriness with eculizumab, platelet counts would increase to higher numbers after platelet transfusions, decreasing the risk of bleeding complications associated with having a low platelet count. The response of the treatment was assessed by the corrected platelet count increment (CCI) 10 - 60 min and 18 - 24 h post transfusion, and any requirement for subsequent platelet transfusions following eculizumab. Reference 1 (PMID: 32086819) contains the main results for this trial.  Study Design:     Clinical Trial Study Type:Clinical TrialSubject Sample Telemetry Report (SSTR) NOTE: This text was scraped from https://www.ncbi.nlm.nih.gov/ on 2023-06-01 and may not include exact formatting or images.	phs003212.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003212.v1.p1		Study Registration: dbGaP								
phs003288.v1.p1.c1	6814	phs003288.v1.p1.c1			/programs/BioLINCC/projects/BL_MESA_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Multi-Ethnic Study of Atherosclerosis (BioLINCC)							BL_MESA_HMB			The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.Data available for request include data from exam 1 through exam 5 and events data updated through calendar year 2015. Also included are data from eleven ancillary studies: #079 (NT-ProBNP and Troponin), #042 (Epidemiology of Vascular Inflammation and Atherosclerosis), #081 (Apolipoproteins B and A-1), #067 (MRI RV-Function), #057 (Cystatin-C), #244 (NT Pro-BNP and HS Cardiac Troponin-T), #205 (Brachial IMT), #113 (Exam 5 Sleep), #047/075 (Vitamin D), #195 (Fatty Acid), #200 (Total FFA), #324 (Lipoprotein A), #023 (Neighborhood Racial Segregation), and #118 (Stress Cortisol).	phs003288.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003288.v1.p1		Study Registration: dbGaP								
phs003288.v1.p1.c2	6043	phs003288.v1.p1.c2			/programs/BioLINCC/projects/BL_MESA_HMB-NPU	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Multi-Ethnic Study of Atherosclerosis (BioLINCC)							BL_MESA_HMB-NPU			The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent.Data available for request include data from exam 1 through exam 5 and events data updated through calendar year 2015. Also included are data from eleven ancillary studies: #079 (NT-ProBNP and Troponin), #042 (Epidemiology of Vascular Inflammation and Atherosclerosis), #081 (Apolipoproteins B and A-1), #067 (MRI RV-Function), #057 (Cystatin-C), #244 (NT Pro-BNP and HS Cardiac Troponin-T), #205 (Brachial IMT), #113 (Exam 5 Sleep), #047/075 (Vitamin D), #195 (Fatty Acid), #200 (Total FFA), #324 (Lipoprotein A), #023 (Neighborhood Racial Segregation), and #118 (Stress Cortisol).	phs003288.v1.p1.c2		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003288.v1.p1		Study Registration: dbGaP								
phs003419.v1.p1.c1	1376	phs003419.v1.p1.c1			/programs/COVID19/projects/BLUE_CORAL_HMB	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Prevention and Early Treatment of Acute Lung Injury (PETAL) Network: Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study (BLUE CORAL)							BLUE_CORAL_HMB			The BLUE CORAL study is a research study that is collecting information to learn more about SARS-CoV-2, the virus that causes COVID-19, and how to better care for people who are sick from COVID-19. BLUE CORAL is a detailed prospective cohort study of patients hospitalized with acute SARS-CoV2 infection at PETAL Network hospitals. The primary objective of BLUE CORAL is to describe the clinical characteristics, treatments, biology and outcomes of 1500 hospitalized patients with Covid-19. In addition to all hospital data collected in RED CORAL, BLUE CORAL adds (1) in-hospital surveys detailing premorbid function, (2) biospecimen collection, and (3) centralized post-hospital telephone follow-up at 1, 3 and 6 months after hospital discharge.	phs003419.v1.p1.c1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs003419.v1.p1		Program: COVID 19	Study Registration: dbGaP							
tutorial-RECOVER_synthetic_data_set_1	92	RECOVER_synthetic_data_set_1			/programs/tutorial/projects/RECOVER_synthetic_data_set_1	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov									Researching COVID to Enhance Recovery (RECOVER) - Synthetic Dataset							RECOVER_synthetic_data_set_1			The National Institutes of Health (NIH) created the RECOVER Initiative to learn about the long-term effects of COVID. The goal of RECOVER is to rapidly improve our understanding of and ability to predict, treat, and prevent PASC (post-acute sequelae of SARS-CoV-2), including Long COVID.	RECOVER_synthetic_data_set_1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..										
tutorial-biolincc_camp	695	tutorial-biolincc_camp			/programs/tutorial/projects/biolincc_camp	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																				tutorial-biolincc_camp		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..		Program: Tutorial	Data Type: Clinical Phenotype							
tutorial-biolincc_digitalis	6800	biolincc_digitalis_study			programs/tutorial/projects/biolincc_digitalis	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																				biolincc_digitalis_study		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..		Program: Tutorial	Data Type: Clinical Phenotype							
tutorial-biolincc_framingham	4434	tutorial-biolincc_framingham			/programs/tutorial/projects/biolincc_framingham	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																			The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular\\ndisease among a population of free living subjects in the community of Framingham,\\nMassachusetts. The Framingham Heart Study was a landmark study in epidemiology in that it\\nwas the first prospective study of cardiovascular disease and identified the concept of risk\\nfactors and their joint effects. The study began in 1948 and 5,209 subjects were initially enrolled\\nin the study. Participants have been examined biennially since the inception of the study and all\\nsubjects are continuously followed through regular surveillance for cardiovascular outcomes.\\nClinic examination data has included cardiovascular disease risk factors and markers of\\ndisease such as blood pressure, blood chemistry, lung function, smoking history, health\\nbehaviors, ECG tracings, Echocardiography, and medication use. Through regular surveillance\\nof area hospitals, participant contact, and death certificates, the Framingham Heart Study\\nreviews and adjudicates events for the occurrence of Angina Pectoris, Myocardial Infarction,\\nHeart Failure, and Cerebrovascular disease.\\nThe enclosed dataset is a subset of the data collected as part of the Framingham study and\\nincludes laboratory, clinic, questionnaire, and adjudicated event data on 4,434 participants.\\nParticipant clinic data was collected during three examination periods, approximately 6 years\\napart, from roughly 1956 to 1968. Each participant was followed for a total of 24 years for the\\noutcome of the following events: Angina Pectoris, Myocardial Infarction, Atherothrombotic\\nInfarction or Cerebral Hemorrhage (Stroke) or death. (NOTE: Although the enclosed dataset\\ncontains Framingham data 'as collected' by Framingham investigators, specific methods\\nwere employed to ensure an anonymous dataset that protects patient confidentiality;\\ntherefore, this dataset is inappropriate for publication purposes. All persons teaching\\nwith this dataset are encouraged to ensure all users are aware that this dataset is\\ninappropriate for publication purposes.)	tutorial-biolincc_framingham		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..		Program: Tutorial	Data Type: Clinical Phenotype							
tutorial-synthetic_data_set_1	2504	tutorial-synthetic_data_set_1			/programs/tutorial/projects/synthetic_data_set_1	BioData Catalyst	BioData Catalyst	gen3.biodatacatalyst.nhlbi.nih.gov																			high_coverage_2019_Public	tutorial-synthetic_data_set_1		https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=..		Program: Tutorial	Data Type: Genotype	Data Type: Clinical Phenotype						
4d_lung	20	4d_lung	4d_lung			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	4D_LUNG		Non-small Cell Lung Cancer	10.7937/K9/TCIA.2016.ELN8YGLE			4D_LUNG		CT, RTSTRUCT	Lung				4D_LUNG		Human	This data collection consists of images acquired during chemoradiotherapy of 20 locally-advanced, non-small cell lung cancer patients. The images include four-dimensional (4D) fan beam (4D-FBCT) and 4D cone beam CT (4D-CBCT). All patients underwent concurrent radiochemotherapy to a total dose of 64.8-70 Gy using daily 1.8 or 2 Gy fractions.A single Radiation Oncologist delineated targets and organs at risk in all 4D-FBCT and a limited number of 4D-CBCT images. All patients underwent concurrent radiochemotherapy to a total dose of 64.8-70 Gy using daily 1.8 or 2 Gy fractions.Please see the 4D-Lung  page to learn more about the images and to obtain any supporting metadata for this collection.		4d_lung			disease_type: Non-small Cell Lung Cancer	data_type: Image Analyses	primary_site: Lung						
acrin_flt_breast	83	acrin_flt_breast	acrin_flt_breast			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	ACRIN_FLT_BREAST		Breast Cancer	10.7937/K9/TCIA.2017.OL20ZMXG			ACRIN_FLT_BREAST		CT, OT, PT	Breast				ACRIN_FLT_BREAST		Human	ACRIN 6688, a [18F]-fluorothymidine (FLT) imaging study using positron emission tomography (PET), was designed to evaluate the relationship between [18F] FLT uptake parameters and pathologic complete response to neoadjuvant therapy of the primary tumor in patients with locally advanced breast cancer.Participant Eligibility and Enrollment: Criteria for inclusion were patients with pathologically confirmed breast cancer and determined to be a candidate for primary systemic (neoadjuvant) therapy and for whom surgical resection of residual primary tumor following completion of neoadjuvant therapy is planned.Please see the ACRIN-FLT-Breast  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		acrin_flt_breast			disease_type: Breast Cancer	data_type: Clinical	primary_site: Breast						
acrin_nsclc_fdg_pet	242	acrin_nsclc_fdg_pet	acrin_nsclc_fdg_pet			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	ACRIN_NSCLC_FDG_PET		Non-small Cell Lung Cancer	10.7937/TCIA.2019.30ILQFCL			ACRIN_NSCLC_FDG_PET		CR, CT, DX, MR, NM, PT, SC, SEG	Lung				ACRIN_NSCLC_FDG_PET		Human	Thirty-seven institutions accrued 250 patients to the study ACRIN 6668.  Eligible patients were &gt;18 years with AJCC-criteria clinical stage IIB/III non-small cell lung carcinoma who were being planned for definitive concurrent chemoradiotherapy (inoperable disease). 173 had evaluable post-treatment PET, representing the analysis cohort for the primary end point.Please see the ACRIN-NSCLC-FDG-PET  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		acrin_nsclc_fdg_pet			disease_type: Non-small Cell Lung Cancer	data_type: Clinical	primary_site: Lung						
anti_pd_1_lung	46	anti_pd_1_lung	anti_pd_1_lung			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				ANTI_PD_1_LUNG		Lung Cancer	10.7937/TCIA.2019.ZJJWB9IP			ANTI_PD_1_LUNG		CT, PT, SC, SEG	Lung				ANTI_PD_1_LUNG		Human	This collection includes 46 lung cases treated with anti-PD1 immunotherapy in 2016, each with pre-treatment imaging (CT,PT,SC) and most with 1 imaging follow-up timepoint.Please see the Anti-PD-1_Lung  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		anti_pd_1_lung			disease_type: Lung Cancer	data_type: 	primary_site: Lung						
b_mode_and_ceus_liver	120	b_mode_and_ceus_liver	b_mode_and_ceus_liver			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	B_MODE_AND_CEUS_LIVER		Liver Cancer	10.7937/TCIA.2021.V4Z7-TC39			B_MODE_AND_CEUS_LIVER		US	Liver				B_MODE_AND_CEUS_LIVER		Human	This Collection contains contrast-enhanced ultrasound to a) characterize liver lesions and b) monitor treatment response. Sagittal and transverse plane ultrasound data was obtained with curvilinear probe.Please see the B-mode-and-CEUS-Liver  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		b_mode_and_ceus_liver			disease_type: Liver Cancer	data_type: Clinical	primary_site: Liver						
breast_cancer_screening_dbt	5060	breast_cancer_screening_dbt	breast_cancer_screening_dbt			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	BREAST_CANCER_SCREENING_DBT		Breast Cancer	10.7937/E4WT-CD02			BREAST_CANCER_SCREENING_DBT		MG	Breast				BREAST_CANCER_SCREENING_DBT		Human	Breast cancer is among the most common cancers and a common cause of death among women. Here, we share a curated dataset of digital breast tomosynthesis images that includes normal, actionable, biopsy-proven benign, and biopsy-proven cancer cases.  The dataset contains four components: (1) DICOM images, (2) a spreadsheet indicating which group each case belongs to, and (3) annotation boxes. Please see the Breast-Cancer-Screening-DBT  to learn more about the images and to obtain any supporting metadata for this collection.		breast_cancer_screening_dbt			disease_type: Breast Cancer	data_type: Clinical	primary_site: Breast						
breast_diagnosis	88	breast_diagnosis	breast_diagnosis			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	BREAST_DIAGNOSIS		Breast Cancer	10.7937/K9/TCIA.2015.SDNRQXXR			BREAST_DIAGNOSIS		CT, MG, MR, PT, SR	Breast				BREAST_DIAGNOSIS		Human	The Breast-Diagnosis collection contains cases that are high-risk normals, DCIS, fibroids and lobular carcinomas. Each case has 3 or more distinct MR pulse sequences from a Phillips 1.5 T (usual sequences are labeled T2, STIR and BLISS but may occasionally include other pulse sequences and digital mammogram of tumor specimen).  Multiple time point studies on the same patient are possible. Please see the BREAST-DIAGNOSIS  page to learn more about the images and to obtain any supporting metadata for this collection.		breast_diagnosis			disease_type: Breast Cancer	data_type: Clinical, Image Analyses	primary_site: Breast						
breast_mri_nact_pilot	64	breast_mri_nact_pilot	breast_mri_nact_pilot			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	BREAST_MRI_NACT_PILOT		Breast Cancer	10.7937/K9/TCIA.2016.QHSYHJKY			BREAST_MRI_NACT_PILOT		MR, SEG, SR	Breast				BREAST_MRI_NACT_PILOT		Human	This pilot study to investigate the use of serial DCE MRI examinations during neoadjuvant chemotherapy (NACT) for invasive breast cancer recruited 68 patients with stage II or III locally advanced breast cancer. Longitudinal DCE MRI studies of 64 patients are available.Please see the wiki page Breast-MRI-NACT-Pilot  to learn more about the images and to obtain any supporting metadata for this collection.		breast_mri_nact_pilot			disease_type: Breast Cancer	data_type: Clinical, Image Analyses	primary_site: Breast						
c4kc_kits	210	c4kc_kits	c4kc_kits			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				C4KC_KITS		Kidney Cancer	10.7937/TCIA.2019.IX49E8NX			C4KC_KITS		CT, SEG	Kidney				C4KC_KITS		Human	Data from the training set of the 2019 Kidney and Kidney Tumor Segmentation Challenge (C4KC-KiTS)This collection contains subjects from the training set of the 2019 Kidney and Kidney Tumor Segmentation Challenge  (KiTS19). The challenge aimed to accelerate progress in automatic 3D semantic segmentation by releasing a dataset of CT scans for 210 patients with manual semantic segmentations of the kidneys and tumors in the corticomedullary phase.The imaging was collected during routine care of patients who were treated by either partial or radical nephrectomy at the University of Minnesota Medical Center. Many of the CT scans were acquired at referring institutions and are therefore heterogeneous in terms of scanner manufacturers and acquisition protocols. Semantic segmentations were performed by students under the supervision of an experienced urologic cancer surgeon.Please see the C4KC-KiTS  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		c4kc_kits			disease_type: Kidney Cancer	data_type: 	primary_site: Kidney						
cmmd	1775	cmmd	cmmd			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	CMMD		Breast Cancer	10.7937/TCIA.EQDE-4B16			CMMD		MG	Breast				CMMD		Human	This collection contains clinical data and 3,728 mammographies (MG) from 1,775 patients, with biopsy-confirmed benign or malignant breast tumors. For a subset of 749 patients (D2-####), molecular subtype is included.&#160;Please see the&#160;CMMD&#160; wiki page for further detail and associated metadata.		cmmd			disease_type: Breast Cancer	data_type: Clinical	primary_site: Breast						
covid_19_ar	105	covid_19_ar	covid_19_ar			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	COVID_19_AR		COVID-19 (non-cancer)	10.7937/TCIA.2020.PY71-5978			COVID_19_AR		CR, CT, DX	Lung				COVID_19_AR		Human	Radiology imaging  is playing an increasingly vital role in the diagnosis of COVID-19 patients and determining therapeutic options, patient care management and new research directions. We have published a collection of radiographic and CT imaging studies for patients who tested positive for COVID-19. Each patient is described by a limited set of clinical data correlates that includes demographics, comorbidities, selected lab data and key radiology findings. These data are cross-linked to SARS-COV-2 cDNA sequence data extracted from clinical isolates from the same population, uploaded to the Genbank repository. Please see the COVID-19-AR  page to learn more about the images and to obtain any supporting metadata for this collection.		covid_19_ar			disease_type: COVID-19 (non-cancer)	data_type: Clinical, Genomics	primary_site: Lung						
covid_19_ny_sbu	1384	covid_19_ny_sbu	covid_19_ny_sbu			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	COVID_19_NY_SBU		COVID-19 (non-cancer)	10.7937/TCIA.BBAG-2923			COVID_19_NY_SBU		CR, CT, DX, MR, NM, OT, PT, SR	Lung				COVID_19_NY_SBU		Human	&#10;&#9;The collection of cases was acquired at Stony Brook University from patients who tested positive for COVID-19. The collection includes images from different modalities and organ sites (chest radiographs, chest CTs, brain MRIs, etc.). Radiology imaging data is extremely important in COVID-19 from both a diagnostic and a monitoring perspective, given the crucial nature of COVID-19 pulmonary disease and its rapid phenotypic changes.&#10;&#10;&#9;Please see the Stony Brook University COVID-19 Positive Cases &#160;wiki page to learn more about the images and to obtain any supporting metadata for this collection.&#10;		covid_19_ny_sbu			disease_type: COVID-19 (non-cancer)	data_type: Clinical, Image Analyses	primary_site: Lung						
cptac_ccrcc	227	cptac_ccrcc	cptac_ccrcc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Proteomics	CPTAC_CCRCC		Clear Cell Carcinoma	10.7937/K9/TCIA.2018.OBLAMN27			CPTAC_CCRCC		CT, MR, RTSTRUCT, SM	Kidney				CPTAC_CCRCC		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Clear Cell Renal Cell Carcinoma (CPTAC-CCRCC) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data. Please see the CPTAC-CCRCC  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_ccrcc			disease_type: Clear Cell Carcinoma	data_type: Clinical, Genomics, Proteomics	primary_site: Kidney						
cptac_cm	95	cptac_cm	cptac_cm			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	CPTAC_CM		Cutaneous Melanoma	10.7937/K9/TCIA.2018.ODU24GZE			CPTAC_CM		CT, MR, PT, SM	Skin				CPTAC_CM		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Cutaneous Melanoma (CPTAC-CM) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data. Please see the CPTAC-CM  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_cm			disease_type: Cutaneous Melanoma	data_type: Clinical	primary_site: Skin						
cptac_gbm	178	cptac_gbm	cptac_gbm			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Proteomics	CPTAC_GBM		Glioblastoma Multiforme	10.7937/K9/TCIA.2018.3RJE41Q1			CPTAC_GBM		SM	Brain				CPTAC_GBM		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Glioblastoma Multiforme (CPTAC-GBM) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data. Please see the CPTAC-GBM  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_gbm			disease_type: Glioblastoma Multiforme	data_type: Clinical, Genomics, Proteomics	primary_site: Brain						
cptac_hnscc	112	cptac_hnscc	cptac_hnscc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Proteomics	CPTAC_HNSCC		Head and Neck Cancer	10.7937/K9/TCIA.2018.UW45NH81			CPTAC_HNSCC		SM	Head-Neck				CPTAC_HNSCC		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Head-and-Neck cancer (CPTAC-HNSCC) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data.Please see the CPTAC-HNSCC  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_hnscc			disease_type: Head and Neck Cancer	data_type: Clinical, Genomics, Proteomics	primary_site: Head-Neck						
cptac_lscc	212	cptac_lscc	cptac_lscc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Proteomics	CPTAC_LSCC		Squamous Cell Carcinoma	10.7937/K9/TCIA.2018.6EMUB5L2			CPTAC_LSCC		CT, PT, SM	Lung				CPTAC_LSCC		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Lung Squamous Cell Carcinoma (CPTAC-LSCC) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data. Please see the CPTAC-LSCC  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_lscc			disease_type: Squamous Cell Carcinoma	data_type: Clinical, Genomics, Proteomics	primary_site: Lung						
cptac_luad	244	cptac_luad	cptac_luad			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Proteomics	CPTAC_LUAD		Adenocarcinoma	10.7937/K9/TCIA.2018.PAT12TBS			CPTAC_LUAD		CT, MR, PT, SM	Lung				CPTAC_LUAD		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Lung Adenocarcinoma (CPTAC-LUAD) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data.Please see the CPTAC-LUAD  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_luad			disease_type: Adenocarcinoma	data_type: Clinical, Genomics, Proteomics	primary_site: Lung						
cptac_pda	194	cptac_pda	cptac_pda			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	CPTAC_PDA		Ductal Adenocarcinoma	10.7937/K9/TCIA.2018.SC20FO18			CPTAC_PDA		CT, MR, PT, RTSTRUCT, SM, US	Pancreas				CPTAC_PDA		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Pancreatic Ductal Adenocarcinoma (CPTAC-PDA) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data. Please see the CPTAC-PDA  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_pda			disease_type: Ductal Adenocarcinoma	data_type: Clinical	primary_site: Pancreas						
cptac_sar	88	cptac_sar	cptac_sar			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	CPTAC_SAR		Sarcomas	10.7937/TCIA.2019.9BT23R95			CPTAC_SAR		CT, MR, PT, SM	Abdomen, Arm, Bladder, Chest, Head-Neck, Kidney, Leg, Retroperitoneum, Stomach, Uterus				CPTAC_SAR		Human	This collection contains subjects from the National Cancer Institute&rsquo;s Clinical Proteomic Tumor Analysis Consortium Sarcomas (CPTAC-SAR) cohort.  CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data.Please see the CPTAC-SAR  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_sar			disease_type: Sarcomas	data_type: Clinical	primary_site: Abdomen, Arm, Bladder, Chest, Head-Neck, Kidney, Leg, Retroperitoneum, Stomach, Uterus						
cptac_ucec	250	cptac_ucec	cptac_ucec			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Proteomics	CPTAC_UCEC		Corpus Endometrial Carcinoma	10.7937/K9/TCIA.2018.3R3JUISW			CPTAC_UCEC		CT, MR, PT, RTSTRUCT, SM	Uterus				CPTAC_UCEC		Human	This collection contains subjects from the National Cancer Institute''s Clinical Proteomic Tumor Analysis Consortium Uterine Corpus Endometrial Carcinoma (CPTAC-UCEC) cohort. CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Radiology and pathology images from CPTAC Phase 3 patients are being collected and made publicly available by The Cancer Imaging Archive to enable researchers to investigate cancer phenotypes which may correlate to corresponding proteomic, genomic and clinical data.Please see the CPTAC-UCEC  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		cptac_ucec			disease_type: Corpus Endometrial Carcinoma	data_type: Clinical, Genomics, Proteomics	primary_site: Uterus						
ct_colonography	825	ct_colonography	ct_colonography			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	CT_COLONOGRAPHY		Colon Cancer	10.7937/K9/TCIA.2015.NWTESAY1			CT_COLONOGRAPHY		CT	Colon				CT_COLONOGRAPHY		Human	The CT Colonography collection consists of a limited portion of The National CT Colonography Trial (ACRIN PROTOCOL 6664 ). The collection is offered to enlarge the broader research community''s ability to develop CAD algorithms for polyp detection. Please see the CT COLONOGRAPHY wiki page to learn more about the images and to obtain any supporting metadata for this collection.		ct_colonography			disease_type: Colon Cancer	data_type: Image Analyses	primary_site: Colon						
ct_lymph_nodes	176	ct_lymph_nodes	ct_lymph_nodes			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	CT_LYMPH_NODES		Lymphadenopathy (non-cancer)	10.7937/K9/TCIA.2015.AQIIDCNM			CT_LYMPH_NODES		CT, SEG	Abdomen, Mediastinum				CT_LYMPH_NODES		Human	This collection consists of Computed Tomography (CT) images of the mediastinum and abdomen in which lymph node positions are marked by radiologists at the National Institutes of Health, Clinical Center. Radiologists at the Imaging Biomarkers and Computer-Aided Diagnosis Laboratory labeled a total of 388 mediastinal lymph nodes in CT images of 90 patients and a total of 595 abdominal lymph nodes in 86 patients.Please see the CT Lymph Nodes  wiki page to learn more about the images and to obtain supporting data from this collection.		ct_lymph_nodes			disease_type: Lymphadenopathy (non-cancer)	data_type: Image Analyses	primary_site: Abdomen, Mediastinum						
dro_toolkit	32	dro_toolkit	dro_toolkit			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				DRO_TOOLKIT		Phantom	10.7937/T062-8262			DRO_TOOLKIT		CT, SEG	Phantom				DRO_TOOLKIT		Human	DRO Toolkit: This is a sample collection of synthetic 3D Digital Reference Objects (DROs) intended for standardization of quantitative imaging feature extraction pipelines. We have developed a software toolkit for the creation of DROs with customizable size, shape, intensity, texture, and margin sharpness values. Using user-supplied input parameters, these objects are defined mathematically as continuous functions, discretized, and then saved as DICOM objects. This collection includes objects with a range of values for the various feature categories and many combinations of these categories.Please see the DRO Toolkit  page to learn more about the images and to obtain the supporting metadata for this collection.		dro_toolkit			disease_type: Phantom	data_type: 	primary_site: Phantom						
duke_breast_cancer_mri	922	duke_breast_cancer_mri	duke_breast_cancer_mri			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	DUKE_BREAST_CANCER_MRI		Breast Cancer	10.7937/TCIA.E3SV-RE93			DUKE_BREAST_CANCER_MRI		MR, SEG	Breast				DUKE_BREAST_CANCER_MRI		Human	Dynamic contrast-enhanced magnetic resonance images of breast cancer patients with tumor locations (Duke-Breast-Cancer-MRI)This collection contains MRI imaging and other data for 922 patients with invasive breast cancer. Prone position axial breast MRI images were acquired by 1.5T or 3T scanners;  non-fat saturated T1, fat-saturated gradient echo T1 pre-contrast, and 3-4 post-contrast sequences are included.Please see the Duke-Breast-Cancer-MRI  wiki page to learn more about the images and to obtain the supporting metadata for this collection.		duke_breast_cancer_mri			disease_type: Breast Cancer	data_type: Clinical, Genomics, Image Analyses	primary_site: Breast						
icdc_glioma	80	icdc_glioma	icdc_glioma			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Genomics	ICDC_GLIOMA		Glioma	10.7937/TCIA.SVQT-Q016			ICDC_GLIOMA		MR, SM	Head				ICDC_GLIOMA		Canine	ICDC-Glioma &#160;contains treatment-na&#239;ve naturally-occurring canine glioma participants from the&#160;Integrated Canine Data Commons. Brain radiology (57/81 participant animals) and H&amp;E-stained biopsy or necropsy pathology (76/81 participants) are classified by veterinary and physician neuropathologists.&#10;&#9;&#10;&#9;Please see the wiki ICDC-Glioma &#160;to learn more about the images and to obtain any supporting metadata for this collection.&#10;		icdc_glioma			disease_type: Glioma	data_type: Genomics	primary_site: Head						
ispy1	222	ispy1	ispy1			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	ISPY1		Breast Cancer	10.7937/K9/TCIA.2016.HDHPGJLK			ISPY1		MR, SEG, SR	Breast				ISPY1		Human	ISPY1/ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting pathologic complete response (pCR) and recurrence-free survival (RFS).The collection consists of 847 MR studies from 222 subjects.Please see the ISPY1  page to learn more about the images and to obtain any supporting metadata for this collection.		ispy1			disease_type: Breast Cancer	data_type: Clinical, Image Analyses	primary_site: Breast						
lctsc	60	lctsc	lctsc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	LCTSC		Lung Cancer	10.7937/K9/TCIA.2017.3R3FVZ08			LCTSC		CT, RTSTRUCT	Lung				LCTSC		Human	This Lung CT and Radiation therapy data set was provided in association with an autocontouring challenge competition and related conference session  conducted at the AAPM 2017 Annual Meeting  Please see the LCTSC  wiki page to learn more about the images and to obtain any supporting metadata for this collection. 		lctsc			disease_type: Lung Cancer	data_type: Image Analyses	primary_site: Lung						
lidc_idri	1010	lidc_idri	lidc_idri			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	LIDC_IDRI		Lung Cancer	10.7937/K9/TCIA.2015.LO9QL9SX			LIDC_IDRI		CR, CT, DX, SEG, SR	Chest				LIDC_IDRI		Human	The Lung Image Database Consortium (LIDC-IDRI) image collection consists of diagnostic and lung cancer screening thoracic CT scans with marked-up annotated lesions. It is a web-accessible international resource for development, training, and evaluation of computer-assisted diagnostic (CAD) methods for lung cancer detection and diagnosis. &#10;&#10;For more information about the LIDC-IDRI images please visit the LIDC-IDRI  page.&#160; For comprehensive information about utilizing the associated metadata please see the Research Project page for the Lung Image Database Consortium .		lidc_idri			disease_type: Lung Cancer	data_type: Clinical, Image Analyses	primary_site: Chest						
lung_fused_ct_pathology	6	lung_fused_ct_pathology	lung_fused_ct_pathology			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	LUNG_FUSED_CT_PATHOLOGY		Lung Cancer	10.7937/K9/TCIA.2018.SMT36LPN			LUNG_FUSED_CT_PATHOLOGY		CT, FUSION, SEG	Lung				LUNG_FUSED_CT_PATHOLOGY		Human	This is the first attempt of mapping the extent of Invasive Adenocarcinoma onto in vivo lung CT. The mappings constitute ground truth of disease and may be used to further investigate the imaging signatures of Invasive Adenocarcinoma in ground glass pulmonary nodules. Please see the Lung-Fused-CT-Pathology  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		lung_fused_ct_pathology			disease_type: Lung Cancer	data_type: Image Analyses	primary_site: Lung						
lung_pet_ct_dx	355	lung_pet_ct_dx	lung_pet_ct_dx			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	LUNG_PET_CT_DX		Lung Cancer	10.7937/TCIA.2020.NNC2-0461			LUNG_PET_CT_DX		CT, PT, SEG	Lung				LUNG_PET_CT_DX		Human	This dataset consists of CT and PET-CT DICOM images of lung cancer subjects with XML Annotation files that indicate tumor location with bounding boxes. The images were retrospectively acquired from patients with suspicion of lung cancer, and who underwent standard-of-care lung biopsy and PET/CT. Subjects were grouped according to a tissue histopathological diagnosis. Patients with Names/IDs containing the letter ,,A,, were diagnosed with Adenocarcinoma, ,,B,, with Small Cell Carcinoma, ,,C,, with Large Cell Carcinoma, and ,,G,, with Squamous Cell Carcinoma.Please see the LUNG-PET-CT-Dx  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		lung_pet_ct_dx			disease_type: Lung Cancer	data_type: Image Analyses	primary_site: Lung						
lung_phantom	1	lung_phantom	lung_phantom			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	LUNG_PHANTOM		Phantom	10.7937/K9/TCIA.2015.08A1IXOO			LUNG_PHANTOM		CT, SEG	Lung Phantom				LUNG_PHANTOM		Human	The FDA anthropomorphic thorax phantom with 12 phantom lesions of different sizes (10 and 20 mm in effective diameter), shapes (spherical, elliptical, lobulated, and spiculated), and densities (&minus;630,&minus;10, and +100 HU) was scanned at Columbia University Medical Center on a 64-detector row scanner (LightSpeed VCT, GE Healthcare, Milwaukee, WI). The CT scanning parameters were 120 kVp, 100 mAs, 64x0.625 collimation, and pitch of 1.375. The images were reconstructed with the lung kernel using 1.25 mm slice thickness.Please see the Lung Phantom  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		lung_phantom			disease_type: Phantom	data_type: Image Analyses	primary_site: Lung Phantom						
lungct_diagnosis	61	lungct_diagnosis	lungct_diagnosis			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	LUNGCT_DIAGNOSIS		Lung Cancer	10.7937/K9/TCIA.2015.A6V7JIWX			LUNGCT_DIAGNOSIS		CT	Lung				LUNGCT_DIAGNOSIS		Human	This is a small set of 61 diagnostic contrast enhanced CT scans with known tumors.  The images were retrospectively acquired, to ensure sufficient patient follow-up. Slice thickness is variable : between 3 and 6 mm. All images were done at diagnosis and prior to surgery. Please see the LungCT-Diagnosis  page to learn more about the images and to obtain any supporting metadata for this collection.		lungct_diagnosis			disease_type: Lung Cancer	data_type: Clinical, Image Analyses	primary_site: Lung						
midrc_ricord_1a	110	midrc_ricord_1a	midrc_ricord_1a			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	MIDRC_RICORD_1A		COVID-19 (non-cancer)	10.7937/VTW4-X588			MIDRC_RICORD_1A		CT	Lung				MIDRC_RICORD_1A		Human	The Radiological Society of North America (RSNA) set out to create the RSNA International COVID-19 Open Radiology Database (RICORD)  collection of COVID-related imaging datasets and expert annotations to support research and education. RICORD data will be incorporated in the Medical Imaging and Data Resource Center (MIDRC) , a multi-institutional research data repository funded by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health.Please see the MIDRC-RICORD-1a  WIKI page to learn more about the images and to obtain any supporting metadata for this collection.		midrc_ricord_1a			disease_type: COVID-19 (non-cancer)	data_type: Clinical	primary_site: Lung						
midrc_ricord_1b	117	midrc_ricord_1b	midrc_ricord_1b			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	MIDRC_RICORD_1B		COVID-19 (non-cancer)	10.7937/31V8-4A40			MIDRC_RICORD_1B		CT	Lung				MIDRC_RICORD_1B		Human	The first multi-institutional, multi-national expert annotated COVID-19 imaging dataset made freely available to the machine learning community as a research and educational resource for COVID-19 chest imaging. The Radiological Society of North America (RSNA) assembled the RSNA International COVID-19 Open Radiology Database (RICORD)  collection of COVID-related imaging datasets and expert annotations to support research and education. RICORD data will be incorporated in the Medical Imaging and Data Resource Center (MIDRC) , a multi-institutional research data repository funded by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health.Please see the MIDRC-RICORD-1b  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		midrc_ricord_1b			disease_type: COVID-19 (non-cancer)	data_type: Clinical	primary_site: Lung						
midrc_ricord_1c	361	midrc_ricord_1c	midrc_ricord_1c			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	MIDRC_RICORD_1C		COVID-19 (non-cancer)	10.7937/91AH-V663			MIDRC_RICORD_1C		CR, DX	Lung				MIDRC_RICORD_1C		Human	The first multi-institutional, multi-national expert annotated COVID-19 imaging dataset made freely available to the machine learning community as a research and educational resource for COVID-19 chest imaging. The Radiological Society of North America (RSNA) assembled the RSNA International COVID-19 Open Radiology Database (RICORD)  collection of COVID-related imaging datasets and expert annotations to support research and education. RICORD data will be incorporated in the Medical Imaging and Data Resource Center (MIDRC) , a multi-institutional research data repository funded by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health. The collection contains 998 Chest x-ray examinations.Please see the MIDRC-RICORD-1c  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		midrc_ricord_1c			disease_type: COVID-19 (non-cancer)	data_type: Clinical	primary_site: Lung						
mouse_astrocytoma	48	mouse_astrocytoma	mouse_astrocytoma			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				MOUSE_ASTROCYTOMA		Glioblastoma Multiforme	10.7937/K9TCIA.2017.SGW7CAQW			MOUSE_ASTROCYTOMA		MR	Head				MOUSE_ASTROCYTOMA		Mouse	This collection consists of magnetic resonance images (MRI) of genetically engineered mouse models (GEMMs) of high grade astrocytoma, including glioblastoma multiforme (GBM).The MRI data contained herein includes anatomic T2 weighted images and dynamic contrast enhanced MRI.Please see the Mouse-Astrocytoma   page to learn more about the images and to obtain any supporting metadata for this collection.		mouse_astrocytoma			disease_type: Glioblastoma Multiforme	data_type: 	primary_site: Head						
mouse_mammary	32	mouse_mammary	mouse_mammary			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				MOUSE_MAMMARY		Breast Cancer	10.7937/K9/TCIA.2015.9P42KSE6			MOUSE_MAMMARY		MR	Abdomen				MOUSE_MAMMARY		Mouse	This collection consists of Magnetic Resonance Imaging (MRI) of mouse breast cancer in 32 mice.  Please see the Mouse-Mammary  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		mouse_mammary			disease_type: Breast Cancer	data_type: 	primary_site: Abdomen						
naf_prostate	9	naf_prostate	naf_prostate			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				NAF_PROSTATE		Prostate Cancer	10.7937/K9/TCIA.2015.ISOQTHKO			NAF_PROSTATE		CT, PT	Prostate				NAF_PROSTATE		Human	This is a collection of F-18 NaF positron emission tomography/computed tomography (PET/CT) images in patients with prostate cancer, with suspected or known bone involvement.Please see the NaF PROSTATE  page to learn more about the images and to obtain any supporting metadata for this collection.		naf_prostate			disease_type: Prostate Cancer	data_type: 	primary_site: Prostate						
nlst	26408	nlst	nlst			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	NLST		Lung Cancer	10.7937/TCIA.HMQ8-J677			NLST		CT, SEG, SM, SR	Chest				NLST		Human	This collection contains all CT exams from the National Lung Screening Trial (NLST), which  was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer for persons at high risk for lung cancer at 33 U.S. medical centers.  Participants were randomly assigned to undergo three annual screenings between 2002-2004.&#160;NOTE: The full dataset occupies over 11 Terabytes on disk. Ensure you have what you need before downloading.Please see the NLST  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		nlst			disease_type: Lung Cancer	data_type: Clinical	primary_site: Chest						
nsclc_radiogenomics	211	nsclc_radiogenomics	nsclc_radiogenomics			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses, Genomics	NSCLC_RADIOGENOMICS		Non-small Cell Lung Cancer	10.7937/K9/TCIA.2017.7HS46ERV			NSCLC_RADIOGENOMICS		CT, PT, SEG	Chest				NSCLC_RADIOGENOMICS		Human	This collection contains images from patients with non-small cell lung cancer imaged prior to surgical excision with both thin-section CT and whole body PET/CT scans acquired under IRB approval from Stanford University and the Veterans Administration Palo Alto Health Care System.The first installment of 26 cases (see shared list &quot;NSCLC Radiogenomics: Initial Stanford Study of 26 Cases&quot;) corresponds to microarray data acquired from the excised samples, which is available on the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28827), where DICOM patient names are identical to microarray sample names.Please see the NSCLC Radiogenomics  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		nsclc_radiogenomics			disease_type: Non-small Cell Lung Cancer	data_type: Clinical, Image Analyses, Genomics	primary_site: Chest						
nsclc_radiomics	422	nsclc_radiomics	nsclc_radiomics			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	NSCLC_RADIOMICS		Lung Cancer	10.7937/K9/TCIA.2015.PF0M9REI			NSCLC_RADIOMICS		CT, RTSTRUCT, SEG, SR	Lung				NSCLC_RADIOMICS		Human	This collection contains images from 422 non-small cell lung cancer (NSCLC) patients. For these patients pretreatment CT scans and clinical outcome data are available. This dataset refers to the Lung1 dataset of the study published in Nature CommunicationsPlease see the NSCLC-Radiomics  page to learn more about the images and to obtain any supporting metadata for this collection.		nsclc_radiomics			disease_type: Lung Cancer	data_type: Clinical, Image Analyses	primary_site: Lung						
nsclc_radiomics_genomics	89	nsclc_radiomics_genomics	nsclc_radiomics_genomics			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	NSCLC_RADIOMICS_GENOMICS		Lung Cancer	10.7937/K9/TCIA.2015.L4FRET6Z			NSCLC_RADIOMICS_GENOMICS		CT	Lung				NSCLC_RADIOMICS_GENOMICS		Human	This collection contains images from 89 non-small cell lung cancer (NSCLC) patients that were treated with surgery. For these patients pretreatment CT scans, gene expression, and clinical data are available. This dataset refers to the Lung3 dataset of the study published in Nature Communications.Please see the NSCLC Radiomics Genomics  page to learn more about the images and to obtain any supporting metadata for this collection. 		nsclc_radiomics_genomics			disease_type: Lung Cancer	data_type: Clinical, Genomics	primary_site: Lung						
nsclc_radiomics_interobserver1	22	nsclc_radiomics_interobserver1	nsclc_radiomics_interobserver1			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	NSCLC_RADIOMICS_INTEROBSERVER1		Non-small Cell Lung Cancer	10.7937/TCIA.2019.CWVLPD26			NSCLC_RADIOMICS_INTEROBSERVER1		CT, RTSTRUCT, SEG	Lung				NSCLC_RADIOMICS_INTEROBSERVER1		Human	NSCLC-Radiomics-Interobserver1  contains clinical data and computed tomography (CT) from 22 non-small cell lung cancer (NSCLC) radiotherapy patients.  This dataset refers to the &#34;Multiple delineation&#34; dataset of the study published in Nature Communications (https://doi.org/10.1038/ncomms5006 ). In short, the publication used a radiomics approach to computed tomography data of 1,019 patients with lung or head-and-neck cancer.Please see the NSCLC-Radiomics-Interobserver1  page to learn more about the images and to obtain any supporting metadata for this collection.		nsclc_radiomics_interobserver1			disease_type: Non-small Cell Lung Cancer	data_type: Clinical	primary_site: Lung						
pancreas_ct	80	pancreas_ct	pancreas_ct			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	PANCREAS_CT		Healthy Controls (non-cancer)	10.7937/K9/TCIA.2016.TNB1KQBU			PANCREAS_CT		CT	Pancreas				PANCREAS_CT		Human	The National Institutes of Health Clinical Center performed 82 abdominal contrast enhanced 3D CT scans (~70 seconds after intravenous contrast injection in portal-venous) from 53 male and 27 female subjects.  Seventeen of the subjects are healthy kidney donors scanned prior to nephrectomy.  The remaining 65 patients were selected by a radiologist from patients who neither had major abdominal pathologies nor pancreatic cancer lesions. A medical student manually performed slice-by-slice segmentations of the pancreas as ground-truth and these were verified/modified by an experienced radiologist.Please see the Pancreas-CT  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		pancreas_ct			disease_type: Healthy Controls (non-cancer)	data_type: Image Analyses	primary_site: Pancreas						
pdmr_292921_168_r	20	pdmr_292921_168_r	pdmr_292921_168_r			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	PDMR_292921_168_R		Adenocarcinoma Pancreas	10.7937/TCIA.2020.PCAK-8Z10			PDMR_292921_168_R		MR, SR	Abdomen				PDMR_292921_168_R		Mouse	We identified and characterized a patient derived xenograft model with metastatic potential, adenocarcinoma pancreas xenograft 292921-168-R. In this study we performed a detailed imaging characterization of this model, which develops spontaneous lung metastases. Please see the Imaging characterization of a metastatic patient derived model of adenocarcinoma pancreas: PDMR-292921-168-R  wiki page to learn more about the images and to obtain any supporting metadata for this collection. 		pdmr_292921_168_r			disease_type: Adenocarcinoma Pancreas	data_type: Clinical	primary_site: Abdomen						
pdmr_425362_245_t	20	pdmr_425362_245_t	pdmr_425362_245_t			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	PDMR_425362_245_T		Melanoma	10.7937/TCIA.2020.7YRS-7J97			PDMR_425362_245_T		MR, SR	Abdomen				PDMR_425362_245_T		Mouse	We identified and characterized a patient derived xenograft model with metastatic potential, melanoma xenograft 425362-245-T. In this study we performed a detailed imaging characterization of this model, which develops spontaneous lung metastases.Please see the PDMR-425362-245-T  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		pdmr_425362_245_t			disease_type: Melanoma	data_type: Clinical	primary_site: Abdomen						
pdmr_833975_119_r	20	pdmr_833975_119_r	pdmr_833975_119_r			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	PDMR_833975_119_R		Adenocarcinoma Pancreas	10.7937/TCIA.0ECK-C338			PDMR_833975_119_R		MR, SR	Abdomen				PDMR_833975_119_R		Mouse	PDMR-833975-119-R  is a dataset of detailed MRI, PET/CT (FDG and FLT) in patient-derived xenograft in mouse model of pancreatic adenocarcinoma from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/) with baseline and bi-weekly monitoring imaging.Please see the PDMR-833975-119-R  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		pdmr_833975_119_r			disease_type: Adenocarcinoma Pancreas	data_type: Clinical	primary_site: Abdomen						
pdmr_997537_175_t	24	pdmr_997537_175_t	pdmr_997537_175_t			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	PDMR_997537_175_T		Adenocarcinoma Colon	10.7937/TCIA.2020.BRY9-4N29			PDMR_997537_175_T		MR, SR	Colon				PDMR_997537_175_T		Mouse	We identified and characterized a patient derived xenograft model with metastatic potential, adenocarcinoma colon xenograft 997537-175-T. In this study we performed a detailed imaging characterization of this model, which develops spontaneous lung metastases.Please see the PDMR-997537-175-T  wiki page to learn more about the images and to obtain any supporting metadata for this collection. 		pdmr_997537_175_t			disease_type: Adenocarcinoma Colon	data_type: Clinical	primary_site: Colon						
pdmr_bl0293_f563	19	pdmr_bl0293_f563	pdmr_bl0293_f563			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	PDMR_BL0293_F563		Bladder Cancer	10.7937/TCIA.2019.B6U7WMQW			PDMR_BL0293_F563		MR	Bladder				PDMR_BL0293_F563		Mouse	We identified and characterized a patient-derived xenograft model with metastatic potential, bladder xenograft BL0293-F563. In this study we performed a detailed imaging characterization of this model, which develops spontaneous liver and bone metastases.Please see the PDMR-BL0293-F563  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		pdmr_bl0293_f563			disease_type: Bladder Cancer	data_type: Clinical	primary_site: Bladder						
pelvic_reference_data	58	pelvic_reference_data	pelvic_reference_data			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	PELVIC_REFERENCE_DATA		Prostate, Anal	10.7937/TCIA.2019.WOSKQ5OO			PELVIC_REFERENCE_DATA		CT	Pelvis, Prostate, Anus				PELVIC_REFERENCE_DATA		Human	This collection links expertly selected landmark points on clinical image pairs to provide a basis for rigid registration validation. Using combinatorial rigid registration optimization (CORRO) we provide a statistically characterized reference data set for image registration of the pelvis by estimating the optimal ground truth. Landmark points for each CT/CBCT image pair for 58 pelvic cases were identified. The mean and the standard deviation of the registration were used as the final registration for each image pair.Please see the Pelvic-Reference-Data  wiki page to learn more about the images and to obtain any supporting metadata for this collection. 		pelvic_reference_data			disease_type: Prostate, Anal	data_type: Image Analyses	primary_site: Pelvis, Prostate, Anus						
phantom_fda	7	phantom_fda	phantom_fda			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				PHANTOM_FDA		Phantom	10.7937/K9/TCIA.2015.ORBJKMUX			PHANTOM_FDA		CT	Lung Phantom				PHANTOM_FDA		Human	A series of CT sets scanned at differing slice thicknesses and exposure parameters of a chest simulating phantom containing lung nodules. It was constructed by an NCI-FDA joint effort to provide data for nodule-detecting CAD processes.Please see the Phantom FDA  page to learn more about the images and to obtain any supporting metadata for this collection.		phantom_fda			disease_type: Phantom	data_type: 	primary_site: Lung Phantom						
prostate_3t	64	prostate_3t	prostate_3t			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	PROSTATE_3T		Prostate Cancer	10.7937/K9/TCIA.2015.QJTV5IL5			PROSTATE_3T		MR	Prostate				PROSTATE_3T		Human	Prostate transversal T2 -weighted MRIs acquired on a 3.0T Siemens TrioTim using only a pelvic phased array coil. Images were acquired for prostate cancer detection. Please see the Prostate-3T   page to learn more about the images and to obtain any supporting metadata for this collection.		prostate_3t			disease_type: Prostate Cancer	data_type: Image Analyses	primary_site: Prostate						
prostate_diagnosis	92	prostate_diagnosis	prostate_diagnosis			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	PROSTATE_DIAGNOSIS		Prostate Cancer	10.7937/K9/TCIA.2015.FOQEUJVT			PROSTATE_DIAGNOSIS		MR	Prostate				PROSTATE_DIAGNOSIS		Human	Prostate, cancer-confirmed, MRIs obtained using endorectal and phased array surface coils at 1.5T (Philips Achieva). Pulse sequences include T1, T2 and DCE (&ldquo;BLISS&rdquo; sequence using Magnevist injected i.v.). Linked clinical information, including matched patient demographics, radiology and pathology reports in XLS format are available.Please see the Prostate-Diagnosis  page to learn more about the images and to obtain any supporting metadata for this collection.Data was provided by Boston Medical Center courtesy Dr. Nicolas Bloch. 		prostate_diagnosis			disease_type: Prostate Cancer	data_type: Clinical, Image Analyses	primary_site: Prostate						
prostate_fused_mri_pathology	28	prostate_fused_mri_pathology	prostate_fused_mri_pathology			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	PROSTATE_FUSED_MRI_PATHOLOGY		Prostate Cancer	10.7937/K9/TCIA.2016.TLPMR1AM			PROSTATE_FUSED_MRI_PATHOLOGY		MR	Prostate				PROSTATE_FUSED_MRI_PATHOLOGY		Human	This collection comprises a total of 28 3 Tesla T1-weighted, T2-weighted, Diffusion weighted and Dynamic Contrast Enhanced prostate MRI along with accompanying digitized histopathology (H&amp;Estained) images of corresponding radical prostatectomy specimens.Fused MATLAB objects are also provided combining both the MR and Pathology Images.Please see the Prostate Fused-MRI-Pathology  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		prostate_fused_mri_pathology			disease_type: Prostate Cancer	data_type: Image Analyses	primary_site: Prostate						
prostate_mri	26	prostate_mri	prostate_mri			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				PROSTATE_MRI		Prostate Cancer	10.7937/K9/TCIA.2016.6046GUDV			PROSTATE_MRI		MR	Prostate				PROSTATE_MRI		Human	This is a collection of  MRIs of the prostate obtained with an endorectal coil and phased array surface coil at 3T (Philips Achieva).  Each patient had biopsy confirmation of cancer and then underwent robotic assisted radical prostatectomy.  A mold was generated from each MRI and the prostatectomy specimen was first placed in the mold and then cut in the same plane as the MRI.  The data was generated at the National Cancer Institute, Bethesda, Maryland, USA between 2008-2010.Please see the Prostate-MRI  page to learn more about the images and to obtain any supporting metadata for this collection.		prostate_mri			disease_type: Prostate Cancer	data_type: 	primary_site: Prostate						
prostate_mri_us_biopsy	1151	prostate_mri_us_biopsy	prostate_mri_us_biopsy			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	PROSTATE_MRI_US_BIOPSY		Prostate Cancer	10.7937/TCIA.2020.A61IOC1A			PROSTATE_MRI_US_BIOPSY		M3D, MR, SEG, US	Prostate				PROSTATE_MRI_US_BIOPSY		Human	This dataset was derived from tracked biopsy sessions using the Artemis biopsy system, many of which included image fusion with MRI targets. Patients received a 3D transrectal ultrasound scan, after which nonrigid registration (e.g. &ldquo;fusion&rdquo;)  was performed between real-time ultrasound and preoperative MRI, enabling biopsy cores to be sampled from MR regions of interest. Most cases also included sampling of systematic biopsy cores using a 12-core digital template. The Artemis system tracked targeted and systematic core locations using encoder kinematics of a mechanical arm, and recorded locations relative to the Ultrasound scan. MRI biopsy coordinates were also recorded for most cases. Please see the Prostate-MRI-US-Biopsy  page to learn more about the images and to obtain any supporting metadata for this collection.		prostate_mri_us_biopsy			disease_type: Prostate Cancer	data_type: Image Analyses	primary_site: Prostate						
prostatex	346	prostatex	prostatex			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	PROSTATEX		Prostate Cancer	10.7937/K9TCIA.2017.MURS5CL			PROSTATEX		MR, SEG	Prostate				PROSTATEX		Human	"SPIE, along with the support of the American Association of Physicists in Medicine (AAPM) and the National Cancer Institute (NCI), will conduct a &#8220;Grand Challenge&#8221; on quantitative image analysis methods for the diagnostic classification of clinically significant prostate lesions.  As part of the 2017 SPIE Medical Imaging Symposium, the PROSTATEx Challenge will provide a unique opportunity for participants to compare their algorithms with those of others from academia, industry, and government in a structured, direct way using the same data sets.  For more details, go to https://www.spie.org/search?&amp;term=PROSTATEx . rel=""nofollow""&gt;http://spiechallenges.cloudapp.net/. &#10;&#10;&#9;&#10;&#9;&#9;Release date of training set cases with truth: &#160;November 21, 2016&#10;&#9;&#10;&#9;&#9;Release date of test set cases without truth: &#160;December 12, 2016&#10;&#9;&#10;&#9;&#9;Submission date for participants&#8217; test set classification output: &#160;January 15, 2017&#10;&#9;&#10;&#9;&#9;Challenge results released to participants:&#160; January 20, 2017&#10;&#9;&#10;&#9;&#9;SPIE Medical Imaging Symposium: &#160;February 13-16, 2017Please see the  PROSTATEx  page to learn more about the images and to obtain any supporting metadata for this collection."		prostatex			disease_type: Prostate Cancer	data_type: Image Analyses	primary_site: Prostate						
pseudo_phi_dicom_data	42	pseudo_phi_dicom_data	pseudo_phi_dicom_data			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				PSEUDO_PHI_DICOM_DATA		Various	10.7937/S17Z-R072			PSEUDO_PHI_DICOM_DATA		CR, CT, DX, MG, MR, PT	Various				PSEUDO_PHI_DICOM_DATA		Human	The process of image de-identification is time consuming, requires significant human resources, and is prone to human error.  Automated image de-identification algorithms have been developed but the research community requires some method of evaluation before such tools can be widely accepted.  This evaluation requires a robust dataset that can be used as part of an evaluation process for de-identification algorithms.  We developed a DICOM dataset that can be used to evaluate the performance of de-identification algorithms.  Please see the Medical Imaging De-Identification Initiative (MIDI)  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		pseudo_phi_dicom_data			disease_type: Various	data_type: 	primary_site: Various						
qiba_ct_1c	1	qiba_ct_1c	qiba_ct_1c			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				QIBA_CT_1C		Phantom	10.7937/K9/TCIA.2016.YXGR4BLU			QIBA_CT_1C		CT, PR, SEG, SR	Phantom				QIBA_CT_1C		Human	Phantom data provided by the RSNA Quantitative Imaging Biomarkers Alliance,,s 1C group.&#160;&#10;&#9;Please see the QIBA  wiki page through RSNA, and TCIA,,s QIBA CT-1C  page,&#160; to learn more about the images and to obtain any supporting metadata for this collection.		qiba_ct_1c			disease_type: Phantom	data_type: 	primary_site: Phantom						
qin_breast	68	qin_breast	qin_breast			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical	QIN_BREAST		Breast Cancer	10.7937/K9/TCIA.2016.21JUEBH0			QIN_BREAST		CT, MR, PT, SEG	Breast				QIN_BREAST		Human	This collection contains longitudinal PET/CT and quantitative MR images collected for the purpose of studying treatment assessment in breast cancer in the neoadjuvant setting. Images were acquired at three time points: prior to the start of treatment (t1), after the first cycle of treatment (t2), and either after the second cycle of treatment or at the completion of all treatments (prior to surgery) (t3). The PET/CT images were acquired with a support device built in-house to allow the patient to be in the prone position to facilitate registration with the MRI data. The value of this collection is to provide clinical imaging data for the development and evaluation of quantitative imaging methods for treatment assessment early in the course of therapy for breast cancer.  An extension of this dataset is available via the QIN-BREAST-02  collection. Please see the QIN-Breast  wiki page to learn more about the images and to obtain any supporting metadata for this collection.   		qin_breast			disease_type: Breast Cancer	data_type: Clinical	primary_site: Breast						
qin_breast_dce_mri	10	qin_breast_dce_mri	qin_breast_dce_mri			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	QIN_BREAST_DCE_MRI		Breast Cancer	10.7937/K9/TCIA.2014.A2N1IXOX			QIN_BREAST_DCE_MRI		KO, MR	Breast				QIN_BREAST_DCE_MRI		Human	This collection of breast dynamic contrast-enhanced (DCE) MRI data contains images from a longitudinal study to assess breast cancer response to neoadjuvant chemotherapy. Images were acquired at four time points: prior to the start of treatment (Visit 1, V1), after the first cycle of treatment (Visit 2, V2), at midpoint of treatment course (Visit 3, V3), and after completion of treatment (prior to surgery) (Visit 4, V4). The value of this collection is to provide clinical imaging data for the development and validation of quantitative imaging methods for assessment of breast cancer response to treatment.Please see the QIN Breast DCE-MRI  page to learn more about the images and to obtain any supporting metadata for this collection.		qin_breast_dce_mri			disease_type: Breast Cancer	data_type: Clinical, Image Analyses	primary_site: Breast						
qin_lung_ct	47	qin_lung_ct	qin_lung_ct			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				QIN_LUNG_CT		Non-small Cell Lung Cancer	10.7937/K9/TCIA.2015.NPGZYZBZ			QIN_LUNG_CT		CT, SEG	Lung				QIN_LUNG_CT		Human	The Computed tomography (CT) Image data was obtained on patients diagnosed with Non-Small Cell Lung Cancer (NSCLC) with mixed stage &amp; histology from the H. Lee Moffitt Cancer Center and Research Institute. Scans were obtained from patients who underwent surgical resection and had corresponding pre-surgery diagnostic CTs. Please see the QIN LUNG CT   page to learn more about the images and to obtain any supporting metadata for this collection.		qin_lung_ct			disease_type: Non-small Cell Lung Cancer	data_type: 	primary_site: Lung						
qin_prostate_repeatability	15	qin_prostate_repeatability	qin_prostate_repeatability			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	QIN_PROSTATE_REPEATABILITY		Prostate Cancer	10.7937/K9/TCIA.2018.MR1CKGND			QIN_PROSTATE_REPEATABILITY		MR, SEG, SR	Prostate				QIN_PROSTATE_REPEATABILITY		Human	This is a dataset with multiparametric prostate MRI applied in a test-retest setting, allowing to evaluate repeatability of the MRI-based measurements in the prostate. There is very limited data about the repeatability in mpMRI of the prostate, while such information is critical for establishing technical characteristics of mpMRI as imaging biomarker of prostate cancer.Please see the QIN-PROSTATE-Repeatability  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		qin_prostate_repeatability			disease_type: Prostate Cancer	data_type: Image Analyses	primary_site: Prostate						
rider_breast_mri	5	rider_breast_mri	rider_breast_mri			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				RIDER_BREAST_MRI		Breast Cancer	10.7937/K9/TCIA.2015.H1SXNUXL			RIDER_BREAST_MRI		MR	Breast				RIDER_BREAST_MRI		Human	RIDER Breast MRI   is a subsection of the broader Reference Image  Database to Evaluate  Therapy Response (RIDER) collection. RIDER is a targeted data collection for the purpose of generating an initial consensus on how to harmonize data collection and analysis for quantitative imaging methods as applied to measure the response to drug or radiation therapy. The  long term goal is to provide a resource to permit harmonized methods for data collection and analysis across different commercial imaging  platforms, as required to support multi-site clinical trials, using  imaging as a biomarker for therapy  response.More information about the RIDER Breast MRI  sub-collection page can be found in the corresponding section of the RIDER  wiki page.		rider_breast_mri			disease_type: Breast Cancer	data_type: 	primary_site: Breast						
rider_lung_ct	32	rider_lung_ct	rider_lung_ct			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	RIDER_LUNG_CT		Lung Cancer	10.7937/K9/TCIA.2015.U1X8A5NR			RIDER_LUNG_CT		CT, PR, RTSTRUCT, SEG, SR	Chest				RIDER_LUNG_CT		Human	RIDER Lung CT   is a subsection of the broader Reference Image   Database to  Evaluate Therapy Response (RIDER) collection.  RIDER is a   targeted  data collection for the purpose of generating an initial   consensus on  how to harmonize data collection and analysis for   quantitative imaging  methods as applied to measure the response to drug   or radiation  therapy. The long term goal is to provide a resource to   permit  harmonized methods for data collection and analysis across   different  commercial imaging platforms, as required to support   multi-site  clinical trials, using imaging as a biomarker for therapy   response.More information about the RIDER Lung CT  sub-collection page can be  found in the corresponding section of the RIDER   page.		rider_lung_ct			disease_type: Lung Cancer	data_type: Image Analyses	primary_site: Chest						
rider_lung_pet_ct	243	rider_lung_pet_ct	rider_lung_pet_ct			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				RIDER_LUNG_PET_CT		Lung Cancer	10.7937/K9/TCIA.2015.OFIP7TVM			RIDER_LUNG_PET_CT		CT, PT, SEG	Lung				RIDER_LUNG_PET_CT		Human	RIDER Lung PET-CT  is a subsection of the broader Reference Image   Database to  Evaluate Therapy Response (RIDER) collection.  RIDER is a   targeted  data collection for the purpose of generating an initial   consensus on  how to harmonize data collection and analysis for   quantitative imaging  methods as applied to measure the response to drug   or radiation  therapy. The long term goal is to provide a resource to   permit  harmonized methods for data collection and analysis across   different  commercial imaging platforms, as required to support   multi-site  clinical trials, using imaging as a biomarker for therapy   response.More information about the RIDER Lung PET-CT  sub-collection can be  found in the corresponding section of the RIDER  wiki  page.		rider_lung_pet_ct			disease_type: Lung Cancer	data_type: 	primary_site: Lung						
soft_tissue_sarcoma	51	soft_tissue_sarcoma	soft_tissue_sarcoma			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses, Software/Source Code	SOFT_TISSUE_SARCOMA		Soft-tissue Sarcoma	10.7937/K9/TCIA.2015.7GO2GSKS			SOFT_TISSUE_SARCOMA		CT, MR, PT, RTSTRUCT	Extremities				SOFT_TISSUE_SARCOMA		Human	In this study, a cohort of 51 patients with histologically proven soft-tissue sarcomas (STSs) of the extremities was retrospectively evaluated. During the follow-up period, 19 patients developed lung metastases. Patients with metastatic and/or recurrent STSs at presentation were excluded from the study. All patients had pre-treatment FDG-PET/CT and MRI scans.Please see the Soft Tissue Sarcoma  page to learn more about the images and to obtain any supporting metadata for this collection.		soft_tissue_sarcoma			disease_type: Soft-tissue Sarcoma	data_type: Clinical, Image Analyses, Software/Source Code	primary_site: Extremities						
spie_aapm_lung_ct_challenge	70	spie_aapm_lung_ct_challenge	spie_aapm_lung_ct_challenge			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Image Analyses	SPIE_AAPM_LUNG_CT_CHALLENGE		Lung Cancer	10.7937/K9/TCIA.2015.UZLSU3FL			SPIE_AAPM_LUNG_CT_CHALLENGE		CT	Lung				SPIE_AAPM_LUNG_CT_CHALLENGE		Human	As part of the 2015 SPIE Medical Imaging Conference, SPIE &ndash; with the support of American Association of Physicists in Medicine (AAPM) and the National Cancer Institute (NCI) &ndash; conducted a &ldquo;Grand Challenge&rdquo; on quantitative image analysis methods for the diagnostic classification of malignant and benign lung nodules. The LUNGx Challenge provided a unique opportunity for participants to compare their algorithms to those of others from academia, industry, and government in a structured, direct way using the same data sets.Please see the SPIE-AAPM Lung CT Challenge  page to learn more about the images and to obtain any supporting metadata for this collection.		spie_aapm_lung_ct_challenge			disease_type: Lung Cancer	data_type: Clinical, Image Analyses	primary_site: Lung						
tcga_blca	412	tcga_blca	tcga_blca			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_BLCA		Bladder Endothelial Carcinoma	10.7937/K9/TCIA.2016.8LNG8XDR			TCGA_BLCA		CR, CT, DX, MR, PT, SM	Bladder				TCGA_BLCA		Human	The Cancer Genome Atlas-Bladder Endothelial Carcinoma (TCGA-BLCA) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP), with the cooperation of several of the TCGA tissue-contributing institutions, has archived a large portion of the radiological images of the genetically-analyzed BLCA cases.Please see the TCGA-BLCA  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_blca			disease_type: Bladder Endothelial Carcinoma	data_type: Clinical, Genomics	primary_site: Bladder						
tcga_brca	1098	tcga_brca	tcga_brca			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_BRCA		Breast Cancer	10.7937/K9/TCIA.2016.AB2NAZRP			TCGA_BRCA		MG, MR, SM, SR	Breast				TCGA_BRCA		Human	The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this MR multi-sequence image collection of breast invasive carcinoma patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome. Please see the TCGA-BRCA  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_brca			disease_type: Breast Cancer	data_type: Clinical, Genomics, Image Analyses	primary_site: Breast						
tcga_cesc	307	tcga_cesc	tcga_cesc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_CESC		Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	10.7937/K9/TCIA.2016.SQ4M8YP4			TCGA_CESC		MR, SM	Cervix				TCGA_CESC		Human	The Cancer Genome Atlas-Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA-CESC) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed CESC cases.Please see the TCGA-CESC  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_cesc			disease_type: Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	data_type: Clinical, Genomics	primary_site: Cervix						
tcga_coad	464	tcga_coad	tcga_coad			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_COAD		Colon Adenocarcinoma	10.7937/K9/TCIA.2016.HJJHBOXZ			TCGA_COAD		CT, OT, SM	Colon				TCGA_COAD		Human	The Cancer Genome Atlas-Colon Adenocarcinoma (TCGA-COAD) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP), with the cooperation of several of the TCGA tissue-contributing institutions, has archived a large portion of the radiological images of the COAD cases.Please see the TCGA-COAD  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_coad			disease_type: Colon Adenocarcinoma	data_type: Clinical, Genomics	primary_site: Colon						
tcga_esca	185	tcga_esca	tcga_esca			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_ESCA		Esophageal Carcinoma	10.7937/K9/TCIA.2016.VPTNRGFY			TCGA_ESCA		CT, SM	Esophagus				TCGA_ESCA		Human	The Cancer Genome Atlas-Esophageal Carcinoma (TCGA-ESCA) data collection is part of a larger effort to enhance the TCGA  data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed ESCA cases.Please see the TCGA-ESCA  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_esca			disease_type: Esophageal Carcinoma	data_type: Clinical, Genomics	primary_site: Esophagus						
tcga_gbm	608	tcga_gbm	tcga_gbm			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_GBM		Glioblastoma Multiforme	10.7937/K9/TCIA.2016.RNYFUYE9			TCGA_GBM		SM	Brain				TCGA_GBM		Human	The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal Currently this large MR multi-sequence image collection of glioblastoma patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome. TCGA-GBM  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_gbm			disease_type: Glioblastoma Multiforme	data_type: Clinical, Genomics, Image Analyses	primary_site: Brain						
tcga_hnsc	528	tcga_hnsc	tcga_hnsc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_HNSC		Head and Neck Squamous Cell Carcinoma	10.7937/K9/TCIA.2016.LXKQ47MS			TCGA_HNSC		SM	Head-Neck				TCGA_HNSC		Human	The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this large PET/CT multi-sequence image collection of  head and neck squamous cell carcinoma (HNSC) patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome.Please see the TCGA-HNSC  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_hnsc			disease_type: Head and Neck Squamous Cell Carcinoma	data_type: Clinical, Genomics	primary_site: Head-Neck						
tcga_kich	113	tcga_kich	tcga_kich			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_KICH		Kidney Chromophobe	10.7937/K9/TCIA.2016.YU3RBCZN			TCGA_KICH		CT, MR, SM	Kidney				TCGA_KICH		Human	The Cancer Genome Atlas-Kidney Chromophobe (TCGA-KICH) data collection is part of a larger effort to enhance the The Cancer Genome Atlas (TCGA) https://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions has archived a large portion of the radiological images of the genetically-analyzed KICH cases.Please see the TCGA-KICH  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_kich			disease_type: Kidney Chromophobe	data_type: Clinical, Genomics	primary_site: Kidney						
tcga_kirc	537	tcga_kirc	tcga_kirc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_KIRC		Kidney Renal Clear Cell Carcinoma	10.7937/K9/TCIA.2016.V6PBVTDR			TCGA_KIRC		CR, CT, MR, SEG, SM	Kidney				TCGA_KIRC		Human	The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this large CT and MR multi-sequence image collection of kidney renal clear cell carcinoma (KIRC) patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome.Please see the TCGA -KIRC   page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_kirc			disease_type: Kidney Renal Clear Cell Carcinoma	data_type: Clinical, Genomics, Image Analyses	primary_site: Kidney						
tcga_kirp	291	tcga_kirp	tcga_kirp			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_KIRP		Kidney Renal Papillary Cell Carcinoma	10.7937/K9/TCIA.2016.ACWOGBEF			TCGA_KIRP		CT, MR, PT, SM	Kidney				TCGA_KIRP		Human	 The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this large CT and MR multi-sequence image collection of  kidney renal papillary cell carcinoma (KIRP) patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome. TCGA-KIRP  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_kirp			disease_type: Kidney Renal Papillary Cell Carcinoma	data_type: Clinical, Genomics	primary_site: Kidney						
tcga_lgg	518	tcga_lgg	tcga_lgg			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_LGG		Low Grade Glioma	10.7937/K9/TCIA.2016.L4LTD3TK			TCGA_LGG		SM	Brain				TCGA_LGG		Human	Note: This collection has special restrictions on its usage. See Data Usage Policies and Restrictions .The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this large MR multi-sequence image collection of low grade glioma patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome.Please see the TCGA-LGG  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_lgg			disease_type: Low Grade Glioma	data_type: Clinical, Genomics, Image Analyses	primary_site: Brain						
tcga_lihc	377	tcga_lihc	tcga_lihc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_LIHC		Liver Hepatocellular Carcinoma	10.7937/K9/TCIA.2016.IMMQW8UQ			TCGA_LIHC		CT, MR, PT, SEG, SM	Liver				TCGA_LIHC		Human	The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this CT and MR multi-sequence image collection of liver hepatocellular carcinoma (LIHC) patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome.TCGA-LIHC    page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_lihc			disease_type: Liver Hepatocellular Carcinoma	data_type: Clinical, Genomics, Image Analyses	primary_site: Liver						
tcga_luad	560	tcga_luad	tcga_luad			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_LUAD		Lung Adenocarcinoma	10.7937/K9/TCIA.2016.JGNIHEP5			TCGA_LUAD		CT, NM, PT, SEG, SM	Chest				TCGA_LUAD		Human	The Cancer Imaging Program (CIP)  is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal Currently this large CT multi-sequence image collection of lung adenocarcinoma (LUAD) patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome.Please see the TCGA-LUAD  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_luad			disease_type: Lung Adenocarcinoma	data_type: Clinical, Genomics, Image Analyses	primary_site: Chest						
tcga_lusc	504	tcga_lusc	tcga_lusc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_LUSC		Lung Squamous Cell Carcinoma	10.7937/K9/TCIA.2016.TYGKKFMQ			TCGA_LUSC		CT, NM, PT, SEG, SM	Lung				TCGA_LUSC		Human	The Cancer Genome Atlas-Lung Squamous Cell Carcinoma (TCGA-LUSC) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the LUSC cases.Please see the TCGA-LUSC  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_lusc			disease_type: Lung Squamous Cell Carcinoma	data_type: Clinical, Genomics	primary_site: Lung						
tcga_ov	591	tcga_ov	tcga_ov			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics, Image Analyses	TCGA_OV		Ovarian Serous Cystadenocarcinoma	10.7937/K9/TCIA.2016.NDO1MDFQ			TCGA_OV		CT, MR, OT, SM	Ovary				TCGA_OV		Human	The Cancer Genome Atlas-Ovarian Cancer (TCGA-OV) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed OV cases.Please see the TCGA-OV  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_ov			disease_type: Ovarian Serous Cystadenocarcinoma	data_type: Clinical, Genomics, Image Analyses	primary_site: Ovary						
tcga_prad	500	tcga_prad	tcga_prad			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_PRAD		Prostate Cancer	10.7937/K9/TCIA.2016.YXOGLM4Y			TCGA_PRAD		CT, MR, PT, SM	Prostate				TCGA_PRAD		Human	The Cancer Imaging Program (CIP) is working directly with primary investigators from institutes participating in TCGA to obtain and load images relating to the genomic, clinical, and pathological data being stored within the TCGA Data Portal. Currently this image collection of prostate adenocarcinoma (PRAD) patients can be matched by each unique case identifier with the extensive gene and expression data of the same case from The Cancer Genome Atlas Data Portal to research the link between clinical phenome and tissue genome. Please see the TCGA-PRAD  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_prad			disease_type: Prostate Cancer	data_type: Clinical, Genomics	primary_site: Prostate						
tcga_read	171	tcga_read	tcga_read			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_READ		Rectum Adenocarcinoma	10.7937/K9/TCIA.2016.F7PPNPNU			TCGA_READ		CT, MR, SM	Rectum				TCGA_READ		Human	The Cancer Genome Atlas-Rectum Adenocarcinoma (TCGA-READ) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP), with the cooperation of several TCGA tissue-contributing institutions, has archived a large portion of the radiological images of the genetically-analyzed READ cases.Please see the TCGA-READ  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_read			disease_type: Rectum Adenocarcinoma	data_type: Clinical, Genomics	primary_site: Rectum						
tcga_sarc	261	tcga_sarc	tcga_sarc			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_SARC		Sarcomas	10.7937/K9/TCIA.2016.CX6YLSUX			TCGA_SARC		CT, MR, SM	Chest-Abdomen-Pelvis, Leg, TSpine				TCGA_SARC		Human	The Cancer Genome Atlas-Sarcoma Cancer (TCGA-SARC) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed SARC cases.Please see the TCGA-SARC  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_sarc			disease_type: Sarcomas	data_type: Clinical, Genomics	primary_site: Chest-Abdomen-Pelvis, Leg, TSpine						
tcga_stad	443	tcga_stad	tcga_stad			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_STAD		Stomach Adenocarcinoma	10.7937/K9/TCIA.2016.GDHL9KIM			TCGA_STAD		CT, SM	Stomach				TCGA_STAD		Human	The Cancer Genome Atlas-Stomach Adenoarcinoma (TCGA-STAD) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed STAD cases.Please see the TCGA-STAD  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_stad			disease_type: Stomach Adenocarcinoma	data_type: Clinical, Genomics	primary_site: Stomach						
tcga_thca	507	tcga_thca	tcga_thca			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_THCA		Thyroid Cancer	10.7937/K9/TCIA.2016.9ZFRVF1B			TCGA_THCA		CT, PT, SM	Thyroid				TCGA_THCA		Human	The Cancer Genome Atlas-Thyroid Cancer (TCGA-THCA) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed THCA cases.Please see the TCGA-THCA  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_thca			disease_type: Thyroid Cancer	data_type: Clinical, Genomics	primary_site: Thyroid						
tcga_ucec	560	tcga_ucec	tcga_ucec			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Clinical, Genomics	TCGA_UCEC		Uterine Corpus Endometrial Carcinoma	10.7937/K9/TCIA.2016.GKJ0ZWAC			TCGA_UCEC		CR, CT, MR, PT, SM	Uterus				TCGA_UCEC		Human	The Cancer Genome Atlas-Uterine Corpus Endometrial Carcinoma (TCGA-UCEC) data collection is part of a larger effort to enhance the TCGA http://cancergenome.nih.gov/ data set with characterized radiological images. The Cancer Imaging Program (CIP) with the cooperation of several of the TCGA tissue-contributing institutions are working to archive a large portion of the radiological images of the genetically-analyzed UCEC cases.Please see the TCGA-UCEC  page to learn more about the images and to obtain any supporting metadata for this collection.		tcga_ucec			disease_type: Uterine Corpus Endometrial Carcinoma	data_type: Clinical, Genomics	primary_site: Uterus						
vestibular_schwannoma_seg	242	vestibular_schwannoma_seg	vestibular_schwannoma_seg			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons			Image Analyses	VESTIBULAR_SCHWANNOMA_SEG		Vestibular Schwannoma (non-cancer)	10.7937/TCIA.9YTJ-5Q73			VESTIBULAR_SCHWANNOMA_SEG		MR, RTDOSE, RTPLAN, RTSTRUCT	Ear				VESTIBULAR_SCHWANNOMA_SEG		Human	This collection contains a labelled dataset of MRI images collected on 242 consecutive patients with vestibular schwannoma (VS) undergoing Gamma Knife stereotactic radiosurgery (GK SRS). The structural images included contrast-enhanced T1-weighted (ceT1) images and high-resolution T2-weighted (hrT2) images. Each imaging dataset is accompanied by the patient&rsquo;s radiation therapy (RT) dataset including the RTDose, RTStructures and RTPlan.Please see the Vestibular-Schwannoma-SEG  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		vestibular_schwannoma_seg			disease_type: Vestibular Schwannoma (non-cancer)	data_type: Image Analyses	primary_site: Ear						
victre	2994	victre	victre			CRDC Cancer Imaging Data Commons	CRDC Cancer Imaging Data Commons				VICTRE		Breast Cancer	10.7937/TCIA.2019.HO23NXAW			VICTRE		MG	Breast				VICTRE		Human	The VICTRE Trial: Open-Source, In-Silico Clinical Trial For Evaluating Digital Breast TomosynthesisA total of 2986 subjects, with breast sizes and radiographic densities representative of a screening population and compressed thicknesses from 3.5 to 6 cm, were simulated and imaged on in-silico versions of DM and DBT systems using fast Monte Carlo x-ray transport. Images were interpreted by a computational reader detecting the presence of lesions. The in-silico trial (VICTRE) was designed to replicate a comparative trial from a previous regulatory submission. The endpoint was the difference in area under the receiver-operating-characteristic curve between modalities (delta-AUC) for lesion detection.See the VICTRE Collection  wiki page to learn more about the images and to obtain any supporting metadata for this collection.		victre			disease_type: Breast Cancer	data_type: 	primary_site: Breast						
APOLLO-LUAD	87	APOLLO-LUAD	APOLLO-LUAD			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs003011	Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Bronchus and lung']	"[""Adenomas and Adenocarcinomas""]"			1455.0	APOLLO1: Proteogenomic characterization of lung adenocarcinoma			"[""Bronchus and lung""]"		APOLLO-LUAD		APOLLO-LUAD					APOLLO-LUAD		87.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Bronchus and lung							
BEATAML1.0-COHORT	826	BEATAML1.0-COHORT	BEATAML1.0-COHORT			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001657	Genomic Data Commons study of ['Myeloid Leukemias', 'Chronic Myeloproliferative Disorders', 'Plasma Cell Tumors', 'Unknown', 'Myelodysplastic Syndromes', 'Leukemias, NOS'] in ['Hematopoietic and reticuloendothelial systems']	"[""Myeloid Leukemias"", ""Chronic Myeloproliferative Disorders"", ""Plasma Cell Tumors"", ""Unknown"", ""Myelodysplastic Syndromes"", ""Leukemias, NOS""]"			16746.0	Functional Genomic Landscape of Acute Myeloid Leukemia			"[""Hematopoietic and reticuloendothelial systems""]"		BEATAML1.0-COHORT		BEATAML1.0-COHORT					BEATAML1.0-COHORT		826.0	disease_type: Myeloid Leukemias	primary_site: Hematopoietic and reticuloendothelial systems							
BEATAML1.0-CRENOLANIB	56	BEATAML1.0-CRENOLANIB	BEATAML1.0-CRENOLANIB			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001628	Genomic Data Commons study of ['Myeloid Leukemias'] in ['Hematopoietic and reticuloendothelial systems']	"[""Myeloid Leukemias""]"			547.0	Clinical Resistance to Crenolanib in Acute Myeloid Leukemia Due to Diverse Molecular Mechanisms			"[""Hematopoietic and reticuloendothelial systems""]"		BEATAML1.0-CRENOLANIB		BEATAML1.0-CRENOLANIB					BEATAML1.0-CRENOLANIB		56.0	disease_type: Myeloid Leukemias	primary_site: Hematopoietic and reticuloendothelial systems							
CDDP_EAGLE-1	50	CDDP_EAGLE-1	CDDP_EAGLE-1			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001239	Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Bronchus and lung']	"[""Adenomas and Adenocarcinomas""]"			1747.0	CDDP Integrative Analysis of Lung Adenocarcinoma (Phase 2)			"[""Bronchus and lung""]"		CDDP_EAGLE-1		CDDP_EAGLE-1					CDDP_EAGLE-1		50.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Bronchus and lung							
CGCI-BLGSP	324	CGCI-BLGSP	CGCI-BLGSP			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000527	Genomic Data Commons study of ['Mature B-Cell Lymphomas'] in ['Hematopoietic and reticuloendothelial systems']	"[""Mature B-Cell Lymphomas""]"			10654.0	Burkitt Lymphoma Genome Sequencing Project			"[""Hematopoietic and reticuloendothelial systems""]"		CGCI-BLGSP		CGCI-BLGSP					CGCI-BLGSP		324.0	disease_type: Mature B-Cell Lymphomas	primary_site: Hematopoietic and reticuloendothelial systems							
CGCI-HTMCP-CC	212	CGCI-HTMCP-CC	CGCI-HTMCP-CC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000528	Genomic Data Commons study of ['Squamous Cell Neoplasms', 'Epithelial Neoplasms, NOS', 'Adenomas and Adenocarcinomas', 'Complex Epithelial Neoplasms'] in ['Cervix uteri']	"[""Squamous Cell Neoplasms"", ""Epithelial Neoplasms, NOS"", ""Adenomas and Adenocarcinomas"", ""Complex Epithelial Neoplasms""]"			5856.0	HIV+ Tumor Molecular Characterization Project - Cervical Cancer			"[""Cervix uteri""]"		CGCI-HTMCP-CC		CGCI-HTMCP-CC					CGCI-HTMCP-CC		212.0	disease_type: Squamous Cell Neoplasms	primary_site: Cervix uteri							
CGCI-HTMCP-DLBCL	70	CGCI-HTMCP-DLBCL	CGCI-HTMCP-DLBCL			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000529	Genomic Data Commons study of ['Mature B-Cell Lymphomas'] in ['Hematopoietic and reticuloendothelial systems']	"[""Mature B-Cell Lymphomas""]"			1712.0	HIV+ Tumor Molecular Characterization Project - Diffuse Large B-Cell Lymphoma			"[""Hematopoietic and reticuloendothelial systems""]"		CGCI-HTMCP-DLBCL		CGCI-HTMCP-DLBCL					CGCI-HTMCP-DLBCL		70.0	disease_type: Mature B-Cell Lymphomas	primary_site: Hematopoietic and reticuloendothelial systems							
CGCI-HTMCP-LC	39	CGCI-HTMCP-LC	CGCI-HTMCP-LC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000530	Genomic Data Commons study of ['Squamous Cell Neoplasms', 'Complex Epithelial Neoplasms', 'Paragangliomas and Glomus Tumors', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Epithelial Neoplasms, NOS'] in ['Bronchus and lung']	"[""Squamous Cell Neoplasms"", ""Complex Epithelial Neoplasms"", ""Paragangliomas and Glomus Tumors"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Epithelial Neoplasms, NOS""]"			896.0	HIV+ Tumor Molecular Characterization Project - Lung Cancer			"[""Bronchus and lung""]"		CGCI-HTMCP-LC		CGCI-HTMCP-LC					CGCI-HTMCP-LC		39.0	disease_type: Squamous Cell Neoplasms	primary_site: Bronchus and lung							
CMI-ASC	36	CMI-ASC	CMI-ASC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001931	Genomic Data Commons study of ['Soft Tissue Tumors and Sarcomas, NOS'] in ['Heart, mediastinum, and pleura', 'Other and ill-defined sites', 'Bladder', 'Skin', 'Breast', 'Bronchus and lung', 'Lymph nodes', 'Other and ill-defined digestive organs', 'Other and ill-defined sites within respiratory system and intrathoracic organs']	"[""Soft Tissue Tumors and Sarcomas, NOS""]"			806.0	Count Me In (CMI): The Angiosarcoma (ASC) Project			"[""Heart, mediastinum, and pleura"", ""Other and ill-defined sites"", ""Bladder"", ""Skin"", ""Breast"", ""Bronchus and lung"", ""Lymph nodes"", ""Other and ill-defined digestive organs"", ""Other and ill-defined sites within respiratory system and intrathoracic organs""]"		CMI-ASC		CMI-ASC					CMI-ASC		36.0	disease_type: Soft Tissue Tumors and Sarcomas, NOS	primary_site: Heart, mediastinum, and pleura							
CMI-MBC	200	CMI-MBC	CMI-MBC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001709	Genomic Data Commons study of ['Ductal and Lobular Neoplasms'] in ['Breast']	"[""Ductal and Lobular Neoplasms""]"			5454.0	Count Me In (CMI): The Metastatic Breast Cancer (MBC) Project			"[""Breast""]"		CMI-MBC		CMI-MBC					CMI-MBC		200.0	disease_type: Ductal and Lobular Neoplasms	primary_site: Breast							
CMI-MPC	63	CMI-MPC	CMI-MPC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001939	Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Prostate gland', 'Lymph nodes']	"[""Adenomas and Adenocarcinomas""]"			1305.0	Count Me In (CMI): The Metastatic Prostate Cancer (MPC) Project			"[""Prostate gland"", ""Lymph nodes""]"		CMI-MPC		CMI-MPC					CMI-MPC		63.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Prostate gland							
CPTAC-2	342	CPTAC-2	CPTAC-2			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000892	Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Not Reported', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Other and unspecified female genital organs', 'Colon', 'Retroperitoneum and peritoneum', 'Rectum', 'Breast', 'Ovary']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Not Reported"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas""]"			9244.0	CPTAC-Breast, Colon, Ovary			"[""Other and unspecified female genital organs"", ""Colon"", ""Retroperitoneum and peritoneum"", ""Rectum"", ""Breast"", ""Ovary""]"		CPTAC-2		CPTAC-2					CPTAC-2		342.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Other and unspecified female genital organs							
CPTAC-3	1235	CPTAC-3	CPTAC-3			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001287	Genomic Data Commons study of ['Squamous Cell Neoplasms', 'Gliomas', 'Not Applicable', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Kidney', 'Bronchus and lung', 'Pancreas', 'Brain', 'Other and ill-defined sites', 'Uterus, NOS']	"[""Squamous Cell Neoplasms"", ""Gliomas"", ""Not Applicable"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas""]"			66786.0	CPTAC-Brain, Head and Neck, Kidney, Lung, Pancreas, Uterus			"[""Kidney"", ""Bronchus and lung"", ""Pancreas"", ""Brain"", ""Other and ill-defined sites"", ""Uterus, NOS""]"		CPTAC-3		CPTAC-3					CPTAC-3		1235.0	disease_type: Squamous Cell Neoplasms	primary_site: Kidney							
CTSP-DLBCL1	45	CTSP-DLBCL1	CTSP-DLBCL1			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001184	Genomic Data Commons study of ['Mature B-Cell Lymphomas'] in ['Lymph nodes', 'Unknown']	"[""Mature B-Cell Lymphomas""]"			553.0	CTSP Diffuse Large B-Cell Lymphoma (DLBCL) CALGB 50303			"[""Lymph nodes"", ""Unknown""]"		CTSP-DLBCL1		CTSP-DLBCL1					CTSP-DLBCL1		45.0	disease_type: Mature B-Cell Lymphomas	primary_site: Lymph nodes							
EXCEPTIONAL_RESPONDERS-ER	84	EXCEPTIONAL_RESPONDERS-ER	EXCEPTIONAL_RESPONDERS-ER			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Nevi and Melanomas', 'Squamous Cell Neoplasms', 'Complex Mixed and Stromal Neoplasms', 'Gliomas', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Epithelial Neoplasms, NOS', 'Myomatous Neoplasms'] in ['Other and unspecified female genital organs', 'Connective, subcutaneous and other soft tissues', 'Bladder', 'Stomach', 'Other and ill-defined sites', 'Skin', 'Kidney', 'Bronchus and lung', 'Esophagus', 'Ovary', 'Anus and anal canal', 'Other and unspecified parts of biliary tract', 'Unknown', 'Rectum', 'Pancreas', 'Other and ill-defined digestive organs', 'Brain', 'Uterus, NOS', 'Colon', 'Breast']	"[""Nevi and Melanomas"", ""Squamous Cell Neoplasms"", ""Complex Mixed and Stromal Neoplasms"", ""Gliomas"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Epithelial Neoplasms, NOS"", ""Myomatous Neoplasms""]"			1826.0	Exceptional Responders			"[""Other and unspecified female genital organs"", ""Connective, subcutaneous and other soft tissues"", ""Bladder"", ""Stomach"", ""Other and ill-defined sites"", ""Skin"", ""Kidney"", ""Bronchus and lung"", ""Esophagus"", ""Ovary"", ""Anus and anal canal"", ""Other and unspecified parts of biliary tract"", ""Unknown"", ""Rectum"", ""Pancreas"", ""Other and ill-defined digestive organs"", ""Brain"", ""Uterus, NOS"", ""Colon"", ""Breast""]"		EXCEPTIONAL_RESPONDERS-ER		EXCEPTIONAL_RESPONDERS-ER					EXCEPTIONAL_RESPONDERS-ER		84.0	disease_type: Nevi and Melanomas	primary_site: Other and unspecified female genital organs							
FM-AD	18004	FM-AD	FM-AD			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001179	Genomic Data Commons study of ['Ductal and Lobular Neoplasms', 'Thymic Epithelial Neoplasms', 'Germ Cell Neoplasms', 'Nevi and Melanomas', 'Acinar Cell Neoplasms', 'Meningiomas', 'Gliomas', 'Neuroepitheliomatous Neoplasms', 'Basal Cell Neoplasms', 'Transitional Cell Papillomas and Carcinomas', 'Adnexal and Skin Appendage Neoplasms', 'Epithelial Neoplasms, NOS', 'Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Complex Mixed and Stromal Neoplasms', 'Adenomas and Adenocarcinomas', 'Mesothelial Neoplasms', 'Specialized Gonadal Neoplasms', 'Miscellaneous Tumors', 'Mucoepidermoid Neoplasms', 'Not Reported', 'Complex Epithelial Neoplasms', 'Paragangliomas and Glomus Tumors'] in ['Other and unspecified female genital organs', 'Bladder', 'Adrenal gland', 'Stomach', 'Small intestine', 'Other and ill-defined sites', 'Eye and adnexa', 'Thymus', 'Skin', 'Nasopharynx', 'Kidney', 'Ureter', 'Cervix uteri', 'Peripheral nerves and autonomic nervous system', 'Bronchus and lung', 'Penis', 'Esophagus', 'Ovary', 'Spinal cord, cranial nerves, and other parts of central nervous system', 'Anus and anal canal', 'Other and unspecified urinary organs', 'Thyroid gland', 'Other and unspecified parts of biliary tract', 'Unknown', 'Testis', 'Liver and intrahepatic bile ducts', 'Rectum', 'Retroperitoneum and peritoneum', 'Other endocrine glands and related structures', 'Pancreas', 'Trachea', 'Heart, mediastinum, and pleura', 'Other and ill-defined digestive organs', 'Uterus, NOS', 'Gallbladder', 'Vagina', 'Vulva', 'Colon', 'Not Reported', 'Breast', 'Other and unspecified major salivary glands', 'Prostate gland']	"[""Ductal and Lobular Neoplasms"", ""Thymic Epithelial Neoplasms"", ""Germ Cell Neoplasms"", ""Nevi and Melanomas"", ""Acinar Cell Neoplasms"", ""Meningiomas"", ""Gliomas"", ""Neuroepitheliomatous Neoplasms"", ""Basal Cell Neoplasms"", ""Transitional Cell Papillomas and Carcinomas"", ""Adnexal and Skin Appendage Neoplasms"", ""Epithelial Neoplasms, NOS"", ""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Complex Mixed and Stromal Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Mesothelial Neoplasms"", ""Specialized Gonadal Neoplasms"", ""Miscellaneous Tumors"", ""Mucoepidermoid Neoplasms"", ""Not Reported"", ""Complex Epithelial Neoplasms"", ""Paragangliomas and Glomus Tumors""]"			54096.0	Foundation Medicine Adult Cancer Clinical Dataset (FM-AD)			"[""Other and unspecified female genital organs"", ""Bladder"", ""Adrenal gland"", ""Stomach"", ""Small intestine"", ""Other and ill-defined sites"", ""Eye and adnexa"", ""Thymus"", ""Skin"", ""Nasopharynx"", ""Kidney"", ""Ureter"", ""Cervix uteri"", ""Peripheral nerves and autonomic nervous system"", ""Bronchus and lung"", ""Penis"", ""Esophagus"", ""Ovary"", ""Spinal cord, cranial nerves, and other parts of central nervous system"", ""Anus and anal canal"", ""Other and unspecified urinary organs"", ""Thyroid gland"", ""Other and unspecified parts of biliary tract"", ""Unknown"", ""Testis"", ""Liver and intrahepatic bile ducts"", ""Rectum"", ""Retroperitoneum and peritoneum"", ""Other endocrine glands and related structures"", ""Pancreas"", ""Trachea"", ""Heart, mediastinum, and pleura"", ""Other and ill-defined digestive organs"", ""Uterus, NOS"", ""Gallbladder"", ""Vagina"", ""Vulva"", ""Colon"", ""Not Reported"", ""Breast"", ""Other and unspecified major salivary glands"", ""Prostate gland""]"		FM-AD		FM-AD					FM-AD		18004.0	disease_type: Ductal and Lobular Neoplasms	primary_site: Other and unspecified female genital organs							
HCMI-CMDC	278	HCMI-CMDC	HCMI-CMDC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Soft Tissue Tumors and Sarcomas, NOS', 'Blood Vessel Tumors', 'Squamous Cell Neoplasms', 'Miscellaneous Bone Tumors', 'Epithelial Neoplasms, NOS', 'Osseous and Chondromatous Neoplasms', 'Gliomas', 'Nevi and Melanomas', 'Complex Epithelial Neoplasms', 'Cystic, Mucinous and Serous Neoplasms', 'Fibromatous Neoplasms', 'Complex Mixed and Stromal Neoplasms', 'Acinar Cell Neoplasms', 'Ductal and Lobular Neoplasms', 'Myomatous Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Corpus uteri', 'Other and unspecified parts of mouth', 'Stomach', 'Bones, joints and articular cartilage of other and unspecified sites', 'Colon', 'Small intestine', 'Other and unspecified parts of biliary tract', 'Liver and intrahepatic bile ducts', 'Pancreas', 'Other and ill-defined sites', 'Rectum', 'Gallbladder', 'Rectosigmoid junction', 'Connective, subcutaneous and other soft tissues', 'Ovary', 'Esophagus', 'Skin', 'Other and unspecified parts of tongue', 'Brain', 'Uterus, NOS', 'Nasal cavity and middle ear', 'Kidney', 'Breast', 'Bronchus and lung']	"[""Soft Tissue Tumors and Sarcomas, NOS"", ""Blood Vessel Tumors"", ""Squamous Cell Neoplasms"", ""Miscellaneous Bone Tumors"", ""Epithelial Neoplasms, NOS"", ""Osseous and Chondromatous Neoplasms"", ""Gliomas"", ""Nevi and Melanomas"", ""Complex Epithelial Neoplasms"", ""Cystic, Mucinous and Serous Neoplasms"", ""Fibromatous Neoplasms"", ""Complex Mixed and Stromal Neoplasms"", ""Acinar Cell Neoplasms"", ""Ductal and Lobular Neoplasms"", ""Myomatous Neoplasms"", ""Adenomas and Adenocarcinomas""]"			19034.0	NCI Cancer Model Development for the Human Cancer Model Initiative			"[""Corpus uteri"", ""Other and unspecified parts of mouth"", ""Stomach"", ""Bones, joints and articular cartilage of other and unspecified sites"", ""Colon"", ""Small intestine"", ""Other and unspecified parts of biliary tract"", ""Liver and intrahepatic bile ducts"", ""Pancreas"", ""Other and ill-defined sites"", ""Rectum"", ""Gallbladder"", ""Rectosigmoid junction"", ""Connective, subcutaneous and other soft tissues"", ""Ovary"", ""Esophagus"", ""Skin"", ""Other and unspecified parts of tongue"", ""Brain"", ""Uterus, NOS"", ""Nasal cavity and middle ear"", ""Kidney"", ""Breast"", ""Bronchus and lung""]"		HCMI-CMDC		HCMI-CMDC					HCMI-CMDC		278.0	disease_type: Soft Tissue Tumors and Sarcomas, NOS	primary_site: Corpus uteri							
MATCH-B	33	MATCH-B	MATCH-B			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs002028	Genomic Data Commons study of ['Transitional Cell Papillomas and Carcinomas', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Nerve Sheath Tumors', 'Epithelial Neoplasms, NOS'] in ['Other and unspecified parts of biliary tract', 'Breast', 'Colon', 'Rectosigmoid junction', 'Rectum', 'Cervix uteri', 'Prostate gland', 'Unknown', 'Small intestine', 'Other and unspecified female genital organs', 'Renal pelvis', 'Parotid gland', 'Liver and intrahepatic bile ducts', 'Skin', 'Bladder', 'Ovary', 'Gallbladder']	"[""Transitional Cell Papillomas and Carcinomas"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Nerve Sheath Tumors"", ""Epithelial Neoplasms, NOS""]"			810.0	Genomic Characterization CS-MATCH-0007 Arm B			"[""Other and unspecified parts of biliary tract"", ""Breast"", ""Colon"", ""Rectosigmoid junction"", ""Rectum"", ""Cervix uteri"", ""Prostate gland"", ""Unknown"", ""Small intestine"", ""Other and unspecified female genital organs"", ""Renal pelvis"", ""Parotid gland"", ""Liver and intrahepatic bile ducts"", ""Skin"", ""Bladder"", ""Ovary"", ""Gallbladder""]"		MATCH-B		MATCH-B					MATCH-B		33.0	disease_type: Transitional Cell Papillomas and Carcinomas	primary_site: Other and unspecified parts of biliary tract							
MATCH-H	21	MATCH-H	MATCH-H			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001888	Genomic Data Commons study of ['Adenomas and Adenocarcinomas', 'Gliomas', 'Epithelial Neoplasms, NOS', 'Neoplasms, NOS'] in ['Colon', 'Ovary', 'Brain', 'Bronchus and lung', 'Unknown', 'Other and unspecified female genital organs', 'Other and ill-defined digestive organs', 'Liver and intrahepatic bile ducts', 'Pancreas', 'Anus and anal canal', 'Bones, joints and articular cartilage of other and unspecified sites']	"[""Adenomas and Adenocarcinomas"", ""Gliomas"", ""Epithelial Neoplasms, NOS"", ""Neoplasms, NOS""]"			509.0	Genomic Characterization CS-MATCH-0007 Arm H			"[""Colon"", ""Ovary"", ""Brain"", ""Bronchus and lung"", ""Unknown"", ""Other and unspecified female genital organs"", ""Other and ill-defined digestive organs"", ""Liver and intrahepatic bile ducts"", ""Pancreas"", ""Anus and anal canal"", ""Bones, joints and articular cartilage of other and unspecified sites""]"		MATCH-H		MATCH-H					MATCH-H		21.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Colon							
MATCH-I	60	MATCH-I	MATCH-I			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs002181	Genomic Data Commons study of ['Gliomas', 'Adenomas and Adenocarcinomas', 'Nevi and Melanomas', 'Myomatous Neoplasms', 'Osseous and Chondromatous Neoplasms', 'Neoplasms, NOS', 'Soft Tissue Tumors and Sarcomas, NOS', 'Squamous Cell Neoplasms', 'Epithelial Neoplasms, NOS'] in ['Retroperitoneum and peritoneum', 'Kidney', 'Liver and intrahepatic bile ducts', 'Corpus uteri', 'Rectosigmoid junction', 'Vagina', 'Accessory sinuses', 'Other and unspecified female genital organs', 'Oropharynx', 'Other and unspecified parts of mouth', 'Connective, subcutaneous and other soft tissues', 'Colon', 'Other and unspecified major salivary glands', 'Unknown', 'Cervix uteri', 'Skin', 'Anus and anal canal', 'Tonsil', 'Base of tongue', 'Nasopharynx', 'Rectum', 'Esophagus', 'Bronchus and lung', 'Prostate gland', 'Brain', 'Ovary']	"[""Gliomas"", ""Adenomas and Adenocarcinomas"", ""Nevi and Melanomas"", ""Myomatous Neoplasms"", ""Osseous and Chondromatous Neoplasms"", ""Neoplasms, NOS"", ""Soft Tissue Tumors and Sarcomas, NOS"", ""Squamous Cell Neoplasms"", ""Epithelial Neoplasms, NOS""]"			1419.0	Genomic Characterization CS-MATCH-0007 Arm I			"[""Retroperitoneum and peritoneum"", ""Kidney"", ""Liver and intrahepatic bile ducts"", ""Corpus uteri"", ""Rectosigmoid junction"", ""Vagina"", ""Accessory sinuses"", ""Other and unspecified female genital organs"", ""Oropharynx"", ""Other and unspecified parts of mouth"", ""Connective, subcutaneous and other soft tissues"", ""Colon"", ""Other and unspecified major salivary glands"", ""Unknown"", ""Cervix uteri"", ""Skin"", ""Anus and anal canal"", ""Tonsil"", ""Base of tongue"", ""Nasopharynx"", ""Rectum"", ""Esophagus"", ""Bronchus and lung"", ""Prostate gland"", ""Brain"", ""Ovary""]"		MATCH-I		MATCH-I					MATCH-I		60.0	disease_type: Gliomas	primary_site: Retroperitoneum and peritoneum							
MATCH-N	21	MATCH-N	MATCH-N			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs002151	Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Complex Mixed and Stromal Neoplasms', 'Gliomas', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Epithelial Neoplasms, NOS', 'Myomatous Neoplasms'] in ['Small intestine', 'Base of tongue', 'Oropharynx', 'Corpus uteri', 'Prostate gland', 'Unknown', 'Kidney', 'Cervix uteri', 'Breast', 'Bronchus and lung', 'Brain']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Complex Mixed and Stromal Neoplasms"", ""Gliomas"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Epithelial Neoplasms, NOS"", ""Myomatous Neoplasms""]"			510.0	Genomic Characterization CS-MATCH-0007 Arm N			"[""Small intestine"", ""Base of tongue"", ""Oropharynx"", ""Corpus uteri"", ""Prostate gland"", ""Unknown"", ""Kidney"", ""Cervix uteri"", ""Breast"", ""Bronchus and lung"", ""Brain""]"		MATCH-N		MATCH-N					MATCH-N		21.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Small intestine							
MATCH-Q	35	MATCH-Q	MATCH-Q			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001926	Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Epithelial Neoplasms, NOS'] in ['Other and unspecified female genital organs', 'Other and unspecified parts of biliary tract', 'Corpus uteri', 'Rectosigmoid junction', 'Colon', 'Ovary', 'Other and unspecified male genital organs', 'Rectum', 'Cervix uteri', 'Bronchus and lung', 'Parotid gland', 'Other and ill-defined digestive organs', 'Gallbladder']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Epithelial Neoplasms, NOS""]"			852.0	Genomic Characterization CS-MATCH-0007 Arm Q			"[""Other and unspecified female genital organs"", ""Other and unspecified parts of biliary tract"", ""Corpus uteri"", ""Rectosigmoid junction"", ""Colon"", ""Ovary"", ""Other and unspecified male genital organs"", ""Rectum"", ""Cervix uteri"", ""Bronchus and lung"", ""Parotid gland"", ""Other and ill-defined digestive organs"", ""Gallbladder""]"		MATCH-Q		MATCH-Q					MATCH-Q		35.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Other and unspecified female genital organs							
MATCH-U	23	MATCH-U	MATCH-U			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs002179	Genomic Data Commons study of ['Mesothelial Neoplasms', 'Adenomas and Adenocarcinomas', 'Fibromatous Neoplasms', 'Neoplasms, NOS', 'Nerve Sheath Tumors', 'Squamous Cell Neoplasms', 'Epithelial Neoplasms, NOS'] in ['Other and unspecified parts of biliary tract', 'Heart, mediastinum, and pleura', 'Brain', 'Bronchus and lung', 'Kidney', 'Liver and intrahepatic bile ducts', 'Other and unspecified female genital organs', 'Cervix uteri', 'Meninges', 'Ovary', 'Connective, subcutaneous and other soft tissues']	"[""Mesothelial Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Fibromatous Neoplasms"", ""Neoplasms, NOS"", ""Nerve Sheath Tumors"", ""Squamous Cell Neoplasms"", ""Epithelial Neoplasms, NOS""]"			545.0	Genomic Characterization CS-MATCH-0007 Arm U			"[""Other and unspecified parts of biliary tract"", ""Heart, mediastinum, and pleura"", ""Brain"", ""Bronchus and lung"", ""Kidney"", ""Liver and intrahepatic bile ducts"", ""Other and unspecified female genital organs"", ""Cervix uteri"", ""Meninges"", ""Ovary"", ""Connective, subcutaneous and other soft tissues""]"		MATCH-U		MATCH-U					MATCH-U		23.0	disease_type: Mesothelial Neoplasms	primary_site: Other and unspecified parts of biliary tract							
MATCH-W	45	MATCH-W	MATCH-W			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001948	Genomic Data Commons study of ['Gliomas', 'Transitional Cell Papillomas and Carcinomas', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas', 'Cystic, Mucinous and Serous Neoplasms', 'Neoplasms, NOS', 'Squamous Cell Neoplasms', 'Epithelial Neoplasms, NOS'] in ['Breast', 'Corpus uteri', 'Rectum', 'Other and unspecified major salivary glands', 'Bronchus and lung', 'Prostate gland', 'Other and unspecified urinary organs', 'Liver and intrahepatic bile ducts', 'Other and unspecified female genital organs', 'Renal pelvis', 'Anus and anal canal', 'Parotid gland', 'Cervix uteri', 'Brain', 'Bladder', 'Pancreas', 'Thyroid gland', 'Gallbladder']	"[""Gliomas"", ""Transitional Cell Papillomas and Carcinomas"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Cystic, Mucinous and Serous Neoplasms"", ""Neoplasms, NOS"", ""Squamous Cell Neoplasms"", ""Epithelial Neoplasms, NOS""]"			1091.0	Genomic Characterization CS-MATCH-0007 Arm W			"[""Breast"", ""Corpus uteri"", ""Rectum"", ""Other and unspecified major salivary glands"", ""Bronchus and lung"", ""Prostate gland"", ""Other and unspecified urinary organs"", ""Liver and intrahepatic bile ducts"", ""Other and unspecified female genital organs"", ""Renal pelvis"", ""Anus and anal canal"", ""Parotid gland"", ""Cervix uteri"", ""Brain"", ""Bladder"", ""Pancreas"", ""Thyroid gland"", ""Gallbladder""]"		MATCH-W		MATCH-W					MATCH-W		45.0	disease_type: Gliomas	primary_site: Breast							
MATCH-Y	31	MATCH-Y	MATCH-Y			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001904	Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Fibromatous Neoplasms', 'Squamous Cell Neoplasms', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Transitional Cell Papillomas and Carcinomas', 'Epithelial Neoplasms, NOS', 'Myomatous Neoplasms'] in ['Other and unspecified female genital organs', 'Corpus uteri', 'Connective, subcutaneous and other soft tissues', 'Skin', 'Retroperitoneum and peritoneum', 'Renal pelvis', 'Pancreas', 'Breast', 'Cervix uteri', 'Bronchus and lung']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Fibromatous Neoplasms"", ""Squamous Cell Neoplasms"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Transitional Cell Papillomas and Carcinomas"", ""Epithelial Neoplasms, NOS"", ""Myomatous Neoplasms""]"			783.0	Genomic Characterization CS-MATCH-0007 Arm Y			"[""Other and unspecified female genital organs"", ""Corpus uteri"", ""Connective, subcutaneous and other soft tissues"", ""Skin"", ""Retroperitoneum and peritoneum"", ""Renal pelvis"", ""Pancreas"", ""Breast"", ""Cervix uteri"", ""Bronchus and lung""]"		MATCH-Y		MATCH-Y					MATCH-Y		31.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Other and unspecified female genital organs							
MATCH-Z1A	45	MATCH-Z1A	MATCH-Z1A			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001973	Genomic Data Commons study of ['Mesothelial Neoplasms', 'Transitional Cell Papillomas and Carcinomas', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Squamous Cell Neoplasms', 'Epithelial Neoplasms, NOS'] in ['Colon', 'Corpus uteri', 'Rectosigmoid junction', 'Rectum', 'Heart, mediastinum, and pleura', 'Trachea', 'Unknown', 'Liver and intrahepatic bile ducts', 'Other and ill-defined digestive organs', 'Bladder', 'Thyroid gland', 'Ovary', 'Connective, subcutaneous and other soft tissues', 'Bones, joints and articular cartilage of other and unspecified sites']	"[""Mesothelial Neoplasms"", ""Transitional Cell Papillomas and Carcinomas"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Squamous Cell Neoplasms"", ""Epithelial Neoplasms, NOS""]"			1090.0	Genomic Characterization CS-MATCH-0007 Arm Z1A			"[""Colon"", ""Corpus uteri"", ""Rectosigmoid junction"", ""Rectum"", ""Heart, mediastinum, and pleura"", ""Trachea"", ""Unknown"", ""Liver and intrahepatic bile ducts"", ""Other and ill-defined digestive organs"", ""Bladder"", ""Thyroid gland"", ""Ovary"", ""Connective, subcutaneous and other soft tissues"", ""Bones, joints and articular cartilage of other and unspecified sites""]"		MATCH-Z1A		MATCH-Z1A					MATCH-Z1A		45.0	disease_type: Mesothelial Neoplasms	primary_site: Colon							
MATCH-Z1D	36	MATCH-Z1D	MATCH-Z1D			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001859	Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Complex Mixed and Stromal Neoplasms', 'Gliomas', 'Ductal and Lobular Neoplasms', 'Adenomas and Adenocarcinomas', 'Neoplasms, NOS', 'Myomatous Neoplasms'] in ['Small intestine', 'Thyroid gland', 'Other and unspecified female genital organs', 'Other and unspecified parts of biliary tract', 'Corpus uteri', 'Uterus, NOS', 'Liver and intrahepatic bile ducts', 'Other endocrine glands and related structures', 'Breast', 'Esophagus', 'Brain', 'Other and unspecified major salivary glands', 'Prostate gland', 'Bones, joints and articular cartilage of other and unspecified sites', 'Stomach']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Complex Mixed and Stromal Neoplasms"", ""Gliomas"", ""Ductal and Lobular Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Neoplasms, NOS"", ""Myomatous Neoplasms""]"			891.0	Genomic Characterization CS-MATCH-0007 Arm Z1D			"[""Small intestine"", ""Thyroid gland"", ""Other and unspecified female genital organs"", ""Other and unspecified parts of biliary tract"", ""Corpus uteri"", ""Uterus, NOS"", ""Liver and intrahepatic bile ducts"", ""Other endocrine glands and related structures"", ""Breast"", ""Esophagus"", ""Brain"", ""Other and unspecified major salivary glands"", ""Prostate gland"", ""Bones, joints and articular cartilage of other and unspecified sites"", ""Stomach""]"		MATCH-Z1D		MATCH-Z1D					MATCH-Z1D		36.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Small intestine							
MMRF-COMMPASS	995	MMRF-COMMPASS	MMRF-COMMPASS			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000748	Genomic Data Commons study of ['Plasma Cell Tumors'] in ['Hematopoietic and reticuloendothelial systems']	"[""Plasma Cell Tumors""]"			27014.0	Multiple Myeloma CoMMpass Study			"[""Hematopoietic and reticuloendothelial systems""]"		MMRF-COMMPASS		MMRF-COMMPASS					MMRF-COMMPASS		995.0	disease_type: Plasma Cell Tumors	primary_site: Hematopoietic and reticuloendothelial systems							
MP2PRT-ALL	1510	MP2PRT-ALL	MP2PRT-ALL			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs002005	Genomic Data Commons study of ['Acute Lymphoblastic Leukemia', 'Lymphoid Leukemias'] in ['Hematopoietic and reticuloendothelial systems']	"[""Acute Lymphoblastic Leukemia"", ""Lymphoid Leukemias""]"			48755.0	Molecular Profiling to Predict Response to Treatment for Acute Lymphoblastic Leukemia			"[""Hematopoietic and reticuloendothelial systems""]"		MP2PRT-ALL		MP2PRT-ALL					MP2PRT-ALL		1510.0	disease_type: Acute Lymphoblastic Leukemia	primary_site: Hematopoietic and reticuloendothelial systems							
MP2PRT-WT	52	MP2PRT-WT	MP2PRT-WT			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001965	Genomic Data Commons study of ['Neoplasms, NOS'] in ['Kidney']	"[""Neoplasms, NOS""]"			1571.0	Molecular Profiling to Predict Response to Treatment - Wilms Tumor			"[""Kidney""]"		MP2PRT-WT		MP2PRT-WT					MP2PRT-WT		52.0	disease_type: Neoplasms, NOS	primary_site: Kidney							
NCICCR-DLBCL	489	NCICCR-DLBCL	NCICCR-DLBCL			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Mature B-Cell Lymphomas'] in ['Lymph nodes']	"[""Mature B-Cell Lymphomas""]"			5286.0	Genomic Variation in Diffuse Large B Cell Lymphomas			"[""Lymph nodes""]"		NCICCR-DLBCL		NCICCR-DLBCL					NCICCR-DLBCL		489.0	disease_type: Mature B-Cell Lymphomas	primary_site: Lymph nodes							
OHSU-CNL	176	OHSU-CNL	OHSU-CNL			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001799	Genomic Data Commons study of ['Chronic Myeloproliferative Disorders'] in ['Hematopoietic and reticuloendothelial systems']	"[""Chronic Myeloproliferative Disorders""]"			1628.0	Philadelphia-Negative Neutrophilic Leukemias (CNL/aCML/MDS/MPNu)			"[""Hematopoietic and reticuloendothelial systems""]"		OHSU-CNL		OHSU-CNL					OHSU-CNL		176.0	disease_type: Chronic Myeloproliferative Disorders	primary_site: Hematopoietic and reticuloendothelial systems							
ORGANOID-PANCREATIC	70	ORGANOID-PANCREATIC	ORGANOID-PANCREATIC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001611	Genomic Data Commons study of ['Unknown', 'Adenomas and Adenocarcinomas'] in ['Pancreas']	"[""Unknown"", ""Adenomas and Adenocarcinomas""]"			896.0	Pancreas Cancer Organoid Profiling			"[""Pancreas""]"		ORGANOID-PANCREATIC		ORGANOID-PANCREATIC					ORGANOID-PANCREATIC		70.0	disease_type: Unknown	primary_site: Pancreas							
REBC-THYR	440	REBC-THYR	REBC-THYR			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Thyroid gland']	"[""Adenomas and Adenocarcinomas""]"			11553.0	Comprehensive genomic characterization of radiation-related papillary thyroid cancer in the Ukraine			"[""Thyroid gland""]"		REBC-THYR		REBC-THYR					REBC-THYR		440.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Thyroid gland							
TARGET-ALL-P1	24	TARGET-ALL-P1	TARGET-ALL-P1			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000463	Genomic Data Commons study of ['Lymphoid Leukemias'] in ['Hematopoietic and reticuloendothelial systems']	"[""Lymphoid Leukemias""]"			101.0	Acute Lymphoblastic Leukemia - Phase I			"[""Hematopoietic and reticuloendothelial systems""]"		TARGET-ALL-P1		TARGET-ALL-P1					TARGET-ALL-P1		24.0	disease_type: Lymphoid Leukemias	primary_site: Hematopoietic and reticuloendothelial systems							
TARGET-ALL-P2	1587	TARGET-ALL-P2	TARGET-ALL-P2			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000464	Genomic Data Commons study of ['Lymphoid Leukemias'] in ['Hematopoietic and reticuloendothelial systems']	"[""Lymphoid Leukemias""]"			17584.0	Acute Lymphoblastic Leukemia - Phase II			"[""Hematopoietic and reticuloendothelial systems""]"		TARGET-ALL-P2		TARGET-ALL-P2					TARGET-ALL-P2		1587.0	disease_type: Lymphoid Leukemias	primary_site: Hematopoietic and reticuloendothelial systems							
TARGET-ALL-P3	191	TARGET-ALL-P3	TARGET-ALL-P3			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Not Applicable', 'Leukemias, NOS', 'Myeloid Leukemias', 'Lymphoid Leukemias'] in ['Unknown', 'Hematopoietic and reticuloendothelial systems']	"[""Not Applicable"", ""Leukemias, NOS"", ""Myeloid Leukemias"", ""Lymphoid Leukemias""]"			3736.0	Acute Lymphoblastic Leukemia - Phase III			"[""Unknown"", ""Hematopoietic and reticuloendothelial systems""]"		TARGET-ALL-P3		TARGET-ALL-P3					TARGET-ALL-P3		191.0	disease_type: Not Applicable	primary_site: Unknown							
TARGET-AML	2492	TARGET-AML	TARGET-AML			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000465	Genomic Data Commons study of ['Not Applicable', 'Myeloid Leukemias'] in ['Unknown', 'Hematopoietic and reticuloendothelial systems']	"[""Not Applicable"", ""Myeloid Leukemias""]"			38590.0	Acute Myeloid Leukemia			"[""Unknown"", ""Hematopoietic and reticuloendothelial systems""]"		TARGET-AML		TARGET-AML					TARGET-AML		2492.0	disease_type: Not Applicable	primary_site: Unknown							
TARGET-CCSK	13	TARGET-CCSK	TARGET-CCSK			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000466	Genomic Data Commons study of ['Complex Mixed and Stromal Neoplasms'] in ['Kidney']	"[""Complex Mixed and Stromal Neoplasms""]"			185.0	Clear Cell Sarcoma of the Kidney			"[""Kidney""]"		TARGET-CCSK		TARGET-CCSK					TARGET-CCSK		13.0	disease_type: Complex Mixed and Stromal Neoplasms	primary_site: Kidney							
TARGET-NBL	1132	TARGET-NBL	TARGET-NBL			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000467	Genomic Data Commons study of ['Not Applicable', 'Neuroepitheliomatous Neoplasms'] in ['Meninges', 'Connective, subcutaneous and other soft tissues', 'Adrenal gland', 'Stomach', 'Other and ill-defined sites', 'Skin', 'Renal pelvis', 'Kidney', 'Peripheral nerves and autonomic nervous system', 'Lymph nodes', 'Spinal cord, cranial nerves, and other parts of central nervous system', 'Unknown', 'Retroperitoneum and peritoneum', 'Liver and intrahepatic bile ducts', 'Other endocrine glands and related structures', 'Heart, mediastinum, and pleura', 'Uterus, NOS', 'Bones, joints and articular cartilage of other and unspecified sites', 'Bones, joints and articular cartilage of limbs', 'Hematopoietic and reticuloendothelial systems']	"[""Not Applicable"", ""Neuroepitheliomatous Neoplasms""]"			5705.0	Neuroblastoma			"[""Meninges"", ""Connective, subcutaneous and other soft tissues"", ""Adrenal gland"", ""Stomach"", ""Other and ill-defined sites"", ""Skin"", ""Renal pelvis"", ""Kidney"", ""Peripheral nerves and autonomic nervous system"", ""Lymph nodes"", ""Spinal cord, cranial nerves, and other parts of central nervous system"", ""Unknown"", ""Retroperitoneum and peritoneum"", ""Liver and intrahepatic bile ducts"", ""Other endocrine glands and related structures"", ""Heart, mediastinum, and pleura"", ""Uterus, NOS"", ""Bones, joints and articular cartilage of other and unspecified sites"", ""Bones, joints and articular cartilage of limbs"", ""Hematopoietic and reticuloendothelial systems""]"		TARGET-NBL		TARGET-NBL					TARGET-NBL		1132.0	disease_type: Not Applicable	primary_site: Meninges							
TARGET-OS	383	TARGET-OS	TARGET-OS			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000468	Genomic Data Commons study of ['Osseous and Chondromatous Neoplasms'] in ['Bones, joints and articular cartilage of limbs', 'Not Reported', 'Bones, joints and articular cartilage of other and unspecified sites']	"[""Osseous and Chondromatous Neoplasms""]"			2972.0	Osteosarcoma			"[""Bones, joints and articular cartilage of limbs"", ""Not Reported"", ""Bones, joints and articular cartilage of other and unspecified sites""]"		TARGET-OS		TARGET-OS					TARGET-OS		383.0	disease_type: Osseous and Chondromatous Neoplasms	primary_site: Bones, joints and articular cartilage of limbs							
TARGET-RT	69	TARGET-RT	TARGET-RT			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000470	Genomic Data Commons study of ['Complex Mixed and Stromal Neoplasms'] in ['Lip', 'Liver and intrahepatic bile ducts', 'Kidney']	"[""Complex Mixed and Stromal Neoplasms""]"			1036.0	Rhabdoid Tumor			"[""Lip"", ""Liver and intrahepatic bile ducts"", ""Kidney""]"		TARGET-RT		TARGET-RT					TARGET-RT		69.0	disease_type: Complex Mixed and Stromal Neoplasms	primary_site: Lip							
TARGET-WT	652	TARGET-WT	TARGET-WT			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs000471	Genomic Data Commons study of ['Complex Mixed and Stromal Neoplasms'] in ['Kidney']	"[""Complex Mixed and Stromal Neoplasms""]"			6415.0	High-Risk Wilms Tumor			"[""Kidney""]"		TARGET-WT		TARGET-WT					TARGET-WT		652.0	disease_type: Complex Mixed and Stromal Neoplasms	primary_site: Kidney							
TCGA-ACC	92	TCGA-ACC	TCGA-ACC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Adrenal gland']	"[""Adenomas and Adenocarcinomas""]"			5134.0	Adrenocortical Carcinoma			"[""Adrenal gland""]"		TCGA-ACC		TCGA-ACC					TCGA-ACC		92.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Adrenal gland							
TCGA-BLCA	412	TCGA-BLCA	TCGA-BLCA			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas', 'Squamous Cell Neoplasms', 'Transitional Cell Papillomas and Carcinomas', 'Epithelial Neoplasms, NOS'] in ['Bladder']	"[""Adenomas and Adenocarcinomas"", ""Squamous Cell Neoplasms"", ""Transitional Cell Papillomas and Carcinomas"", ""Epithelial Neoplasms, NOS""]"			23394.0	Bladder Urothelial Carcinoma			"[""Bladder""]"		TCGA-BLCA		TCGA-BLCA					TCGA-BLCA		412.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Bladder							
TCGA-BRCA	1098	TCGA-BRCA	TCGA-BRCA			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Complex Epithelial Neoplasms', 'Epithelial Neoplasms, NOS', 'Adnexal and Skin Appendage Neoplasms', 'Squamous Cell Neoplasms', 'Basal Cell Neoplasms', 'Cystic, Mucinous and Serous Neoplasms', 'Adenomas and Adenocarcinomas', 'Fibroepithelial Neoplasms', 'Ductal and Lobular Neoplasms'] in ['Breast']	"[""Complex Epithelial Neoplasms"", ""Epithelial Neoplasms, NOS"", ""Adnexal and Skin Appendage Neoplasms"", ""Squamous Cell Neoplasms"", ""Basal Cell Neoplasms"", ""Cystic, Mucinous and Serous Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Fibroepithelial Neoplasms"", ""Ductal and Lobular Neoplasms""]"			60945.0	Breast Invasive Carcinoma			"[""Breast""]"		TCGA-BRCA		TCGA-BRCA					TCGA-BRCA		1098.0	disease_type: Complex Epithelial Neoplasms	primary_site: Breast							
TCGA-CESC	307	TCGA-CESC	TCGA-CESC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Complex Epithelial Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Cervix uteri']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Complex Epithelial Neoplasms"", ""Adenomas and Adenocarcinomas""]"			16418.0	Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma			"[""Cervix uteri""]"		TCGA-CESC		TCGA-CESC					TCGA-CESC		307.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Cervix uteri							
TCGA-CHOL	51	TCGA-CHOL	TCGA-CHOL			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Other and unspecified parts of biliary tract', 'Liver and intrahepatic bile ducts', 'Gallbladder']	"[""Adenomas and Adenocarcinomas""]"			2486.0	Cholangiocarcinoma			"[""Other and unspecified parts of biliary tract"", ""Liver and intrahepatic bile ducts"", ""Gallbladder""]"		TCGA-CHOL		TCGA-CHOL					TCGA-CHOL		51.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Other and unspecified parts of biliary tract							
TCGA-COAD	461	TCGA-COAD	TCGA-COAD			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Epithelial Neoplasms, NOS', 'Complex Epithelial Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Rectosigmoid junction', 'Colon']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Epithelial Neoplasms, NOS"", ""Complex Epithelial Neoplasms"", ""Adenomas and Adenocarcinomas""]"			25657.0	Colon Adenocarcinoma			"[""Rectosigmoid junction"", ""Colon""]"		TCGA-COAD		TCGA-COAD					TCGA-COAD		461.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Rectosigmoid junction							
TCGA-DLBC	58	TCGA-DLBC	TCGA-DLBC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Not Reported', 'Mature B-Cell Lymphomas'] in ['Small intestine', 'Thyroid gland', 'Heart, mediastinum, and pleura', 'Connective, subcutaneous and other soft tissues', 'Colon', 'Testis', 'Retroperitoneum and peritoneum', 'Breast', 'Other and unspecified major salivary glands', 'Brain', 'Lymph nodes', 'Hematopoietic and reticuloendothelial systems', 'Bones, joints and articular cartilage of other and unspecified sites', 'Stomach']	"[""Not Reported"", ""Mature B-Cell Lymphomas""]"			2528.0	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma			"[""Small intestine"", ""Thyroid gland"", ""Heart, mediastinum, and pleura"", ""Connective, subcutaneous and other soft tissues"", ""Colon"", ""Testis"", ""Retroperitoneum and peritoneum"", ""Breast"", ""Other and unspecified major salivary glands"", ""Brain"", ""Lymph nodes"", ""Hematopoietic and reticuloendothelial systems"", ""Bones, joints and articular cartilage of other and unspecified sites"", ""Stomach""]"		TCGA-DLBC		TCGA-DLBC					TCGA-DLBC		58.0	disease_type: Not Reported	primary_site: Small intestine							
TCGA-ESCA	185	TCGA-ESCA	TCGA-ESCA			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Squamous Cell Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Esophagus', 'Stomach']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Squamous Cell Neoplasms"", ""Adenomas and Adenocarcinomas""]"			10234.0	Esophageal Carcinoma			"[""Esophagus"", ""Stomach""]"		TCGA-ESCA		TCGA-ESCA					TCGA-ESCA		185.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Esophagus							
TCGA-GBM	617	TCGA-GBM	TCGA-GBM			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Not Reported', 'Gliomas'] in ['Brain']	"[""Not Reported"", ""Gliomas""]"			23446.0	Glioblastoma Multiforme			"[""Brain""]"		TCGA-GBM		TCGA-GBM					TCGA-GBM		617.0	disease_type: Not Reported	primary_site: Brain							
TCGA-HNSC	528	TCGA-HNSC	TCGA-HNSC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Squamous Cell Neoplasms'] in ['Larynx', 'Other and unspecified parts of tongue', 'Other and unspecified parts of mouth', 'Hypopharynx', 'Bones, joints and articular cartilage of other and unspecified sites', 'Palate', 'Lip', 'Tonsil', 'Floor of mouth', 'Other and ill-defined sites in lip, oral cavity and pharynx', 'Oropharynx', 'Gum', 'Base of tongue']	"[""Squamous Cell Neoplasms""]"			29386.0	Head and Neck Squamous Cell Carcinoma			"[""Larynx"", ""Other and unspecified parts of tongue"", ""Other and unspecified parts of mouth"", ""Hypopharynx"", ""Bones, joints and articular cartilage of other and unspecified sites"", ""Palate"", ""Lip"", ""Tonsil"", ""Floor of mouth"", ""Other and ill-defined sites in lip, oral cavity and pharynx"", ""Oropharynx"", ""Gum"", ""Base of tongue""]"		TCGA-HNSC		TCGA-HNSC					TCGA-HNSC		528.0	disease_type: Squamous Cell Neoplasms	primary_site: Larynx							
TCGA-KICH	113	TCGA-KICH	TCGA-KICH			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Kidney']	"[""Adenomas and Adenocarcinomas""]"			4345.0	Kidney Chromophobe			"[""Kidney""]"		TCGA-KICH		TCGA-KICH					TCGA-KICH		113.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Kidney							
TCGA-KIRC	537	TCGA-KIRC	TCGA-KIRC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Kidney']	"[""Adenomas and Adenocarcinomas""]"			29352.0	Kidney Renal Clear Cell Carcinoma			"[""Kidney""]"		TCGA-KIRC		TCGA-KIRC					TCGA-KIRC		537.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Kidney							
TCGA-KIRP	291	TCGA-KIRP	TCGA-KIRP			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Kidney']	"[""Adenomas and Adenocarcinomas""]"			16431.0	Kidney Renal Papillary Cell Carcinoma			"[""Kidney""]"		TCGA-KIRP		TCGA-KIRP					TCGA-KIRP		291.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Kidney							
TCGA-LAML	200	TCGA-LAML	TCGA-LAML			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Myeloid Leukemias'] in ['Hematopoietic and reticuloendothelial systems']	"[""Myeloid Leukemias""]"			8656.0	Acute Myeloid Leukemia			"[""Hematopoietic and reticuloendothelial systems""]"		TCGA-LAML		TCGA-LAML					TCGA-LAML		200.0	disease_type: Myeloid Leukemias	primary_site: Hematopoietic and reticuloendothelial systems							
TCGA-LGG	516	TCGA-LGG	TCGA-LGG			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Gliomas'] in ['Brain']	"[""Gliomas""]"			28512.0	Brain Lower Grade Glioma			"[""Brain""]"		TCGA-LGG		TCGA-LGG					TCGA-LGG		516.0	disease_type: Gliomas	primary_site: Brain							
TCGA-LIHC	377	TCGA-LIHC	TCGA-LIHC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Liver and intrahepatic bile ducts']	"[""Adenomas and Adenocarcinomas""]"			20820.0	Liver Hepatocellular Carcinoma			"[""Liver and intrahepatic bile ducts""]"		TCGA-LIHC		TCGA-LIHC					TCGA-LIHC		377.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Liver and intrahepatic bile ducts							
TCGA-LUAD	585	TCGA-LUAD	TCGA-LUAD			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Adenomas and Adenocarcinomas', 'Acinar Cell Neoplasms'] in ['Bronchus and lung']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Adenomas and Adenocarcinomas"", ""Acinar Cell Neoplasms""]"			31867.0	Lung Adenocarcinoma			"[""Bronchus and lung""]"		TCGA-LUAD		TCGA-LUAD					TCGA-LUAD		585.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Bronchus and lung							
TCGA-LUSC	504	TCGA-LUSC	TCGA-LUSC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Squamous Cell Neoplasms'] in ['Bronchus and lung']	"[""Squamous Cell Neoplasms""]"			29183.0	Lung Squamous Cell Carcinoma			"[""Bronchus and lung""]"		TCGA-LUSC		TCGA-LUSC					TCGA-LUSC		504.0	disease_type: Squamous Cell Neoplasms	primary_site: Bronchus and lung							
TCGA-MESO	87	TCGA-MESO	TCGA-MESO			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Mesothelial Neoplasms'] in ['Heart, mediastinum, and pleura', 'Bronchus and lung']	"[""Mesothelial Neoplasms""]"			4832.0	Mesothelioma			"[""Heart, mediastinum, and pleura"", ""Bronchus and lung""]"		TCGA-MESO		TCGA-MESO					TCGA-MESO		87.0	disease_type: Mesothelial Neoplasms	primary_site: Heart, mediastinum, and pleura							
TCGA-OV	608	TCGA-OV	TCGA-OV			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Not Reported', 'Cystic, Mucinous and Serous Neoplasms'] in ['Ovary']	"[""Not Reported"", ""Cystic, Mucinous and Serous Neoplasms""]"			28473.0	Ovarian Serous Cystadenocarcinoma			"[""Ovary""]"		TCGA-OV		TCGA-OV					TCGA-OV		608.0	disease_type: Not Reported	primary_site: Ovary							
TCGA-PAAD	185	TCGA-PAAD	TCGA-PAAD			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Ductal and Lobular Neoplasms', 'Epithelial Neoplasms, NOS', 'Cystic, Mucinous and Serous Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Pancreas']	"[""Ductal and Lobular Neoplasms"", ""Epithelial Neoplasms, NOS"", ""Cystic, Mucinous and Serous Neoplasms"", ""Adenomas and Adenocarcinomas""]"			10894.0	Pancreatic Adenocarcinoma			"[""Pancreas""]"		TCGA-PAAD		TCGA-PAAD					TCGA-PAAD		185.0	disease_type: Ductal and Lobular Neoplasms	primary_site: Pancreas							
TCGA-PCPG	179	TCGA-PCPG	TCGA-PCPG			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Paragangliomas and Glomus Tumors'] in ['Other and ill-defined sites', 'Connective, subcutaneous and other soft tissues', 'Retroperitoneum and peritoneum', 'Other endocrine glands and related structures', 'Heart, mediastinum, and pleura', 'Adrenal gland', 'Spinal cord, cranial nerves, and other parts of central nervous system']	"[""Paragangliomas and Glomus Tumors""]"			9623.0	Pheochromocytoma and Paraganglioma			"[""Other and ill-defined sites"", ""Connective, subcutaneous and other soft tissues"", ""Retroperitoneum and peritoneum"", ""Other endocrine glands and related structures"", ""Heart, mediastinum, and pleura"", ""Adrenal gland"", ""Spinal cord, cranial nerves, and other parts of central nervous system""]"		TCGA-PCPG		TCGA-PCPG					TCGA-PCPG		179.0	disease_type: Paragangliomas and Glomus Tumors	primary_site: Other and ill-defined sites							
TCGA-PRAD	500	TCGA-PRAD	TCGA-PRAD			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Ductal and Lobular Neoplasms', 'Cystic, Mucinous and Serous Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Prostate gland']	"[""Ductal and Lobular Neoplasms"", ""Cystic, Mucinous and Serous Neoplasms"", ""Adenomas and Adenocarcinomas""]"			27793.0	Prostate Adenocarcinoma			"[""Prostate gland""]"		TCGA-PRAD		TCGA-PRAD					TCGA-PRAD		500.0	disease_type: Ductal and Lobular Neoplasms	primary_site: Prostate gland							
TCGA-READ	172	TCGA-READ	TCGA-READ			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Connective, subcutaneous and other soft tissues', 'Unknown', 'Rectosigmoid junction', 'Rectum', 'Colon']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Adenomas and Adenocarcinomas""]"			8887.0	Rectum Adenocarcinoma			"[""Connective, subcutaneous and other soft tissues"", ""Unknown"", ""Rectosigmoid junction"", ""Rectum"", ""Colon""]"		TCGA-READ		TCGA-READ					TCGA-READ		172.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Connective, subcutaneous and other soft tissues							
TCGA-SARC	261	TCGA-SARC	TCGA-SARC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Synovial-like Neoplasms', 'Fibromatous Neoplasms', 'Soft Tissue Tumors and Sarcomas, NOS', 'Lipomatous Neoplasms', 'Nerve Sheath Tumors', 'Myomatous Neoplasms'] in ['Meninges', 'Connective, subcutaneous and other soft tissues', 'Corpus uteri', 'Colon', 'Retroperitoneum and peritoneum', 'Other and unspecified male genital organs', 'Kidney', 'Other and unspecified parts of tongue', 'Peripheral nerves and autonomic nervous system', 'Ovary', 'Bones, joints and articular cartilage of limbs', 'Uterus, NOS', 'Stomach']	"[""Synovial-like Neoplasms"", ""Fibromatous Neoplasms"", ""Soft Tissue Tumors and Sarcomas, NOS"", ""Lipomatous Neoplasms"", ""Nerve Sheath Tumors"", ""Myomatous Neoplasms""]"			14184.0	Sarcoma			"[""Meninges"", ""Connective, subcutaneous and other soft tissues"", ""Corpus uteri"", ""Colon"", ""Retroperitoneum and peritoneum"", ""Other and unspecified male genital organs"", ""Kidney"", ""Other and unspecified parts of tongue"", ""Peripheral nerves and autonomic nervous system"", ""Ovary"", ""Bones, joints and articular cartilage of limbs"", ""Uterus, NOS"", ""Stomach""]"		TCGA-SARC		TCGA-SARC					TCGA-SARC		261.0	disease_type: Synovial-like Neoplasms	primary_site: Meninges							
TCGA-SKCM	470	TCGA-SKCM	TCGA-SKCM			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Nevi and Melanomas'] in ['Skin']	"[""Nevi and Melanomas""]"			24540.0	Skin Cutaneous Melanoma			"[""Skin""]"		TCGA-SKCM		TCGA-SKCM					TCGA-SKCM		470.0	disease_type: Nevi and Melanomas	primary_site: Skin							
TCGA-STAD	443	TCGA-STAD	TCGA-STAD			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Cystic, Mucinous and Serous Neoplasms', 'Adenomas and Adenocarcinomas'] in ['Stomach']	"[""Cystic, Mucinous and Serous Neoplasms"", ""Adenomas and Adenocarcinomas""]"			25204.0	Stomach Adenocarcinoma			"[""Stomach""]"		TCGA-STAD		TCGA-STAD					TCGA-STAD		443.0	disease_type: Cystic, Mucinous and Serous Neoplasms	primary_site: Stomach							
TCGA-TGCT	263	TCGA-TGCT	TCGA-TGCT			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Germ Cell Neoplasms'] in ['Testis']	"[""Germ Cell Neoplasms""]"			10290.0	Testicular Germ Cell Tumors			"[""Testis""]"		TCGA-TGCT		TCGA-TGCT					TCGA-TGCT		263.0	disease_type: Germ Cell Neoplasms	primary_site: Testis							
TCGA-THCA	507	TCGA-THCA	TCGA-THCA			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Epithelial Neoplasms, NOS', 'Adenomas and Adenocarcinomas'] in ['Thyroid gland']	"[""Epithelial Neoplasms, NOS"", ""Adenomas and Adenocarcinomas""]"			28245.0	Thyroid Carcinoma			"[""Thyroid gland""]"		TCGA-THCA		TCGA-THCA					TCGA-THCA		507.0	disease_type: Epithelial Neoplasms, NOS	primary_site: Thyroid gland							
TCGA-THYM	124	TCGA-THYM	TCGA-THYM			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Thymic Epithelial Neoplasms'] in ['Thymus', 'Heart, mediastinum, and pleura']	"[""Thymic Epithelial Neoplasms""]"			6576.0	Thymoma			"[""Thymus"", ""Heart, mediastinum, and pleura""]"		TCGA-THYM		TCGA-THYM					TCGA-THYM		124.0	disease_type: Thymic Epithelial Neoplasms	primary_site: Thymus							
TCGA-UCEC	560	TCGA-UCEC	TCGA-UCEC			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Not Reported', 'Cystic, Mucinous and Serous Neoplasms', 'Epithelial Neoplasms, NOS', 'Adenomas and Adenocarcinomas'] in ['Corpus uteri', 'Uterus, NOS']	"[""Not Reported"", ""Cystic, Mucinous and Serous Neoplasms"", ""Epithelial Neoplasms, NOS"", ""Adenomas and Adenocarcinomas""]"			28417.0	Uterine Corpus Endometrial Carcinoma			"[""Corpus uteri"", ""Uterus, NOS""]"		TCGA-UCEC		TCGA-UCEC					TCGA-UCEC		560.0	disease_type: Not Reported	primary_site: Corpus uteri							
TCGA-UCS	57	TCGA-UCS	TCGA-UCS			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Complex Mixed and Stromal Neoplasms'] in ['Uterus, NOS']	"[""Complex Mixed and Stromal Neoplasms""]"			3095.0	Uterine Carcinosarcoma			"[""Uterus, NOS""]"		TCGA-UCS		TCGA-UCS					TCGA-UCS		57.0	disease_type: Complex Mixed and Stromal Neoplasms	primary_site: Uterus, NOS							
TCGA-UVM	80	TCGA-UVM	TCGA-UVM			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Nevi and Melanomas'] in ['Eye and adnexa']	"[""Nevi and Melanomas""]"			4549.0	Uveal Melanoma			"[""Eye and adnexa""]"		TCGA-UVM		TCGA-UVM					TCGA-UVM		80.0	disease_type: Nevi and Melanomas	primary_site: Eye and adnexa							
TRIO-CRU	339	TRIO-CRU	TRIO-CRU			CRDC Genomic Data Commons	CRDC Genomic Data Commons					Genomic Data Commons study of ['Not Applicable'] in []	"[""Not Applicable""]"			339.0	Ukrainian National Research Center for Radiation Medicine Trio Study			[]		TRIO-CRU		TRIO-CRU					TRIO-CRU		339.0	disease_type: Not Applicable	primary_site: 							
VAREPOP-APOLLO	7	VAREPOP-APOLLO	VAREPOP-APOLLO			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001374	Genomic Data Commons study of ['Squamous Cell Neoplasms', 'Epithelial Neoplasms, NOS'] in ['Bronchus and lung']	"[""Squamous Cell Neoplasms"", ""Epithelial Neoplasms, NOS""]"			42.0	VA Research Precision Oncology Program			"[""Bronchus and lung""]"		VAREPOP-APOLLO		VAREPOP-APOLLO					VAREPOP-APOLLO		7.0	disease_type: Squamous Cell Neoplasms	primary_site: Bronchus and lung							
WCDT-MCRPC	101	WCDT-MCRPC	WCDT-MCRPC			CRDC Genomic Data Commons	CRDC Genomic Data Commons				phs001648	Genomic Data Commons study of ['Adenomas and Adenocarcinomas'] in ['Prostate gland']	"[""Adenomas and Adenocarcinomas""]"			1093.0	Genomic Characterization of Metastatic Castration Resistant Prostate Cancer			"[""Prostate gland""]"		WCDT-MCRPC		WCDT-MCRPC					WCDT-MCRPC		101.0	disease_type: Adenomas and Adenocarcinomas	primary_site: Prostate gland							
PDC000109	100	PDC000109	PDC000109	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Colon Adenocarcinoma		Label Free	2423.0	Prospective Colon VU Proteome			Colon	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective COAD Proteome S037-1					PDC000109			disease_type: Colon Adenocarcinoma	primary_site: Colon							
PDC000110	97	PDC000110	PDC000110	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT10	1268.0	Prospective Ovarian JHU Proteome			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Ovarian JHU Proteome v2					PDC000110			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000111	90	PDC000111	PDC000111	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Colon Adenocarcinoma;Rectum Adenocarcinoma		Label Free	5723.0	TCGA Colon Cancer Proteome			Colon;Rectum	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA COAD Proteome S016-1					PDC000111			disease_type: Colon Adenocarcinoma;Rectum Adenocarcinoma	primary_site: Colon;Rectum							
PDC000112	124	PDC000112	PDC000112	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		iTRAQ4	540.0	TCGA Ovarian JHU Glycoproteome			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA OV Glycoproteome S020-1					PDC000112			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000113	124	PDC000113	PDC000113	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		iTRAQ4	4412.0	TCGA Ovarian JHU Proteome			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA OV Proteome S020-2					PDC000113			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000114	85	PDC000114	PDC000114	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		iTRAQ4	2700.0	TCGA Ovarian PNNL Proteome			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA OV Proteome S020-3					PDC000114			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000115	70	PDC000115	PDC000115	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		iTRAQ4	1116.0	TCGA Ovarian PNNL Phosphoproteome Velos Qexactive			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA OV Phosphoproteome S020-4					PDC000115			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000116	102	PDC000116	PDC000116	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Colon Adenocarcinoma;Other		TMT10	1080.0	Prospective Colon PNNL Proteome Qeplus			Colon;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective COAD Proteome S037-2					PDC000116			disease_type: Colon Adenocarcinoma;Other	primary_site: Colon;Not Reported							
PDC000117	102	PDC000117	PDC000117	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Colon Adenocarcinoma;Other		TMT10	554.0	Prospective Colon PNNL Phosphoproteome Lumos			Colon;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective COAD Phosphoproteome S037-3					PDC000117			disease_type: Colon Adenocarcinoma;Other	primary_site: Colon;Not Reported							
PDC000118	95	PDC000118	PDC000118	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT10	1170.0	Prospective Ovarian PNNL Proteome Qeplus			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective OV Proteome S038-2					PDC000118			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000119	95	PDC000119	PDC000119	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT10	595.0	Prospective Ovarian PNNL Phosphoproteome Lumos			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective OV Phosphoproteome S038-3					PDC000119			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000120	127	PDC000120	PDC000120	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	1724.0	Prospective Breast BI Proteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Breast BI Proteome					PDC000120			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000121	127	PDC000121	PDC000121	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	909.0	Prospective Breast BI Phosphoproteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Breast BI Phosphoproteome					PDC000121			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000123	2	PDC000123	PDC000123	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	200.0	CPTAC UCEC Discovery Study - CompRef Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	UCEC Discovery - CompRef Phosphoproteome S043-2					PDC000123			disease_type: Other	primary_site: Not Reported							
PDC000124	2	PDC000124	PDC000124	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	391.0	CPTAC UCEC Discovery Study - CompRef Proteome 			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	UCEC Discovery - CompRef Proteome S043-1					PDC000124			disease_type: Other	primary_site: Not Reported							
PDC000125	123	PDC000125	PDC000125	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT10	1655.0	CPTAC UCEC Discovery Study - Proteome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	UCEC Discovery - Proteome S043-1					PDC000125			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000126	123	PDC000126	PDC000126	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT10	840.0	CPTAC UCEC Discovery Study - Phosphoproteome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	UCEC Discovery - Phosphoproteome S043-2					PDC000126			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000127	124	PDC000127	PDC000127	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other		TMT10	2320.0	CPTAC CCRCC Discovery Study - Proteome			Kidney;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Discovery Study - Proteome S044-1					PDC000127			disease_type: Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other	primary_site: Kidney;Not Reported							
PDC000128	124	PDC000128	PDC000128	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other		TMT10	1217.0	CPTAC CCRCC Discovery Study - Phosphoproteome			Kidney;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Discovery Study - Phosphoproteome S044-2					PDC000128			disease_type: Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other	primary_site: Kidney;Not Reported							
PDC000129	2	PDC000129	PDC000129	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	308.0	CPTAC CCRCC Discovery Study - CompRef Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Discovery Study - CompRef Proteome S044-1					PDC000129			disease_type: Other	primary_site: Not Reported							
PDC000130	2	PDC000130	PDC000130	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	165.0	CPTAC CCRCC Discovery Study - CompRef Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Discovery Study - CompRef Phosphoproteome S044-2					PDC000130			disease_type: Other	primary_site: Not Reported							
PDC000149	115	PDC000149	PDC000149	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		TMT10	1323.0	CPTAC LUAD Discovery Study - Phosphoproteome			Bronchus and lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LUAD Discovery Study - Phosphoproteome					PDC000149			disease_type: Lung Adenocarcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000152	9	PDC000152	PDC000152	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Chromophobe Renal Cell Carcinoma;Clear Cell Renal Cell Carcinoma;Papillary Renal Cell Carcinoma		Label Free	36.0	PCT SWATH Kidney			Kidney	Quantitative digital maps of tissue biopsies		Quantitative digital maps of tissue biopsies	guo_kidney ST25730263					PDC000152			disease_type: Chromophobe Renal Cell Carcinoma;Clear Cell Renal Cell Carcinoma;Papillary Renal Cell Carcinoma	primary_site: Kidney							
PDC000153	115	PDC000153	PDC000153	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		TMT10	2523.0	CPTAC LUAD Discovery Study - Proteome			Bronchus and lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LUAD Discovery Study - Proteome					PDC000153			disease_type: Lung Adenocarcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000154	2	PDC000154	PDC000154	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	415.0	CPTAC LUAD Discovery Study - CompRef Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LUAD Discovery Study - CompRef Proteome					PDC000154			disease_type: Other	primary_site: Not Reported							
PDC000155	2	PDC000155	PDC000155	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	224.0	CPTAC LUAD Discovery Study - CompRef Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LUAD Discovery Study - CompRef Phosphoproteome					PDC000155			disease_type: Other	primary_site: Not Reported							
PDC000173	109	PDC000173	PDC000173	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		iTRAQ4	3818.0	TCGA Breast Cancer Proteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA BRCA Proteome S015-1					PDC000173			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000174	109	PDC000174	PDC000174	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		iTRAQ4	1943.0	TCGA Breast Cancer Phosphoproteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA BRCA Phosphoproteome S015-2					PDC000174			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000176	207	PDC000176	PDC000176	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pediatric/AYA Brain Tumors		TMT11	210.0	Pediatric Brain Cancer Pilot Study - Phosphoproteome			Brain;Not Reported	Pediatric Brain Tumor Atlas - CBTN		Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Pediatric Brain Cancer Pilot Study - Phosphoproteome					PDC000176			disease_type: Other;Pediatric/AYA Brain Tumors	primary_site: Brain;Not Reported							
PDC000180	207	PDC000180	PDC000180	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pediatric/AYA Brain Tumors		TMT11	1128.0	Pediatric Brain Cancer Pilot Study - Proteome			Brain;Not Reported	Pediatric Brain Tumor Atlas - CBTN		Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Pediatric Brain Cancer Pilot Study - Proteome					PDC000180			disease_type: Other;Pediatric/AYA Brain Tumors	primary_site: Brain;Not Reported							
PDC000198	171	PDC000198	PDC000198	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Hepatocellular Carcinoma ;Other		TMT11	6347.0	HBV-Related Hepatocellular Carcinoma - Proteome			Liver;Not Reported	International Cancer Proteogenome Consortium		Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	HBV-Related Hepatocellular Carcinoma - Proteome					PDC000198			disease_type: Hepatocellular Carcinoma ;Other	primary_site: Liver;Not Reported							
PDC000199	171	PDC000199	PDC000199	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Hepatocellular Carcinoma ;Other		TMT11	3896.0	HBV-Related Hepatocellular Carcinoma - Phosphoproteome			Liver;Not Reported	International Cancer Proteogenome Consortium		Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	HBV-Related Hepatocellular Carcinoma - Phosphoproteome					PDC000199			disease_type: Hepatocellular Carcinoma ;Other	primary_site: Liver;Not Reported							
PDC000200	110	PDC000200	PDC000200	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma		Label Free	208.0	CPTAC CCRCC Discovery Study - DIA Proteome			Kidney	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Discovery Study - DIA Proteome					PDC000200			disease_type: Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma	primary_site: Kidney							
PDC000203	2	PDC000203	PDC000203	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT11	305.0	CPTAC GBM Discovery Study - CompRef Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC GBM Discovery Study - CompRef Proteome					PDC000203			disease_type: Other	primary_site: Not Reported							
PDC000204	111	PDC000204	PDC000204	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Glioblastoma;Other		TMT11	1082.0	CPTAC GBM Discovery Study - Proteome			Brain	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC GBM Discovery Study - Proteome					PDC000204			disease_type: Glioblastoma;Other	primary_site: Brain							
PDC000205	111	PDC000205	PDC000205	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Glioblastoma;Other		TMT11	555.0	CPTAC GBM Discovery Study - Phosphoproteome			Brain	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC GBM Discovery Study - Phosphoproteome					PDC000205			disease_type: Glioblastoma;Other	primary_site: Brain							
PDC000206	2	PDC000206	PDC000206	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT11	162.0	CPTAC GBM Discovery Study - CompRef Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC GBM Discovery Study - CompRef Phosphoproteome					PDC000206			disease_type: Other	primary_site: Not Reported							
PDC000214	80	PDC000214	PDC000214	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Early Onset Gastric Cancer		iTRAQ4	6250.0	Proteogenomics of Gastric Cancer - Proteome			Stomach	International Cancer Proteogenome Consortium		Human Early-Onset Gastric Cancer - Korea University	Proteogenomics of Gastric Cancer - Proteome					PDC000214			disease_type: Early Onset Gastric Cancer	primary_site: Stomach							
PDC000215	80	PDC000215	PDC000215	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Early Onset Gastric Cancer		iTRAQ4	3131.0	Proteogenomics of Gastric Cancer - Phosphoproteome			Stomach	International Cancer Proteogenome Consortium		Human Early-Onset Gastric Cancer - Korea University	Proteogenomics of Gastric Cancer - Phosphoproteome					PDC000215			disease_type: Early Onset Gastric Cancer	primary_site: Stomach							
PDC000216	80	PDC000216	PDC000216	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Early Onset Gastric Cancer		iTRAQ4	1562.0	Proteogenomics of Gastric Cancer - Glycoproteome			Stomach	International Cancer Proteogenome Consortium		Human Early-Onset Gastric Cancer - Korea University	Proteogenomics of Gastric Cancer - Glycoproteome					PDC000216			disease_type: Early Onset Gastric Cancer	primary_site: Stomach							
PDC000219	110	PDC000219	PDC000219	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Lung Squamous Cell Carcinoma;Other		TMT10	5167.0	Academia Sinica LUAD100-Proteome			Lung	International Cancer Proteogenome Consortium		Academia Sinica LUAD-100	Academia Sinica LUAD100-Proteome					PDC000219			disease_type: Lung Adenocarcinoma;Lung Squamous Cell Carcinoma;Other	primary_site: Lung							
PDC000220	86	PDC000220	PDC000220	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Lung Squamous Cell Carcinoma;Other		TMT10	2032.0	Academia Sinica LUAD100-Phosphoproteome			Lung	International Cancer Proteogenome Consortium		Academia Sinica LUAD-100	Academia Sinica LUAD100-Phosphoproteome					PDC000220			disease_type: Lung Adenocarcinoma;Lung Squamous Cell Carcinoma;Other	primary_site: Lung							
PDC000221	124	PDC000221	PDC000221	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Head and Neck Squamous Cell Carcinoma;Other		TMT11	2015.0	CPTAC HNSCC Discovery Study - Proteome			Head and Neck;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC HNSCC Discovery Study - Proteome					PDC000221			disease_type: Head and Neck Squamous Cell Carcinoma;Other	primary_site: Head and Neck;Not Reported							
PDC000222	124	PDC000222	PDC000222	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Head and Neck Squamous Cell Carcinoma;Other		TMT11	1055.0	CPTAC HNSCC Discovery Study - Phosphoproteome			Head and Neck;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC HNSCC Discovery Study - Phosphoproteome					PDC000222			disease_type: Head and Neck Squamous Cell Carcinoma;Other	primary_site: Head and Neck;Not Reported							
PDC000224	115	PDC000224	PDC000224	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		TMT10	423.0	CPTAC LUAD Discovery Study - Acetylome			Bronchus And Lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LUAD Discovery Study - Acetylome					PDC000224			disease_type: Lung Adenocarcinoma;Other	primary_site: Bronchus And Lung;Not Reported							
PDC000225	2	PDC000225	PDC000225	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	80.0	CPTAC LUAD Discovery Study - CompRef Acetylome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LUAD Discovery Study - CompRef Acetylome					PDC000225			disease_type: Other	primary_site: Not Reported							
PDC000226	123	PDC000226	PDC000226	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT10	294.0	CPTAC UCEC Discovery Study - Acetylome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Discovery Study - Acetylome					PDC000226			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000227	2	PDC000227	PDC000227	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	72.0	CPTAC UCEC Discovery Study - CompRef Acetylome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Discovery Study - CompRef Acetylome					PDC000227			disease_type: Other	primary_site: Not Reported							
PDC000231	11	PDC000231	PDC000231	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		iTRAQ8	152.0	Georgetown Lung Cancer Proteomics Study			Lung	Georgetown Proteomics Research Program		Georgetown Lung Cancer Proteomics Study	Georgetown Lung Cancer Proteomics Study					PDC000231			disease_type: Lung Adenocarcinoma;Other	primary_site: Lung							
PDC000232	115	PDC000232	PDC000232	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Squamous Cell Carcinoma;Other		TMT11	1169.0	CPTAC LSCC Discovery Study - Phosphoproteome			Bronchus and lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LSCC Discovery Study - Phosphoproteome					PDC000232			disease_type: Lung Squamous Cell Carcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000233	115	PDC000233	PDC000233	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Squamous Cell Carcinoma;Other		TMT11	377.0	CPTAC LSCC Discovery Study - Acetylome			Bronchus and lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LSCC Discovery Study - Acetylome					PDC000233			disease_type: Lung Squamous Cell Carcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000234	115	PDC000234	PDC000234	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Squamous Cell Carcinoma;Other		TMT11	2224.0	CPTAC LSCC Discovery Study - Proteome			Bronchus and lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LSCC Discovery Study - Proteome					PDC000234			disease_type: Lung Squamous Cell Carcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000237	89	PDC000237	PDC000237	Ubiquitylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Squamous Cell Carcinoma;Other		TMT11	145.0	CPTAC LSCC Discovery Study - Ubiquitylome			Bronchus and lung;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC LSCC Discovery Study - Ubiquitylome					PDC000237			disease_type: Lung Squamous Cell Carcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000239	127	PDC000239	PDC000239	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	437.0	Prospective Breast BI Acetylome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Breast BI Acetylome					PDC000239			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000240	2	PDC000240	PDC000240	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	107.0	Prospective Breast BI - CompRef Acetylome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Breast BI - CompRef Acetylome					PDC000240			disease_type: Other	primary_site: Not Reported							
PDC000242	2	PDC000242	PDC000242	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	410.0	Prospective Breast BI - CompRef Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Breast BI - CompRef Proteome					PDC000242			disease_type: Other	primary_site: Not Reported							
PDC000244	2	PDC000244	PDC000244	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	219.0	Prospective Breast BI - CompRef Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Breast BI - CompRef Phosphoproteome					PDC000244			disease_type: Other	primary_site: Not Reported							
PDC000245	111	PDC000245	PDC000245	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Glioblastoma;Other		TMT11	202.0	CPTAC GBM Discovery Study - Acetylome			Brain	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC GBM Discovery Study - Acetylome					PDC000245			disease_type: Glioblastoma;Other	primary_site: Brain							
PDC000246	2	PDC000246	PDC000246	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT11	66.0	CPTAC GBM Discovery Study - CompRef Acetylome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC GBM Discovery Study - CompRef Acetylome					PDC000246			disease_type: Other	primary_site: Not Reported							
PDC000248	154	PDC000248	PDC000248	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Pancreatic Ductal Adenocarcinoma		TMT10	1639.0	KU PDAC Discovery Study - Global proteome			Pancreas	International Cancer Proteogenome Consortium		Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	KU PDAC Discovery Study - Global proteome					PDC000248			disease_type: Pancreatic Ductal Adenocarcinoma	primary_site: Pancreas							
PDC000249	154	PDC000249	PDC000249	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Pancreatic Ductal Adenocarcinoma		TMT10	1448.0	KU PDAC Discovery Study - Phosphoproteome			Pancreas	International Cancer Proteogenome Consortium		Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	KU PDAC Discovery Study - Phosphoproteome					PDC000249			disease_type: Pancreatic Ductal Adenocarcinoma	primary_site: Pancreas							
PDC000250	97	PDC000250	PDC000250	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT10	90.0	Prospective Ovarian JHU Intact Glycoproteome			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Ovarian JHU Intact Glycoproteome					PDC000250			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000251	97	PDC000251	PDC000251	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT10	176.0	Prospective Ovarian JHU N-linked Glycosite-containing peptide			Not Reported;Ovary	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Confirmatory	Prospective Ovarian JHU N-linked Glycosite-containing peptide					PDC000251			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported;Ovary							
PDC000262	39	PDC000262	PDC000262	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Oral Squamous Cell Carcinoma;Other		iTRAQ4	3349.0	Oral Squamous Cell Carcinoma Study - Proteome			Head and Neck;Not Reported	International Cancer Proteogenome Consortium		Oral Squamous Cell Carcinoma - Chang Gung University	Oral Squamous Cell Carcinoma Study - Proteome					PDC000262			disease_type: Oral Squamous Cell Carcinoma;Other	primary_site: Head and Neck;Not Reported							
PDC000270	166	PDC000270	PDC000270	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pancreatic Ductal Adenocarcinoma		TMT11	2517.0	CPTAC PDA Discovery Study - Proteome			Not Reported;Pancreas	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC PDA Discovery Study - Proteome					PDC000270			disease_type: Other;Pancreatic Ductal Adenocarcinoma	primary_site: Not Reported;Pancreas							
PDC000271	166	PDC000271	PDC000271	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pancreatic Ductal Adenocarcinoma		TMT11	1218.0	CPTAC PDA Discovery Study - Phosphoproteome			Not Reported;Pancreas	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC PDA Discovery Study - Phosphoproteome					PDC000271			disease_type: Other;Pancreatic Ductal Adenocarcinoma	primary_site: Not Reported;Pancreas							
PDC000272	166	PDC000272	PDC000272	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pancreatic Ductal Adenocarcinoma		TMT11	610.0	CPTAC PDA Discovery Study - Intact Glycoproteome			Not Reported;Pancreas	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC PDA Discovery Study - Intact Glycoproteome					PDC000272			disease_type: Other;Pancreatic Ductal Adenocarcinoma	primary_site: Not Reported;Pancreas							
PDC000278	30	PDC000278	PDC000278	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		Label Free	3605.0	VU Normal Colon Epithelium - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	VU Normal Colon Epithelium - Proteome					PDC000278			disease_type: Other	primary_site: Not Reported							
PDC000289	2	PDC000289	PDC000289	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		Label Free	1926.0	TCGA Colorectal Cancer CompRef Samples - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA Colorectal Cancer CompRef Samples - Proteome					PDC000289			disease_type: Other	primary_site: Not Reported							
PDC000290	2	PDC000290	PDC000290	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	505.0	TCGA Breast Cancer CompRef Samples - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA Breast Cancer CompRef Samples - Proteome					PDC000290			disease_type: Other	primary_site: Not Reported							
PDC000291	2	PDC000291	PDC000291	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	265.0	TCGA Breast Cancer CompRef Samples - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA Breast Cancer CompRef Samples - Phosphoproteome					PDC000291			disease_type: Other	primary_site: Not Reported							
PDC000292	2	PDC000292	PDC000292	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	599.0	TCGA Ovarian CompRef Samples JHU Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA Ovarian CompRef Samples JHU Proteome					PDC000292			disease_type: Other	primary_site: Not Reported							
PDC000293	2	PDC000293	PDC000293	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	487.0	TCGA Ovarian CompRef Samples PNNL Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA Ovarian CompRef Samples PNNL Proteome					PDC000293			disease_type: Other	primary_site: Not Reported							
PDC000294	2	PDC000294	PDC000294	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	203.0	TCGA Ovarian CompRef Samples PNNL Phosphoproteome Velos Qexactive			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2 Retrospective	TCGA Ovarian CompRef Samples PNNL Phosphoproteome Velos Qexactive					PDC000294			disease_type: Other	primary_site: Not Reported							
PDC000295	1	PDC000295	PDC000295	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	111.0	NCI-7 Cell Line Panel - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	NCI-7 Cell Line Panel - Proteome					PDC000295			disease_type: Other	primary_site: Not Reported							
PDC000296	1	PDC000296	PDC000296	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	107.0	NCI-7 Cell Line Panel Experimental Application - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	NCI-7 Cell Line Panel Experimental Application - Proteome					PDC000296			disease_type: Other	primary_site: Not Reported							
PDC000297	1	PDC000297	PDC000297	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	63.0	NCI-7 Cell Line Panel - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	NCI-7 Cell Line Panel - Phosphoproteome					PDC000297			disease_type: Other	primary_site: Not Reported							
PDC000303	27	PDC000303	PDC000303	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	452.0	Therapeutic Targets in Breast Cancer Xenografts -  Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2-Other	Therapeutic Targets in Breast Cancer Xenografts -  Proteome					PDC000303			disease_type: Other	primary_site: Not Reported							
PDC000304	27	PDC000304	PDC000304	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		iTRAQ4	235.0	Therapeutic Targets in Breast Cancer Xenografts -  Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2-Other	Therapeutic Targets in Breast Cancer Xenografts -  Phosphoproteome					PDC000304			disease_type: Other	primary_site: Not Reported							
PDC000307	7	PDC000307	PDC000307	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT6	154.0	Buparlisib Treated Xenograft Tumors of TNBC - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2-Other	Buparlisib Treated Xenograft Tumors of TNBC - Proteome					PDC000307			disease_type: Other	primary_site: Not Reported							
PDC000308	7	PDC000308	PDC000308	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT6	82.0	Buparlisib Treated Xenograft Tumors of TNBC - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC2-Other	Buparlisib Treated Xenograft Tumors of TNBC - Phosphoproteome					PDC000308			disease_type: Other	primary_site: Not Reported							
PDC000309	2	PDC000309	PDC000309	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	214.0	Reproducible Proteome and Phosphoproteome Workflow BI - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Reproducible Proteome and Phosphoproteome Workflow BI - Proteome					PDC000309			disease_type: Other	primary_site: Not Reported							
PDC000310	2	PDC000310	PDC000310	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	214.0	Reproducible Proteome and Phosphoproteome Workflow PNNL - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Reproducible Proteome and Phosphoproteome Workflow PNNL - Proteome					PDC000310			disease_type: Other	primary_site: Not Reported							
PDC000311	2	PDC000311	PDC000311	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	214.0	Reproducible Proteome and Phosphoproteome Workflow JHU - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Reproducible Proteome and Phosphoproteome Workflow JHU - Proteome					PDC000311			disease_type: Other	primary_site: Not Reported							
PDC000312	2	PDC000312	PDC000312	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	119.0	Reproducible Proteome and Phosphoproteome Workflow BI - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Reproducible Proteome and Phosphoproteome Workflow BI - Phosphoproteome					PDC000312			disease_type: Other	primary_site: Not Reported							
PDC000313	2	PDC000313	PDC000313	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	119.0	Reproducible Proteome and Phosphoproteome Workflow JHU - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Reproducible Proteome and Phosphoproteome Workflow JHU - Phosphoproteome					PDC000313			disease_type: Other	primary_site: Not Reported							
PDC000314	2	PDC000314	PDC000314	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT10	119.0	Reproducible Proteome and Phosphoproteome Workflow PNNL - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Reproducible Proteome and Phosphoproteome Workflow PNNL - Phosphoproteome					PDC000314			disease_type: Other	primary_site: Not Reported							
PDC000315	3	PDC000315	PDC000315	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	203.0	AML Gilteritinib Resistance -  Proteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Gilteritinib Resistance -  Proteome					PDC000315			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000316	2	PDC000316	PDC000316	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	155.0	AML Gilteritinib TimeCourse -  Proteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Gilteritinib TimeCourse -  Proteome					PDC000316			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000317	2	PDC000317	PDC000317	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	107.0	AML Quizartinib Resistance -  Proteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Quizartinib Resistance -  Proteome					PDC000317			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000318	3	PDC000318	PDC000318	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	108.0	AML Gilteritinib Resistance -  Phosphoproteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Gilteritinib Resistance -  Phosphoproteome					PDC000318			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000319	2	PDC000319	PDC000319	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	84.0	AML Gilteritinib TimeCourse -  Phosphoproteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Gilteritinib TimeCourse -  Phosphoproteome					PDC000319			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000320	2	PDC000320	PDC000320	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	60.0	AML Quizartinib Resistance -  Phosphoproteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Quizartinib Resistance -  Phosphoproteome					PDC000320			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000325	17	PDC000325	PDC000325	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT11	394.0	Microscaled Proteogenomic Methods for Precision Oncology DP1 Clinical Trial - Proteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Microscaled Proteogenomic Methods for Precision Oncology DP1 Clinical Trial - Proteome					PDC000325			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000326	17	PDC000326	PDC000326	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT11	171.0	Microscaled Proteogenomic Methods for Precision Oncology DP1 Clinical Trial - Phosphoproteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Microscaled Proteogenomic Methods for Precision Oncology DP1 Clinical Trial - Phosphoproteome					PDC000326			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000327	6	PDC000327	PDC000327	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	106.0	Microscaled Proteogenomic Methods for Precision Oncology PDX bulk - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Microscaled Proteogenomic Methods for Precision Oncology PDX bulk - Proteome					PDC000327			disease_type: Breast Invasive Carcinoma;Other	primary_site: Not Reported							
PDC000328	6	PDC000328	PDC000328	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	63.0	Microscaled Proteogenomic Methods for Precision Oncology PDX bulk - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Microscaled Proteogenomic Methods for Precision Oncology PDX bulk - Phosphoproteome					PDC000328			disease_type: Breast Invasive Carcinoma;Other	primary_site: Not Reported							
PDC000329	6	PDC000329	PDC000329	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	106.0	Microscaled Proteogenomic Methods for Precision Oncology PDX cores - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Microscaled Proteogenomic Methods for Precision Oncology PDX cores - Proteome					PDC000329			disease_type: Breast Invasive Carcinoma;Other	primary_site: Not Reported							
PDC000330	6	PDC000330	PDC000330	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT10	43.0	Microscaled Proteogenomic Methods for Precision Oncology PDX cores - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	Microscaled Proteogenomic Methods for Precision Oncology PDX cores - Phosphoproteome					PDC000330			disease_type: Breast Invasive Carcinoma;Other	primary_site: Not Reported							
PDC000341	105	PDC000341	PDC000341	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pancreatic Ductal Adenocarcinoma		Label Free	187.0	CPTAC PDA Discovery Study - DIA Proteome			Not Reported;Pancreas	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC PDA Discovery Study - DIA Proteome					PDC000341			disease_type: Other;Pancreatic Ductal Adenocarcinoma	primary_site: Not Reported;Pancreas							
PDC000351	3	PDC000351	PDC000351	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		Label Free	16.0	CPTAC Deep Proteomics 2D-DIA			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3-Other	CPTAC Deep Proteomics 2D-DIA					PDC000351			disease_type: Other	primary_site: Not Reported							
PDC000357	21	PDC000357	PDC000357	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Ovarian Serous Cystadenocarcinoma		TMT11	18.0	PTRC HGSOC FFPE Validation - Phosphoproteome			Ovary	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC HGSOC FFPE Validation - Phosphoproteome					PDC000357			disease_type: Ovarian Serous Cystadenocarcinoma	primary_site: Ovary							
PDC000358	21	PDC000358	PDC000358	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Ovarian Serous Cystadenocarcinoma		TMT11	200.0	PTRC HGSOC FFPE Validation - Proteome			Ovary	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC HGSOC FFPE Validation - Proteome					PDC000358			disease_type: Ovarian Serous Cystadenocarcinoma	primary_site: Ovary							
PDC000359	161	PDC000359	PDC000359	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT11	94.0	PTRC HGSOC FFPE Discovery - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC HGSOC FFPE Discovery - Phosphoproteome					PDC000359			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported							
PDC000360	161	PDC000360	PDC000360	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT11	2024.0	PTRC HGSOC FFPE Discovery - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC HGSOC FFPE Discovery - Proteome					PDC000360			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported							
PDC000361	66	PDC000361	PDC000361	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT11	394.0	PTRC HGSOC Frozen Validation - Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC HGSOC Frozen Validation - Phosphoproteome					PDC000361			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported							
PDC000362	66	PDC000362	PDC000362	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Ovarian Serous Cystadenocarcinoma		TMT11	776.0	PTRC HGSOC Frozen Validation - Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC HGSOC Frozen Validation - Proteome					PDC000362			disease_type: Other;Ovarian Serous Cystadenocarcinoma	primary_site: Not Reported							
PDC000393	7	PDC000393	PDC000393	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pancreatic Ductal Adenocarcinoma		TMT10	307.0	Sampling techniques for enrichment of PDAC - Proteome			Not Reported;Pancreas	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	Sampling techniques for enrichment of PDAC - Proteome					PDC000393			disease_type: Other;Pancreatic Ductal Adenocarcinoma	primary_site: Not Reported;Pancreas							
PDC000398	18	PDC000398	PDC000398	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT10	200.0	AML Ex Vivo Drug Response - Primary Cohort - Proteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Ex Vivo Drug Response - Primary Cohort - Proteome					PDC000398			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000399	18	PDC000399	PDC000399	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT10	57.0	AML Ex Vivo Drug Response - Primary Cohort - Phosphoproteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Ex Vivo Drug Response - Primary Cohort - Phosphoproteome					PDC000399			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000400	5	PDC000400	PDC000400	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT10	104.0	AML Ex Vivo Drug Response - Sorafenib Treatment - Proteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Ex Vivo Drug Response - Sorafenib Treatment - Proteome					PDC000400			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000401	5	PDC000401	PDC000401	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT10	57.0	AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Ex Vivo Drug Response - Sorafenib Treatment - Phosphoproteome					PDC000401			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000402	20	PDC000402	PDC000402	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	104.0	AML Ex Vivo Drug Response - Combination Treatment - Proteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Ex Vivo Drug Response - Combination Treatment - Proteome					PDC000402			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000403	20	PDC000403	PDC000403	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Acute Myeloid Leukemia;Other		TMT11	57.0	AML Ex Vivo Drug Response - Combination Treatment - Phosphoproteome			Hematopoietic and reticuloendothelial systems;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	AML Ex Vivo Drug Response - Combination Treatment - Phosphoproteome					PDC000403			disease_type: Acute Myeloid Leukemia;Other	primary_site: Hematopoietic and reticuloendothelial systems;Not Reported							
PDC000408	58	PDC000408	PDC000408	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT11	586.0	PTRC TNBC - Proteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC TNBC - Proteome					PDC000408			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000409	58	PDC000409	PDC000409	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT11	395.0	PTRC TNBC - Phosphoproteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC TNBC - Phosphoproteome					PDC000409			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000410	11	PDC000410	PDC000410	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Breast Invasive Carcinoma;Other		TMT11	86.0	PTRC TNBC PDX - Proteome			Breast;Not Reported	Clinical Proteomic Tumor Analysis Consortium		Proteogenomic Translational Research Centers (PTRC)	PTRC TNBC PDX - Proteome					PDC000410			disease_type: Breast Invasive Carcinoma;Other	primary_site: Breast;Not Reported							
PDC000411	110	PDC000411	PDC000411	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma		Label Free	211.0	CPTAC CCRCC Confirmatory Study - DIA Proteome			Kidney	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Confirmatory Study - DIA Proteome					PDC000411			disease_type: Clear Cell Renal Cell Carcinoma	primary_site: Kidney							
PDC000412	110	PDC000412	PDC000412	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma		Label Free	208.0	CPTAC CCRCC Confirmatory Study - DIA Phosphoproteome			Kidney	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Confirmatory Study - DIA Phosphoproteome					PDC000412			disease_type: Clear Cell Renal Cell Carcinoma	primary_site: Kidney							
PDC000413	110	PDC000413	PDC000413	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma		Label Free	209.0	CPTAC CCRCC Confirmatory Study - DIA Intact Glycoproteome			Kidney	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Confirmatory Study - DIA Intact Glycoproteome					PDC000413			disease_type: Clear Cell Renal Cell Carcinoma	primary_site: Kidney							
PDC000414	40	PDC000414	PDC000414	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma		Label Free	138.0	CPTAC CCRCC Confirmatory Study - Intratumor Heterogeneity - DIA Proteome			Kidney	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Confirmatory Study - Intratumor Heterogeneity - DIA Proteome					PDC000414			disease_type: Clear Cell Renal Cell Carcinoma	primary_site: Kidney							
PDC000415	5	PDC000415	PDC000415	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		Label Free	39.0	CPTAC CCRCC Confirmatory Study - Kinase Inhibition - DIA Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Confirmatory Study - Kinase Inhibition - DIA Phosphoproteome					PDC000415			disease_type: Other	primary_site: Not Reported							
PDC000430	46	PDC000430	PDC000430	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pediatric/AYA Brain Tumors		TMT10	17.0	Broad Institute - Medulloblastoma - Acetylome			Brain;Not Applicable	Broad Institute		Broad	Broad Institute - Medulloblastoma - Acetylome					PDC000430			disease_type: Other;Pediatric/AYA Brain Tumors	primary_site: Brain;Not Applicable							
PDC000431	46	PDC000431	PDC000431	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pediatric/AYA Brain Tumors		TMT10	10.0	Broad Institute - Medulloblastoma - Phospho-tyrosine-enrichments			Brain;Not Applicable	Broad Institute		Broad	Broad Institute - Medulloblastoma - Phospho-tyrosine-enrichments					PDC000431			disease_type: Other;Pediatric/AYA Brain Tumors	primary_site: Brain;Not Applicable							
PDC000432	46	PDC000432	PDC000432	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pediatric/AYA Brain Tumors		TMT10	65.0	Broad Institute - Medulloblastoma - Phosphoproteome			Brain;Not Applicable	Broad Institute		Broad	Broad Institute - Medulloblastoma - Phosphoproteome					PDC000432			disease_type: Other;Pediatric/AYA Brain Tumors	primary_site: Brain;Not Applicable							
PDC000433	46	PDC000433	PDC000433	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Pediatric/AYA Brain Tumors		TMT10	125.0	Broad Institute - Medulloblastoma - Proteome			Brain;Not Applicable	Broad Institute		Broad	Broad Institute - Medulloblastoma - Proteome					PDC000433			disease_type: Other;Pediatric/AYA Brain Tumors	primary_site: Brain;Not Applicable							
PDC000434	101	PDC000434	PDC000434	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		TMT11	1448.0	APOLLO LUAD - Proteome			Bronchus and lung;Not Reported	Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO		APOLLO1	APOLLO LUAD - Proteome					PDC000434			disease_type: Lung Adenocarcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000435	101	PDC000435	PDC000435	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		TMT11	489.0	APOLLO LUAD - Phosphoproteome - TiO2			Bronchus and lung;Not Reported	Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO		APOLLO1	APOLLO LUAD - Phosphoproteome - TiO2					PDC000435			disease_type: Lung Adenocarcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000436	101	PDC000436	PDC000436	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Lung Adenocarcinoma;Other		TMT11	489.0	APOLLO LUAD - Phosphoproteome - FeNTA			Bronchus and lung;Not Reported	Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO		APOLLO1	APOLLO LUAD - Phosphoproteome - FeNTA					PDC000436			disease_type: Lung Adenocarcinoma;Other	primary_site: Bronchus and lung;Not Reported							
PDC000439	159	PDC000439	PDC000439	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT11	1547.0	CPTAC UCEC Confirmatory Study - Proteome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - Proteome					PDC000439			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000440	2	PDC000440	PDC000440	Proteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT11	394.0	CPTAC UCEC Confirmatory Study - CompRef Proteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - CompRef Proteome					PDC000440			disease_type: Other	primary_site: Not Reported							
PDC000441	159	PDC000441	PDC000441	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT11	779.0	CPTAC UCEC Confirmatory Study - Phosphoproteome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - Phosphoproteome					PDC000441			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000442	2	PDC000442	PDC000442	Phosphoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT11	203.0	CPTAC UCEC Confirmatory Study - CompRef Phosphoproteome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - CompRef Phosphoproteome					PDC000442			disease_type: Other	primary_site: Not Reported							
PDC000443	159	PDC000443	PDC000443	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT11	267.0	CPTAC UCEC Confirmatory Study - Acetylome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - Acetylome					PDC000443			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000444	2	PDC000444	PDC000444	Acetylome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other		TMT11	74.0	CPTAC UCEC Confirmatory Study - CompRef Acetylome			Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - CompRef Acetylome					PDC000444			disease_type: Other	primary_site: Not Reported							
PDC000445	159	PDC000445	PDC000445	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Other;Uterine Corpus Endometrial Carcinoma		TMT11	259.0	CPTAC UCEC Confirmatory Study - Glycoproteome			Not Reported;Uterus, NOS	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC UCEC Confirmatory Study - Glycoproteome					PDC000445			disease_type: Other;Uterine Corpus Endometrial Carcinoma	primary_site: Not Reported;Uterus, NOS							
PDC000471	124	PDC000471	PDC000471	Glycoproteome		CRDC Proteomic Data Commons	CRDC Proteomic Data Commons						Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other		TMT10	600.0	CPTAC CCRCC Discovery Study - Intact Glycoproteome			Kidney;Not Reported	Clinical Proteomic Tumor Analysis Consortium		CPTAC3 Discovery and Confirmatory	CPTAC CCRCC Discovery Study - Intact Glycoproteome					PDC000471			disease_type: Clear Cell Renal Cell Carcinoma;Non-Clear Cell Renal Cell Carcinoma;Other	primary_site: Kidney;Not Reported							
1U2CDA050098-01_a	1000	1U2CDA050098-01_a			/programs/JCOIN/projects/SURVEYS	JCOIN	JCOIN	jcoin.datacommons.io	available								Methodology and Advanced Analytics Resource Center							Amerispeak Brief Stigma Survey (JCOIN 026)			Abstract:  Tracking changes in stigma associated with OUD is important,for as stigma intensifies over time it might make it more difficult to find positive treatment effects in JCOIN. Given the critical importance of public opinion towards policy making and approaches used in the justice system, this project will measure public support for OUD treatment in the general public, assess stigma associated with OUD, and perceptions of criminality around OUD. Using a nationally representative survey panel, we will administer 5-10 minute surveys twice a year, with a target to complete 1,000 surveys each wave. The data will allow us to assess the public opinion on issues related to OUD, stigma, and the justice system and monitor trends over time.	1U2CDA050098-01_a				Study Setting: Community	Substance Use: Opioid Use	Other: Practice	Other: Quality	Subject Characteristics: Racial and Ethnic Populations	Subject Characteristics: Justice-involved Populations	Study Design: Observational	Study Setting: Clinical	Pain: Pain Treatment
1U2CDA050098-01_b	0	1U2CDA050098-01_b			/programs/JCOIN/projects/OEPS	JCOIN	JCOIN	jcoin.datacommons.io	available								Methodology and Advanced Analytics Resource Center							Opioid Environment Policy Scan (OEPS) 			The Opioid Environment Policy Scan (OEPS) is a free, open-source data warehouse centered on the multi-dimensional risk environment impacting opioid use and health outcomes, particularly for justice communities, across the United States. \\nThe OEPS consolidates cleaned and processed data spanning Medications for Opioid Use Disorder (MOUD) Access, Health, Built Environment, Economic, and other contextual data at the Census tract, zip code, county, and state levels. Its data supports JCOIN research into the communities and conditions impacting and impacted by opioid use and identifying strategies or policies to reduce harm in communities nationwide.	1U2CDA050098-01_b				Study Setting: Community	Substance Use: Opioid Use	Other: Practice	Other: Quality	Subject Characteristics: Racial and Ethnic Populations	Subject Characteristics: Justice-involved Populations			
NIDA_PDAPS_1a	0	NIDA_PDAPS_1a			/programs/NIDA/projects/PDAPS	JCOIN	JCOIN	jcoin.datacommons.io									Prescription Drug Abuse Policy System (NIDA)							Prescription Drug Abuse Policy System (NIDA)			PDAPS is funded by the National Institute on Drug Abuse to track key state laws related to prescription drug abuse. PDAPS has broken down its datasets into the following major topics: Expanded Access to Naloxone, Good Samaritan 911 Immunity, Medical Marijuana, Opioid Related Controls, Prescription Drug Monitoring Program, and Related Topics. It is intended to be used as a source of rigorous legal data for researchers and provide detailed policy information for the public.	NIDA_PDAPS_1a				Substance Use: Opioid Use								
COVID-19-CT-Images	661	COVID-19-CT-Images			/programs/TCIA/projects/COVID-19-CT_Images	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									CT Images in COVID-19							COVID-19-CT-Images			Link to publication below contains AI model that was only partly derived from this data, and also from other data not present here on TCIA.	COVID-19-CT-Images		https://wiki.cancerimagingarchive.net/display/Public/CT+Images+in+COVID-19#70227107347cd6d9a7bc447a8c4f0fcd6e3585dd		disease_type: COVID-19								
COVID-19-SBU	[1, 384]	COVID-19-NY-SBU			/programs/TCIA/projects/COVID-19-NY-SBU	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									Stony Brook University COVID-19 Positive Cases (COVID-19-NY-SBU)							COVID-19-NY-SBU			The main data file is named deidentified_overlap_tcia.csv.cleaned.csv. The file contains one row per patient whose images have been extracted. For each patient one encounter is selected using an algorithm. The algorithm is designed to select the Covid+ encounter where the patient had their most severe encounter. Images should be interpreted and aligned with the date-shifted field visit_start_datetime to correlate severity with the imaging data.	COVID-19-NY-SBU		https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=89096912#89096912ba2395418c464f7e88aed9d9ffbb8de3		disease_type: COVID-19								
Open-PETAL_REDCORAL	1480	Open-PETAL_REDCORAL			/programs/Open/projects/A1_PETAL_REDCORAL	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									CT_Images_in_COVID-19							Open-PETAL REDCORAL			Eligible participants were hospitalized adult patients who had a positive test for COVID-19 within 14 days of admission. Patients had evidence of acute COVID-19 as characterized by signs and symptoms such as fever, cough, dyspnea, hypoxemia, and infiltrates on chest imaging. PETAL-RED CORAL includes patients who presented for admission to study hospitals between March 1st, 2020 and April 1st, 2020.	Open-PETAL_REDCORAL		https://biolincc.nhlbi.nih.gov/studies/petal_red_coral/		disease_type: COVID-19	primary_site: Chest							
P67C-YW55	5000	P67C-YW55			/programs/Open	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									MIDRC Stratified Sampling Manuscript Cohort							10.60701/P67C-YW55			MIDRC Stratified Sampling Manuscript Cohort	P67C-YW55		https://github.com/MIDRC/Stratified_Sampling/										
TCIA-COVID-19-AR	105	COVID-19-AR			/programs/TCIA/projects/COVID-19-AR	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									Chest Imaging with Clinical and Genomic Correlates Representing a Rural COVID-19 Positive Population (COVID-19-AR)							COVID-19-AR			 	COVID-19-AR		https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=70226443		disease_type: COVID-19	primary_site: Chest							
TCIA-RICORD-1a	110	TCIA-RICORD-1a			/programs/TCIA/projects/RICORD	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									Medical Imaging Data Resource Center (MIDRC) - RSNA International COVID-19 Open Radiology Database (RICORD) Release 1a - Chest CT Covid+ (MIDRC-RICORD-1a)							MIDRC-RICORD Release 1a			MIDRC-RICORD dataset 1a consists of 120 thoracic computed tomography (CT) scans from four international sites annotated with detailed segmentation and diagnostic labels.	TCIA-RICORD-1a		https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=80969742		disease_type: COVID-19	primary_site: Chest							
TCIA-RICORD-1b	117	TCIA-RICORD-1b			/programs/TCIA/projects/RICORD	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									Medical Imaging Data Resource Center (MIDRC) - RSNA International COVID-19 Open Radiology Database (RICORD) Release 1b - Chest CT Covid- (MIDRC-RICORD-1b)							MIDRC-RICORD Release 1b			The RSNA International COVID-19 Open Annotated Radiology Database (RICORD) release 1b consists of 120 thoracic computed tomography (CT) scans of COVID negative patients from four international sites.	TCIA-RICORD-1b		https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=80969771		disease_type: COVID-19	primary_site: Chest							
TCIA-RICORD-1c	361	TCIA-RICORD-1c			/programs/TCIA/projects/RICORD	Medical Imaging and Data Resource Center (MIDRC)	MIDRC	data.midrc.org									Medical Imaging Data Resource Center (MIDRC) - RSNA International COVID-19 Open Radiology Database (RICORD) Release 1c - Chest x-ray Covid+ (MIDRC-RICORD-1c)							MIDRC-RICORD Release 1c			The RSNA International COVID-19 Open Annotated Radiology Database (RICORD) consists of 998 chest x-rays from 361 patients at four international sites annotated with diagnostic labels. Patient Selection: Patients at least 18 years in age receiving positive diagnosis for COVID-19.	TCIA-RICORD-1c		https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=70230281#70230281bcab02c187174a288dbcbf95d26179e8		disease_type: COVID-19	primary_site: Chest							
3a39115e-c653-4e87-b1fd-19fd81c8a784	0	3a39115e-c653-4e87-b1fd-19fd81c8a784			/open	NCT	NIAID ClinicalData	accessclinicaldata.niaid.nih.gov									Adaptive COVID-19 Treatment Trial 2 (ACTT-2)							Adaptive COVID-19 Treatment Trial 2 (ACTT-2)			ACTT-2 will evaluate the combination of baricitinib and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (OP) swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary outcome is time to recovery by Day 29.	NCT04401579		https://www.nejm.org/doi/10.1056/NEJMoa 2031994		Access: open	Category: clinical							
3dc11a7d-fc4e-4003-9281-64ae0311bb87	0	3dc11a7d-fc4e-4003-9281-64ae0311bb87			/open	NCT	NIAID ClinicalData	accessclinicaldata.niaid.nih.gov									Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)							Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)			This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. Enrollment will occur at up to 3 domestic clinical research sites. One hundred and fifty-five subjects will be enrolled into one of thirteen cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, and 250 mcg). Subjects will receive an intramuscular (IM) injection (0.5 milliliters [mL]) of mRNA-1273 on Days 1 and 29 in the deltoid muscle and will be followed through 12 months post second vaccination (Day 394). Follow-up visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29, 36, 43, and 57), as well as 3, 6, and 12 months post second vaccination (Days 119, 209, and 394). The primary objective is to evaluate the safety and reactogenicity of a 2-dose vaccination schedule of mRNA-1273, given 28 days apart, across 5 dosages in healthy adults.	NCT04283461		https://pubmed.ncbi.nlm.nih.gov/32991794/		Acces: open	Category: clinical							
78965284-ee3b-42b1-b2cd-da676f346385	0	78965284-ee3b-42b1-b2cd-da676f346385			/open	NCT	NIAID ClinicalData	accessclinicaldata.niaid.nih.gov									Adaptive COVID-19 Treatment Trial (ACTT-1)							Adaptive COVID-19 Treatment Trial (ACTT-1)			The initial iteration of ACTT (ACTT-1) evaluated remdesivir vs placebo. Participants had to have a laboratory-confirmed SARS-CoV-2 and meet one of the following criteria suggestive of lower respiratory tract infection at the time of enrollment: radiographic infiltrates by imaging study, peripheral oxygen saturation (SpO2) 94% on room air, or requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).	NCT04280705		https://pubmed.ncbi.nlm.nih.gov/32445440/		Access: open	Category: clinical							
